Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:aminopyrimidine
go back to main search page
Accession:CHEBI:38338 term browser browse the term
Definition:A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
Synonyms:related_synonym: aminopyrimidines



show annotations for term's descendants           Sort by:
2'-deoxycytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 multiple interactions ISO Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] CTD PMID:9297556 PMID:9403342 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Dck deoxycytidine kinase affects binding ISO Deoxycytidine binds to DCK protein CTD PMID:17530837 NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
JBrowse link
G Slc28a1 solute carrier family 28 member 1 increases transport ISO SLC28A1 protein results in increased transport of Deoxycytidine CTD PMID:10772724 NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
JBrowse link
2,6-diamino-5-formamido-4-hydroxypyrimidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Neil1 nei-like DNA glycosylase 1 affects metabolic processing ISO NEIL1 protein affects the metabolism of 2,6-diamino-4-hydroxy-5-formamidopyrimidine CTD PMID:17389588 PMID:20067321 NCBI chr 8:57,550,142...57,556,884
Ensembl chr 8:57,550,147...57,556,258
JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase affects metabolic processing ISO OGG1 protein affects the metabolism of 2,6-diamino-4-hydroxy-5-formamidopyrimidine CTD PMID:20067321 NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
JBrowse link
3,N(4)-ethenocytosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase affects glycosylation ISO MBD4 protein affects the glycosylation of 3,N(4)-ethenocytosine CTD PMID:11056019 NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
JBrowse link
G Tdg thymine-DNA glycosylase increases metabolic processing ISO TDG protein results in increased metabolism of 3,N(4)-ethenocytosine CTD PMID:10626224 NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567
JBrowse link
4,6-diamino-5-formamidopyrimidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Neil1 nei-like DNA glycosylase 1 affects metabolic processing ISO NEIL1 protein affects the metabolism of 4,6-diamino-5-N-formamidopyrimidine CTD PMID:17389588 NCBI chr 8:57,550,142...57,556,884
Ensembl chr 8:57,550,147...57,556,258
JBrowse link
5-(hydroxymethyl)cytosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atm ATM serine/threonine kinase decreases methylation ISO 5-hydroxymethylcytosine results in decreased methylation of ATM gene CTD PMID:30990028 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Cmahp cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene multiple interactions ISO [bisphenol A results in decreased methylation of CMAH intron] which results in decreased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr17:40,557,161...40,642,350
Ensembl chr17:40,583,667...40,642,275
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO DNMT1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; DNMT1 protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] CTD PMID:32105160 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions ISO DNMT3A protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; DNMT3A protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] CTD PMID:32105160 NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
JBrowse link
G Esr1 estrogen receptor 1 decreases abundance
multiple interactions
ISO ESR1 protein results in decreased abundance of 5-hydroxymethylcytosine
ESR1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; ESR1 protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine]
CTD PMID:32105160 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions ISO [Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of FTL mRNA CTD PMID:24214992 NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [hydroquinone affects the methylation of GCLC promoter] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:23940045 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gnas GNAS complex locus multiple interactions ISO [bisphenol A results in increased methylation of GNAS intron] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262
JBrowse link
G Grb10 growth factor receptor bound protein 10 multiple interactions ISO [bisphenol A results in increased methylation of GRB10 intron] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases abundance ISO IDH2 protein mutant form results in decreased abundance of 5-hydroxymethylcytosine CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 multiple interactions ISO [bisphenol A results in decreased methylation of KCNQ1 intron] which results in decreased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
JBrowse link
G Klf14 KLF transcription factor 14 multiple interactions ISO [bisphenol A results in decreased methylation of KLF14 exon] which results in decreased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 4:59,554,011...59,556,933
Ensembl chr 4:59,554,011...59,556,933
JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions ISO [bisphenol A results in increased methylation of PDE10A intron] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
JBrowse link
G Pde4d phosphodiesterase 4D multiple interactions ISO [bisphenol A results in increased methylation of PDE4D exon] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
JBrowse link
G Plagl1 PLAG1 like zinc finger 1 multiple interactions ISO [bisphenol A results in increased methylation of PLAGL1 exon] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
JBrowse link
G Ppp1r9a protein phosphatase 1, regulatory subunit 9A multiple interactions ISO [bisphenol A results in decreased methylation of PPP1R9A intron] which results in decreased abundance of 5-hydroxymethylcytosine CTD PMID:30044229 NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
JBrowse link
G Sfn stratifin multiple interactions ISO [hydroquinone affects the methylation of SFN promoter] which results in increased abundance of 5-hydroxymethylcytosine CTD PMID:23940045 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
JBrowse link
G Tet1 tet methylcytosine dioxygenase 1 multiple interactions ISO TET1 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET1 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine] CTD PMID:24214992 NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
JBrowse link
G Tet2 tet methylcytosine dioxygenase 2 multiple interactions
increases abundance
ISO TET2 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET2 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine]
TET2 protein results in increased abundance of 5-hydroxymethylcytosine
bisphenol A promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; bisphenol S promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine]
CTD PMID:24214992 PMID:32105160 NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
JBrowse link
G Ubc ubiquitin C multiple interactions ISO [Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of UBC mRNA CTD PMID:24214992 NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
JBrowse link
5-fluorocytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cda cytidine deaminase increases metabolic processing ISO CDA protein results in increased metabolism of 5-fluorocytidine CTD PMID:21804305 NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
JBrowse link
5-methylcytosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [hydroquinone affects the methylation of GCLC promoter] which results in decreased abundance of 5-Methylcytosine CTD PMID:23940045 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Sfn stratifin multiple interactions ISO [hydroquinone affects the methylation of SFN promoter] which results in decreased abundance of 5-Methylcytosine CTD PMID:23940045 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
JBrowse link
G Tet1 tet methylcytosine dioxygenase 1 multiple interactions ISO TET1 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased oxidation of 5-Methylcytosine]; TET1 protein affects the reaction [Chloranil results in increased oxidation of 5-Methylcytosine] CTD PMID:24214992 NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
JBrowse link
G Tet2 tet methylcytosine dioxygenase 2 multiple interactions ISO TET2 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased oxidation of 5-Methylcytosine]; TET2 protein affects the reaction [Chloranil results in increased oxidation of 5-Methylcytosine] CTD PMID:24214992 NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
JBrowse link
G Wrap53 WD repeat containing, antisense to TP53 multiple interactions ISO [Pesticides results in increased methylation of WRAP53 gene] which results in increased abundance of 5-Methylcytosine CTD PMID:31243981 NCBI chr10:54,282,092...54,299,908
Ensembl chr10:54,282,105...54,298,929
JBrowse link
6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atr ATR serine/threonine kinase multiple interactions
decreases activity
ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of ATR protein]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased phosphorylation of ATR protein]; [4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine results in decreased activity of ATR] which results in increased susceptibility to Cisplatin; [4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine results in decreased activity of ATR] which results in increased susceptibility to Hydroxyurea; [4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine results in decreased activity of ATR] which results in increased susceptibility to Temozolomide CTD PMID:21730979 PMID:25748550 NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
JBrowse link
G Casp7 caspase 7 multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine promotes the reaction [1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea results in increased cleavage of CASP7 protein] CTD PMID:26208482 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine promotes the reaction [1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea results in increased cleavage of CASP8 protein] CTD PMID:26208482 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine promotes the reaction [1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea results in increased cleavage of CASP9 protein] CTD PMID:26208482 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea results in increased phosphorylation of CHEK1 protein] CTD PMID:26208482 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea results in increased phosphorylation of CHEK2 protein] CTD PMID:26208482 NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine co-treated with 1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea] results in increased cleavage of PARP1 protein CTD PMID:26208482 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased expression of and results in increased stability of TNF mRNA]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased expression of TNF protein]
4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of ATR protein]
CTD PMID:24817034 PMID:25748550 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
annomontine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases expression ISO annomontine results in increased expression of AHR mRNA CTD PMID:20449727 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor increases expression ISO annomontine results in increased expression of AHRR mRNA CTD PMID:20449727 NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression ISO annomontine results in increased expression of CYP1A1 mRNA CTD PMID:20449727 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
benfotiamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA]
benphothiamine metabolite results in increased expression of GCLM mRNA; benphothiamine results in increased expression of GCLM mRNA
CTD PMID:29860433 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA] CTD PMID:29860433 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
ISO benphothiamine metabolite results in increased expression of HMOX1 mRNA; benphothiamine results in increased expression of HMOX1 mRNA
benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]
CTD PMID:29860433 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein CTD PMID:29860433 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mapt microtubule-associated protein tau decreases phosphorylation
multiple interactions
ISO benphothiamine results in decreased phosphorylation of MAPT protein
[benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein; [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; [benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA; benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein]; benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]
CTD PMID:29860433 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA] CTD PMID:29860433 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA] CTD PMID:29860433 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions
ISO benphothiamine metabolite results in increased expression of NQO1 mRNA; benphothiamine results in increased expression of NQO1 mRNA
[benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA]
CTD PMID:29860433 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein] CTD PMID:29860433 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein CTD PMID:29860433 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein CTD PMID:29860433 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein] CTD PMID:29860433 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Tkt transketolase multiple interactions EXP
ISO
[benphothiamine co-treated with Streptozocin] results in increased activity of TKT protein
benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]
CTD PMID:12592403 PMID:29860433 NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein CTD PMID:29860433 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Txn1 thioredoxin 1 multiple interactions ISO [benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA CTD PMID:29860433 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
JBrowse link
Bisibuthiamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP sulbutiamine inhibits the reaction [Streptozocin results in increased expression of HAVCR1 protein] CTD PMID:37224990 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP sulbutiamine inhibits the reaction [Streptozocin results in increased expression of IL1B protein] CTD PMID:37224990 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP sulbutiamine inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] CTD PMID:37224990 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP sulbutiamine inhibits the reaction [Streptozocin results in increased expression of TLR4 protein] CTD PMID:37224990 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP sulbutiamine inhibits the reaction [Streptozocin results in increased expression of TNF protein] CTD PMID:37224990 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
BKM120 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccne1 cyclin E1 decreases expression EXP BKM120 decreases expression of cyclin E protein in rat pituitary tumor cell line RGD PMID:26983879 RGD:152177690 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Prl prolactin decreases expression EXP BKM120 decreases expression of prolactin protein in serum of treated rats RGD PMID:26983879 RGD:152177690 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
bupirimate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity ISO bupirimate results in increased activity of NR1I2 protein CTD PMID:16565514 PMID:21924250 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO bupirimate results in increased activity of NR1I3 protein CTD PMID:21924250 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
capecitabine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb7 ATP binding cassette subfamily B member 7 decreases response to substance ISO ABCB7 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr  X:69,295,598...69,436,775
Ensembl chr  X:69,295,552...69,436,858
JBrowse link
G Acaa1a acetyl-CoA acyltransferase 1A increases response to substance ISO ACAA1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 increases response to substance ISO AGPAT2 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
JBrowse link
G Agr2 anterior gradient 2, protein disulphide isomerase family member increases response to substance ISO AGR2 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 decreases response to substance ISO AKR1B1 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases response to substance ISO AKR1C3 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO capecitabine decreases expression and phosphorylation of AKT1 protein in colon RGD PMID:30789971 RGD:151893289 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aqp8 aquaporin 8 increases expression ISO Capecitabine results in increased expression of AQP8 mRNA CTD PMID:36183961 NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
JBrowse link
G Arl4d ADP-ribosylation factor like GTPase 4D decreases response to substance ISO ARL4D protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
JBrowse link
G Atp12a ATPase H+/K+ transporting non-gastric alpha2 subunit increases expression ISO Capecitabine results in increased expression of ATP12A mRNA CTD PMID:36183961 NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
JBrowse link
G Axl Axl receptor tyrosine kinase decreases response to substance ISO AXL protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
JBrowse link
G C3 complement C3 decreases expression ISO Capecitabine results in decreased expression of C3 mRNA CTD PMID:36183961 NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
JBrowse link
G Canx calnexin multiple interactions ISO CANX results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
JBrowse link
G Cat catalase decreases activity EXP Capecitabine results in decreased activity of CAT protein CTD PMID:29117755 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl19 C-C motif chemokine ligand 19 decreases expression ISO Capecitabine results in decreased expression of CCL19 mRNA CTD PMID:36183961 NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
JBrowse link
G Ccl21 C-C motif chemokine ligand 21 decreases expression ISO Capecitabine results in decreased expression of CCL21 mRNA CTD PMID:36183961 NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
JBrowse link
G Ccn1 cellular communication network factor 1 decreases response to substance
decreases expression
ISO CCN1 protein results in decreased susceptibility to Capecitabine
Capecitabine results in decreased expression of CCN1 mRNA
CTD PMID:16734730 PMID:36183961 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A decreases expression ISO Capecitabine results in decreased expression of CDKN2A protein CTD PMID:17904787 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Ces1d carboxylesterase 1D multiple interactions ISO CES1 protein results in increased hydrolysis of and results in increased activity of Capecitabine CTD PMID:15687373 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
JBrowse link
G Ces2h carboxylesterase 2H multiple interactions
increases response to substance
ISO CES2 protein results in increased hydrolysis of and results in increased activity of Capecitabine
CES2 gene polymorphism results in increased susceptibility to Capecitabine
CTD PMID:15687373 PMID:18473752 NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
JBrowse link
G Cib1 calcium and integrin binding 1 increases response to substance ISO CIB1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
JBrowse link
G Cldn3 claudin 3 increases response to substance ISO CLDN3 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression ISO Capecitabine decreases expression of CXCL12 protein in liver and colon RGD PMID:30789971 RGD:151893289 NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression ISO Capecitabine results in increased expression of CXCL1 CTD PMID:35147423 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Capecitabine decreases expression of CXCR4 protein in liver and colon RGD PMID:30789971 RGD:151893289 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Dpyd dihydropyrimidine dehydrogenase increases expression
decreases response to substance
affects response to substance
ISO Capecitabine results in increased expression of DPYD mRNA
DPYD protein results in decreased susceptibility to Capecitabine
DPYD protein affects the susceptibility to Capecitabine
CTD PMID:16734730 PMID:17611699 PMID:18846242 NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
JBrowse link
G Dse dermatan sulfate epimerase decreases response to substance ISO DSE protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr20:26,118,194...26,196,889
Ensembl chr20:26,118,196...26,196,992
JBrowse link
G Eps8 EGFR pathway substrate 8, signaling adaptor increases response to substance ISO EPS8 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 increases response to substance ISO ERBB3 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
JBrowse link
G Fcrla Fc receptor-like A decreases expression ISO Capecitabine results in decreased expression of FCRLA mRNA CTD PMID:36183961 NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762
JBrowse link
G Fhl1 four and a half LIM domains 1 decreases response to substance ISO FHL1 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr  X:134,555,399...134,614,930
Ensembl chr  X:134,555,479...134,614,928
JBrowse link
G Flii FLII, actin remodeling protein decreases response to substance ISO FLII protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970
JBrowse link
G Fuca1 alpha-L-fucosidase 1 increases response to substance ISO FUCA1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 5:148,152,718...148,169,972
Ensembl chr 5:148,152,700...148,169,972
JBrowse link
G Gatd3a glutamine amidotransferase class 1 domain containing 3A increases expression ISO Capecitabine results in increased expression of GATD3A mRNA CTD PMID:36183961 NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
JBrowse link
G Gpx1 glutathione peroxidase 1 decreases activity EXP Capecitabine results in decreased activity of GPX1 protein CTD PMID:29117755 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases expression ISO Capecitabine results in decreased expression of HBA1 mRNA CTD PMID:36183961 NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
JBrowse link
G Hba-a3 hemoglobin alpha, adult chain 3 decreases expression ISO Capecitabine results in decreased expression of HBA2 mRNA CTD PMID:36183961 NCBI chr10:15,311,637...15,312,481
Ensembl chr10:15,311,634...15,312,481
JBrowse link
G Hbb hemoglobin subunit beta decreases expression ISO Capecitabine results in decreased expression of HBB mRNA CTD PMID:36183961 NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
JBrowse link
G Hdgfl3 HDGF like 3 decreases response to substance ISO HDGFL3 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:135,822,600...135,876,719
Ensembl chr 1:135,827,549...135,876,719
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases response to substance
ameliorates
ISO HIF1A protein results in decreased susceptibility to Capecitabine
capecitabine decreases expression of HIF1A protein in colon
CTD
RGD
PMID:16734730 PMID:30789971 RGD:151893289 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hras HRas proto-oncogene, GTPase decreases response to substance ISO HRAS protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Il17rb interleukin 17 receptor B increases response to substance ISO IL17RB protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
JBrowse link
G Il1r2 interleukin 1 receptor type 2 increases response to substance ISO IL1R2 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
ISO Capecitabine metabolite results in increased expression of IL6 mRNA; Capecitabine results in increased expression of IL6
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Capecitabine metabolite results in increased expression of IL6 mRNA]
CTD PMID:35147423 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO JUNB results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
JBrowse link
G Lgals4 galectin 4 increases response to substance ISO LGALS4 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481
JBrowse link
G Lrrc15 leucine rich repeat containing 15 decreases expression ISO Capecitabine results in decreased expression of LRRC15 mRNA CTD PMID:36183961 NCBI chr11:70,469,817...70,484,268
Ensembl chr11:70,469,804...70,484,267
JBrowse link
G Mdm4 MDM4 regulator of p53 multiple interactions ISO MDM4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
decreases expression
ISO MMP2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine]
capecitabine decreases expression of MMP2 protein in colon
CTD
RGD
PMID:18678097 PMID:30789971 RGD:151893289 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mre11 MRE11 homolog, double strand break repair nuclease decreases response to substance ISO MRE11 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
JBrowse link
G Ms4a1 membrane spanning 4-domains A1 decreases expression ISO Capecitabine results in decreased expression of MS4A1 mRNA CTD PMID:36183961 NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512
JBrowse link
G Myb MYB proto-oncogene, transcription factor increases response to substance ISO MYB protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
JBrowse link
G Myrf myelin regulatory factor increases response to substance ISO MYRF protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:206,854,175...206,886,276
Ensembl chr 1:206,854,175...206,886,157
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 decreases expression ISO Capecitabine results in decreased expression of NR4A1 mRNA CTD PMID:36183961 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 decreases expression ISO Capecitabine results in decreased expression of NR4A2 mRNA CTD PMID:36183961 NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
JBrowse link
G Pax5 paired box 5 decreases expression ISO Capecitabine results in decreased expression of PAX5 mRNA CTD PMID:36183961 NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
JBrowse link
G Pik3cb phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta multiple interactions ISO capecitabine decreases expression and phosphorylation of PIK3CB protein in colon RGD PMID:30789971 RGD:151893289 NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
JBrowse link
G Pkd2 polycystin 2, transient receptor potential cation channel decreases response to substance ISO PKD2 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr14:5,237,135...5,280,455
Ensembl chr14:5,237,135...5,280,825
JBrowse link
G Pkp2 plakophilin 2 increases response to substance ISO PKP2 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730
JBrowse link
G Plce1 phospholipase C, epsilon 1 increases response to substance ISO PLCE1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
JBrowse link
G Ppa1 inorganic pyrophosphatase 1 increases response to substance ISO PPA1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
JBrowse link
G Prkacb protein kinase cAMP-activated catalytic subunit beta decreases response to substance ISO PRKACB protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression ISO Capecitabine results in decreased expression of PTGS2 protein
Capecitabine metabolite results in decreased expression of PTGS2
CTD PMID:17904787 PMID:35147423 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Ptpn13 protein tyrosine phosphatase, non-receptor type 13 decreases response to substance ISO PTPN13 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563
JBrowse link
G Pygb glycogen phosphorylase B increases response to substance ISO PYGB protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
JBrowse link
G Rab40b Rab40b, member RAS oncogene family increases response to substance ISO RAB40B protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO RB1 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rbbp4 RB binding protein 4, chromatin remodeling factor multiple interactions ISO RBBP4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284
JBrowse link
G Rpa1 replication protein A1 decreases response to substance ISO RPA1 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949
JBrowse link
G Rras2 RAS related 2 decreases response to substance ISO RRAS2 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111
JBrowse link
G RT1-Ba RT1 class II, locus Ba decreases expression ISO Capecitabine results in decreased expression of HLA-DQA1 mRNA CTD PMID:36183961 NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
JBrowse link
G Sik1 salt-inducible kinase 1 decreases expression ISO Capecitabine results in decreased expression of SIK1 mRNA CTD PMID:36183961 NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991
JBrowse link
G Slc26a3 solute carrier family 26 member 3 increases expression ISO Capecitabine results in increased expression of SLC26A3 mRNA CTD PMID:36183961 NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions ISO Capecitabine inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] CTD PMID:30863990 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
JBrowse link
G Sod1 superoxide dismutase 1 decreases activity EXP Capecitabine results in decreased activity of SOD1 protein CTD PMID:29117755 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Stip1 stress-induced phosphoprotein 1 decreases response to substance ISO STIP1 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
JBrowse link
G Tcf7l2 transcription factor 7 like 2 multiple interactions ISO TCF7L2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] CTD PMID:18678097 NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967
JBrowse link
G Tead1 TEA domain transcription factor 1 decreases response to substance ISO TEAD1 protein results in decreased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 1:166,791,900...167,010,591
Ensembl chr 1:166,792,628...167,003,369
JBrowse link
G Tff1 trefoil factor 1 increases response to substance ISO TFF1 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Trim15 tripartite motif containing 15 increases response to substance ISO TRIM15 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr20:1,700,905...1,710,249
Ensembl chr20:1,700,905...1,710,249
JBrowse link
G Trim31 tripartite motif-containing 31 increases expression ISO Capecitabine results in increased expression of TRIM31 mRNA CTD PMID:36183961 NCBI chr20:1,653,165...1,666,494
Ensembl chr20:1,653,165...1,666,494
JBrowse link
G Tyms thymidylate synthetase affects expression
decreases response to substance
multiple interactions
ISO Capecitabine affects the expression of TYMS mRNA
TYMS protein results in decreased susceptibility to Capecitabine
[TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin]
CTD PMID:16438929 PMID:16734730 PMID:21048041 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
JBrowse link
G Upk3a uroplakin 3A increases expression ISO Capecitabine results in increased expression of UPK3A mRNA CTD PMID:36183961 NCBI chr 7:116,128,981...116,139,950
Ensembl chr 7:116,134,874...116,139,948
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO [TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin]
capecitabine decreases expression of VEGFA protein in blood serum and colon
CTD
RGD
PMID:21048041 PMID:30789971 RGD:151893289 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Zfp706 zinc finger protein 706 increases response to substance ISO ZNF706 protein results in increased susceptibility to Capecitabine CTD PMID:16734730 NCBI chr 7:68,167,496...68,174,121
Ensembl chr 7:68,166,323...68,174,148
JBrowse link
CDP-choline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 decreases expression ISO Cytidine Diphosphate Choline results in decreased expression of CASP3 protein CTD PMID:12443983 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Icam1 intercellular adhesion molecule 1 decreases expression EXP Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA CTD PMID:16193989 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Nceh1 neutral cholesterol ester hydrolase 1 multiple interactions ISO NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] CTD PMID:18164358 NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 decreases expression ISO Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form CTD PMID:12443983 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions
EXP Cytidine Diphosphate Choline results in increased expression of SIRT1 protein
Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein
CTD PMID:23600725 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
JBrowse link
ceritinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO ceritinib analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein CTD PMID:35803438 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alk ALK receptor tyrosine kinase affects response to substance
decreases phosphorylation
decreases activity
ISO ALK protein affects the susceptibility to ceritinib
ceritinib analog results in decreased phosphorylation of ALK protein
ceritinib results in decreased activity of ALK protein
CTD PMID:26144315 PMID:29458018 PMID:35803438 NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression ISO ceritinib analog results in increased expression of BAX protein CTD PMID:35803438 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO ceritinib analog results in decreased expression of BCL2 protein CTD PMID:35803438 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Casp3 caspase 3 increases cleavage ISO ceritinib analog results in increased cleavage of CASP3 protein CTD PMID:35803438 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases cleavage ISO ceritinib analog results in increased cleavage of CASP9 protein CTD PMID:35803438 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO ceritinib analog affects the localization of CYCS protein CTD PMID:35803438 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO ceritinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Jak3 Janus kinase 3 decreases expression ISO ceritinib analog results in decreased expression of JAK3 protein CTD PMID:35803438 NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO ceritinib analog results in decreased expression of and results in decreased phosphorylation of MAPK1 protein CTD PMID:35803438 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO ceritinib analog results in decreased expression of and results in decreased phosphorylation of MAPK3 protein CTD PMID:35803438 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO ceritinib analog results in decreased expression of MCL1 protein CTD PMID:35803438 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO ceritinib analog results in decreased expression of and results in decreased phosphorylation of NFKBIA protein CTD PMID:35803438 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 decreases expression ISO ceritinib analog results in decreased expression of PIK3C3 protein CTD PMID:35803438 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects localization
multiple interactions
ISO ceritinib analog affects the localization of RELA protein
ceritinib analog results in decreased expression of and results in decreased phosphorylation of RELA protein
CTD PMID:35803438 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO ceritinib analog results in decreased expression of and results in decreased phosphorylation of STAT3 protein CTD PMID:35803438 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Traf2 Tnf receptor-associated factor 2 decreases expression ISO ceritinib analog results in decreased expression of TRAF2 protein CTD PMID:35803438 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
JBrowse link
CHIR 99021 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA CTD PMID:34480604 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA CTD PMID:34480604 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Acadvl acyl-CoA dehydrogenase, very long chain decreases expression ISO Chir 99021 results in decreased expression of ACADVL mRNA CTD PMID:29883716 NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
JBrowse link
G Acan aggrecan decreases expression ISO Chir 99021 results in decreased expression of ACAN mRNA CTD PMID:32220932 NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA CTD PMID:34480604 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
JBrowse link
G Actn2 actinin alpha 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA CTD PMID:34480604 NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
JBrowse link
G Afp alpha-fetoprotein increases expression
multiple interactions
ISO Chir 99021 results in increased expression of AFP mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA
CTD PMID:31711903 PMID:34480604 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions ISO Chir 99021 binds to and results in increased activity of AHR protein; Chir 99021 inhibits the reaction [AHR protein results in decreased expression of VIM protein] CTD PMID:26259606 PMID:27752740 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in decreased phosphorylation of AKT1 protein] CTD PMID:34687144 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alb albumin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA CTD PMID:34480604 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of ALDH1A2 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A2 mRNA CTD PMID:31711903 NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
JBrowse link
G Aldoa aldolase, fructose-bisphosphate A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA CTD PMID:34480604 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
JBrowse link
G Amhr2 anti-Mullerian hormone receptor type 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA CTD PMID:34480604 NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
JBrowse link
G Anxa1 annexin A1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA CTD PMID:34480604 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
JBrowse link
G Apoa1 apolipoprotein A1 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of APOA1 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of APOA1 mRNA]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of APOA1 mRNA]; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA
CTD PMID:31711903 PMID:34480604 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA CTD PMID:34480604 NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in increased expression of BAX protein] CTD PMID:34687144 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of BCL2 protein] CTD PMID:34687144 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO Chir 99021 results in increased expression of BGLAP mRNA CTD PMID:32220932 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EGLN3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GPX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HMOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACTN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALDOA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ELAVL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FAH mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IFI44 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KEAP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MAFG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NEUROG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of OLIG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RARA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SH3BP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2B mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CD68 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CSF2 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of HOPX mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC1 protein; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC5AC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of NKX2-1 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of PPARG mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPA mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SOX9 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of TTF1 protein CTD PMID:34480604 PMID:35267148 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA CTD PMID:34480604 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA CTD PMID:34480604 NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in increased cleavage of CASP3 protein] CTD PMID:34687144 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Chir 99021 affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of CCND1 protein] CTD PMID:32005247 PMID:34687144 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cd68 Cd68 molecule multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CD68 mRNA CTD PMID:35267148 NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA CTD PMID:34480604 NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in increased expression of CDH1 protein] CTD PMID:34687144 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh10 cadherin 10 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA CTD PMID:34480604 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
JBrowse link
G Cdx1 caudal type homeo box 1 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of CDX1 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of CDX1 mRNA]; Tretinoin inhibits the reaction [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of CDX1 mRNA]]
CTD PMID:31711903 NCBI chr18:54,472,587...54,490,913
Ensembl chr18:54,473,444...54,490,814
JBrowse link
G Ceacam6 CEA cell adhesion molecule 6 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA CTD PMID:34480604 NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA CTD PMID:34480604 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA CTD PMID:34480604 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Cryab crystallin, alpha B multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA CTD PMID:34480604 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CSF2 mRNA CTD PMID:35267148 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Ctnnb1 catenin beta 1 increases expression
multiple interactions
affects localization
ISO
EXP
Chir 99021 results in increased expression of CTNNB1 protein
Chir 99021 affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Chir 99021 inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]; Chir 99021 inhibits the reaction [KIF23 protein affects the expression of CTNNB1 protein]; Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of CTNNB1 protein]
Chir 99021 affects the localization of CTNNB1 protein
Chir 99021 promotes the reaction [CTNNB1 protein binds to GJA1 promoter]; Chir 99021 promotes the reaction [Ketamine results in increased expression of CTNNB1 protein]
CTD PMID:26259606 PMID:31715269 PMID:32005247 PMID:32220932 PMID:34283317 More... NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [EP300 protein binds to CYP1A1 promoter]]; Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:34403729 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of CYP1A2 mRNA
Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]
CTD PMID:26259606 PMID:34403729 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [EP300 protein binds to CYP1B1 promoter]]; Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] CTD PMID:34403729 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA CTD PMID:34480604 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA CTD PMID:34480604 NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions
increases expression
ISO Chir 99021 results in increased expression of and results in increased activity of CYP2E1 protein
Chir 99021 results in increased expression of CYP2E1 mRNA
CTD PMID:26259606 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO Chir 99021 results in increased expression of CYP3A4 mRNA CTD PMID:26259606 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA CTD PMID:34480604 NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
JBrowse link
G Dcn decorin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA CTD PMID:34480604 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Dcx doublecortin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA CTD PMID:34480604 NCBI chr  X:107,430,767...107,573,612
Ensembl chr  X:107,430,767...107,507,476
JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA CTD PMID:34480604 NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA CTD PMID:34480604 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Ebf1 EBF transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA CTD PMID:34480604 NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
JBrowse link
G Ebf3 EBF transcription factor 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA CTD PMID:34480604 NCBI chr 1:191,996,726...192,114,593
Ensembl chr 1:191,996,730...192,114,359
JBrowse link
G Ecscr endothelial cell surface expressed chemotaxis and apoptosis regulator multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA CTD PMID:34480604 NCBI chr18:27,309,711...27,319,106
Ensembl chr18:27,309,718...27,319,032
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA CTD PMID:34480604 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
JBrowse link
G Eif2b5 eukaryotic translation initiation factor 2B subunit epsilon multiple interactions ISO Chir 99021 promotes the reaction [GSK3B protein affects the phosphorylation of EIF2B5 protein] CTD PMID:29883716 NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419
JBrowse link
G Elavl3 ELAV like RNA binding protein 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA CTD PMID:34480604 NCBI chr 8:20,547,108...20,583,369
Ensembl chr 8:20,550,201...20,583,641
JBrowse link
G Elavl4 ELAV like RNA binding protein 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA CTD PMID:34480604 NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446
JBrowse link
G Emx2 empty spiracles homeobox 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA CTD PMID:34480604 NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
JBrowse link
G Ep300 E1A binding protein p300 multiple interactions ISO Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [EP300 protein binds to CYP1A1 promoter]]; Chir 99021 inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [EP300 protein binds to CYP1B1 promoter]] CTD PMID:34403729 NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088
JBrowse link
G Esrra estrogen related receptor, alpha increases expression ISO Chir 99021 results in increased expression of ESRRA mRNA CTD PMID:29883716 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA1 mRNA; Tretinoin inhibits the reaction [[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA1 mRNA] CTD PMID:31711903 NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA CTD PMID:34480604 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fah fumarylacetoacetate hydrolase multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA CTD PMID:34480604 NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
JBrowse link
G Fbxo32 F-box protein 32 decreases expression
multiple interactions
ISO Chir 99021 results in decreased expression of FBXO32 mRNA
Chir 99021 inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA
CTD PMID:21832246 PMID:34480604 NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
JBrowse link
G Fgb fibrinogen beta chain multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA CTD PMID:34480604 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
JBrowse link
G Fgf10 fibroblast growth factor 10 multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CD68 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CSF2 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of HOPX mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC1 protein; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC5AC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of NKX2-1 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of PPARG mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPA mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SOX9 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of TTF1 protein CTD PMID:35267148 NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866
JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CD68 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of CSF2 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of HOPX mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC1 protein; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC5AC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of NKX2-1 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of PPARG mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPA mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPC mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SOX9 mRNA; [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of TTF1 protein CTD PMID:34480604 PMID:35267148 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Fgf8 fibroblast growth factor 8 multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of FGF8 mRNA] CTD PMID:31711903 NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
JBrowse link
G Fgg fibrinogen gamma chain multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA CTD PMID:34480604 NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
JBrowse link
G Flrt3 fibronectin leucine rich transmembrane protein 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA CTD PMID:34480604 NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA CTD PMID:34480604 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
JBrowse link
G Foxa1 forkhead box A1 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of FOXA1 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of FOXA1 mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of FOXA1 mRNA]
CTD PMID:31711903 NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
JBrowse link
G Foxa2 forkhead box A2 decreases expression
multiple interactions
EXP Chir 99021 results in decreased expression of FOXA2 mRNA; Chir 99021 results in decreased expression of FOXA2 protein
Chir 99021 inhibits the reaction [FOXA2 protein binds to GJA1 promoter]
CTD PMID:34283317 NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
JBrowse link
G Foxc2 forkhead box C2 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; Tretinoin inhibits the reaction [[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA] CTD PMID:31711903 NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
JBrowse link
G Foxd3 forkhead box D3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA CTD PMID:34480604 NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:114,335,408...114,336,817
JBrowse link
G Foxg1 forkhead box G1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA CTD PMID:34480604 NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA CTD PMID:34480604 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gata6 GATA binding protein 6 multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of GATA6 mRNA]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of GATA6 mRNA]; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA CTD PMID:31711903 PMID:34480604 NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLC mRNA CTD PMID:34480604 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA CTD PMID:34480604 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gja1 gap junction protein, alpha 1 decreases expression
multiple interactions
EXP Chir 99021 results in decreased expression of GJA1 mRNA
Benzo(a)pyrene promotes the reaction [Chir 99021 results in decreased expression of GJA1 mRNA]; Chir 99021 inhibits the reaction [FOXA2 protein binds to GJA1 promoter]; Chir 99021 promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA]; Chir 99021 promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein]; Chir 99021 promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 mRNA]; Chir 99021 promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein]; Chir 99021 promotes the reaction [CTNNB1 protein binds to GJA1 promoter]; Chir 99021 results in decreased expression of and affects the localization of GJA1 protein
CTD PMID:34283317 PMID:36863560 NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
JBrowse link
G Gpr183 G protein-coupled receptor 183 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA CTD PMID:34480604 NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA CTD PMID:34480604 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA CTD PMID:34480604 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA CTD PMID:34480604 NCBI chr  X:120,238,515...120,504,106
Ensembl chr  X:120,238,534...120,504,096
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta affects phosphorylation
decreases activity
multiple interactions
ISO
EXP
Chir 99021 affects the phosphorylation of GSK3B protein
Chir 99021 results in decreased activity of GSK3B protein
Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium promotes the reaction [GSK3B protein binds to TFEB protein]]; Chir 99021 promotes the reaction [GSK3B protein affects the expression of PPARGC1A protein]; Chir 99021 promotes the reaction [GSK3B protein affects the phosphorylation of EIF2B5 protein]
Chir 99021 inhibits the reaction [Ketamine results in increased phosphorylation of GSK3B protein]
Chir 99021 inhibits the reaction [SC-66 compound results in decreased phosphorylation of GSK3B protein]
CTD PMID:27752740 PMID:29883716 PMID:30165626 PMID:34283317 PMID:34687144 More... NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA CTD PMID:34480604 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA CTD PMID:34480604 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
JBrowse link
G Gsto1 glutathione S-transferase omega 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA CTD PMID:34480604 NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA CTD PMID:34480604 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA CTD PMID:34480604 NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
JBrowse link
G H19 H19 imprinted maternally expressed transcript increases expression ISO Chir 99021 results in increased expression of H19 mRNA CTD PMID:31711903 NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
JBrowse link
G Hand2 heart and neural crest derivatives expressed 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA CTD PMID:34480604 NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA CTD PMID:34480604 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hes5 hes family bHLH transcription factor 5 multiple interactions ISO [2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide co-treated with SU 5402 co-treated with Chir 99021] results in decreased expression of HES5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA
CTD PMID:20865013 PMID:34480604 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
JBrowse link
G Hes7 hes family bHLH transcription factor 7 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of HES7 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of HES7 mRNA]; Tretinoin inhibits the reaction [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of HES7 mRNA]]
CTD PMID:31711903 NCBI chr10:53,824,124...53,828,934
Ensembl chr10:53,825,574...53,828,097
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA CTD PMID:34480604 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HMOX1 mRNA CTD PMID:34480604 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hopx HOP homeobox multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of HOPX mRNA CTD PMID:35267148 NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA1 mRNA CTD PMID:34480604 NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
JBrowse link
G Hoxa2 homeobox A2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA CTD PMID:34480604 NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044
JBrowse link
G Hoxa5 homeo box A5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA CTD PMID:34480604 NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
JBrowse link
G Hoxb1 homeo box B1 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXB1 mRNA CTD PMID:31711903 NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
JBrowse link
G Hoxb3 homeo box B3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXB3 mRNA CTD PMID:31711903 PMID:34480604 NCBI chr10:81,258,739...81,314,134
Ensembl chr10:81,299,357...81,313,107
JBrowse link
G Hoxb5 homeo box B5 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide affects the reaction [Chir 99021 results in increased expression of HOXB5 mRNA]; Tretinoin affects the reaction [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide affects the reaction [Chir 99021 results in increased expression of HOXB5 mRNA]] CTD PMID:31711903 NCBI chr10:81,269,372...81,271,580
Ensembl chr10:81,269,372...81,271,580
JBrowse link
G Hoxb7 homeo box B7 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of HOXB7 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of HOXB7 mRNA]
CTD PMID:31711903 NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
JBrowse link
G Hoxb9 homeo box B9 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXB9 mRNA CTD PMID:31711903 NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
JBrowse link
G Hoxd4 homeo box D4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA CTD PMID:34480604 NCBI chr 3:59,614,464...59,634,042
Ensembl chr 3:59,614,464...59,631,528
JBrowse link
G Hoxd8 homeobox D8 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA CTD PMID:34480604 NCBI chr 3:59,607,793...59,610,359
Ensembl chr 3:59,607,996...59,610,361
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA CTD PMID:34480604 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
JBrowse link
G Ifi44 interferon-induced protein 44 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IFI44 mRNA CTD PMID:34480604 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA CTD PMID:34480604 NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
JBrowse link
G Ihh Indian hedgehog signaling molecule multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of IHH mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of IHH mRNA] CTD PMID:31711903 NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA CTD PMID:34480604 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Inhba inhibin subunit beta A multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EGLN3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GPX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HMOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACTN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALDOA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ELAVL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FAH mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IFI44 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KEAP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MAFG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NEUROG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of OLIG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RARA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SH3BP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2B mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA CTD PMID:34480604 NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA CTD PMID:34480604 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Kif23 kinesin family member 23 multiple interactions ISO Chir 99021 inhibits the reaction [KIF23 protein affects the expression of CTNNB1 protein] CTD PMID:34933054 NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of LAMP1 protein] CTD PMID:30165626 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA CTD PMID:34480604 NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA CTD PMID:34480604 NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
JBrowse link
G Lgr5 leucine rich repeat containing G protein coupled receptor 5 increases expression ISO Chir 99021 results in increased expression of LGR5 mRNA CTD PMID:26259606 NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446
JBrowse link
G Lum lumican multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA CTD PMID:34480604 NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA CTD PMID:34480604 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions ISO Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MAP1LC3A protein] CTD PMID:30165626 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
JBrowse link
G Meox1 mesenchyme homeobox 1 multiple interactions ISO [Chir 99021 co-treated with 2,4-di-tert-butylphenol] results in decreased expression of MEOX1 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; Tretinoin inhibits the reaction [[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA] CTD PMID:31711903 PMID:36682590 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
JBrowse link
G Mesp2 mesoderm posterior bHLH transcription factor 2 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MESP2 mRNA; Tretinoin inhibits the reaction [[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MESP2 mRNA] CTD PMID:31711903 NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
JBrowse link
G Mlip muscular LMNA-interacting protein multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA CTD PMID:34480604 NCBI chr 8:77,935,087...78,204,725
Ensembl chr 8:77,935,079...78,204,254
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA CTD PMID:34480604 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of MMP2 protein] CTD PMID:34687144 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mpp1 MAGUK p55 scaffold protein 1 multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of MPP1 mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of MPP1 mRNA] CTD PMID:31711903
G Mpzl1 myelin protein zero-like 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA CTD PMID:34480604 NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
JBrowse link
G Msgn1 mesogenin 1 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of MSGN1 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of MSGN1 mRNA]; Tretinoin inhibits the reaction [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of MSGN1 mRNA]]
CTD PMID:31711903 NCBI chr 6:33,912,787...33,913,427
Ensembl chr 6:33,912,787...33,913,427
JBrowse link
G Muc1 mucin 1, cell surface associated multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC1 protein CTD PMID:35267148 NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of MUC5AC mRNA CTD PMID:35267148 NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO Chir 99021 results in increased expression of MYC protein CTD PMID:25897075 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Myl4 myosin, light chain 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA CTD PMID:34480604 NCBI chr10:89,449,456...89,485,365
Ensembl chr10:89,449,443...89,485,363
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions ISO Chir 99021 affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Chir 99021 affects the reaction [NAMPT protein affects the expression of CTNNB1 protein] CTD PMID:32005247 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Nanog Nanog homeobox decreases expression
multiple interactions
ISO Chir 99021 results in decreased expression of NANOG mRNA
[Chir 99021 co-treated with 2,4-di-tert-butylphenol] results in increased expression of NANOG mRNA
CTD PMID:31711903 PMID:36682590 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
JBrowse link
G Nes nestin multiple interactions ISO [2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide co-treated with SU 5402 co-treated with Chir 99021] results in decreased expression of NES mRNA CTD PMID:20865013 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
JBrowse link
G Neurog2 neurogenin 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NEUROG2 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of NEUROG2 mRNA CTD PMID:31711903 PMID:34480604 NCBI chr 2:216,092,709...216,095,276
Ensembl chr 2:216,093,363...216,094,154
JBrowse link
G Nkx2-1 NK2 homeobox 1 multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of NKX2-1 mRNA CTD PMID:35267148 NCBI chr 6:73,996,601...74,001,483
Ensembl chr 6:73,996,601...73,999,791
JBrowse link
G Nodal nodal growth differentiation factor multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of NODAL mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of NODAL mRNA] CTD PMID:31711903 NCBI chr20:29,368,436...29,376,837
Ensembl chr20:29,368,436...29,376,837
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA CTD PMID:34480604 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Chir 99021 binds to and results in increased activity of NR1I2 protein CTD PMID:26259606 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA CTD PMID:34480604 NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA CTD PMID:34480604 NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
JBrowse link
G Nrf1 nuclear respiratory factor 1 decreases expression ISO Chir 99021 results in decreased expression of NRF1 mRNA CTD PMID:29883716 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Olig2 oligodendrocyte transcription factor 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA CTD PMID:34480604 NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
JBrowse link
G Olig3 oligodendrocyte transcription factor 3 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of OLIG3 mRNA CTD PMID:31711903 NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149
JBrowse link
G Otx2 orthodenticle homeobox 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA CTD PMID:34480604 NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416
JBrowse link
G Pax3 paired box 3 multiple interactions ISO [Chir 99021 co-treated with 2,4-di-tert-butylphenol] results in decreased expression of PAX3 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of PAX3 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA CTD PMID:31711903 PMID:36682590 NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
JBrowse link
G Pax6 paired box 6 multiple interactions
increases expression
ISO [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] promotes the reaction [Chir 99021 results in increased expression of PAX6 mRNA] CTD PMID:31711903 NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
JBrowse link
G Pde1a phosphodiesterase 1A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA CTD PMID:34480604 NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
JBrowse link
G Perm1 PPARGC1 and ESRR induced regulator, muscle 1 increases expression ISO Chir 99021 results in increased expression of PERM1 mRNA CTD PMID:29883716 NCBI chr 5:166,800,030...166,805,323
Ensembl chr 5:166,800,030...166,805,323
JBrowse link
G Pln phospholamban multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA CTD PMID:34480604 NCBI chr20:32,629,537...32,639,559 JBrowse link
G Pou5f1 POU class 5 homeobox 1 decreases expression
multiple interactions
ISO Chir 99021 results in decreased expression of POU5F1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [Chir 99021 co-treated with 2,4-di-tert-butylphenol] results in increased expression of POU5F1 mRNA
CTD PMID:31711903 PMID:34480604 PMID:36682590 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases expression ISO Chir 99021 results in decreased expression of PPARA mRNA CTD PMID:29883716 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta decreases expression ISO Chir 99021 results in decreased expression of PPARD mRNA CTD PMID:29883716 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of PPARG mRNA CTD PMID:35267148 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions
increases expression
ISO Chir 99021 promotes the reaction [GSK3B protein affects the expression of PPARGC1A protein]
Chir 99021 results in increased expression of PPARGC1A mRNA; Chir 99021 results in increased expression of PPARGC1A protein
CTD PMID:29883716 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RARA mRNA CTD PMID:34480604 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
JBrowse link
G Rbm20 RNA binding motif protein 20 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA CTD PMID:34480604 NCBI chr 1:252,683,760...252,907,465
Ensembl chr 1:252,683,771...252,886,060
JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 increases expression ISO Chir 99021 results in increased expression of RICTOR protein CTD PMID:25897075 NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
JBrowse link
G Rrad RRAD, Ras related glycolysis inhibitor and calcium channel regulator multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA CTD PMID:34480604 NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO Chir 99021 results in increased expression of RUNX2 mRNA CTD PMID:32220932 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA CTD PMID:34480604 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Scn2a sodium voltage-gated channel alpha subunit 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA CTD PMID:34480604 NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214
JBrowse link
G Sema3c semaphorin 3C multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA CTD PMID:34480604 NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534
JBrowse link
G Serpina1 serpin family A member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA CTD PMID:34480604 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
JBrowse link
G Sfrp2 secreted frizzled-related protein 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA CTD PMID:34480604 NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
JBrowse link
G Sftpc surfactant protein C multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SFTPC mRNA CTD PMID:35267148 NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
JBrowse link
G Sh3bp5 SH3-domain binding protein 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA CTD PMID:34480604 NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA CTD PMID:34480604 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of SNAI1 protein] CTD PMID:34687144 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
JBrowse link
G Sox1 SRY-box transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA CTD PMID:34480604 NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762
JBrowse link
G Sox17 SRY-box transcription factor 17 multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Chir 99021 results in increased expression of SOX17 mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in increased expression of SOX17 mRNA] CTD PMID:31711903 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228
JBrowse link
G Sox2 SRY-box transcription factor 2 decreases expression
multiple interactions
ISO Chir 99021 results in decreased expression of SOX2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] inhibits the reaction [Chir 99021 results in decreased expression of SOX2 mRNA]; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA
CTD PMID:31711903 PMID:34480604 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Chir 99021 results in decreased expression of SOX9 mRNA
[Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of SOX9 mRNA
CTD PMID:32220932 PMID:35267148 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Sp7 Sp7 transcription factor increases expression
affects localization
ISO Chir 99021 results in increased expression of SP7 mRNA
Chir 99021 affects the localization of SP7 protein
CTD PMID:32220932 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
JBrowse link
G Sptssb serine palmitoyltransferase, small subunit B multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA CTD PMID:34480604 NCBI chr 2:154,133,728...154,162,127
Ensembl chr 2:154,133,733...154,163,120
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SQSTM1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA
CTD PMID:30165626 PMID:34480604 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srxn1 sulfiredoxin 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA CTD PMID:34480604 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Stmn2 stathmin 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA CTD PMID:34480604 NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
JBrowse link
G Syp synaptophysin multiple interactions ISO [2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide co-treated with SU 5402 co-treated with Chir 99021] results in decreased expression of SYP mRNA CTD PMID:20865013 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745
JBrowse link
G Tbx1 T-box transcription factor 1 multiple interactions
increases expression
ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of BRACHYURY mRNA]; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of BRACHYURY mRNA CTD PMID:31711903 NCBI chr11:82,409,275...82,419,058
Ensembl chr11:82,409,275...82,418,380
JBrowse link
G Tbx2 T-box transcription factor 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA CTD PMID:34480604 NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
JBrowse link
G Tbx6 T-box transcription factor 6 increases expression
multiple interactions
ISO Chir 99021 results in increased expression of TBX6 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of TBX6 mRNA]; [Chir 99021 co-treated with 2,4-di-tert-butylphenol] results in decreased expression of TBX6 mRNA; Tretinoin inhibits the reaction [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of TBX6 mRNA]]
CTD PMID:31711903 PMID:36682590 NCBI chr 1:181,387,851...181,392,762
Ensembl chr 1:181,388,684...181,392,593
JBrowse link
G Tcf15 transcription factor 15 multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of TCF15 mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCF15 mRNA CTD PMID:31711903 NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766
JBrowse link
G Tf transferrin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA CTD PMID:34480604 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA CTD PMID:34480604 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
JBrowse link
G Tfap2b transcription factor AP-2 beta multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2B mRNA CTD PMID:34480604 NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520
JBrowse link
G Tfeb transcription factor EB multiple interactions ISO Chir 99021 affects the reaction [1-Methyl-4-phenylpyridinium affects the localization of TFEB protein]; Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium promotes the reaction [GSK3B protein binds to TFEB protein]]; Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium promotes the reaction [YWHAQ protein binds to TFEB protein]] CTD PMID:30165626 NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
JBrowse link
G Tm4sf4 transmembrane 4 L six family member 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA CTD PMID:34480604 NCBI chr 2:141,570,321...141,621,263
Ensembl chr 2:141,481,902...141,621,200
JBrowse link
G Trpc3 transient receptor potential cation channel, subfamily C, member 3 multiple interactions EXP Chir 99021 promotes the reaction [Ketamine results in decreased expression of TRPC3 protein] CTD PMID:36334642 NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
JBrowse link
G Ttf1 transcription termination factor 1 multiple interactions ISO [Chir 99021 co-treated with BMP4 protein co-treated with FGF10 protein co-treated with FGF7 protein co-treated with Tretinoin] results in increased expression of TTF1 protein CTD PMID:35267148 NCBI chr 3:12,384,626...12,409,257
Ensembl chr 3:12,384,655...12,409,257
JBrowse link
G Ttr transthyretin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA CTD PMID:34480604 NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide co-treated with SU 5402 co-treated with Chir 99021] results in decreased expression of TUBB3 mRNA CTD PMID:20865013 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA CTD PMID:34480604 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Ugt2a3 UDP glucuronosyltransferase family 2 member A3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA CTD PMID:34480604 NCBI chr14:20,572,793...20,590,795
Ensembl chr14:20,572,808...20,590,729
JBrowse link
G Uncx UNC homeobox multiple interactions ISO [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNCX mRNA; Tretinoin inhibits the reaction [[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNCX mRNA] CTD PMID:31711903 NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA CTD PMID:34480604 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vdr vitamin D receptor decreases expression EXP Chir 99021 results in decreased expression of VDR mRNA; Chir 99021 results in decreased expression of VDR protein CTD PMID:34283317 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
G Vgll1 vestigial-like family member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA CTD PMID:34480604 NCBI chr  X:134,979,657...134,996,007 JBrowse link
G Vim vimentin multiple interactions ISO Chir 99021 inhibits the reaction [AHR protein results in decreased expression of VIM protein]; Chir 99021 inhibits the reaction [SC-66 compound results in decreased expression of VIM protein] CTD PMID:27752740 PMID:34687144 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
G Vtn vitronectin multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA CTD PMID:34480604 NCBI chr10:63,394,732...63,397,812
Ensembl chr10:63,394,719...63,397,810
JBrowse link
G Wnt3a Wnt family member 3A increases expression
multiple interactions
ISO Chir 99021 results in increased expression of WNT3A mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [Chir 99021 results in increased expression of WNT3A mRNA]; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of WNT3A mRNA
CTD PMID:31711903 PMID:34480604 NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
JBrowse link
G Wnt5a Wnt family member 5A increases expression
multiple interactions
ISO Chir 99021 results in increased expression of WNT5A mRNA
[Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of WNT5A mRNA; [Chir 99021 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA
CTD PMID:31711903 NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
JBrowse link
G Ywhaq tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta multiple interactions ISO Chir 99021 inhibits the reaction [1-Methyl-4-phenylpyridinium promotes the reaction [YWHAQ protein binds to TFEB protein]] CTD PMID:30165626 NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
JBrowse link
G Zfand2a zinc finger AN1-type containing 2A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
JBrowse link
CHIR-98014 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nanog Nanog homeobox decreases expression ISO Chir 98014 results in decreased expression of NANOG mRNA CTD PMID:22723015 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
JBrowse link
G Otx2 orthodenticle homeobox 2 decreases expression ISO Chir 98014 results in decreased expression of OTX2 mRNA CTD PMID:22723015 NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416
JBrowse link
G Pax6 paired box 6 decreases expression ISO Chir 98014 results in decreased expression of PAX6 mRNA CTD PMID:22723015 NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
JBrowse link
CMP-N-acetyl-beta-neuraminic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cmas cytidine monophosphate N-acetylneuraminic acid synthetase affects abundance ISO CMAS protein affects the abundance of Cytidine Monophosphate N-Acetylneuraminic Acid CTD PMID:27380425 NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
JBrowse link
co-trimoxazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ins2 insulin 2 increases secretion ISO Trimethoprim, Sulfamethoxazole Drug Combination results in increased secretion of INS protein modified form CTD PMID:14714756 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
copanlisib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO copanlisib results in decreased phosphorylation of AKT1 protein CTD PMID:31445927 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Fas Fas cell surface death receptor affects response to substance ISO copanlisib affects the susceptibility to FAS protein CTD PMID:31445927 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Tnf tumor necrosis factor increases response to substance ISO copanlisib results in increased susceptibility to TNF protein CTD PMID:31445927 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
CTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions EXP Cytidine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G App amyloid beta precursor protein increases secretion ISO Cytidine Triphosphate results in increased secretion of APP protein modified form CTD PMID:22906069 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G P2rx1 purinergic receptor P2X 1 affects binding EXP CTP binds to P2rx1 protein RGD PMID:12237343 RGD:727431 NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
JBrowse link
G P2rx5 purinergic receptor P2X 5 affects transport EXP CTP affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
JBrowse link
cyprodinil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions
increases activity
decreases expression
affects localization
ISO
EXP
cyprodinil binds to and results in increased activity of AHR protein
cyprodinil results in increased activity of AHR protein
cyprodinil results in decreased expression of AHR protein
AHR protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein]
cyprodinil affects the localization of AHR protein
CTD PMID:23228475 PMID:23436777 PMID:28728110 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein
CTD PMID:31939705 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
JBrowse link
G Anxa10 annexin A10 increases expression ISO cyprodinil results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions
ISO cyprodinil binds to APP protein modified form
[APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to cyprodinil; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil]
CTD PMID:31939705 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Ar androgen receptor affects binding
increases activity
multiple interactions
increases expression
ISO cyprodinil binds to AR protein
cyprodinil results in increased activity of AR protein
cyprodinil inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; cyprodinil inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]
cyprodinil results in increased expression of AR mRNA
CTD PMID:21310686 PMID:23436777 PMID:28728110 PMID:28803809 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arg1 arginase 1 decreases expression ISO cyprodinil results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator multiple interactions ISO ARNT protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein] CTD PMID:23228475 NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of BACE1 protein CTD PMID:31939705 NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
ISO cyprodinil results in increased expression of CASP3 mRNA
[pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of CASP3 mRNA
CTD PMID:22880100 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO fulvestrant inhibits the reaction [cyprodinil results in increased expression of CCND1 protein] CTD PMID:26344002 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccne1 cyclin E1 increases expression
multiple interactions
ISO cyprodinil results in increased expression of CCNE1 protein
fulvestrant inhibits the reaction [cyprodinil results in increased expression of CCNE1 protein]
CTD PMID:26344002 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein CTD PMID:34503147 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Ctsd cathepsin D increases expression
multiple interactions
ISO cyprodinil results in increased expression of CTSD protein
fulvestrant inhibits the reaction [cyprodinil results in increased expression of CTSD protein]
CTD PMID:26344002 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]
cyprodinil results in increased expression of CYP1A1 mRNA; cyprodinil results in increased expression of CYP1A1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein]; ARNT protein affects the reaction [cyprodinil results in increased expression of CYP1A1 protein]
CTD PMID:23228475 PMID:32194361 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases expression ISO cyprodinil results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA CTD PMID:25028461 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression ISO cyprodinil results in decreased expression of CYP7A1 mRNA; cyprodinil results in decreased expression of CYP7A1 protein CTD PMID:32194361 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G Esr1 estrogen receptor 1 affects binding
increases activity
ISO
EXP
cyprodinil binds to ESR1 protein
cyprodinil results in increased activity of ESR1 protein
CTD PMID:27999363 PMID:33352482 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO cyprodinil results in decreased expression of G6PC1 mRNA CTD PMID:32194361 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
CTD PMID:31939705 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Gpx1 glutathione peroxidase 1 affects expression
multiple interactions
ISO cyprodinil affects the expression of GPX1 mRNA
[pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of GPX1 mRNA
CTD PMID:22880100 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G H2ax H2A.X variant histone increases phosphorylation
multiple interactions
ISO cyprodinil results in increased phosphorylation of H2AX protein
[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein
CTD PMID:22389207 PMID:34503147 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein] CTD PMID:31939705 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein] CTD PMID:31939705 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO cyprodinil results in increased phosphorylation of MAPK1 protein CTD PMID:23228475 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO cyprodinil results in increased phosphorylation of MAPK3 protein CTD PMID:23228475 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
ISO [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein
cyprodinil results in increased activity of NR1I2 protein
CTD PMID:25028461 PMID:28728110 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nrf1 nuclear respiratory factor 1 increases expression ISO cyprodinil results in increased expression of NRF1 mRNA CTD PMID:33352482 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression ISO cyprodinil results in increased expression of PCNA protein CTD PMID:26344002 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [cyprodinil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 CTD PMID:26359731 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Tff1 trefoil factor 1 increases expression ISO cyprodinil results in increased expression of TFF1 mRNA CTD PMID:33352482 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein CTD PMID:34503147 NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
JBrowse link
cytarabine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects response to substance
increases expression
ISO ABCB1 protein affects the susceptibility to Cytarabine
Cytarabine results in increased expression of ABCB1
CTD PMID:11573427 PMID:17852453 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 protein affects the susceptibility to Cytarabine CTD PMID:17852453 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Acap1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 increases expression ISO Cytarabine results in increased expression of ACAP1 mRNA CTD PMID:19194470 NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472
JBrowse link
G Ache acetylcholinesterase multiple interactions
increases activity
EXP betanin inhibits the reaction [Cytarabine results in increased activity of ACHE protein]; thymoquinone inhibits the reaction [Cytarabine results in increased activity of ACHE protein]; Vitamin D inhibits the reaction [Cytarabine results in increased activity of ACHE protein] CTD PMID:36419121 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Acta1 actin, alpha 1, skeletal muscle increases expression ISO Cytarabine results in increased expression of ACTA1 mRNA CTD PMID:21198554 NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
JBrowse link
G Actc1 actin, alpha, cardiac muscle 1 decreases expression ISO Cytarabine results in decreased expression of ACTC1 mRNA CTD PMID:21198554 NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
JBrowse link
G Adam19 ADAM metallopeptidase domain 19 decreases expression ISO Cytarabine results in decreased expression of ADAM19 mRNA CTD PMID:21198554 NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 decreases expression ISO Cytarabine results in decreased expression of ADAMTS1 mRNA CTD PMID:21198554 NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
JBrowse link
G Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 decreases expression ISO Cytarabine results in decreased expression of ADAMTS9 mRNA CTD PMID:21198554 NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
JBrowse link
G Adgrb3 adhesion G protein-coupled receptor B3 increases expression ISO Cytarabine results in increased expression of ADGRB3 mRNA CTD PMID:21198554 NCBI chr 9:27,421,168...28,148,979
Ensembl chr 9:27,421,168...28,148,855
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO [2,2-bis(4-glycidyloxyphenyl)propane co-treated with Cytarabine] results in decreased expression of ADIPOQ mRNA CTD PMID:23264188 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Afap1l2 actin filament associated protein 1-like 2 decreases expression ISO Cytarabine results in decreased expression of AFAP1L2 mRNA CTD PMID:21198554 NCBI chr 1:255,964,238...256,060,828
Ensembl chr 1:255,964,238...256,060,820
JBrowse link
G Ahi1 Abelson helper integration site 1 increases expression ISO Cytarabine results in increased expression of AHI1 protein alternative form CTD PMID:19379585 NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
JBrowse link
G Ahnak AHNAK nucleoprotein decreases expression ISO Cytarabine results in decreased expression of AHNAK mRNA CTD PMID:21198554 NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
JBrowse link
G Aif1l allograft inflammatory factor 1-like increases expression ISO Cytarabine results in increased expression of AIF1L mRNA CTD PMID:21198554 NCBI chr 3:15,229,476...15,254,033
Ensembl chr 3:15,229,524...15,254,023
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 decreases expression ISO Cytarabine results in decreased expression of AKR1B15 mRNA CTD PMID:21198554 NCBI chr 4:62,997,241...63,009,815
Ensembl chr 4:62,997,161...63,010,097
JBrowse link
G Alpk2 alpha-kinase 2 decreases expression ISO Cytarabine results in decreased expression of ALPK2 mRNA CTD PMID:21198554 NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258
JBrowse link
G Angptl2 angiopoietin-like 2 decreases expression ISO Cytarabine results in decreased expression of ANGPTL2 mRNA CTD PMID:21198554 NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
JBrowse link
G Anks1a ankyrin repeat and sterile alpha motif domain containing 1A decreases expression ISO Cytarabine results in decreased expression of ANKS1A mRNA CTD PMID:21198554 NCBI chr20:5,963,658...6,117,139
Ensembl chr20:5,963,678...6,117,148
JBrowse link
G Ano8 anoctamin 8 increases expression ISO Cytarabine results in increased expression of ANO8 mRNA CTD PMID:21198554 NCBI chr16:18,163,853...18,173,248
Ensembl chr16:18,163,843...18,173,545
JBrowse link
G Anxa2 annexin A2 decreases expression
increases expression
ISO Cytarabine results in decreased expression of ANXA2 mRNA
Cytarabine results in increased expression of ANXA2 mRNA
CTD PMID:12165291 PMID:21198554 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
JBrowse link
G Anxa6 annexin A6 decreases expression ISO Cytarabine results in decreased expression of ANXA6 mRNA CTD PMID:21198554 NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
JBrowse link
G Anxa8 annexin A8 decreases expression ISO Cytarabine results in decreased expression of ANXA8 mRNA CTD PMID:21198554 NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
JBrowse link
G Aplnr apelin receptor decreases expression ISO Cytarabine results in decreased expression of APLNR mRNA CTD PMID:21198554 NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
JBrowse link
G Aqp1 aquaporin 1 decreases expression ISO Cytarabine results in decreased expression of AQP1 mRNA CTD PMID:21198554 NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
JBrowse link
G Arg2 arginase 2 decreases expression ISO Cytarabine results in decreased expression of ARG2 mRNA CTD PMID:21198554 NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
JBrowse link
G Arhgap44 Rho GTPase activating protein 44 decreases expression ISO Cytarabine results in decreased expression of ARHGAP44 mRNA CTD PMID:21198554 NCBI chr10:49,655,583...49,822,876
Ensembl chr10:49,655,584...49,824,297
JBrowse link
G Arhgdib Rho GDP dissociation inhibitor beta decreases expression ISO Cytarabine results in decreased expression of ARHGDIB mRNA CTD PMID:21198554 NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
JBrowse link
G Arhgef3 Rho guanine nucleotide exchange factor 3 decreases expression ISO Cytarabine results in decreased expression of ARHGEF3 mRNA CTD PMID:21198554 NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945
JBrowse link
G Arl6ip5 ADP-ribosylation factor like GTPase 6 interacting protein 5 increases expression ISO Cytarabine results in increased expression of ARL6IP5 protein CTD PMID:16430862 NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
JBrowse link
G Art4 ADP-ribosyltransferase 4 decreases expression ISO Cytarabine results in decreased expression of ART4 mRNA CTD PMID:21198554 NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665
JBrowse link
G Art5 ADP-ribosyltransferase 5 decreases expression ISO Cytarabine results in decreased expression of ART5 mRNA CTD PMID:21198554 NCBI chr 1:156,473,362...156,483,324
Ensembl chr 1:156,473,362...156,483,324
JBrowse link
G Atf3 activating transcription factor 3 decreases expression
increases expression
ISO Cytarabine results in decreased expression of ATF3 mRNA
Cytarabine results in increased expression of ATF3 mRNA
CTD PMID:21198554 PMID:33770205 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atl1 atlastin GTPase 1 increases expression ISO Cytarabine results in increased expression of ATL1 mRNA CTD PMID:21198554 NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
JBrowse link
G Atn1 atrophin 1 increases expression ISO Cytarabine results in increased expression of ATN1 mRNA CTD PMID:21198554 NCBI chr 4:157,554,287...157,568,092
Ensembl chr 4:157,551,276...157,568,132
JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) increases expression ISO Cytarabine results in increased expression of ATP10D mRNA CTD PMID:19194470 NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564
JBrowse link
G Atp1b1 ATPase Na+/K+ transporting subunit beta 1 decreases expression ISO Cytarabine results in decreased expression of ATP1B1 mRNA CTD PMID:21198554 NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
JBrowse link
G Atp7b ATPase copper transporting beta decreases expression ISO Cytarabine results in decreased expression of ATP7B mRNA CTD PMID:21198554 NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
JBrowse link
G Atp8b4 ATPase phospholipid transporting 8B4 (putative) decreases expression ISO Cytarabine results in decreased expression of ATP8B4 mRNA CTD PMID:21198554 NCBI chr 3:113,554,979...113,757,635
Ensembl chr 3:113,556,192...113,757,225
JBrowse link
G Axl Axl receptor tyrosine kinase decreases expression ISO Cytarabine results in decreased expression of AXL mRNA CTD PMID:21198554 NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
JBrowse link
G B2m beta-2 microglobulin increases expression ISO Cytarabine results in increased expression of B2M protein CTD PMID:11096300 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
JBrowse link
G B4galt7 beta-1,4-galactosyltransferase 7 decreases expression ISO Cytarabine results in decreased expression of B4GALT7 mRNA CTD PMID:21198554 NCBI chr17:9,018,514...9,027,591
Ensembl chr17:9,018,935...9,027,573
JBrowse link
G Bag3 BAG cochaperone 3 decreases expression ISO Cytarabine results in decreased expression of BAG3 mRNA CTD PMID:21198554 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Baiap2l1 BAR/IMD domain containing adaptor protein 2 like 1 decreases expression ISO Cytarabine results in decreased expression of BAIAP2L1 mRNA CTD PMID:21198554 NCBI chr12:10,250,434...10,339,937
Ensembl chr12:10,250,473...10,339,928
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP
ISO
Cytarabine results in increased expression of BAX mRNA
[Cytarabine results in increased expression of TP53 protein] which results in increased expression of BAX protein; Cytarabine results in increased expression of BAX protein
CTD PMID:10200513 PMID:15203180 PMID:16129037 PMID:17490525 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 affects response to substance ISO BBC3 protein affects the susceptibility to Cytarabine CTD PMID:20477944 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcar3 BCAR3 adaptor protein, NSP family member decreases expression ISO Cytarabine results in decreased expression of BCAR3 mRNA CTD PMID:21198554 NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
JBrowse link
G Bche butyrylcholinesterase increases activity
multiple interactions
EXP Cytarabine results in increased activity of BCHE protein
betanin inhibits the reaction [Cytarabine results in increased activity of BCHE protein]
CTD PMID:36419121 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases degradation
decreases expression
ISO [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein]
Cytarabine results in increased degradation of BCL2 protein
Cytarabine results in decreased expression of BCL2 mRNA; Cytarabine results in decreased expression of BCL2 protein
CTD PMID:1450413 PMID:8840993 PMID:9295281 PMID:12853972 PMID:16129037 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO BCL2L1 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein] CTD PMID:8840993 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bhlhe22 basic helix-loop-helix family, member e22 increases expression ISO Cytarabine results in increased expression of BHLHE22 mRNA CTD PMID:21198554 NCBI chr 2:100,486,400...100,489,510
Ensembl chr 2:100,486,400...100,489,510
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Cytarabine co-treated with TNFSF10 protein] results in increased expression of BID protein CTD PMID:12780785 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Bin2 bridging integrator 2 increases expression ISO Cytarabine results in increased expression of BIN2 mRNA CTD PMID:19194470 NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285
JBrowse link
G Bmp4 bone morphogenetic protein 4 decreases expression ISO Cytarabine results in decreased expression of BMP4 mRNA CTD PMID:21198554 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
JBrowse link
G Bmp5 bone morphogenetic protein 5 decreases expression ISO Cytarabine results in decreased expression of BMP5 mRNA CTD PMID:21198554 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Bnc1 basonuclin zinc finger protein 1 decreases expression ISO Cytarabine results in decreased expression of BNC1 mRNA CTD PMID:21198554 NCBI chr 1:135,917,676...135,943,333
Ensembl chr 1:135,917,687...135,943,333
JBrowse link
G Bnc2 basonuclin zinc finger protein 2 decreases expression ISO Cytarabine results in decreased expression of BNC2 mRNA CTD PMID:21198554 NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426
JBrowse link
G Bora bora, aurora kinase A activator decreases expression ISO Cytarabine results in decreased expression of BORA mRNA CTD PMID:17374387 NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
JBrowse link
G Bpnt2 3'(2'), 5'-bisphosphate nucleotidase 2 decreases expression ISO Cytarabine results in decreased expression of BPNT2 mRNA CTD PMID:21198554 NCBI chr 5:17,775,684...17,802,570
Ensembl chr 5:17,772,608...17,802,570
JBrowse link
G Brca2 BRCA2, DNA repair associated increases expression ISO Cytarabine results in increased expression of BRCA2 mRNA CTD PMID:19194470 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Bscl2 BSCL2 lipid droplet biogenesis associated, seipin increases expression ISO Cytarabine results in increased expression of BSCL2 mRNA CTD PMID:22003191 NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression ISO Cytarabine results in decreased expression of BST2 mRNA CTD PMID:21198554 NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression ISO Cytarabine results in increased expression of BTG2 mRNA CTD PMID:21382384 NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
JBrowse link
G C2cd2 C2 calcium-dependent domain containing 2 decreases expression ISO Cytarabine results in decreased expression of C2CD2 mRNA CTD PMID:21198554 NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739
JBrowse link
G C3ar1 complement C3a receptor 1 increases expression ISO Cytarabine results in increased expression of C3AR1 mRNA CTD PMID:19194470 NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
JBrowse link
G Cab39l calcium binding protein 39-like decreases expression ISO Cytarabine results in decreased expression of CAB39L mRNA CTD PMID:21198554 NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
JBrowse link
G Calb1 calbindin 1 decreases expression EXP Cytarabine results in decreased expression of CALB1 protein CTD PMID:22212197 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
JBrowse link
G Calb2 calbindin 2 decreases expression ISO Cytarabine results in decreased expression of CALB2 mRNA CTD PMID:21198554 NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
JBrowse link
G Calcr calcitonin receptor increases response to substance ISO CALCR results in increased susceptibility to Cytarabine CTD PMID:21755009 NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392
JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 increases expression ISO Cytarabine results in increased expression of CAMK2N1 mRNA CTD PMID:21198554 NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
JBrowse link
G Capn1 calpain 1 decreases expression ISO Cytarabine results in decreased expression of CAPN1 mRNA CTD PMID:21198554 NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
JBrowse link
G Car12 carbonic anhydrase 12 decreases expression ISO Cytarabine results in decreased expression of CA12 mRNA CTD PMID:21198554 NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
JBrowse link
G Carmil1 capping protein regulator and myosin 1 linker 1 decreases expression ISO Cytarabine results in decreased expression of CARMIL1 mRNA CTD PMID:21198554 NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression
ISO
EXP
[Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein
Cytarabine results in increased activity of CASP3 protein
Cytarabine results in increased expression of CASP3 protein
CTD PMID:8840993 PMID:12780785 PMID:12781215 PMID:14766721 PMID:22212197 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; Cytarabine promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Cytarabine results in increased expression of and results in increased cleavage of CASP8 protein CTD PMID:12780785 PMID:18549619 PMID:22010212 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Cavin1 caveolae associated protein 1 decreases expression ISO Cytarabine results in decreased expression of CAVIN1 mRNA CTD PMID:21198554 NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120
JBrowse link
G Cavin3 caveolae associated protein 3 decreases expression ISO Cytarabine results in decreased expression of CAVIN3 mRNA CTD PMID:21198554 NCBI chr 1:159,826,549...159,828,138
Ensembl chr 1:159,826,549...159,828,161
JBrowse link
G Ccdc102a coiled-coil domain containing 102A decreases expression ISO Cytarabine results in decreased expression of CCDC102A mRNA CTD PMID:21198554 NCBI chr19:10,102,543...10,118,657
Ensembl chr19:10,103,361...10,118,657
JBrowse link
G Ccdc112 coiled-coil domain containing 112 increases expression ISO Cytarabine results in increased expression of CCDC112 mRNA CTD PMID:21198554 NCBI chr18:38,998,139...39,032,329
Ensembl chr18:38,998,139...39,032,329
JBrowse link
G Ccdc15 coiled-coil domain containing 15 increases expression ISO Cytarabine results in increased expression of CCDC15 mRNA CTD PMID:21198554 NCBI chr 8:36,991,147...37,068,849
Ensembl chr 8:36,998,867...37,068,919
JBrowse link
G Cckbr cholecystokinin B receptor decreases expression ISO Cytarabine results in decreased expression of CCKBR mRNA CTD PMID:21198554 NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO Cytarabine results in decreased expression of CCND3 mRNA CTD PMID:21198554 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Ccne2 cyclin E2 increases expression ISO Cytarabine results in increased expression of CCNE2 mRNA CTD PMID:21198554 NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
JBrowse link
G Ccng1 cyclin G1 increases expression EXP Cytarabine results in increased expression of CCNG1 mRNA CTD PMID:14766721 PMID:15203180 NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
JBrowse link
G Cd44 CD44 molecule decreases expression ISO Cytarabine results in decreased expression of CD44 mRNA CTD PMID:21198554 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
JBrowse link
G Cd8a CD8 subunit alpha increases expression ISO Cytarabine results in increased expression of CD8A mRNA CTD PMID:19194470 NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040
JBrowse link
G Cdc42ep5 CDC42 effector protein 5 decreases expression ISO Cytarabine results in decreased expression of CDC42EP5 mRNA CTD PMID:21198554 NCBI chr 1:70,035,921...70,038,990 JBrowse link
G Cdca8 cell division cycle associated 8 decreases expression ISO Cytarabine results in decreased expression of CDCA8 mRNA CTD PMID:17374387 NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
JBrowse link
G Cdh11 cadherin 11 decreases expression ISO Cytarabine results in decreased expression of CDH11 mRNA CTD PMID:21198554 NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
JBrowse link
G Cdh3 cadherin 3 decreases expression ISO Cytarabine results in decreased expression of CDH3 mRNA CTD PMID:21198554 NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 increases expression ISO Cytarabine results in increased expression of CDK5R1 mRNA CTD PMID:33770205 NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
ISO
EXP
[fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased expression of CDKN1A protein; Caffeine inhibits the reaction [Cytarabine results in increased expression of CDKN1A protein]
Cytarabine results in increased expression of CDKN1A mRNA; Cytarabine results in increased expression of CDKN1A protein
CTD PMID:9703875 PMID:14766721 PMID:15203180 PMID:17977830 PMID:33770205 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C decreases expression ISO Cytarabine results in decreased expression of CDKN1C mRNA CTD PMID:21198554 NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta decreases expression ISO Cytarabine results in decreased expression of CEBPD mRNA CTD PMID:21198554 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Celf3 CUGBP, Elav-like family member 3 increases expression ISO Cytarabine results in increased expression of CELF3 mRNA CTD PMID:21198554 NCBI chr 2:182,116,034...182,130,163
Ensembl chr 2:182,116,073...182,130,163
JBrowse link
G Cemip cell migration inducing hyaluronidase 1 decreases expression ISO Cytarabine results in decreased expression of CEMIP mRNA CTD PMID:21198554 NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
JBrowse link
G Chat choline O-acetyltransferase increases activity EXP Cytarabine results in increased activity of CHAT protein CTD PMID:2900045 NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
JBrowse link
G Chn1 chimerin 1 decreases expression ISO Cytarabine results in decreased expression of CHN1 mRNA CTD PMID:21198554 NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 decreases expression ISO Cytarabine results in decreased expression of CITED2 mRNA CTD PMID:21198554 NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
JBrowse link
G Ckb creatine kinase B increases expression ISO Cytarabine results in increased expression of CKB mRNA CTD PMID:21198554 NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 decreases expression ISO Cytarabine results in decreased expression of CKS2 mRNA CTD PMID:17374387 NCBI chr17:13,570,611...13,575,770 JBrowse link
G Cldn15 claudin 15 decreases expression ISO Cytarabine results in decreased expression of CLDN15 mRNA CTD PMID:21198554 NCBI chr12:19,698,167...19,708,419
Ensembl chr12:19,698,337...19,706,819
JBrowse link
G Clec1b C-type lectin domain family 1, member B decreases expression ISO Cytarabine results in decreased expression of CLEC1B mRNA CTD PMID:21198554 NCBI chr 4:162,847,978...162,856,291
Ensembl chr 4:162,848,010...162,856,291
JBrowse link
G Cnih2 cornichon family AMPA receptor auxiliary protein 2 increases expression ISO Cytarabine results in increased expression of CNIH2 mRNA CTD PMID:21198554 NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089
JBrowse link
G Cnr1 cannabinoid receptor 1 increases expression ISO Cytarabine results in increased expression of CNR1 mRNA CTD PMID:21198554 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cntfr ciliary neurotrophic factor receptor increases expression ISO Cytarabine results in increased expression of CNTFR mRNA CTD PMID:21198554 NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392
JBrowse link
G Cntrl centriolin increases expression ISO Cytarabine results in increased expression of CNTRL mRNA CTD PMID:21198554 NCBI chr 3:18,428,147...18,500,362
Ensembl chr 3:18,428,103...18,500,380
JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 decreases expression ISO Cytarabine results in decreased expression of COBLL1 mRNA CTD PMID:21198554 NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
JBrowse link
G Col13a1 collagen type XIII alpha 1 chain decreases expression ISO Cytarabine results in decreased expression of COL13A1 mRNA CTD PMID:21198554 NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
JBrowse link
G Col18a1 collagen type XVIII alpha 1 chain decreases expression ISO Cytarabine results in decreased expression of COL18A1 mRNA CTD PMID:21198554 NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression ISO Cytarabine results in decreased expression of COL1A1 mRNA CTD PMID:21198554 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain decreases expression ISO Cytarabine results in decreased expression of COL1A2 mRNA CTD PMID:21198554 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Col3a1 collagen type III alpha 1 chain decreases expression ISO Cytarabine results in decreased expression of COL3A1 mRNA CTD PMID:21198554 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Col5a1 collagen type V alpha 1 chain decreases expression ISO Cytarabine results in decreased expression of COL5A1 mRNA CTD PMID:21198554 NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
JBrowse link
G Col5a2 collagen type V alpha 2 chain decreases expression ISO Cytarabine results in decreased expression of COL5A2 mRNA CTD PMID:21198554 NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
JBrowse link
G Col6a2 collagen type VI alpha 2 chain decreases expression ISO Cytarabine results in decreased expression of COL6A2 mRNA CTD PMID:21198554 NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
JBrowse link
G Col6a3 collagen type VI alpha 3 chain decreases expression ISO Cytarabine results in decreased expression of COL6A3 mRNA CTD PMID:21198554 NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
JBrowse link
G Col9a1 collagen type IX alpha 1 chain increases expression ISO Cytarabine results in increased expression of COL9A1 mRNA CTD PMID:21198554 NCBI chr 9:26,585,034...26,668,222
Ensembl chr 9:26,585,034...26,668,213
JBrowse link
G Colec12 collectin sub-family member 12 decreases expression ISO Cytarabine results in decreased expression of COLEC12 mRNA CTD PMID:21198554 NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
JBrowse link
G Cpz carboxypeptidase Z decreases expression ISO Cytarabine results in decreased expression of CPZ mRNA CTD PMID:21198554 NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 increases expression ISO Cytarabine results in increased expression of CRABP1 mRNA CTD PMID:21198554 NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
JBrowse link
G Crispld2 cysteine-rich secretory protein LCCL domain containing 2 decreases expression ISO Cytarabine results in decreased expression of CRISPLD2 mRNA CTD PMID:21198554 NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
JBrowse link
G Crtap cartilage associated protein decreases expression ISO Cytarabine results in decreased expression of CRTAP mRNA CTD PMID:21198554 NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
JBrowse link
G Cryab crystallin, alpha B decreases expression ISO Cytarabine results in decreased expression of CRYAB mRNA CTD PMID:21198554 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Csnk1d casein kinase 1, delta decreases expression ISO Cytarabine results in decreased expression of CSNK1D mRNA CTD PMID:21198554 NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
JBrowse link
G Csrnp1 cysteine and serine rich nuclear protein 1 decreases expression ISO Cytarabine results in decreased expression of AXUD1 mRNA CTD PMID:21198554 NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
JBrowse link
G Ctsh cathepsin H decreases expression ISO Cytarabine results in decreased expression of CTSH mRNA CTD PMID:21198554 NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
JBrowse link
G Ctsl cathepsin L decreases expression ISO Cytarabine results in decreased expression of CTSL mRNA CTD PMID:21198554 NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 increases expression ISO Cytarabine results in increased expression of CXCR4 mRNA CTD PMID:19194470 PMID:21198554 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Cyb5a cytochrome b5 type A decreases expression ISO Cytarabine results in decreased expression of CYB5A mRNA CTD PMID:21198554 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535
JBrowse link
G Cyb5d1 cytochrome b5 domain containing 1 decreases expression ISO Cytarabine results in decreased expression of CYB5D1 mRNA CTD PMID:21198554 NCBI chr10:54,113,428...54,117,744
Ensembl chr10:54,113,438...54,117,911
JBrowse link
G Cyb5r2 cytochrome b5 reductase 2 decreases expression ISO Cytarabine results in decreased expression of CYB5R2 mRNA CTD PMID:21198554 NCBI chr 1:161,655,862...161,664,359
Ensembl chr 1:161,655,864...161,664,097
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Cytarabine results in decreased expression of CYBA mRNA CTD PMID:21198554 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression ISO Cytarabine results in decreased expression of CYP27A1 mRNA CTD PMID:21198554 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
JBrowse link
G Cyp4x1 cytochrome P450, family 4, subfamily x, polypeptide 1 decreases expression ISO Cytarabine results in decreased expression of CYP4X1 mRNA CTD PMID:21198554 NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779
JBrowse link
G Cyth1 cytohesin 1 increases expression ISO Cytarabine results in increased expression of CYTH1 mRNA CTD PMID:19194470 NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
JBrowse link
G Dab2 DAB adaptor protein 2 decreases expression ISO Cytarabine results in decreased expression of DAB2 mRNA CTD PMID:21198554 NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
JBrowse link
G Dalrd3 DALR anticodon binding domain containing 3 decreases expression ISO Cytarabine results in decreased expression of DALRD3 mRNA CTD PMID:19194470 NCBI chr 8:109,264,100...109,268,560
Ensembl chr 8:109,265,676...109,268,568
JBrowse link
G Dbn1 drebrin 1 decreases expression ISO Cytarabine results in decreased expression of DBN1 mRNA CTD PMID:19194470 NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
JBrowse link
G Dck deoxycytidine kinase affects binding
decreases response to substance
ISO
EXP
Cytarabine binds to DCK protein
Cytarabine binds to Dck protein
DCK gene polymorphism results in decreased susceptibility to Cytarabine
CTD
RGD
PMID:1318170 PMID:18381442 PMID:7532033 RGD:2300399 NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
JBrowse link
G Dcn decorin decreases expression ISO Cytarabine results in decreased expression of DCN mRNA CTD PMID:21198554 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Ddr2 discoidin domain receptor tyrosine kinase 2 decreases expression ISO Cytarabine results in decreased expression of DDR2 mRNA CTD PMID:21198554 NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
JBrowse link
G Dennd1a DENN domain containing 1A increases expression ISO Cytarabine results in increased expression of DENND1A mRNA CTD PMID:19194470 NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
JBrowse link
G Deptor DEP domain containing MTOR-interacting protein decreases expression ISO Cytarabine results in decreased expression of DEPTOR mRNA CTD PMID:21198554 NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
JBrowse link
G Dhcr24 24-dehydrocholesterol reductase decreases expression ISO Cytarabine results in decreased expression of DHCR24 mRNA CTD PMID:21198554 NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
JBrowse link
G Dhfr dihydrofolate reductase increases expression ISO Cytarabine results in increased expression of DHFR mRNA CTD PMID:19194470 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Disp3 dispatched RND transporter family member 3 increases expression ISO Cytarabine results in increased expression of DISP3 mRNA CTD PMID:21198554 NCBI chr 5:158,672,015...158,720,806
Ensembl chr 5:158,672,015...158,720,806
JBrowse link
G Dnah2 dynein, axonemal, heavy chain 2 decreases expression ISO Cytarabine results in decreased expression of DNAH2 mRNA CTD PMID:21198554 NCBI chr10:54,142,648...54,268,901
Ensembl chr10:54,142,737...54,267,298
JBrowse link
G Dok4 docking protein 4 decreases expression ISO Cytarabine results in decreased expression of DOK4 mRNA CTD PMID:21198554 NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
JBrowse link
G Dsc2 desmocollin 2 decreases expression ISO Cytarabine results in decreased expression of DSC2 mRNA CTD PMID:21198554 NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
JBrowse link
G Dsc3 desmocollin 3 decreases expression ISO Cytarabine results in decreased expression of DSC3 mRNA CTD PMID:21198554 NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Cytarabine results in decreased expression of DUSP4 mRNA CTD PMID:19194470 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
JBrowse link
G E2f8 E2F transcription factor 8 increases expression ISO Cytarabine results in increased expression of E2F8 mRNA CTD PMID:33770205 NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
JBrowse link
G Edn1 endothelin 1 multiple interactions ISO EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
EDN1 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
CTD PMID:24184161 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Eef2 eukaryotic translation elongation factor 2 decreases expression ISO Cytarabine results in decreased expression of EEF2 mRNA CTD PMID:21198554 NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
JBrowse link
G Efemp2 EGF containing fibulin extracellular matrix protein 2 decreases expression ISO Cytarabine results in decreased expression of EFEMP2 mRNA CTD PMID:21198554 NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
JBrowse link
G Efhd1 EF-hand domain family, member D1 decreases expression ISO Cytarabine results in decreased expression of EFHD1 mRNA CTD PMID:21198554 NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
JBrowse link
G Efna1 ephrin A1 decreases expression ISO Cytarabine results in decreased expression of EFNA1 mRNA CTD PMID:21198554 NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Egfl6 EGF-like-domain, multiple 6 decreases expression ISO Cytarabine results in decreased expression of EGFL6 mRNA CTD PMID:21198554 NCBI chr  X:27,884,087...27,942,044
Ensembl chr  X:27,884,125...27,942,044
JBrowse link
G Egflam EGF-like, fibronectin type III and laminin G domains decreases expression ISO Cytarabine results in decreased expression of EGFLAM mRNA CTD PMID:21198554 NCBI chr 2:56,301,945...56,476,665
Ensembl chr 2:56,302,566...56,476,298
JBrowse link
G Eif4h eukaryotic translation initiation factor 4H decreases expression ISO Cytarabine results in decreased expression of EIF4H mRNA CTD PMID:21198554 NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
JBrowse link
G Eno3 enolase 3 decreases expression ISO Cytarabine results in decreased expression of ENO3 mRNA CTD PMID:21198554 NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
JBrowse link
G Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 increases expression ISO Cytarabine results in increased expression of ENTPD1 mRNA CTD PMID:19194470 NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
JBrowse link
G Exog exo/endonuclease G decreases expression ISO Cytarabine results in decreased expression of EXOG mRNA CTD PMID:21198554 NCBI chr 8:119,184,974...119,204,819
Ensembl chr 8:119,185,136...119,204,672
JBrowse link
G Ext2 exostosin glycosyltransferase 2 decreases expression ISO Cytarabine results in decreased expression of EXT2 mRNA CTD PMID:21198554 NCBI chr 3:79,665,414...79,798,077
Ensembl chr 3:79,665,415...79,798,059
JBrowse link
G Ezr ezrin decreases expression ISO Cytarabine results in decreased expression of EZR mRNA CTD PMID:21198554 NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
JBrowse link
G F2 coagulation factor II, thrombin affects expression ISO Cytarabine affects the expression of F2 protein CTD PMID:12542493 NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
JBrowse link
G Fabp7 fatty acid binding protein 7 increases expression ISO Cytarabine results in increased expression of FABP7 mRNA CTD PMID:21198554 NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
JBrowse link
G Fam111a FAM111 trypsin like peptidase A increases expression ISO Cytarabine results in increased expression of FAM111A mRNA CTD PMID:19194470 NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
JBrowse link
G Fas Fas cell surface death receptor increases expression EXP
ISO
Cytarabine results in increased expression of FAS mRNA CTD PMID:14766721 PMID:15203180 PMID:33770205 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Fbln1 fibulin 1 decreases expression ISO Cytarabine results in decreased expression of FBLN1 mRNA CTD PMID:21198554 NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
JBrowse link
G Fbxo2 F-box protein 2 decreases expression ISO Cytarabine results in decreased expression of FBXO2 mRNA CTD PMID:21198554 NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
JBrowse link
G Fcgr2a Fc gamma receptor 2A increases expression ISO Cytarabine results in increased expression of FCGR2A mRNA CTD PMID:19194470 NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
JBrowse link
G Flnc filamin C decreases expression ISO Cytarabine results in decreased expression of FLNC mRNA CTD PMID:21198554 NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 decreases expression ISO Cytarabine results in decreased expression of FLRT2 mRNA CTD PMID:21198554 NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 decreases expression ISO Cytarabine results in decreased expression of FMO1 mRNA CTD PMID:21198554 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
JBrowse link
G Fmo4 flavin containing dimethylaniline monoxygenase 4 decreases expression ISO Cytarabine results in decreased expression of FMO4 mRNA CTD PMID:21198554 NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874
JBrowse link
G Frzb frizzled-related protein decreases expression ISO Cytarabine results in decreased expression of FRZB mRNA CTD PMID:21198554 NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
JBrowse link
G Fsip1 fibrous sheath interacting protein 1 increases expression ISO Cytarabine results in increased expression of FSIP1 mRNA CTD PMID:21198554 NCBI chr 3:105,074,584...105,217,180
Ensembl chr 3:105,068,543...105,217,167
JBrowse link
G Fyb2 FYN binding protein 2 decreases expression ISO Cytarabine results in decreased expression of FYB2 mRNA CTD PMID:21198554 NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910
JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase increases expression ISO Cytarabine results in increased expression of FYN mRNA CTD PMID:21198554 NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 decreases expression ISO Cytarabine results in decreased expression of GABARAPL1 mRNA CTD PMID:21198554 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi increases expression ISO Cytarabine results in increased expression of GABRP mRNA CTD PMID:21198554 NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO Cytarabine results in increased expression of GADD45A mRNA CTD PMID:33770205 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 decreases expression ISO Cytarabine results in decreased expression of GALNT10 mRNA CTD PMID:21198554 NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
JBrowse link
G Gap43 growth associated protein 43 increases expression ISO Cytarabine results in increased expression of GAP43 mRNA CTD PMID:21198554 NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases activity
affects localization
increases response to substance
ISO Cytarabine results in decreased activity of GAPDH protein
Cytarabine affects the localization of GAPDH protein
GAPDH protein results in increased susceptibility to Cytarabine
CTD PMID:19628630 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
JBrowse link
G Gata5 GATA binding protein 5 decreases expression ISO Cytarabine results in decreased expression of GATA5 mRNA CTD PMID:21198554 NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751
JBrowse link
G Gbp4 guanylate binding protein 4 decreases expression ISO Cytarabine results in decreased expression of GBP4 mRNA CTD PMID:21198554 NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
JBrowse link
G Gca grancalcin decreases expression ISO Cytarabine results in decreased expression of GCA mRNA CTD PMID:21198554 NCBI chr 3:47,297,320...47,329,913
Ensembl chr 3:47,297,383...47,328,581
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 decreases expression ISO Cytarabine results in decreased expression of GCNT2 mRNA CTD PMID:21198554 NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
JBrowse link
G Ghr growth hormone receptor decreases expression ISO Cytarabine results in decreased expression of GHR mRNA CTD PMID:21198554 NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
JBrowse link
G Gls glutaminase decreases expression ISO Cytarabine results in decreased expression of GLS mRNA CTD PMID:21198554 NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
JBrowse link
G Gnb3 G protein subunit beta 3 decreases expression ISO Cytarabine results in decreased expression of GNB3 mRNA CTD PMID:21198554 NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173
JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 decreases expression ISO Cytarabine results in decreased expression of GPER1 mRNA CTD PMID:21198554 NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
JBrowse link
G Gpm6a glycoprotein m6a increases expression ISO Cytarabine results in increased expression of GPM6A mRNA CTD PMID:21198554 NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475
JBrowse link
G Gpr19 G protein-coupled receptor 19 increases expression ISO Cytarabine results in increased expression of GPR19 mRNA CTD PMID:21198554 NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
JBrowse link
G Gpr83 G protein-coupled receptor 83 decreases expression ISO Cytarabine results in decreased expression of GPR83 mRNA CTD PMID:21198554 NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
JBrowse link
G Gprc5c G protein-coupled receptor, class C, group 5, member C decreases expression ISO Cytarabine results in decreased expression of GPRC5C mRNA CTD PMID:21198554 NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 increases expression ISO Cytarabine results in increased expression of GRIA2 mRNA CTD PMID:21198554 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Grk5 G protein-coupled receptor kinase 5 increases expression ISO Cytarabine results in increased expression of GRK5 mRNA CTD PMID:19194470 NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701
JBrowse link
G Grpr gastrin releasing peptide receptor decreases expression ISO Cytarabine results in decreased expression of GRPR mRNA CTD PMID:21198554 NCBI chr  X:30,998,425...31,038,442
Ensembl chr  X:30,998,416...31,038,442
JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing increases expression ISO Cytarabine results in increased expression of GSTCD mRNA CTD PMID:19194470 NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857
JBrowse link
G Gstm1 glutathione S-transferase mu 1 affects response to substance ISO GSTM1 gene polymorphism affects the susceptibility to Cytarabine CTD PMID:15713801 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
JBrowse link
G Gtpbp1 GTP binding protein 1 increases expression ISO Cytarabine results in increased expression of GTPBP1 mRNA CTD PMID:19194470 NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705
JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 decreases expression ISO Cytarabine results in decreased expression of GUCY1A1 mRNA CTD PMID:21198554 NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
JBrowse link
G H1f2 H1.2 linker histone, cluster member decreases expression ISO Cytarabine results in decreased expression of H1-2 mRNA CTD PMID:21198554 NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
JBrowse link
G H2aj H2A.J histone decreases expression ISO Cytarabine results in decreased expression of H2AJ mRNA CTD PMID:21198554 NCBI chr 4:169,675,718...169,676,202
Ensembl chr 4:169,675,752...169,677,006
JBrowse link
G H2ax H2A.X variant histone increases phosphorylation ISO Cytarabine results in increased phosphorylation of H2AX protein CTD PMID:19628630 PMID:34510228 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 decreases expression ISO Cytarabine results in decreased expression of HAND1 mRNA CTD PMID:21198554 NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
JBrowse link
G Hand2 heart and neural crest derivatives expressed 2 decreases expression ISO Cytarabine results in decreased expression of HAND2 mRNA CTD PMID:21198554 NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891
JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 decreases expression ISO Cytarabine results in decreased expression of HAPLN1 mRNA CTD PMID:21198554 NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
JBrowse link
G Has2 hyaluronan synthase 2 decreases expression ISO Cytarabine results in decreased expression of HAS2 mRNA CTD PMID:21198554 NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
JBrowse link
G Hcfc1r1 host cell factor C1 regulator 1 decreases expression ISO Cytarabine results in decreased expression of HCFC1R1 mRNA CTD PMID:21198554 NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850
JBrowse link
G Hes5 hes family bHLH transcription factor 5 increases expression ISO Cytarabine results in increased expression of HES5 mRNA CTD PMID:21198554 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
JBrowse link
G Hey1 hes-related family bHLH transcription factor with YRPW motif 1 decreases expression ISO Cytarabine results in decreased expression of HEY1 mRNA CTD PMID:33770205 NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Cytarabine results in increased expression of HIF1A mRNA CTD PMID:23264188 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hmgb1 high mobility group box 1 decreases response to substance
increases secretion
ISO HMGB1 protein results in decreased susceptibility to Cytarabine
Cytarabine results in increased secretion of HMGB1 protein
CTD PMID:27807322 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression ISO Cytarabine results in decreased expression of HMGCS2 mRNA CTD PMID:21198554 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
JBrowse link
G Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3 decreases expression ISO Cytarabine results in decreased expression of HNRNPA3 mRNA CTD PMID:21198554 NCBI chr 3:60,578,574...60,588,755
Ensembl chr 3:60,578,673...60,588,306
JBrowse link
G Hoxa2 homeobox A2 increases expression ISO Cytarabine results in increased expression of HOXA2 mRNA CTD PMID:21198554 NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044
JBrowse link
G Hoxa5 homeo box A5 increases expression ISO Cytarabine results in increased expression of HOXA5 mRNA CTD PMID:21198554 NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
JBrowse link
G Hoxb4 homeo box B4 decreases expression ISO Cytarabine results in decreased expression of HOXB4 mRNA CTD PMID:21198554 NCBI chr10:81,284,552...81,287,134
Ensembl chr10:81,284,552...81,287,128
JBrowse link
G Hoxb6 homeo box B6 decreases expression ISO Cytarabine results in decreased expression of HOXB6 mRNA CTD PMID:21198554 NCBI chr10:81,258,726...81,267,458
Ensembl chr10:81,265,056...81,267,449
JBrowse link
G Hoxb8 homeo box B8 decreases expression ISO Cytarabine results in decreased expression of HOXB8 mRNA CTD PMID:21198554 NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
JBrowse link
G Hoxc6 homeo box C6 decreases expression ISO Cytarabine results in decreased expression of HOXC6 mRNA CTD PMID:21198554 NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392
JBrowse link
G Hoxc8 homeobox C8 decreases expression ISO Cytarabine results in decreased expression of HOXC8 mRNA CTD PMID:21198554 NCBI chr 7:134,127,937...134,130,503
Ensembl chr 7:134,127,913...134,130,503
JBrowse link
G Hs3st1 heparan sulfate-glucosamine 3-sulfotransferase 1 decreases expression ISO Cytarabine results in decreased expression of HS3ST1 mRNA CTD PMID:21198554 NCBI chr14:71,185,826...71,223,263
Ensembl chr14:71,185,682...71,223,248
JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO Cytarabine results in increased expression of HSPA6 mRNA CTD PMID:19194470 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Htra1 HtrA serine peptidase 1 decreases expression ISO Cytarabine results in decreased expression of HTRA1 mRNA CTD PMID:21198554 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression ISO Cytarabine results in decreased expression of IGFBP3 mRNA CTD PMID:21198554 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression ISO Cytarabine results in decreased expression of IGFBP5 mRNA CTD PMID:21198554 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
JBrowse link
G Il6 interleukin 6 increases expression ISO Cytarabine results in increased expression of IL6 protein CTD PMID:11745875 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ina internexin neuronal intermediate filament protein, alpha increases expression ISO Cytarabine results in increased expression of INA mRNA CTD PMID:21198554 NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
JBrowse link
G Irx5 iroquois homeobox 5 increases expression ISO Cytarabine results in increased expression of IRX5 mRNA CTD PMID:21198554 NCBI chr19:14,639,052...14,643,911
Ensembl chr19:14,624,225...14,642,318
JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression ISO Cytarabine results in decreased expression of ITGB5 mRNA CTD PMID:21198554 NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
JBrowse link
G Itm2c integral membrane protein 2C decreases expression ISO Cytarabine results in decreased expression of ITM2C mRNA CTD PMID:21198554 NCBI chr 9:86,545,927...86,559,745
Ensembl chr 9:86,545,921...86,559,742
JBrowse link
G Jam2 junctional adhesion molecule 2 increases expression ISO Cytarabine results in increased expression of JAM2 mRNA CTD PMID:21198554 NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Cytarabine results in increased expression of JUN; Cytarabine results in increased expression of JUN mRNA CTD PMID:1450413 PMID:7949469 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kank4 KN motif and ankyrin repeat domains 4 decreases expression ISO Cytarabine results in decreased expression of KANK4 mRNA CTD PMID:21198554 NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
JBrowse link
G Kcnn2 potassium calcium-activated channel subfamily N member 2 decreases expression ISO Cytarabine results in decreased expression of KCNN2 mRNA CTD PMID:21198554 NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 decreases expression ISO Cytarabine results in decreased expression of KCTD12 mRNA CTD PMID:21198554 NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
JBrowse link
G Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3 decreases expression ISO Cytarabine results in decreased expression of KDELR3 mRNA CTD PMID:21198554 NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
JBrowse link
G Kiaa1671 KIAA1671 homolog decreases expression ISO Cytarabine results in decreased expression of KIAA1671 mRNA CTD PMID:21198554 NCBI chr12:43,409,479...43,552,152
Ensembl chr12:43,411,069...43,552,157
JBrowse link
G Kif15 kinesin family member 15 increases expression ISO Cytarabine results in increased expression of KIF15 mRNA CTD PMID:21198554 NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
JBrowse link
G Klhl41 kelch-like family member 41 decreases expression ISO Cytarabine results in decreased expression of KLHL41 mRNA CTD PMID:21198554 NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222
JBrowse link
G Klk6 kallikrein related-peptidase 6 decreases expression ISO Cytarabine results in decreased expression of KLK6 mRNA CTD PMID:21198554 NCBI chr 1:94,278,863...94,286,136
Ensembl chr 1:94,280,340...94,286,121
JBrowse link
G Kmo kynurenine 3-monooxygenase increases response to substance ISO KMO results in increased susceptibility to Cytarabine CTD PMID:21755009 NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
JBrowse link
G Kmt2a lysine methyltransferase 2A increases response to substance ISO KMT2A gene mutant form results in increased susceptibility to Cytarabine CTD PMID:14712291 NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
JBrowse link
G Kpna2 karyopherin subunit alpha 2 decreases expression ISO Cytarabine results in decreased expression of KPNA2 mRNA CTD PMID:17374387 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
JBrowse link
G Krt19 keratin 19 decreases expression ISO Cytarabine results in decreased expression of KRT19 mRNA CTD PMID:21198554 NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
JBrowse link
G Krt24 keratin 24 decreases expression ISO Cytarabine results in decreased expression of KRT24 mRNA CTD PMID:21198554 NCBI chr10:84,232,163...84,237,299
Ensembl chr10:84,232,164...84,237,299
JBrowse link
G Krt8 keratin 8 decreases expression ISO Cytarabine results in decreased expression of KRT8 mRNA CTD PMID:21198554 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
JBrowse link
G Kynu kynureninase decreases expression ISO Cytarabine results in decreased expression of KYNU mRNA CTD PMID:21198554 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
JBrowse link
G Lbh LBH regulator of WNT signaling pathway decreases expression ISO Cytarabine results in decreased expression of LBH mRNA CTD PMID:21198554 NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079
JBrowse link
G Lepr leptin receptor decreases expression ISO Cytarabine results in decreased expression of LEPR mRNA CTD PMID:21198554 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression ISO Cytarabine results in increased expression of LHFPL6 mRNA CTD PMID:21198554 NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
JBrowse link
G Limch1 LIM and calponin homology domains 1 increases expression ISO Cytarabine results in increased expression of LIMCH1 mRNA CTD PMID:21198554 NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
JBrowse link
G Lmcd1 LIM and cysteine-rich domains 1 decreases expression ISO Cytarabine results in decreased expression of LMCD1 mRNA CTD PMID:21198554 NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
JBrowse link
G Lox lysyl oxidase decreases expression ISO Cytarabine results in decreased expression of LOX mRNA CTD PMID:21198554 NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
JBrowse link
G Loxl4 lysyl oxidase-like 4 decreases expression ISO Cytarabine results in decreased expression of LOXL4 mRNA CTD PMID:21198554 NCBI chr 1:241,396,183...241,416,385
Ensembl chr 1:241,397,983...241,416,322
JBrowse link
G Lrba LPS responsive beige-like anchor protein decreases expression ISO Cytarabine results in decreased expression of LRBA mRNA CTD PMID:21198554 NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724
JBrowse link
G Lrfn5 leucine rich repeat and fibronectin type III domain containing 5 decreases expression ISO Cytarabine results in decreased expression of LRFN5 mRNA CTD PMID:21198554 NCBI chr 6:79,466,403...79,822,821
Ensembl chr 6:79,467,961...79,822,815
JBrowse link
G Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 increases expression ISO Cytarabine results in increased expression of LRIG1 mRNA CTD PMID:21198554 NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513
JBrowse link
G Lrp1b LDL receptor related protein 1B decreases expression ISO Cytarabine results in decreased expression of LRP1B mRNA CTD PMID:21198554 NCBI chr 3:24,594,302...26,715,037
Ensembl chr 3:24,594,991...26,715,505
JBrowse link
G Lrrc32 leucine rich repeat containing 32 decreases expression ISO Cytarabine results in decreased expression of LRRC32 mRNA CTD PMID:21198554 NCBI chr 1:152,785,709...152,802,997
Ensembl chr 1:152,786,511...152,798,373
JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Cytarabine results in decreased expression of LRRC41 mRNA CTD PMID:21198554 NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
JBrowse link
G Lrrn2 leucine rich repeat neuronal 2 decreases expression ISO Cytarabine results in decreased expression of LRRN2 mRNA CTD PMID:21198554 NCBI chr13:44,321,944...44,382,454
Ensembl chr13:44,321,364...44,382,482
JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 increases expression ISO Cytarabine results in increased expression of LRRN3 mRNA CTD PMID:21198554 NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 decreases expression ISO Cytarabine results in decreased expression of LRRN4 mRNA CTD PMID:21198554 NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831
JBrowse link
G Lum lumican decreases expression ISO Cytarabine results in decreased expression of LUM mRNA CTD PMID:21198554 NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
JBrowse link
G Ly6h lymphocyte antigen 6 family member H decreases expression ISO Cytarabine results in decreased expression of LY6H mRNA CTD PMID:21198554 NCBI chr 7:107,258,779...107,261,270
Ensembl chr 7:107,258,779...107,261,454
JBrowse link
G Ly75 lymphocyte antigen 75 increases expression ISO Cytarabine results in increased expression of LY75 mRNA CTD PMID:19194470 NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374
JBrowse link
G Lyl1 LYL1, basic helix-loop-helix family member decreases response to substance ISO LYL1 protein results in decreased susceptibility to Cytarabine CTD PMID:16094422 NCBI chr19:23,452,140...23,455,007
Ensembl chr19:23,452,140...23,455,007
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase decreases expression ISO Cytarabine results in decreased expression of LYN mRNA CTD PMID:21198554 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
JBrowse link
G Lyz2 lysozyme 2 increases expression ISO Cytarabine results in increased expression of LYZ mRNA CTD PMID:19194470 NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
JBrowse link
G Mab21l2 mab-21 like 2 decreases expression ISO Cytarabine results in decreased expression of MAB21L2 mRNA CTD PMID:21198554 NCBI chr 2:171,946,573...171,949,655
Ensembl chr 2:171,946,573...171,949,655
JBrowse link
G Magi1 membrane associated guanylate kinase, WW and PDZ domain containing 1 increases expression ISO Cytarabine results in increased expression of MAGI1 mRNA CTD PMID:21198554 NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
JBrowse link
G Map2 microtubule-associated protein 2 decreases expression
increases expression
ISO Cytarabine results in decreased expression of MAP2 protein
Cytarabine results in increased expression of MAP2 mRNA
CTD PMID:21198554 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Marchf3 membrane associated ring-CH-type finger 3 decreases expression ISO Cytarabine results in decreased expression of MARCHF3 mRNA CTD PMID:21198554 NCBI chr18:50,237,218...50,389,343
Ensembl chr18:50,237,230...50,389,150
JBrowse link
G Matn2 matrilin 2 decreases expression ISO Cytarabine results in decreased expression of MATN2 mRNA CTD PMID:21198554 NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
JBrowse link
G Mbtd1 mbt domain containing 1 increases expression ISO Cytarabine results in increased expression of MBTD1 mRNA CTD PMID:21198554 NCBI chr10:78,839,140...78,895,413
Ensembl chr10:78,839,036...78,893,720
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO Cytarabine results in decreased expression of MCL1 protein CTD PMID:16818278 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 decreases expression ISO Cytarabine results in decreased expression of MCOLN3 mRNA CTD PMID:21198554 NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047
JBrowse link
G Mdk midkine decreases expression ISO Cytarabine results in decreased expression of MDK mRNA CTD PMID:21198554 NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
JBrowse link
G Med9 mediator complex subunit 9 decreases expression ISO Cytarabine results in decreased expression of MED9 mRNA CTD PMID:19194470 NCBI chr10:44,750,667...44,765,464
Ensembl chr10:44,750,698...44,765,464
JBrowse link
G Megf10 multiple EGF-like domains 10 increases expression ISO Cytarabine results in increased expression of MEGF10 mRNA CTD PMID:21198554 NCBI chr18:50,605,231...50,755,441
Ensembl chr18:50,605,656...50,754,456
JBrowse link
G Meis1 Meis homeobox 1 increases expression ISO Cytarabine results in increased expression of MEIS1 mRNA CTD PMID:21198554 NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265
JBrowse link
G Mertk MER proto-oncogene, tyrosine kinase decreases expression ISO Cytarabine results in decreased expression of MERTK mRNA CTD PMID:21198554 NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
JBrowse link
G Mfap4 microfibril associated protein 4 decreases expression ISO Cytarabine results in decreased expression of MFAP4 mRNA CTD PMID:21198554 NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
JBrowse link
G Mgarp mitochondria-localized glutamic acid-rich protein decreases expression ISO Cytarabine results in decreased expression of MGARP mRNA CTD PMID:21198554 NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612
JBrowse link
G Mgp matrix Gla protein decreases expression ISO Cytarabine results in decreased expression of MGP mRNA CTD PMID:21198554 NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
JBrowse link
G Mindy4 MINDY lysine 48 deubiquitinase 4 decreases expression ISO Cytarabine results in decreased expression of MINDY4 mRNA CTD PMID:21198554 NCBI chr 4:84,358,660...84,469,189
Ensembl chr 4:84,358,902...84,463,395
JBrowse link
G Mmp23 matrix metallopeptidase 23 decreases expression ISO Cytarabine results in decreased expression of MMP23B mRNA CTD PMID:21198554 NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:166,239,644...166,242,433
JBrowse link
G Mpzl1 myelin protein zero-like 1 decreases expression ISO Cytarabine results in decreased expression of MPZL1 mRNA CTD PMID:21198554 NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
JBrowse link
G Msx1 msh homeobox 1 decreases expression ISO Cytarabine results in decreased expression of MSX1 mRNA CTD PMID:21198554 NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966
JBrowse link
G Mt1 metallothionein 1 decreases expression ISO Cytarabine results in decreased expression of MT1A mRNA CTD PMID:21198554 NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 decreases expression ISO Cytarabine results in decreased expression of MT1E mRNA CTD PMID:21198554 NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
JBrowse link
G Mt2A metallothionein 2A decreases expression ISO Cytarabine results in decreased expression of MT2A mRNA CTD PMID:21198554 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
JBrowse link
G Mthfr methylenetetrahydrofolate reductase affects response to substance ISO MTHFR protein affects the susceptibility to Cytarabine CTD PMID:18202788 NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
JBrowse link
G Mtus1 microtubule associated scaffold protein 1 increases expression ISO Cytarabine results in increased expression of MTUS1 mRNA CTD PMID:21198554 NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
JBrowse link
G Mvb12a multivesicular body subunit 12A decreases expression ISO Cytarabine results in decreased expression of MVB12A mRNA CTD PMID:21198554 NCBI chr16:18,252,227...18,257,111
Ensembl chr16:18,252,222...18,257,539
JBrowse link
G Mxd3 Max dimerization protein 3 increases expression ISO Cytarabine results in increased expression of MXD3 mRNA CTD PMID:21198554 NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157
JBrowse link
G Mxra7 matrix remodeling associated 7 decreases expression ISO Cytarabine results in decreased expression of MXRA7 mRNA CTD PMID:21198554 NCBI chr10:102,003,034...102,031,428
Ensembl chr10:102,003,319...102,031,409
JBrowse link
G Myadm myeloid-associated differentiation marker decreases expression ISO Cytarabine results in decreased expression of MYADM mRNA CTD PMID:21198554 NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035
JBrowse link
G Mydgf myeloid-derived growth factor decreases expression ISO Cytarabine results in decreased expression of MYDGF mRNA CTD PMID:21198554 NCBI chr 9:999,659...1,008,804
Ensembl chr 9:1,000,722...1,008,822
JBrowse link
G Myl4 myosin, light chain 4 decreases expression ISO Cytarabine results in decreased expression of MYL4 mRNA CTD PMID:21198554 NCBI chr10:89,449,456...89,485,365
Ensembl chr10:89,449,443...89,485,363
JBrowse link
G Myl7 myosin light chain 7 decreases expression ISO Cytarabine results in decreased expression of MYL7 mRNA CTD PMID:21198554 NCBI chr14:80,780,684...80,783,259
Ensembl chr14:80,779,776...80,783,244
JBrowse link
G Mylip myosin regulatory light chain interacting protein decreases expression ISO Cytarabine results in decreased expression of MYLIP mRNA CTD PMID:21198554 NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295
JBrowse link
G Myof myoferlin decreases expression ISO Cytarabine results in decreased expression of MYOF mRNA CTD PMID:21198554 NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
JBrowse link
G Nav2 neuron navigator 2 decreases expression ISO Cytarabine results in decreased expression of NAV2 mRNA CTD PMID:21198554 NCBI chr 1:98,957,629...99,322,339
Ensembl chr 1:98,663,759...99,322,337
JBrowse link
G Ncald neurocalcin delta increases expression ISO Cytarabine results in increased expression of NCALD mRNA CTD PMID:21198554 NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
JBrowse link
G Ndc80 NDC80 kinetochore complex component increases expression ISO Cytarabine results in increased expression of NDC80 mRNA CTD PMID:19194470 NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
JBrowse link
G Ndrg1 N-myc downstream regulated 1 decreases expression ISO Cytarabine results in decreased expression of NDRG1 mRNA CTD PMID:21198554 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
JBrowse link
G Ndrg2 NDRG family member 2 decreases expression ISO Cytarabine results in decreased expression of NDRG2 mRNA CTD PMID:21198554 NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
JBrowse link
G Nell2 neural EGFL like 2 increases expression ISO Cytarabine results in increased expression of NELL2 mRNA CTD PMID:21198554 NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:126,198,851...126,733,503
JBrowse link
G Nes nestin increases expression
decreases expression
ISO Cytarabine results in increased expression of NES mRNA
Cytarabine results in decreased expression of NES protein
CTD PMID:21198554 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
JBrowse link
G Nfib nuclear factor I/B increases expression ISO Cytarabine results in increased expression of NFIB mRNA CTD PMID:21198554 NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479
JBrowse link
G Nherf1 NHERF family PDZ scaffold protein 1 decreases expression ISO Cytarabine results in decreased expression of NHERF1 mRNA CTD PMID:21198554 NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598
JBrowse link
G Niban2 niban apoptosis regulator 2 decreases expression ISO Cytarabine results in decreased expression of NIBAN2 mRNA CTD PMID:21198554 NCBI chr 3:16,174,674...16,224,293
Ensembl chr 3:16,174,659...16,224,293
JBrowse link
G Nmu neuromedin U increases expression ISO Cytarabine results in increased expression of NMU mRNA CTD PMID:21198554 NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
JBrowse link
G Nova1 NOVA alternative splicing regulator 1 increases expression ISO Cytarabine results in increased expression of NOVA1 mRNA CTD PMID:21198554 NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
JBrowse link
G Nox4 NADPH oxidase 4 decreases expression ISO Cytarabine results in decreased expression of NOX4 mRNA CTD PMID:21198554 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nppb natriuretic peptide B increases expression ISO Cytarabine results in increased expression of NPPB mRNA; Cytarabine results in increased expression of NPPB protein CTD PMID:16151589 PMID:21198554 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
JBrowse link
G Npy neuropeptide Y decreases expression ISO Cytarabine results in decreased expression of NPY mRNA CTD PMID:21198554 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
JBrowse link
G Nrip3 nuclear receptor interacting protein 3 decreases expression ISO Cytarabine results in decreased expression of NRIP3 mRNA CTD PMID:21198554 NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600
JBrowse link
G Nrp1 neuropilin 1 multiple interactions ISO [2,2-bis(4-glycidyloxyphenyl)propane co-treated with Cytarabine] results in decreased expression of NRP1 mRNA CTD PMID:23264188 NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
JBrowse link
G Ntm neurotrimin decreases expression ISO Cytarabine results in decreased expression of NTM mRNA CTD PMID:21198554 NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595
JBrowse link
G Ntng1 netrin G1 increases expression ISO Cytarabine results in increased expression of NTNG1 mRNA CTD PMID:21198554 NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:197,463,945...197,826,997
JBrowse link
G Odam odontogenic, ameloblast associated decreases expression ISO Cytarabine results in decreased expression of ODAM mRNA CTD PMID:21198554 NCBI chr14:20,193,286...20,202,517
Ensembl chr14:20,193,302...20,202,517
JBrowse link
G Olfml3 olfactomedin-like 3 decreases expression ISO Cytarabine results in decreased expression of OLFML3 mRNA CTD PMID:21198554 NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 decreases expression ISO Cytarabine results in decreased expression of OLR1 mRNA CTD PMID:21198554 NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
JBrowse link
G Osbpl10 oxysterol binding protein-like 10 decreases expression ISO Cytarabine results in decreased expression of OSBPL10 mRNA CTD PMID:21198554 NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:114,660,743...114,918,625
JBrowse link
G Osr1 odd-skipped related transcription factor 1 decreases expression ISO Cytarabine results in decreased expression of OSR1 mRNA CTD PMID:21198554 NCBI chr 6:32,369,561...32,380,822
Ensembl chr 6:32,373,816...32,380,817
JBrowse link
G P4ha2 prolyl 4-hydroxylase subunit alpha 2 decreases expression ISO Cytarabine results in decreased expression of P4HA2 mRNA CTD PMID:21198554 NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314
JBrowse link
G Pals2 protein associated with LIN7 2, MAGUK p55 family member decreases expression ISO Cytarabine results in decreased expression of PALS2 mRNA CTD PMID:21198554 NCBI chr 4:79,173,488...79,257,542
Ensembl chr 4:79,124,806...79,254,140
JBrowse link
G Pamr1 peptidase domain containing associated with muscle regeneration 1 decreases expression ISO Cytarabine results in decreased expression of PAMR1 mRNA CTD PMID:21198554 NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606
JBrowse link
G Pard6a par-6 family cell polarity regulator alpha decreases expression ISO Cytarabine results in decreased expression of PARD6A mRNA CTD PMID:19194470 NCBI chr19:33,589,531...33,591,900
Ensembl chr19:33,589,542...33,591,900
JBrowse link
G Parm1 prostate androgen-regulated mucin-like protein 1 decreases expression ISO Cytarabine results in decreased expression of PARM1 mRNA CTD PMID:21198554 NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases degradation
ISO [Cytarabine co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein] CTD PMID:8840993 PMID:12780785 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pax6 paired box 6 increases expression
decreases expression
ISO Cytarabine results in increased expression of PAX6 mRNA
Cytarabine results in decreased expression of PAX6 protein
CTD PMID:21198554 NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
JBrowse link
G Pcdh20 protocadherin 20 decreases expression ISO Cytarabine results in decreased expression of PCDH20 mRNA CTD PMID:21198554 NCBI chr15:64,425,534...64,431,790
Ensembl chr15:64,425,534...64,431,790
JBrowse link
G Pcdh7 protocadherin 7 decreases expression ISO Cytarabine results in decreased expression of PCDH7 mRNA CTD PMID:21198554 NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051
JBrowse link
G Pced1b PC-esterase domain containing 1B decreases expression ISO Cytarabine results in decreased expression of PCED1B mRNA CTD PMID:21198554 NCBI chr 7:128,394,388...128,528,231
Ensembl chr 7:128,391,319...128,528,231
JBrowse link
G Pcsk5 proprotein convertase subtilisin/kexin type 5 decreases expression ISO Cytarabine results in decreased expression of PCSK5 mRNA CTD PMID:21198554 NCBI chr 1:214,837,847...215,267,626
Ensembl chr 1:214,837,927...215,267,600
JBrowse link
G Pde1a phosphodiesterase 1A increases expression ISO Cytarabine results in increased expression of PDE1A mRNA CTD PMID:21198554 NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
JBrowse link
G Pde1b phosphodiesterase 1B increases expression ISO Cytarabine results in increased expression of PDE1B mRNA CTD PMID:21198554 NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
JBrowse link
G Pde4b phosphodiesterase 4B increases expression ISO Cytarabine results in increased expression of PDE4B mRNA CTD PMID:21198554 NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
JBrowse link
G Pde6d phosphodiesterase 6D decreases expression ISO Cytarabine results in decreased expression of PDE6D mRNA CTD PMID:19194470 NCBI chr 9:87,192,989...87,237,979
Ensembl chr 9:87,192,983...87,237,969
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression ISO Cytarabine results in decreased expression of PDGFRB mRNA CTD PMID:21198554 NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
JBrowse link
G Pdlim3 PDZ and LIM domain 3 increases expression ISO Cytarabine results in increased expression of PDLIM3 mRNA CTD PMID:21198554 NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657
JBrowse link
G Pdlim4 PDZ and LIM domain 4 multiple interactions ISO Cytarabine inhibits the reaction [decitabine results in increased expression of PDLIM4 mRNA] CTD PMID:17634552 NCBI chr10:38,198,686...38,212,935
Ensembl chr10:38,198,689...38,212,938
JBrowse link
G Pdpn podoplanin decreases expression ISO Cytarabine results in decreased expression of PDPN mRNA CTD PMID:21198554 NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
JBrowse link
G Peli1 pellino E3 ubiquitin protein ligase 1 increases expression ISO Cytarabine results in increased expression of PELI1 mRNA CTD PMID:21198554 NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285
JBrowse link
G Pfkp phosphofructokinase, platelet decreases expression ISO Cytarabine results in decreased expression of PFKP mRNA CTD PMID:21198554 NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
JBrowse link
G Pgm5 phosphoglucomutase 5 decreases expression ISO Cytarabine results in decreased expression of PGM5 mRNA CTD PMID:21198554 NCBI chr 1:222,325,638...222,513,434
Ensembl chr 1:222,325,643...222,513,437
JBrowse link
G Phactr2 phosphatase and actin regulator 2 decreases expression ISO Cytarabine results in decreased expression of PHACTR2 mRNA CTD PMID:21198554 NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289
JBrowse link
G Phyhipl phytanoyl-CoA 2-hydroxylase interacting protein-like increases expression ISO Cytarabine results in increased expression of PHYHIPL mRNA CTD PMID:21198554 NCBI chr20:18,024,744...18,065,822
Ensembl chr20:18,024,666...18,065,478
JBrowse link
G Pigh phosphatidylinositol glycan anchor biosynthesis, class H decreases expression ISO Cytarabine results in decreased expression of PIGH mRNA CTD PMID:21198554 NCBI chr 6:97,874,903...97,897,188
Ensembl chr 6:97,882,903...97,897,142
JBrowse link
G Pitx1 paired-like homeodomain 1 decreases expression ISO Cytarabine results in decreased expression of PITX1 mRNA CTD PMID:21198554 NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291
JBrowse link
G Pitx2 paired-like homeodomain 2 decreases expression ISO Cytarabine results in decreased expression of PITX2 mRNA CTD PMID:21198554 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pkia cAMP-dependent protein kinase inhibitor alpha decreases expression ISO Cytarabine results in decreased expression of PKIA mRNA CTD PMID:21198554 NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282
JBrowse link
G Pkp2 plakophilin 2 decreases expression ISO Cytarabine results in decreased expression of PKP2 mRNA CTD PMID:21198554 NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730
JBrowse link
G Plac9 placenta associated 9 decreases expression ISO Cytarabine results in decreased expression of PLAC9 mRNA CTD PMID:21198554 NCBI chr16:1,459,450...1,474,275
Ensembl chr16:1,459,456...1,474,399
JBrowse link
G Plat plasminogen activator, tissue type decreases expression ISO Cytarabine results in decreased expression of PLAT mRNA CTD PMID:21198554 NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
JBrowse link
G Plcb2 phospholipase C, beta 2 affects localization
multiple interactions
ISO Cytarabine affects the localization of PLCB2 protein
edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]
CTD PMID:9295281 NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302
JBrowse link
G Plch1 phospholipase C, eta 1 increases expression ISO Cytarabine results in increased expression of PLCH1 mRNA CTD PMID:21198554 NCBI chr 2:148,148,908...148,363,616
Ensembl chr 2:148,148,921...148,364,097
JBrowse link
G Pld3 phospholipase D family, member 3 decreases expression ISO Cytarabine results in decreased expression of PLD3 mRNA CTD PMID:21198554 NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072
JBrowse link
G Plekhg3 pleckstrin homology and RhoGEF domain containing G3 decreases expression ISO Cytarabine results in decreased expression of PLEKHG3 mRNA CTD PMID:21198554 NCBI chr 6:95,265,756...95,308,952
Ensembl chr 6:95,266,058...95,310,359
JBrowse link
G Plg plasminogen affects localization ISO Cytarabine affects the localization of PLG protein CTD PMID:12165291 NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
JBrowse link
G Plin3 perilipin 3 decreases expression ISO Cytarabine results in decreased expression of PLIN3 mRNA CTD PMID:21198554 NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147
JBrowse link
G Pllp plasmolipin decreases expression ISO Cytarabine results in decreased expression of PLLP mRNA CTD PMID:21198554 NCBI chr19:10,315,104...10,335,892
Ensembl chr19:10,315,104...10,335,892
JBrowse link
G Plod1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 decreases expression ISO Cytarabine results in decreased expression of PLOD1 mRNA CTD PMID:21198554 NCBI chr 5:158,340,674...158,367,581
Ensembl chr 5:158,340,490...158,367,620
JBrowse link
G Plp1 proteolipid protein 1 increases expression ISO Cytarabine results in increased expression of PLP1 mRNA CTD PMID:21198554 NCBI chr  X:100,184,039...100,201,035
Ensembl chr  X:100,185,767...100,201,032
JBrowse link
G Pltp phospholipid transfer protein decreases expression ISO Cytarabine results in decreased expression of PLTP mRNA CTD PMID:21198554 NCBI chr 3:153,574,825...153,592,647
Ensembl chr 3:153,574,825...153,592,647
JBrowse link
G Pmel premelanosome protein increases expression ISO Cytarabine results in increased expression of PMEL mRNA CTD PMID:21198554 NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
JBrowse link
G Pmp22 peripheral myelin protein 22 decreases expression ISO Cytarabine results in decreased expression of PMP22 mRNA CTD PMID:21198554 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
JBrowse link
G Podxl podocalyxin-like decreases expression ISO Cytarabine results in decreased expression of PODXL mRNA CTD PMID:21198554 NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
JBrowse link
G Podxl2 podocalyxin-like 2 increases expression ISO Cytarabine results in increased expression of PODXL2 mRNA CTD PMID:21198554 NCBI chr 4:121,306,224...121,338,070
Ensembl chr 4:121,306,224...121,338,112
JBrowse link
G Postn periostin decreases expression ISO Cytarabine results in decreased expression of POSTN mRNA CTD PMID:21198554 NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of PPARG mRNA] CTD PMID:23264188 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppic peptidylprolyl isomerase C decreases expression ISO Cytarabine results in decreased expression of PPIC mRNA CTD PMID:21198554 NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017
JBrowse link
G Ppm1m protein phosphatase, Mg2+/Mn2+ dependent, 1M decreases expression ISO Cytarabine results in decreased expression of PPM1M mRNA CTD PMID:21198554 NCBI chr 8:106,836,221...106,843,472
Ensembl chr 8:106,837,037...106,842,057
JBrowse link
G Ppt2 palmitoyl-protein thioesterase 2 decreases expression ISO Cytarabine results in decreased expression of PPT2 mRNA CTD PMID:21198554 NCBI chr20:4,112,520...4,132,774
Ensembl chr20:4,122,463...4,132,774
JBrowse link
G Prc1 protein regulator of cytokinesis 1 decreases expression ISO Cytarabine results in decreased expression of PRC1 mRNA CTD PMID:17374387 NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
JBrowse link
G Prdm8 PR/SET domain 8 increases expression ISO Cytarabine results in increased expression of PRDM8 mRNA CTD PMID:21198554 NCBI chr14:11,403,202...11,424,059
Ensembl chr14:11,404,407...11,410,993
JBrowse link
G Prickle1 prickle planar cell polarity protein 1 decreases expression ISO Cytarabine results in decreased expression of PRICKLE1 mRNA CTD PMID:21198554 NCBI chr 7:124,639,142...124,735,027
Ensembl chr 7:124,639,142...124,658,113
JBrowse link
G Prkcz protein kinase C, zeta decreases response to substance ISO PRKCZ protein results in decreased susceptibility to Cytarabine CTD PMID:21863889 NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
JBrowse link
G Prl prolactin increases expression ISO Cytarabine results in increased expression of PRL protein CTD PMID:8312290 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
G Prnp prion protein decreases expression ISO Cytarabine results in decreased expression of PRNP mRNA CTD PMID:21198554 NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
JBrowse link
G Prph peripherin decreases expression ISO Cytarabine results in decreased expression of PRPH mRNA CTD PMID:21198554 NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
JBrowse link
G Prrc2c proline-rich coiled-coil 2C decreases expression ISO Cytarabine results in decreased expression of PRRC2C mRNA CTD PMID:19194470 NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643
JBrowse link
G Prss35 serine protease 35 decreases expression ISO Cytarabine results in decreased expression of PRSS35 mRNA CTD PMID:21198554 NCBI chr 8:87,714,449...87,731,009
Ensembl chr 8:87,714,966...87,731,009
JBrowse link
G Psd3 pleckstrin and Sec7 domain containing 3 increases expression ISO Cytarabine results in increased expression of PSD3 mRNA CTD PMID:21198554 NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
JBrowse link
G Psrc1 proline and serine rich coiled-coil 1 decreases expression ISO Cytarabine results in decreased expression of PSRC1 mRNA CTD PMID:17374387 NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
JBrowse link
G Pstpip2 proline-serine-threonine phosphatase-interacting protein 2 decreases expression ISO Cytarabine results in decreased expression of PSTPIP2 mRNA CTD PMID:19194470 NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
JBrowse link
G Pten phosphatase and tensin homolog increases response to substance ISO PTEN protein results in increased susceptibility to Cytarabine CTD PMID:22185283 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO PTGS2 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
CTD PMID:24184161 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pth1r parathyroid hormone 1 receptor decreases expression ISO Cytarabine results in decreased expression of PTH1R mRNA CTD PMID:21198554 NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
JBrowse link
G Ptprz1 protein tyrosine phosphatase, receptor type Z1 increases expression ISO Cytarabine results in increased expression of PTPRZ1 mRNA CTD PMID:21198554 NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218
JBrowse link
G Qprt quinolinate phosphoribosyltransferase decreases expression ISO Cytarabine results in decreased expression of QPRT mRNA CTD PMID:21198554 NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486
JBrowse link
G Rab37 RAB37, member RAS oncogene family decreases expression ISO Cytarabine results in decreased expression of RAB37 mRNA CTD PMID:21198554 NCBI chr10:100,334,639...100,401,974
Ensembl chr10:100,334,216...100,401,474
JBrowse link
G Rab5b RAB5B, member RAS oncogene family increases expression ISO Cytarabine results in increased expression of RAB5B mRNA CTD PMID:19194470 NCBI chr 7:1,109,449...1,128,348
Ensembl chr 7:1,109,454...1,128,268
JBrowse link
G Rabggtb Rab geranylgeranyltransferase subunit beta decreases expression ISO Cytarabine results in decreased expression of RABGGTB mRNA CTD PMID:19194470 NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050
JBrowse link
G Rad23a RAD23 homolog A, nucleotide excision repair protein decreases expression ISO Cytarabine results in decreased expression of RAD23A mRNA CTD PMID:19194470 NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
JBrowse link
G Rad51 RAD51 recombinase increases expression ISO Cytarabine results in increased expression of RAD51 mRNA CTD PMID:19194470 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
JBrowse link
G Ralgdsl1 ral guanine nucleotide dissociation stimulator like 1 decreases expression ISO Cytarabine results in decreased expression of RGL1 mRNA CTD PMID:21198554 NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191
JBrowse link
G Ramp1 receptor activity modifying protein 1 decreases expression ISO Cytarabine results in decreased expression of RAMP1 mRNA CTD PMID:21198554 NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
JBrowse link
G Rassf2 Ras association domain family member 2 increases expression ISO Cytarabine results in increased expression of RASSF2 mRNA CTD PMID:21198554 NCBI chr 3:119,244,288...119,280,462
Ensembl chr 3:119,245,821...119,280,431
JBrowse link
G Rbm34 RNA binding motif protein 34 decreases expression ISO Cytarabine results in decreased expression of RBM34 mRNA CTD PMID:19194470 NCBI chr19:54,936,516...54,956,810
Ensembl chr19:54,936,531...54,956,715
JBrowse link
G Recql5 RecQ like helicase 5 decreases expression ISO Cytarabine results in decreased expression of RECQL5 mRNA CTD PMID:19194470 NCBI chr10:101,126,544...101,165,739
Ensembl chr10:101,126,547...101,165,652
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases phosphorylation
decreases activity
ISO calyculin A inhibits the reaction [Cytarabine results in decreased activity of RELA protein]
Cytarabine results in decreased phosphorylation of RELA protein
CTD PMID:12853972 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Reln reelin decreases expression ISO Cytarabine results in decreased expression of RELN mRNA CTD PMID:21198554 NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
JBrowse link
G Rerg RAS-like, estrogen-regulated, growth-inhibitor decreases expression ISO Cytarabine results in decreased expression of RERG mRNA CTD PMID:21198554 NCBI chr 4:169,981,634...170,089,777
Ensembl chr 4:169,982,279...170,089,715
JBrowse link
G Rexo4 REX4 homolog, 3'-5' exonuclease decreases expression ISO Cytarabine results in decreased expression of REXO4 mRNA CTD PMID:21198554 NCBI chr 3:10,280,654...10,291,003
Ensembl chr 3:10,280,654...10,290,996
JBrowse link
G Rgmb repulsive guidance molecule BMP co-receptor b increases expression ISO Cytarabine results in increased expression of RGMB mRNA CTD PMID:21198554 NCBI chr 1:56,766,598...56,792,396
Ensembl chr 1:56,767,850...56,792,425
JBrowse link
G Rgs1 regulator of G-protein signaling 1 decreases expression ISO Cytarabine results in decreased expression of RGS1 mRNA CTD PMID:21198554 NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984
JBrowse link
G Rgs13 regulator of G-protein signaling 13 decreases expression ISO Cytarabine results in decreased expression of RGS13 mRNA CTD PMID:21198554 NCBI chr13:55,922,290...55,955,753
Ensembl chr13:55,922,395...55,955,648
JBrowse link
G Rgs20 regulator of G-protein signaling 20 increases expression ISO Cytarabine results in increased expression of RGS20 mRNA CTD PMID:21198554 NCBI chr 5:14,484,436...14,614,317
Ensembl chr 5:14,534,775...14,614,084
JBrowse link
G Rgs4 regulator of G-protein signaling 4 decreases expression ISO Cytarabine results in decreased expression of RGS4 mRNA CTD PMID:21198554 NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
JBrowse link
G Rhoc ras homolog family member C decreases expression ISO Cytarabine results in decreased expression of RHOC mRNA CTD PMID:21198554 NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
JBrowse link
G Rhpn2 rhophilin, Rho GTPase binding protein 2 decreases expression ISO Cytarabine results in decreased expression of RHPN2 mRNA CTD PMID:21198554 NCBI chr 1:87,991,143...88,051,895
Ensembl chr 1:87,991,144...88,051,902
JBrowse link
G Rnase2 ribonuclease A family member 2 increases expression ISO Cytarabine results in increased expression of RNASE2 mRNA CTD PMID:19194470 NCBI chr15:24,449,618...24,450,427
Ensembl chr15:24,449,611...24,450,479
JBrowse link
G Robo3 roundabout guidance receptor 3 increases expression ISO Cytarabine results in increased expression of ROBO3 mRNA CTD PMID:21198554 NCBI chr 8:37,133,542...37,151,674
Ensembl chr 8:37,133,916...37,151,315
JBrowse link
G Rpp25 ribonuclease P and MRP subunit p25 decreases expression ISO Cytarabine results in decreased expression of RPP25 mRNA CTD PMID:21198554 NCBI chr 8:57,907,352...57,908,732
Ensembl chr 8:57,907,352...57,908,732
JBrowse link
G Rprml reprimo-like increases expression ISO Cytarabine results in increased expression of RPRML mRNA CTD PMID:21198554 NCBI chr10:88,560,248...88,561,252
Ensembl chr10:88,560,248...88,561,252
JBrowse link
G Rras RAS related decreases expression ISO Cytarabine results in decreased expression of RRAS mRNA CTD PMID:21198554 NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357
JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 increases expression ISO Cytarabine results in increased expression of RRM2 mRNA CTD PMID:19194470 NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
JBrowse link
G Rspo2 R-spondin 2 decreases expression ISO Cytarabine results in decreased expression of RSPO2 mRNA CTD PMID:21198554 NCBI chr 7:74,096,378...74,239,398
Ensembl chr 7:74,103,090...74,238,933
JBrowse link
G Rsrp1 arginine and serine rich protein 1 decreases expression ISO Cytarabine results in decreased expression of RSRP1 mRNA CTD PMID:21198554 NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523
JBrowse link
G Rtn1 reticulon 1 increases expression ISO Cytarabine results in increased expression of RTN1 mRNA CTD PMID:21198554 NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
JBrowse link
G Rwdd1 RWD domain containing 1 increases expression ISO Cytarabine results in increased expression of RWDD1 mRNA CTD PMID:21198554 NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193
JBrowse link
G S100a10 S100 calcium binding protein A10 decreases expression ISO Cytarabine results in decreased expression of S100A10 mRNA CTD PMID:21198554 NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
JBrowse link
G S100a4 S100 calcium-binding protein A4 decreases expression ISO Cytarabine results in decreased expression of S100A4 mRNA CTD PMID:21198554 NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
JBrowse link
G Saraf store-operated calcium entry-associated regulatory factor decreases expression ISO Cytarabine results in decreased expression of SARAF mRNA CTD PMID:21198554 NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
JBrowse link
G Sbspon somatomedin B and thrombospondin, type 1 domain containing decreases expression ISO Cytarabine results in decreased expression of SBSPON mRNA CTD PMID:21198554 NCBI chr 5:3,402,763...3,433,338
Ensembl chr 5:3,402,648...3,435,420
JBrowse link
G Scamp5 secretory carrier membrane protein 5 increases expression ISO Cytarabine results in increased expression of SCAMP5 mRNA CTD PMID:21198554 NCBI chr 8:57,845,831...57,884,516
Ensembl chr 8:57,846,659...57,872,027
JBrowse link
G Scyl1 SCY1 like pseudokinase 1 decreases expression ISO Cytarabine results in decreased expression of SCYL1 mRNA CTD PMID:21198554 NCBI chr 1:203,045,776...203,059,550
Ensembl chr 1:203,045,741...203,059,533
JBrowse link
G Sdc4 syndecan 4 decreases expression ISO Cytarabine results in decreased expression of SDC4 mRNA CTD PMID:21198554 NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
JBrowse link
G Sec14l1 SEC14-like lipid binding 1 decreases expression ISO Cytarabine results in decreased expression of SEC14L1 mRNA CTD PMID:21198554 NCBI chr10:102,319,920...102,367,070
Ensembl chr10:102,319,920...102,367,068
JBrowse link
G Selenom selenoprotein M decreases expression ISO Cytarabine results in decreased expression of SELENOM mRNA CTD PMID:21198554 NCBI chr14:78,395,826...78,398,429
Ensembl chr14:78,395,826...78,398,429
JBrowse link
G Sema5b semaphorin 5B increases expression ISO Cytarabine results in increased expression of SEMA5B mRNA CTD PMID:21198554 NCBI chr11:65,102,532...65,225,456
Ensembl chr11:65,102,031...65,225,311
JBrowse link
G Serpina1 serpin family A member 1 increases expression ISO Cytarabine results in increased expression of SERPINA1 mRNA CTD PMID:19194470 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
JBrowse link
G Serpinb6a serpin family B member 6A decreases expression ISO Cytarabine results in decreased expression of SERPINB6 mRNA CTD PMID:21198554 NCBI chr17:30,871,468...30,989,703
Ensembl chr17:30,871,468...31,014,427
JBrowse link
G Serpinb9 serpin family B member 9 decreases expression ISO Cytarabine results in decreased expression of SERPINB9 mRNA CTD PMID:21198554 NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
JBrowse link
G Serpinh1 serpin family H member 1 decreases expression ISO Cytarabine results in decreased expression of SERPINH1 mRNA CTD PMID:21198554 NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
JBrowse link
G Sertad1 SERTA domain containing 1 decreases expression ISO Cytarabine results in decreased expression of SERTAD1 mRNA CTD PMID:21198554 NCBI chr 1:82,775,692...82,778,961
Ensembl chr 1:82,775,252...82,779,091
JBrowse link
G Sesn3 sestrin 3 decreases expression ISO Cytarabine results in decreased expression of SESN3 mRNA CTD PMID:33770205 NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842
JBrowse link
G Sfn stratifin decreases response to substance ISO SFN protein results in decreased susceptibility to Cytarabine CTD PMID:25189999 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
JBrowse link
G Sfrp1 secreted frizzled-related protein 1 increases expression ISO Cytarabine results in increased expression of SFRP1 mRNA CTD PMID:21198554 NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286
JBrowse link
G Sfrp2 secreted frizzled-related protein 2 increases expression ISO Cytarabine results in increased expression of SFRP2 mRNA CTD PMID:21198554 NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
JBrowse link
G Sgip1 SH3GL interacting endocytic adaptor 1 increases expression ISO Cytarabine results in increased expression of SGIP1 mRNA CTD PMID:21198554 NCBI chr 5:117,536,752...117,734,593
Ensembl chr 5:117,537,746...117,734,575
JBrowse link
G Sh3rf2 SH3 domain containing ring finger 2 decreases expression ISO Cytarabine results in decreased expression of SH3RF2 mRNA CTD PMID:21198554 NCBI chr18:34,045,715...34,148,342
Ensembl chr18:34,046,879...34,146,856
JBrowse link
G Sipa1l2 signal-induced proliferation-associated 1 like 2 decreases expression ISO Cytarabine results in decreased expression of SIPA1L2 mRNA CTD PMID:21198554 NCBI chr19:53,389,792...53,540,466
Ensembl chr19:53,389,805...53,540,428
JBrowse link
G Sla src-like adaptor increases expression ISO Cytarabine results in increased expression of SLA mRNA CTD PMID:19194470 NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
JBrowse link
G Slc12a6 solute carrier family 12, member 6 decreases expression ISO Cytarabine results in decreased expression of SLC12A6 mRNA CTD PMID:33770205 NCBI chr 3:99,071,577...99,170,266
Ensembl chr 3:99,071,391...99,170,258
JBrowse link
G Slc16a3 solute carrier family 16 member 3 decreases expression ISO Cytarabine results in decreased expression of SLC16A3 mRNA CTD PMID:21198554 NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
JBrowse link
G Slc16a9 solute carrier family 16, member 9 increases expression ISO Cytarabine results in increased expression of SLC16A9 mRNA CTD PMID:21198554 NCBI chr20:18,335,862...18,377,125
Ensembl chr20:18,335,862...18,377,022
JBrowse link
G Slc17a6 solute carrier family 17 member 6 increases expression ISO Cytarabine results in increased expression of SLC17A6 mRNA CTD PMID:21198554 NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
JBrowse link
G Slc28a1 solute carrier family 28 member 1 multiple interactions ISO
EXP
Cytarabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]
Cytarabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]
CTD PMID:8713072 PMID:10772724 NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
JBrowse link
G Slc29a1 solute carrier family 29 member 1 decreases response to substance ISO SLC29A1 gene polymorphism results in decreased susceptibility to Cytarabine CTD PMID:18381442 NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
JBrowse link
G Slc2a1 solute carrier family 2 member 1 decreases expression ISO Cytarabine results in decreased expression of SLC2A1 mRNA CTD PMID:21198554 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
JBrowse link
G Slc39a2 solute carrier family 39 member 2 decreases expression ISO Cytarabine results in decreased expression of SLC39A2 mRNA CTD PMID:21198554 NCBI chr15:24,590,738...24,592,850
Ensembl chr15:24,590,738...24,592,850
JBrowse link
G Slc40a1 solute carrier family 40 member 1 decreases expression ISO Cytarabine results in decreased expression of SLC40A1 mRNA CTD PMID:21198554 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
JBrowse link
G Slc43a3 solute carrier family 43, member 3 increases expression ISO Cytarabine results in increased expression of SLC43A3 mRNA CTD PMID:19194470 NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749
JBrowse link
G Slc47a1 solute carrier family 47 member 1 decreases expression ISO Cytarabine results in decreased expression of SLC47A1 mRNA CTD PMID:21198554 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
JBrowse link
G Slc4a8 solute carrier family 4 member 8 decreases expression ISO Cytarabine results in decreased expression of SLC4A8 mRNA CTD PMID:21198554 NCBI chr 7:131,861,284...131,939,295
Ensembl chr 7:131,864,102...131,931,051
JBrowse link
G Slc5a12 solute carrier family 5 member 12 decreases expression ISO Cytarabine results in decreased expression of SLC5A12 mRNA CTD PMID:21198554 NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405
JBrowse link
G Slc7a2 solute carrier family 7 member 2 decreases expression ISO Cytarabine results in decreased expression of SLC7A2 mRNA CTD PMID:21198554 NCBI chr16:51,417,478...51,470,784
Ensembl chr16:51,417,493...51,470,784
JBrowse link
G Slc7a7 solute carrier family 7 member 7 decreases expression ISO Cytarabine results in decreased expression of SLC7A7 mRNA CTD PMID:21198554 NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648
JBrowse link
G Slfn9 schlafen family member 9 increases expression ISO Cytarabine results in increased expression of SLFN11 mRNA CTD PMID:21198554 NCBI chr10:67,909,105...67,955,912
Ensembl chr10:67,909,106...67,925,383
JBrowse link
G Slit2 slit guidance ligand 2 decreases expression ISO Cytarabine results in decreased expression of SLIT2 mRNA CTD PMID:21198554 NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
JBrowse link
G Slitrk3 SLIT and NTRK-like family, member 3 decreases expression ISO Cytarabine results in decreased expression of SLITRK3 mRNA CTD PMID:21198554 NCBI chr 2:157,680,067...157,697,404
Ensembl chr 2:157,687,535...157,696,709
JBrowse link
G Slitrk5 SLIT and NTRK-like family, member 5 decreases expression ISO Cytarabine results in decreased expression of SLITRK5 mRNA CTD PMID:19194470 NCBI chr15:88,848,123...88,858,809
Ensembl chr15:88,847,535...88,856,836
JBrowse link
G Sln sarcolipin decreases expression ISO Cytarabine results in decreased expression of SLN mRNA CTD PMID:21198554 NCBI chr 8:54,221,389...54,248,110
Ensembl chr 8:54,243,542...54,247,791
JBrowse link
G Smad6 SMAD family member 6 decreases expression ISO Cytarabine results in decreased expression of SMAD6 mRNA CTD PMID:21198554 NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763
JBrowse link
G Smoc2 SPARC related modular calcium binding 2 decreases expression ISO Cytarabine results in decreased expression of SMOC2 mRNA CTD PMID:21198554 NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693
JBrowse link
G Smpdl3a sphingomyelin phosphodiesterase, acid-like 3A decreases expression ISO Cytarabine results in decreased expression of SMPDL3A mRNA CTD PMID:21198554 NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567
JBrowse link
G Snai2 snail family transcriptional repressor 2 decreases expression ISO Cytarabine results in decreased expression of SNAI2 mRNA CTD PMID:21198554 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
JBrowse link
G Snap91 synaptosome associated protein 91 increases expression ISO Cytarabine results in increased expression of SNAP91 mRNA CTD PMID:21198554 NCBI chr 8:87,738,056...87,852,690
Ensembl chr 8:87,738,824...87,852,367
JBrowse link
G Snca synuclein alpha multiple interactions ISO Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to ferrous chloride]; Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron] CTD PMID:14535945 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
JBrowse link
G Snd1 staphylococcal nuclease and tudor domain containing 1 decreases expression ISO Cytarabine results in decreased expression of SND1 mRNA CTD PMID:21198554 NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
JBrowse link
G Snf8 SNF8 subunit of ESCRT-II decreases expression ISO Cytarabine results in decreased expression of SNF8 mRNA CTD PMID:21198554 NCBI chr10:80,984,337...80,996,724
Ensembl chr10:80,984,363...80,996,734
JBrowse link
G Sorbs2 sorbin and SH3 domain containing 2 increases expression ISO Cytarabine results in increased expression of SORBS2 mRNA CTD PMID:21198554 NCBI chr16:46,435,220...46,748,743
Ensembl chr16:46,435,237...46,626,514
JBrowse link
G Sox21 SRY-box transcription factor 21 increases expression ISO Cytarabine results in increased expression of SOX21 mRNA CTD PMID:21198554 NCBI chr15:95,292,429...95,296,024
Ensembl chr15:95,292,265...95,296,091
JBrowse link
G Sox3 SRY-box transcription factor 3 increases expression ISO Cytarabine results in increased expression of SOX3 mRNA CTD PMID:21198554 NCBI chr  X:139,308,608...139,310,687
Ensembl chr  X:139,309,329...139,310,678
JBrowse link
G Spag16 sperm associated antigen 16 increases expression ISO Cytarabine results in increased expression of SPAG16 mRNA CTD PMID:21198554 NCBI chr 9:71,333,005...72,252,772
Ensembl chr 9:71,332,992...72,252,708
JBrowse link
G Sparc secreted protein acidic and cysteine rich decreases expression ISO Cytarabine results in decreased expression of SPARC mRNA CTD PMID:21198554 NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
JBrowse link
G Spata7 spermatogenesis associated 7 increases expression ISO Cytarabine results in increased expression of SPATA7 mRNA CTD PMID:21198554 NCBI chr 6:117,879,828...117,925,284
Ensembl chr 6:117,879,823...117,925,284
JBrowse link
G Spin4 spindlin family, member 4 decreases expression ISO Cytarabine results in decreased expression of SPIN4 mRNA CTD PMID:21198554 NCBI chr  X:59,888,728...59,892,817
Ensembl chr  X:59,891,581...59,892,330
JBrowse link
G Spink1 serine peptidase inhibitor, Kazal type 1 increases expression ISO Cytarabine results in increased expression of SPINK1 mRNA CTD PMID:21198554 NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
JBrowse link
G Spon1 spondin 1 decreases expression ISO Cytarabine results in decreased expression of SPON1 mRNA CTD PMID:21198554 NCBI chr 1:167,929,049...168,228,239
Ensembl chr 1:167,928,972...168,228,226
JBrowse link
G Sptlc3 serine palmitoyltransferase, long chain base subunit 3 decreases expression ISO Cytarabine results in decreased expression of SPTLC3 mRNA CTD PMID:21198554 NCBI chr 3:126,847,878...126,978,010
Ensembl chr 3:126,847,878...126,978,010
JBrowse link
G Srgap3 SLIT-ROBO Rho GTPase activating protein 3 increases expression ISO Cytarabine results in increased expression of SRGAP3 mRNA CTD PMID:21198554 PMID:33770205 NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575
JBrowse link
G Srgn serglycin increases expression ISO Cytarabine results in increased expression of SRGN mRNA CTD PMID:19194470 NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406
JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO Cytarabine results in increased expression of SRXN1 mRNA CTD PMID:22003191 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Ssuh2 ssu-2 homolog increases expression ISO Cytarabine results in increased expression of SSUH2 mRNA CTD PMID:21198554 NCBI chr 4:145,502,942...145,521,881
Ensembl chr 4:145,503,185...145,521,735
JBrowse link
G St18 ST18 C2H2C-type zinc finger transcription factor increases expression ISO Cytarabine results in increased expression of ST18 mRNA CTD PMID:21198554 NCBI chr 5:12,582,493...12,914,221
Ensembl chr 5:12,584,110...12,671,790
JBrowse link
G St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 decreases expression ISO Cytarabine results in decreased expression of ST3GAL1 mRNA CTD PMID:21198554 NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236
JBrowse link
G St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 decreases expression ISO Cytarabine results in decreased expression of ST3GAL5 mRNA CTD PMID:33770205 NCBI chr 4:104,134,613...104,192,558
Ensembl chr 4:104,134,613...104,192,558
JBrowse link
G St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 decreases expression ISO Cytarabine results in decreased expression of ST3GAL6 mRNA CTD PMID:21198554 NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
JBrowse link
G St6galnac3 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 decreases expression ISO Cytarabine results in decreased expression of ST6GALNAC3 mRNA CTD PMID:21198554 NCBI chr 2:242,129,755...242,645,120
Ensembl chr 2:242,129,763...242,645,133
JBrowse link
G St6galnac6 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 decreases expression ISO Cytarabine results in decreased expression of ST6GALNAC6 mRNA CTD PMID:21198554 NCBI chr 3:15,894,275...15,907,502
Ensembl chr 3:15,885,968...15,907,496
JBrowse link
G Stmn4 stathmin 4 increases response to substance ISO STMN4 results in increased susceptibility to Cytarabine CTD PMID:21755009 NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
JBrowse link
G Stom stomatin decreases expression ISO Cytarabine results in decreased expression of STOM mRNA CTD PMID:21198554 NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354
JBrowse link
G Ston1 stonin 1 decreases expression ISO Cytarabine results in decreased expression of STON1 mRNA CTD PMID:21198554 NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449
JBrowse link
G Surf4 surfeit 4 decreases expression ISO Cytarabine results in decreased expression of SURF4 mRNA CTD PMID:21198554 NCBI chr 3:10,248,360...10,261,537
Ensembl chr 3:10,241,837...10,263,315
JBrowse link
G Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 decreases expression ISO Cytarabine results in decreased expression of SVEP1 mRNA CTD PMID:21198554 NCBI chr 5:72,811,200...72,988,185
Ensembl chr 5:72,811,410...72,988,525
JBrowse link
G Sytl2 synaptotagmin-like 2 increases expression ISO Cytarabine results in increased expression of SYTL2 mRNA CTD PMID:21198554 NCBI chr 1:144,272,870...144,379,310
Ensembl chr 1:144,273,360...144,379,222
JBrowse link
G Tac1 tachykinin, precursor 1 increases expression ISO Cytarabine results in increased expression of TAC1 mRNA CTD PMID:21198554 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
JBrowse link
G Tac3 tachykinin precursor 3 decreases expression ISO Cytarabine results in decreased expression of TAC3 mRNA CTD PMID:21198554 NCBI chr 7:63,562,552...63,569,170
Ensembl chr 7:63,562,552...63,569,170
JBrowse link
G Tagln transgelin increases expression ISO Cytarabine results in increased expression of TAGLN mRNA CTD PMID:21198554 NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
JBrowse link
G Tbc1d4 TBC1 domain family, member 4 decreases expression ISO Cytarabine results in decreased expression of TBC1D4 mRNA CTD PMID:21198554 NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
JBrowse link
G Tceal7 transcription elongation factor A like 7 increases expression ISO Cytarabine results in increased expression of TCEAL7 mRNA CTD PMID:21198554 NCBI chr  X:99,228,405...99,230,551
Ensembl chr  X:99,228,458...99,230,543
JBrowse link
G Tcf12 transcription factor 12 increases expression ISO Cytarabine results in increased expression of TCF12 mRNA CTD PMID:21198554 NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
JBrowse link
G Tcf21 transcription factor 21 decreases expression ISO Cytarabine results in decreased expression of TCF21 mRNA CTD PMID:21198554 NCBI chr 1:22,701,353...22,704,212
Ensembl chr 1:22,701,353...22,704,202
JBrowse link
G Tcf25 transcription factor 25 decreases expression ISO Cytarabine results in decreased expression of TCF25 mRNA CTD PMID:21198554 NCBI chr19:51,415,341...51,449,725
Ensembl chr19:51,415,543...51,449,723
JBrowse link
G Tecrl trans-2,3-enoyl-CoA reductase-like decreases expression ISO Cytarabine results in decreased expression of TECRL mRNA CTD PMID:21198554 NCBI chr14:24,732,241...24,805,272
Ensembl chr14:24,732,241...24,805,272
JBrowse link
G Tek TEK receptor tyrosine kinase decreases expression ISO Cytarabine results in decreased expression of TEK mRNA CTD PMID:21198554 NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
JBrowse link
G Tent5a terminal nucleotidyltransferase 5A decreases expression ISO Cytarabine results in decreased expression of TENT5A mRNA CTD PMID:21198554 NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045
JBrowse link
G Tent5c terminal nucleotidyltransferase 5C decreases expression ISO Cytarabine results in decreased expression of TENT5C mRNA CTD PMID:21198554 NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions
increases expression
ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA] CTD PMID:23264188 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
JBrowse link
G Tfe3 transcription factor binding to IGHM enhancer 3 increases expression ISO Cytarabine results in increased expression of TFE3 mRNA CTD PMID:19194470 NCBI chr  X:14,729,547...14,742,830
Ensembl chr  X:14,729,550...14,742,571
JBrowse link
G Tff3 trefoil factor 3 increases expression ISO Cytarabine results in increased expression of TFF3 mRNA CTD PMID:21198554 NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
JBrowse link
G Tfpi tissue factor pathway inhibitor decreases expression ISO Cytarabine results in decreased expression of TFPI mRNA CTD PMID:21198554 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
JBrowse link
G Tgfbr3 transforming growth factor beta receptor 3 decreases expression ISO Cytarabine results in decreased expression of TGFBR3 mRNA CTD PMID:21198554 NCBI chr14:2,489,397...2,665,383
Ensembl chr14:2,489,397...2,663,341
JBrowse link
G Th tyrosine hydroxylase decreases expression ISO Cytarabine results in decreased expression of TH protein CTD PMID:21198554 NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
JBrowse link
G Thbs1 thrombospondin 1 increases expression ISO Cytarabine results in increased expression of THBS1 mRNA CTD PMID:21198554 NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
JBrowse link
G Thy1 Thy-1 cell surface antigen decreases expression ISO Cytarabine results in decreased expression of THY1 mRNA CTD PMID:19194470 NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 decreases expression ISO Cytarabine results in decreased expression of TIMP1 mRNA CTD PMID:21198554 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 affects response to substance
decreases response to substance
ISO TIMP3 protein affects the susceptibility to Cytarabine
TIMP3 gene modified form results in decreased susceptibility to Cytarabine
CTD PMID:18202788 NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
JBrowse link
G Tk1 thymidine kinase 1 decreases activity
decreases expression
ISO Cytarabine results in decreased activity of TK1 protein
Cytarabine results in decreased expression of TK1 mRNA
CTD PMID:12893260 NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
JBrowse link
G Tk2 thymidine kinase 2 decreases expression
decreases activity
ISO Cytarabine results in decreased expression of TK2 mRNA
Cytarabine results in decreased activity of TK2 protein
CTD PMID:12893260 NCBI chr19:708,859...731,786
Ensembl chr19:708,891...730,924
JBrowse link
G Tln2 talin 2 decreases expression ISO Cytarabine results in decreased expression of TLN2 mRNA CTD PMID:21198554 NCBI chr 8:67,830,920...68,252,240
Ensembl chr 8:67,834,326...68,252,219
JBrowse link
G Tmed1 transmembrane p24 trafficking protein 1 decreases expression ISO Cytarabine results in decreased expression of TMED1 mRNA CTD PMID:21198554 NCBI chr 8:20,059,937...20,063,567
Ensembl chr 8:20,059,892...20,063,677
JBrowse link
G Tmed9 transmembrane p24 trafficking protein 9 decreases expression ISO Cytarabine results in decreased expression of TMED9 mRNA CTD PMID:21198554 NCBI chr17:9,029,646...9,034,160
Ensembl chr17:9,029,646...9,034,176
JBrowse link
G Tmem200a transmembrane protein 200A decreases expression ISO Cytarabine results in decreased expression of TMEM200A mRNA CTD PMID:21198554 NCBI chr 1:19,323,646...19,408,324
Ensembl chr 1:19,323,829...19,406,453
JBrowse link
G Tmem45a transmembrane protein 45A decreases expression ISO Cytarabine results in decreased expression of TMEM45A mRNA CTD PMID:21198554 NCBI chr11:43,713,309...43,799,526
Ensembl chr11:43,713,782...43,799,526
JBrowse link
G Tmem62 transmembrane protein 62 increases expression ISO Cytarabine results in increased expression of TMEM62 mRNA CTD PMID:21198554 NCBI chr 3:107,921,940...107,961,830
Ensembl chr 3:107,927,307...107,961,795
JBrowse link
G Tmem88 transmembrane protein 88 decreases expression ISO Cytarabine results in decreased expression of TMEM88 mRNA CTD PMID:21198554 NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447
JBrowse link
G Tmem98 transmembrane protein 98 decreases expression ISO Cytarabine results in decreased expression of TMEM98 mRNA CTD PMID:21198554 NCBI chr10:65,796,173...65,807,082
Ensembl chr10:65,796,145...65,807,079
JBrowse link
G Tnf tumor necrosis factor increases expression ISO Cytarabine results in increased expression of TNF protein CTD PMID:8318674 PMID:11745875 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 decreases expression ISO Cytarabine results in decreased expression of TNFAIP3 mRNA CTD PMID:21198554 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
JBrowse link
G Tnfrsf19 TNF receptor superfamily member 19 decreases expression ISO Cytarabine results in decreased expression of TNFRSF19 mRNA CTD PMID:33770205 NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases expression
ISO [Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased expression of BID protein; Cytarabine promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Cytarabine promotes the reaction [TNFSF10 protein results in increased expression of TNFRSF10B protein]
Cytarabine results in increased expression of TNFSF10 mRNA
CTD PMID:12780785 PMID:18549619 PMID:19194470 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tnnt2 troponin T2, cardiac type decreases expression ISO Cytarabine results in decreased expression of TNNT2 mRNA CTD PMID:21198554 NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
JBrowse link
G Tnrc6a trinucleotide repeat containing adaptor 6A increases expression ISO Cytarabine results in increased expression of TNRC6A mRNA CTD PMID:21198554 NCBI chr 1:177,561,898...177,715,669
Ensembl chr 1:177,646,030...177,715,660
JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects activity
increases activity
affects response to substance
increases response to substance
increases expression
increases phosphorylation
ISO
EXP
[fludarabine co-treated with Cytarabine co-treated with docetaxel] results in increased expression of TP53 protein; Caffeine inhibits the reaction [Cytarabine results in increased expression of TP53 protein]; Caffeine inhibits the reaction [Cytarabine results in increased phosphorylation of TP53 protein]
Cytarabine affects the activity of TP53 protein; Cytarabine metabolite affects the activity of TP53 protein
Cytarabine results in increased activity of TP53 protein
TRP53 protein affects the susceptibility to Cytarabine
TP53 gene mutant form results in increased susceptibility to Cytarabine
[Cytarabine results in increased expression of TP53 protein] which results in increased expression of BAX protein; Cytarabine results in increased expression of TP53 protein
CTD PMID:9703875 PMID:9880587 PMID:10200513 PMID:12082016 PMID:12781215 More... NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tp53i11 tumor protein p53 inducible protein 11 increases response to substance ISO TP53I11 results in increased susceptibility to Cytarabine CTD PMID:21755009 NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
JBrowse link
G Tpk1 thiamin pyrophosphokinase 1 decreases expression ISO Cytarabine results in decreased expression of TPK1 mRNA CTD PMID:21198554 NCBI chr 4:72,170,134...72,557,707
Ensembl chr 4:72,170,134...72,557,694
JBrowse link
G Tpst1 tyrosylprotein sulfotransferase 1 decreases expression ISO Cytarabine results in decreased expression of TPST1 mRNA CTD PMID:21198554 NCBI chr12:26,544,536...26,605,706
Ensembl chr12:26,544,536...26,605,704
JBrowse link
G Trim5 tripartite motif-containing 5 decreases expression ISO Cytarabine results in decreased expression of TRIM5 mRNA CTD PMID:21198554 NCBI chr 1:158,720,407...158,737,393
Ensembl chr 1:158,720,410...158,814,012
JBrowse link
G Trim6 tripartite motif containing 6 decreases expression ISO Cytarabine results in decreased expression of TRIM6 mRNA CTD PMID:21198554 NCBI chr 1:158,683,746...158,696,936
Ensembl chr 1:158,683,746...158,696,914
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 affects localization ISO Cytarabine affects the localization of TRPV1 protein CTD PMID:18414789 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
JBrowse link
G Trpv2 transient receptor potential cation channel, subfamily V, member 2 decreases expression ISO Cytarabine results in decreased expression of TRPV2 mRNA CTD PMID:21198554 NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260
JBrowse link
G Tspan4 tetraspanin 4 decreases expression ISO Cytarabine results in decreased expression of TSPAN4 mRNA CTD PMID:21198554 NCBI chr 1:196,571,307...196,593,842
Ensembl chr 1:196,572,228...196,617,448
JBrowse link
G Tspo translocator protein decreases expression ISO Cytarabine results in decreased expression of TSPO mRNA CTD PMID:21198554 NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
JBrowse link
G Tst thiosulfate sulfurtransferase decreases expression ISO Cytarabine results in decreased expression of TST mRNA CTD PMID:21198554 NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
JBrowse link
G Ttyh1 tweety family member 1 increases expression ISO Cytarabine results in increased expression of TTYH1 mRNA CTD PMID:21198554 NCBI chr 1:70,053,312...70,071,872
Ensembl chr 1:70,053,324...70,071,845
JBrowse link
G Tubb3 tubulin, beta 3 class III decreases expression ISO Cytarabine results in decreased expression of TUBB3 protein CTD PMID:21198554 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
JBrowse link
G Tyms thymidylate synthetase affects response to substance
increases activity
ISO TYMS gene polymorphism affects the susceptibility to Cytarabine
Cytarabine results in increased activity of TYMS protein
CTD PMID:15713801 PMID:15816533 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
JBrowse link
G U2af1 U2 small nuclear RNA auxiliary factor 1 decreases expression ISO Cytarabine results in decreased expression of U2AF1 mRNA CTD PMID:21198554 NCBI chr20:9,742,904...9,753,840
Ensembl chr20:9,742,905...9,753,832
JBrowse link
G Ube2c ubiquitin-conjugating enzyme E2C decreases expression ISO Cytarabine results in decreased expression of UBE2C mRNA CTD PMID:17374387 NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
JBrowse link
G Ubl3 ubiquitin-like 3 increases expression ISO Cytarabine results in increased expression of UBL3 mRNA CTD PMID:19194470 NCBI chr12:6,473,684...6,518,331
Ensembl chr12:6,473,460...6,518,862
JBrowse link
G Usp7 ubiquitin specific peptidase 7 decreases expression ISO Cytarabine results in decreased expression of USP7 mRNA CTD PMID:19194470 NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355
JBrowse link
G Vasn vasorin decreases expression ISO Cytarabine results in decreased expression of VASN mRNA CTD PMID:21198554 NCBI chr10:10,917,750...10,928,259
Ensembl chr10:10,917,605...10,928,357
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression ISO Cytarabine results in increased expression of VCAM1 mRNA CTD PMID:21198554 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vdr vitamin D receptor affects response to substance ISO VDR gene polymorphism affects the susceptibility to Cytarabine CTD PMID:15713801 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
G Vegfc vascular endothelial growth factor C multiple interactions
decreases response to substance
ISO EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
EDN1 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]; PTGS2 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]
CTD PMID:24184161 NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
JBrowse link
G Vezf1 vascular endothelial zinc finger 1 increases expression ISO Cytarabine results in increased expression of VEZF1 mRNA CTD PMID:19194470 NCBI chr10:72,859,669...72,876,111
Ensembl chr10:72,859,877...72,876,111
JBrowse link
G Vgll4 vestigial-like family member 4 decreases expression ISO Cytarabine results in decreased expression of VGLL4 mRNA CTD PMID:21198554 NCBI chr 4:147,925,630...148,038,519
Ensembl chr 4:147,927,034...148,038,471
JBrowse link
G Vrk2 VRK serine/threonine kinase 2 decreases expression ISO Cytarabine results in decreased expression of VRK2 mRNA CTD PMID:21198554 NCBI chr14:100,313,771...100,434,520
Ensembl chr14:100,313,601...100,434,527
JBrowse link
G Wfdc3 WAP four-disulfide core domain 3 decreases expression ISO Cytarabine results in decreased expression of WFDC3 mRNA CTD PMID:21198554 NCBI chr 3:153,464,862...153,478,952
Ensembl chr 3:153,464,862...153,478,952
JBrowse link
G Wipf1 WAS/WASL interacting protein family, member 1 decreases expression ISO Cytarabine results in decreased expression of WIPF1 mRNA CTD PMID:21198554 NCBI chr 3:58,314,521...58,416,668
Ensembl chr 3:58,314,542...58,372,742
JBrowse link
G Xiap X-linked inhibitor of apoptosis increases response to substance ISO XIAP protein results in increased susceptibility to Cytarabine CTD PMID:10815900 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 increases expression ISO Cytarabine results in increased expression of XRCC1 mRNA CTD PMID:19194470 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
JBrowse link
G Yif1a Yip1 interacting factor homolog A, membrane trafficking protein decreases expression ISO Cytarabine results in decreased expression of YIF1A mRNA CTD PMID:21198554 NCBI chr 1:202,394,923...202,399,125
Ensembl chr 1:202,394,897...202,399,427
JBrowse link
G Zc3hav1 zinc finger CCCH-type containing, antiviral 1 decreases expression ISO Cytarabine results in decreased expression of ZC3HAV1 mRNA CTD PMID:21198554 NCBI chr 4:67,012,129...67,062,428
Ensembl chr 4:67,012,185...67,062,428
JBrowse link
G Zfhx4 zinc finger homeobox 4 increases expression ISO Cytarabine results in increased expression of ZFHX4 mRNA CTD PMID:21198554 NCBI chr 2:96,224,763...96,408,245
Ensembl chr 2:96,224,767...96,408,228
JBrowse link
G Zfp282 zinc finger protein 282 increases expression ISO Cytarabine results in increased expression of ZNF282 mRNA CTD PMID:33770205 NCBI chr 4:76,884,996...76,910,250
Ensembl chr 4:76,884,924...76,911,370
JBrowse link
G Zfp423 zinc finger protein 423 increases expression ISO Cytarabine results in increased expression of ZNF423 mRNA CTD PMID:21198554 NCBI chr19:19,111,213...19,407,373
Ensembl chr19:19,110,238...19,407,373
JBrowse link
G Zfp467 zinc finger protein 467 decreases expression ISO Cytarabine results in decreased expression of ZNF467 mRNA CTD PMID:21198554 NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
JBrowse link
G Zfpm2 zinc finger protein, multitype 2 decreases expression ISO Cytarabine results in decreased expression of ZFPM2 mRNA CTD PMID:21198554 NCBI chr 7:71,678,658...72,116,209
Ensembl chr 7:71,678,880...72,116,205
JBrowse link
cytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adora1 adenosine A1 receptor increases activity EXP Cytidine results in increased activity of ADORA1 protein CTD PMID:18313046 NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
JBrowse link
G Adora2a adenosine A2a receptor increases activity EXP Cytidine results in increased activity of ADORA2A protein CTD PMID:18313046 NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [Chlorine binds to Cytidine] which results in decreased expression of CCL5 mRNA CTD PMID:31066272 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Gypa glycophorin A multiple interactions ISO Cytidine inhibits the reaction [teriflunomide results in increased expression of GYPA protein] CTD PMID:12181422 NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of Cytidine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cytidine]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Chlorine binds to Cytidine] which results in increased expression of IL1B mRNA; [Chlorine binds to Cytidine] which results in increased expression of IL1B protein CTD PMID:31066272 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Slc28a1 solute carrier family 28 member 1 multiple interactions
increases transport
ISO Cytidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]
SLC28A1 protein results in increased transport of Cytidine
CTD PMID:9124315 PMID:10772724 NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
JBrowse link
G Slc29a1 solute carrier family 29 member 1 multiple interactions ISO
EXP
Cytidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] CTD PMID:9353301 PMID:11085929 NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
JBrowse link
G Slc29a2 solute carrier family 29 member 2 multiple interactions ISO Cytidine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] CTD PMID:11085929 NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
JBrowse link
G Upp1 uridine phosphorylase 1 increases metabolic processing ISO UPP1 protein results in increased metabolism of Cytidine CTD PMID:15772079 NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462
JBrowse link
cytidine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
JBrowse link
dabrafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 increases expression ISO dabrafenib results in increased expression of ABCC1 mRNA CTD PMID:34780725 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression ISO dabrafenib results in increased expression of ABCG2 mRNA CTD PMID:34780725 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
affects response to substance
increases response to substance
decreases activity
ISO [BRAF protein affects the susceptibility to dabrafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]
dabrafenib results in decreased activity of BRAF protein; dabrafenib results in decreased activity of BRAF protein mutant form
CTD PMID:20823850 PMID:23237741 PMID:26978007 PMID:29950559 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] CTD PMID:26978007 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO dabrafenib results in decreased activity of CYP1A2 protein CTD PMID:34780725 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases activity ISO dabrafenib results in decreased activity of CYP2C19 protein CTD PMID:34780725 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO dabrafenib results in decreased activity of CYP2C8 protein CTD PMID:34780725
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression
multiple interactions
decreases activity
ISO dabrafenib results in increased expression of CYP3A4 mRNA
dabrafenib inhibits the reaction [CYP3A4 protein results in decreased susceptibility to Docetaxel]
dabrafenib results in decreased activity of CYP3A4 protein
CTD PMID:34780725 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 decreases activity ISO dabrafenib results in decreased activity of CYP3A5 protein CTD PMID:34780725 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased expression of GPT protein] CTD PMID:27458080 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased expression of ICAM1 mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of ICAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of ICAM1 protein] CTD PMID:27458080 PMID:29042256 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Il6 interleukin 6 multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased secretion of IL6 protein] CTD PMID:27458080 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [ITGAV protein binds to ITGB5 protein]] CTD PMID:29042256 NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
JBrowse link
G Itgb5 integrin subunit beta 5 multiple interactions ISO dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [ITGAV protein binds to ITGB5 protein]] CTD PMID:29042256 NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
multiple interactions
ISO KRAS protein affects the susceptibility to dabrafenib
[KRAS protein affects the susceptibility to dabrafenib] which affects the expression of TNFRSF10B protein; [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK1 protein; [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK3 protein
CTD PMID:27222248 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK1 protein; dabrafenib inhibits the reaction [Polyphosphates results in increased phosphorylation of MAPK1 protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; SRPIN340 inhibits the reaction [dabrafenib results in increased phosphorylation of MAPK1 protein] CTD PMID:26978007 PMID:27222248 PMID:27458080 PMID:31962201 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO [KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK3 protein; dabrafenib inhibits the reaction [Polyphosphates results in increased phosphorylation of MAPK3 protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib]; SRPIN340 inhibits the reaction [dabrafenib results in increased phosphorylation of MAPK3 protein] CTD PMID:26978007 PMID:27222248 PMID:27458080 PMID:31962201 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased activity of RELA protein] CTD PMID:27458080 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sele selectin E multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased expression of SELE mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of SELE protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of SELE protein] CTD PMID:27458080 PMID:29042256 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases cleavage
multiple interactions
ISO dabrafenib results in decreased cleavage of SREBF1 protein
[BRAF protein affects the susceptibility to dabrafenib] which affects the cleavage of SREBF1 protein
CTD PMID:29950559 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Srsf5 serine and arginine rich splicing factor 5 multiple interactions ISO [SRPIN340 co-treated with dabrafenib] results in decreased phosphorylation of SRSF5 protein CTD PMID:31962201 NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177
JBrowse link
G Tgfbi transforming growth factor, beta induced multiple interactions ISO dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TGFBI mRNA]; dabrafenib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TGFBI protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of ICAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of SELE protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of VCAM1 protein] CTD PMID:29042256 NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased expression of TNF protein] CTD PMID:27458080 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO dabrafenib inhibits the reaction [Polyphosphates results in increased expression of VCAM1 mRNA]; dabrafenib inhibits the reaction [Polyphosphates results in increased expression of VCAM1 protein]; dabrafenib inhibits the reaction [TGFBI protein results in increased expression of VCAM1 protein] CTD PMID:27458080 PMID:29042256 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
ethirimol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 increases transport
multiple interactions
ISO ABCG2 protein results in increased transport of ethirimol
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased transport of ethirimol]
CTD PMID:37011773 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
flucytosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Flucytosine results in decreased expression of BCL2 protein CTD PMID:15592511 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Flucytosine results in increased expression of MDM2 protein CTD PMID:15592511 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Tp53 tumor protein p53 increases expression ISO Flucytosine results in increased expression of TP53 protein CTD PMID:15592511 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
lamivudine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadsb acyl-CoA dehydrogenase, short/branched chain multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ACADSB mRNA CTD PMID:18313992 NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
JBrowse link
G Acsl6 acyl-CoA synthetase long-chain family member 6 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ACSL6 mRNA CTD PMID:18313992 NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO Lamivudine results in decreased expression of ACTA2 protein CTD PMID:11738102 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ADIPOQ mRNA CTD PMID:16931933 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Aebp1 AE binding protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of AEBP1 mRNA CTD PMID:16931933 NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
JBrowse link
G Afap1 actin filament associated protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of AFAP1 mRNA CTD PMID:15784690 NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263
JBrowse link
G Alb albumin affects binding ISO Lamivudine binds to ALB protein CTD PMID:15814459 PMID:16336266 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Alox5ap arachidonate 5-lipoxygenase activating protein multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ALOX5AP mRNA CTD PMID:16931933 NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
JBrowse link
G Aqp9 aquaporin 9 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of AQP9 mRNA CTD PMID:18313992 NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
JBrowse link
G Arpp21 cAMP regulated phosphoprotein 21 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ARPP21 mRNA CTD PMID:16931933 NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
JBrowse link
G Asic2 acid sensing ion channel subunit 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ASIC2 mRNA CTD PMID:16931933 NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ASNS mRNA CTD PMID:15784690 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Ass1 argininosuccinate synthase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ASS1 mRNA CTD PMID:15784690 NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ATF3 mRNA CTD PMID:15784690 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atp2a2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA CTD PMID:11706060 NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
JBrowse link
G Atp5f1c ATP synthase F1 subunit gamma multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ATP5F1C mRNA CTD PMID:18313992 NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
JBrowse link
G Atp5mc3 ATP synthase membrane subunit c locus 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5MC3 mRNA CTD PMID:18313992 NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
JBrowse link
G Atp5mf ATP synthase membrane subunit f multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ATP5MF mRNA CTD PMID:18313992 NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
JBrowse link
G Atp5pd ATP synthase peripheral stalk subunit d multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ATP5PD mRNA CTD PMID:18313992 NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
JBrowse link
G Atp5pf ATP synthase peripheral stalk subunit F6 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ATP5PF mRNA CTD PMID:18313992 NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
JBrowse link
G Atp5po ATP synthase peripheral stalk subunit OSCP multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5PO mRNA CTD PMID:18313992 NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of BCL2 mRNA CTD PMID:18313992 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression ISO Lamivudine results in increased expression of BNIP3L protein CTD PMID:23640862 NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
JBrowse link
G C1r complement C1r multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C1R mRNA CTD PMID:16931933 NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
JBrowse link
G C3ar1 complement C3a receptor 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of C3AR1 mRNA CTD PMID:16931933 NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CARS1 mRNA CTD PMID:15784690 NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
JBrowse link
G Casp3 caspase 3 multiple interactions EXP [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] CTD PMID:36309141 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions EXP [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein CTD PMID:34118364 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccna2 cyclin A2 multiple interactions
decreases expression
ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CCNA2 mRNA
Lamivudine results in decreased expression of CCNA2 mRNA
CTD PMID:15784690 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnc cyclin C multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CCNC mRNA CTD PMID:15784690 NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CCND1 mRNA CTD PMID:15784690 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 decreases expression
multiple interactions
ISO Lamivudine results in decreased expression of CCND2 mRNA
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCND2 mRNA
CTD PMID:15784690 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccne2 cyclin E2 multiple interactions
decreases expression
ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CCNE2 mRNA
Lamivudine results in decreased expression of CCNE2 mRNA
CTD PMID:15784690 NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CD36 mRNA CTD PMID:16931933 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Cd44 CD44 molecule multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CD44 mRNA CTD PMID:15784690 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
JBrowse link
G Cd83 CD83 molecule multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CD83 mRNA CTD PMID:15784690 NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
JBrowse link
G Cdk7 cyclin-dependent kinase 7 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CDK7 mRNA CTD PMID:15784690 NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
multiple interactions
ISO Lamivudine results in decreased expression of CDKN1A mRNA
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1A mRNA
CTD PMID:15784690 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1B mRNA CTD PMID:15784690 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1C mRNA CTD PMID:15784690 NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
JBrowse link
G Cdkn2c cyclin-dependent kinase inhibitor 2C multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN2C mRNA CTD PMID:15784690 NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
JBrowse link
G Cfd complement factor D multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CFD mRNA CTD PMID:16931933 NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CIDEC mRNA CTD PMID:16931933 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Clcn3 chloride voltage-gated channel 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of CLCN3 mRNA CTD PMID:16931933 NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
JBrowse link
G Col3a1 collagen type III alpha 1 chain decreases expression ISO Lamivudine results in decreased expression of COL3A1 protein CTD PMID:11738102 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Comt catechol-O-methyltransferase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COMT mRNA CTD PMID:15784690 NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
JBrowse link
G Cox5a cytochrome c oxidase subunit 5A multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of COX5A mRNA CTD PMID:18313992 NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
JBrowse link
G Cox5b cytochrome c oxidase subunit 5B multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COX5B mRNA CTD PMID:18313992 NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
JBrowse link
G Cox6a1 cytochrome c oxidase subunit 6A1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COX6A1 mRNA CTD PMID:18313992 NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041
JBrowse link
G Cox6c cytochrome c oxidase subunit 6C multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COX6C mRNA CTD PMID:18313992 NCBI chr 7:67,129,265...67,142,001
Ensembl chr 7:67,111,024...67,141,963
JBrowse link
G Cox7c cytochrome c oxidase subunit 7C multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COX7C mRNA CTD PMID:18313992 NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CPT1A mRNA CTD PMID:18313992 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Crat carnitine O-acetyltransferase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CRAT mRNA CTD PMID:18313992 NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
JBrowse link
G Cul7 cullin 7 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CUL7 mRNA CTD PMID:18313992 NCBI chr 9:14,319,102...14,333,035
Ensembl chr 9:14,319,108...14,332,741
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of CYB5A mRNA CTD PMID:18313992 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of CYP11A1 mRNA CTD PMID:18313992 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Dck deoxycytidine kinase multiple interactions ISO DCK protein results in increased phosphorylation of and results in increased activity of Lamivudine CTD PMID:17530837 NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
JBrowse link
G Dcn decorin multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DCN mRNA CTD PMID:16931933 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
ISO Lamivudine results in increased expression of DDIT3 mRNA
[Zidovudine co-treated with Lamivudine] results in increased expression of DDIT3 mRNA
CTD PMID:15784690 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dhfr dihydrofolate reductase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of DHFR mRNA CTD PMID:15784690 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of DIABLO mRNA CTD PMID:18313992 NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Dlst dihydrolipoamide S-succinyltransferase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of DLST mRNA CTD PMID:18313992 NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
JBrowse link
G Dnaja3 DnaJ heat shock protein family (Hsp40) member A3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of DNAJA3 mRNA CTD PMID:18313992 NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161
JBrowse link
G Dusp3 dual specificity phosphatase 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of DUSP3 mRNA CTD PMID:16931933 NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962
JBrowse link
G Echs1 enoyl-CoA hydratase, short chain 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of ECHS1 mRNA CTD PMID:18313992 NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
JBrowse link
G Eci1 enoyl-CoA delta isomerase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ECI1 mRNA CTD PMID:18313992 NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
JBrowse link
G Edn1 endothelin 1 multiple interactions
increases secretion
ISO coenzyme Q10 inhibits the reaction [Lamivudine results in increased secretion of EDN1 protein] CTD PMID:23640862 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of EIF4EBP1 mRNA CTD PMID:15784690 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Elovl3 ELOVL fatty acid elongase 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of ELOVL3 mRNA CTD PMID:16931933 NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA CTD PMID:16931933 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Etv6 ETS variant transcription factor 6 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ETV6 mRNA CTD PMID:16931933 NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
JBrowse link
G Fads2 fatty acid desaturase 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of FADS2 mRNA CTD PMID:16931933 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
JBrowse link
G Faim Fas apoptotic inhibitory molecule multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of FAIM mRNA CTD PMID:16931933 NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of FASN mRNA CTD PMID:11741158 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fdxr ferredoxin reductase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of FDXR mRNA CTD PMID:18313992 NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
JBrowse link
G Fh fumarate hydratase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of FH1 mRNA CTD PMID:18313992 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
JBrowse link
G G0s2 G0/G1switch 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of G0S2 mRNA CTD PMID:16931933 NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of G6PC1 mRNA CTD PMID:16931933 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
JBrowse link
G Ganc glucosidase, alpha; neutral C multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of GANC mRNA CTD PMID:16931933 NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
JBrowse link
G Gars1 glycyl-tRNA synthetase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of GARS1 mRNA CTD PMID:15784690 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
JBrowse link
G Gas1 growth arrest-specific 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of GAS1 mRNA CTD PMID:15784690 NCBI chr17:4,482,168...4,485,153 JBrowse link
G Grhl2 grainyhead-like transcription factor 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of GRHL2 mRNA CTD PMID:16931933 NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258
JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of GUCY1B1 mRNA CTD PMID:16931933 NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
JBrowse link
G Gypa glycophorin A multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased mutagenesis of GYPA gene CTD PMID:17358027 NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of HADH mRNA CTD PMID:16931933 NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of HADHA mRNA CTD PMID:18313992 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
JBrowse link
G Hax1 HCLS1 associated protein X-1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of HAX1 mRNA CTD PMID:15784690 NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
JBrowse link
G Hcn1 hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of HCN1 mRNA CTD PMID:16931933 NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774
JBrowse link
G Hist1h4b histone cluster 1 H4 family member B multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of H4C9 mRNA CTD PMID:16931933 NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of HMGCS2 mRNA CTD PMID:18313992 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
JBrowse link
G Hrk harakiri, BCL2 interacting protein multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of HRK mRNA CTD PMID:16931933 NCBI chr12:38,387,484...38,409,652 JBrowse link
G Hsd3b3 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B3 mRNA CTD PMID:18313992 NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of IDH2 mRNA CTD PMID:18313992 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of IDH3A mRNA CTD PMID:18313992 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
JBrowse link
G Idh3g isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of IDH3G mRNA CTD PMID:18313992 NCBI chr  X:151,515,244...151,524,175
Ensembl chr  X:151,515,247...151,524,171
JBrowse link
G Ifng interferon gamma increases expression ISO Lamivudine results in increased expression of IFNG protein CTD PMID:16250037 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Ikzf4 IKAROS family zinc finger 4 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of IKZF4 mRNA CTD PMID:16931933 NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] CTD PMID:36309141 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il27ra interleukin 27 receptor subunit alpha multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of IL27RA mRNA CTD PMID:15784690 NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938
JBrowse link
G Inpp5e inositol polyphosphate-5-phosphatase E multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of INPP5E mRNA CTD PMID:18313992 NCBI chr 3:9,216,776...9,229,539
Ensembl chr 3:9,216,776...9,229,450
JBrowse link
G Kcng1 potassium voltage-gated channel modifier subfamily G member 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of KCNG1 mRNA CTD PMID:15784690 NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
JBrowse link
G Kifc2 kinesin family member C2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of KIFC2 mRNA CTD PMID:16931933 NCBI chr 7:108,380,634...108,388,364
Ensembl chr 7:108,376,011...108,388,484
JBrowse link
G Klf4 KLF transcription factor 4 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of KLF4 mRNA CTD PMID:15784690 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Klhl28 kelch-like family member 28 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of KLHL28 mRNA CTD PMID:16931933 NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164
JBrowse link
G Krt7 keratin 7 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of KRT7 mRNA CTD PMID:15784690 NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
JBrowse link
G Kynu kynureninase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of KYNU mRNA CTD PMID:15784690 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
JBrowse link
G Lamb3 laminin subunit beta 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of LAMB3 mRNA CTD PMID:15784690 NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
JBrowse link
G Lamc2 laminin subunit gamma 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of LAMC2 mRNA CTD PMID:16931933 NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEF1 mRNA CTD PMID:16931933 NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
JBrowse link
G Lep leptin multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEP mRNA CTD PMID:16931933 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lpl lipoprotein lipase decreases expression
multiple interactions
ISO Lamivudine results in decreased expression of LPL mRNA
[Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of LPL mRNA; [Stavudine co-treated with Lamivudine] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of LPL mRNA
CTD PMID:11741158 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mars1 methionyl-tRNA synthetase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of MARS1 mRNA CTD PMID:15784690 NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
JBrowse link
G Me1 malic enzyme 1 multiple interactions
increases expression
ISO [Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine] affects the expression of ME1 mRNA
Lamivudine results in increased expression of ME1 mRNA
CTD PMID:11741158 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
JBrowse link
G Mfn1 mitofusin 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of MFN1 mRNA CTD PMID:18313992 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
JBrowse link
G Mfn2 mitofusin 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of MFN2 mRNA CTD PMID:18313992 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
JBrowse link
G Mgat4c MGAT4 family, member C multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MGAT4C mRNA CTD PMID:16931933 NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO Lamivudine results in increased expression of MMP1 protein CTD PMID:15309715 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP [efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein CTD PMID:34118364 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Mrap melanocortin 2 receptor accessory protein multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of MRAP mRNA CTD PMID:16931933 NCBI chr11:29,991,974...30,003,024
Ensembl chr11:29,992,034...30,003,024
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of COX1 mRNA CTD PMID:17526437 PMID:18313992 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mt-co2 mitochondrially encoded cytochrome c oxidase II multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of COX2 mRNA CTD PMID:18313992 NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
JBrowse link
G Mt-co3 mitochondrially encoded cytochrome c oxidase III multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of COX3 mRNA CTD PMID:17526437 PMID:18313992 NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
JBrowse link
G Mt-nd2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ND2 mRNA CTD PMID:18313992 NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
JBrowse link
G Mt-nd5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of ND5 mRNA CTD PMID:17526437 PMID:18313992 NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of MTHFD2 mRNA CTD PMID:15784690 NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
JBrowse link
G Myod1 myogenic differentiation 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MYOD1 mRNA CTD PMID:16931933 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
JBrowse link
G Nap1l5 nucleosome assembly protein 1-like 5 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NAP1L5 mRNA CTD PMID:16931933 NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654
JBrowse link
G Ndufa4 Ndufa4, mitochondrial complex associated multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFA4 mRNA CTD PMID:18313992 NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
JBrowse link
G Ndufab1 NADH:ubiquinone oxidoreductase subunit AB1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAB1 mRNA CTD PMID:18313992 NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
JBrowse link
G Ndufaf1 NADH:ubiquinone oxidoreductase complex assembly factor 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAF1 mRNA CTD PMID:18313992 NCBI chr 3:106,639,025...106,650,549
Ensembl chr 3:106,639,851...106,650,212
JBrowse link
G Ndufb3 NADH:ubiquinone oxidoreductase subunit B3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB3 mRNA CTD PMID:18313992 NCBI chr 9:60,129,240...60,139,452
Ensembl chr 9:60,129,154...60,139,446
JBrowse link
G Ndufb5 NADH:ubiquinone oxidoreductase subunit B5 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB5 mRNA CTD PMID:18313992 NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
JBrowse link
G Ndufb9 NADH:ubiquinone oxidoreductase subunit B9 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFB9 mRNA CTD PMID:18313992 NCBI chr 7:90,480,948...90,487,367
Ensembl chr 7:90,436,621...90,488,009
JBrowse link
G Ndufc1 NADH:ubiquinone oxidoreductase subunit C1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFC1 mRNA CTD PMID:18313992 NCBI chr 2:135,447,067...135,450,950
Ensembl chr 2:135,447,119...135,450,874
JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NDUFS1 mRNA CTD PMID:18313992 NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
JBrowse link
G Niban1 niban apoptosis regulator 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NIBAN1 mRNA CTD PMID:15784690 NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
JBrowse link
G Noct nocturnin multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of NOCT mRNA CTD PMID:16931933 NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions
decreases phosphorylation
ISO coenzyme Q10 inhibits the reaction [Lamivudine results in decreased phosphorylation of NOS3 protein] CTD PMID:23640862 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Nppa natriuretic peptide A multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NPPA mRNA CTD PMID:11706060 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Nup210 nucleoporin 210 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NUP210 mRNA CTD PMID:16931933 NCBI chr 4:123,511,558...123,609,874
Ensembl chr 4:123,511,559...123,609,874
JBrowse link
G Nxnl2 nucleoredoxin-like 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of NXNL2 mRNA CTD PMID:16931933 NCBI chr17:14,031,151...14,035,897
Ensembl chr17:14,031,153...14,036,189
JBrowse link
G Oaz3 ornithine decarboxylase antizyme 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of OAZ3 mRNA CTD PMID:16931933 NCBI chr 2:182,073,212...182,076,147
Ensembl chr 2:182,073,215...182,082,399
JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of OGT mRNA CTD PMID:15784690 NCBI chr  X:66,771,278...66,816,148
Ensembl chr  X:66,771,349...66,816,146
JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of OPA1 mRNA CTD PMID:18313992 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
JBrowse link
G Oprl1 opioid related nociceptin receptor 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of OPRL1 mRNA CTD PMID:16931933 NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
JBrowse link
G Pcdh15 protocadherin related 15 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PCDH15 mRNA CTD PMID:16931933 NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
JBrowse link
G Pck2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of PCK2 mRNA CTD PMID:15784690 NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
JBrowse link
G Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PFKFB3 mRNA CTD PMID:16931933 NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
JBrowse link
G Pgap6 post-GPI attachment to proteins 6 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of PGAP6 mRNA CTD PMID:16931933 NCBI chr10:15,138,918...15,148,431
Ensembl chr10:15,138,959...15,148,431
JBrowse link
G Phf6 PHD finger protein 6 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of PHF6 mRNA CTD PMID:16931933 NCBI chr  X:132,656,658...132,699,720
Ensembl chr  X:132,656,672...132,699,127
JBrowse link
G Pidd1 p53-induced death domain protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIDD1 mRNA CTD PMID:16931933 NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
JBrowse link
G Piwil2 piwi-like RNA-mediated gene silencing 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PIWIL2 mRNA CTD PMID:16931933 NCBI chr15:45,431,402...45,498,034
Ensembl chr15:45,431,703...45,497,702
JBrowse link
G Porcn porcupine O-acyltransferase multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PPN mRNA CTD PMID:16931933 NCBI chr  X:14,285,864...14,298,481
Ensembl chr  X:14,285,871...14,298,481
JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of POU5F1 mRNA CTD PMID:16931933 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Prdm1 PR/SET domain 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PRDM1 mRNA CTD PMID:16931933 NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
JBrowse link
G Psat1 phosphoserine aminotransferase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of PSAT1 mRNA CTD PMID:15784690 NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
JBrowse link
G Rabepk Rab9 effector protein with kelch motifs multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of RABEPK mRNA CTD PMID:15784690 NCBI chr 3:18,061,299...18,083,191
Ensembl chr 3:18,061,574...18,083,191
JBrowse link
G Rbl1 RB transcriptional corepressor like 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of RBL1 mRNA CTD PMID:15784690 NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
JBrowse link
G Rbl2 RB transcriptional corepressor like 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of RBL2 mRNA CTD PMID:15784690 NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
JBrowse link
G Reep6 receptor accessory protein 6 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of REEP6 mRNA CTD PMID:16931933 NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597
JBrowse link
G Ripk2 receptor-interacting serine-threonine kinase 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of RIPK2 mRNA CTD PMID:15784690 NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657
JBrowse link
G Rnf151 ring finger protein 151 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of RNF151 mRNA CTD PMID:16931933 NCBI chr10:13,742,682...13,747,192
Ensembl chr10:13,742,682...13,745,000
JBrowse link
G Rpain RPA interacting protein multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of RPAIN mRNA CTD PMID:16931933 NCBI chr10:55,692,410...55,699,910
Ensembl chr10:55,692,417...55,699,933
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of S100A8 mRNA CTD PMID:16931933 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of SDHB mRNA CTD PMID:18313992 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Serinc1 serine incorporator 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of SERINC1 mRNA CTD PMID:16931933 NCBI chr20:36,850,062...36,868,999
Ensembl chr20:36,850,076...36,896,691
JBrowse link
G Sfxn1 sideroflexin 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SFXN1 mRNA CTD PMID:18313992 NCBI chr17:10,486,250...10,522,640
Ensembl chr17:10,486,271...10,522,529
JBrowse link
G Sfxn2 sideroflexin 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SFXN2 mRNA CTD PMID:18313992 NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411
JBrowse link
G Sfxn4 sideroflexin 4 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SFXN4 mRNA CTD PMID:18313992 NCBI chr 1:259,976,480...259,998,778
Ensembl chr 1:259,976,481...259,998,754
JBrowse link
G Sgpp1 sphingosine-1-phosphate phosphatase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SGPP1 mRNA CTD PMID:18313992 NCBI chr 6:94,425,339...94,446,534
Ensembl chr 6:94,425,339...94,446,534
JBrowse link
G Slc1a4 solute carrier family 1 member 4 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A4 mRNA CTD PMID:15784690 NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418
JBrowse link
G Slc1a5 solute carrier family 1 member 5 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A5 mRNA CTD PMID:15784690 NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases uptake ISO SLC22A1 protein results in increased uptake of Lamivudine CTD PMID:19141712 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases uptake ISO SLC22A2 protein results in increased uptake of Lamivudine CTD PMID:19141712 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 increases uptake ISO SLC22A3 protein results in increased uptake of Lamivudine CTD PMID:19141712 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
G Slc25a12 solute carrier family 25 member 12 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A12 mRNA CTD PMID:18313992 NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100
JBrowse link
G Slc25a15 solute carrier family 25 member 15 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A15 mRNA CTD PMID:18313992 NCBI chr16:69,631,581...69,654,869
Ensembl chr16:69,634,414...69,653,010
JBrowse link
G Slc25a19 solute carrier family 25 member 19 multiple interactions ISO SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir]
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A19 mRNA
CTD PMID:15951836 PMID:18313992 NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447
JBrowse link
G Slc25a2 solute carrier family 25 member 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A2 mRNA CTD PMID:18313992 NCBI chr18:29,452,943...29,456,324
Ensembl chr18:29,453,582...29,460,383
JBrowse link
G Slc25a20 solute carrier family 25 member 20 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A20 mRNA CTD PMID:18313992 NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
JBrowse link
G Slc25a29 solute carrier family 25 member 29 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A29 mRNA CTD PMID:18313992 NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940
JBrowse link
G Slc25a3 solute carrier family 25 member 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A3 mRNA CTD PMID:18313992 NCBI chr 7:25,611,937...25,619,401
Ensembl chr 7:25,586,725...25,667,727
JBrowse link
G Slc25a4 solute carrier family 25 member 4 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A4 mRNA CTD PMID:18313992 NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
JBrowse link
G Slc28a1 solute carrier family 28 member 1 multiple interactions ISO Lamivudine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] CTD PMID:10772724 NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
JBrowse link
G Slc31a1 solute carrier family 31 member 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC31A1 mRNA CTD PMID:15784690 NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
JBrowse link
G Slc3a2 solute carrier family 3 member 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC3A2 mRNA CTD PMID:15784690 NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
JBrowse link
G Slc40a1 solute carrier family 40 member 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SLC40A1 mRNA CTD PMID:18313992 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
JBrowse link
G Slc6a4 solute carrier family 6 member 4 multiple interactions
increases expression
ISO [Lamivudine co-treated with IFNA2 protein] results in increased expression of SLC6A4 mRNA; Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein
Lamivudine results in increased expression of SLC6A4 mRNA
CTD PMID:16476009 NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
JBrowse link
G Spink5 serine peptidase inhibitor, Kazal type 5 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of SPINK5 mRNA CTD PMID:16931933 NCBI chr18:36,264,452...36,333,143
Ensembl chr18:36,264,452...36,332,185
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of STAR mRNA CTD PMID:18313992 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stc2 stanniocalcin 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of STC2 mRNA CTD PMID:15784690 NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
JBrowse link
G Sub1 SUB1 regulator of transcription multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of SUB1 mRNA CTD PMID:16931933 NCBI chr 2:61,005,646...61,020,486
Ensembl chr 2:61,005,666...61,020,436
Ensembl chr 2:61,005,666...61,020,436
JBrowse link
G Tcea1 transcription elongation factor A1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of TCEA1 mRNA CTD PMID:15784690 NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745
Ensembl chr15:14,631,454...14,668,745
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases expression ISO Lamivudine results in decreased expression of TGFB1 protein CTD PMID:15309715 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Timm17b translocase of inner mitochondrial membrane 17b multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of TIMM17B mRNA CTD PMID:18313992 NCBI chr  X:14,596,330...14,603,491
Ensembl chr  X:14,594,577...14,603,416
JBrowse link
G Timm23 translocase of inner mitochondrial membrane 23 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of TIMM23 mRNA CTD PMID:18313992 NCBI chr16:7,410,308...7,436,392
Ensembl chr16:7,409,688...7,436,379
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 decreases expression ISO Lamivudine results in decreased expression of TIMP1 protein CTD PMID:15309715 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TIMP2 mRNA CTD PMID:16931933 NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
JBrowse link
G Tk2 thymidine kinase 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of TK2 mRNA CTD PMID:18313992 NCBI chr19:708,859...731,786
Ensembl chr19:708,891...730,924
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] CTD PMID:36309141 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of TRIB3 mRNA CTD PMID:15784690 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Trim42 tripartite motif-containing 42 multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TRIM42 mRNA CTD PMID:16931933 NCBI chr 8:97,902,349...97,923,268
Ensembl chr 8:97,902,353...97,923,268
JBrowse link
G Twnk twinkle mtDNA helicase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of TWNK mRNA CTD PMID:18313992 NCBI chr 1:243,867,568...243,874,802
Ensembl chr 1:243,868,330...243,874,802
JBrowse link
G Tyms thymidylate synthetase multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of TYMS mRNA CTD PMID:15784690 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
JBrowse link
G Tyrp1 tyrosinase-related protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of TYRP1 mRNA CTD PMID:15784690 NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
JBrowse link
G Uqcrb ubiquinol-cytochrome c reductase binding protein multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of UQCRB mRNA CTD PMID:18313992 NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150
JBrowse link
G Uqcrc1 ubiquinol-cytochrome c reductase core protein 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of UQCRC1 mRNA CTD PMID:17526437 PMID:18313992 NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of UQCRC2 mRNA CTD PMID:18313992 NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of VDAC1 mRNA CTD PMID:18313992 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of VDR mRNA CTD PMID:11741158 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
G Vps4b vacuolar protein sorting 4 homolog B multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in decreased expression of VPS4B mRNA CTD PMID:16931933 NCBI chr13:22,907,105...22,932,200
Ensembl chr13:22,907,109...22,932,229
JBrowse link
G Wars1 tryptophanyl-tRNA synthetase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of WARS1 mRNA CTD PMID:15784690 NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
JBrowse link
G Wnt10a Wnt family member 10A multiple interactions ISO [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of WNT10A mRNA CTD PMID:16931933 NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
JBrowse link
G Yars1 tyrosyl-tRNA synthetase 1 multiple interactions ISO [Zidovudine co-treated with Lamivudine] results in increased expression of YARS1 mRNA CTD PMID:15784690 NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
JBrowse link
mepanipyrim term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO mepanipyrim binds to and results in increased activity of AHR protein CTD PMID:23436777 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]
CTD PMID:31939705 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
JBrowse link
G App amyloid beta precursor protein multiple interactions ISO [APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to mepanipyrim; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] CTD PMID:31939705 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of BACE1 protein CTD PMID:31939705 NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
JBrowse link
G Esr1 estrogen receptor 1 increases activity EXP mepanipyrim results in increased activity of ESR1 protein CTD PMID:33352482 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
CTD PMID:31939705 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein] CTD PMID:31939705 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein] CTD PMID:31939705 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Nrf1 nuclear respiratory factor 1 increases expression ISO mepanipyrim results in increased expression of NRF1 mRNA CTD PMID:33352482 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
minoxidil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ereg epiregulin decreases expression ISO Minoxidil results in decreased expression of EREG mRNA CTD PMID:32816093 NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
JBrowse link
G Il24 interleukin 24 decreases expression ISO Minoxidil results in decreased expression of IL24 mRNA CTD PMID:32816093 NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases expression ISO Minoxidil results in decreased expression of MET mRNA CTD PMID:32816093 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Ren renin affects expression
increases expression
increases activity
multiple interactions
ISO
EXP
Minoxidil affects the expression of REN protein
Minoxidil results in increased expression of REN protein
Minoxidil results in increased activity of REN protein
Minoxidil binds to and results in decreased activity of REN protein
CTD PMID:28811 PMID:145319 PMID:790007 PMID:8238566 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO Minoxidil results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 increases sulfation ISO
EXP
SULT1A1 protein results in increased sulfation of Minoxidil CTD PMID:11181495 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
JBrowse link
mocetinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd274 CD274 molecule increases expression ISO mocetinostat results in increased expression of CD274 protein CTD PMID:26775640 NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
JBrowse link
G Cd69 Cd69 molecule multiple interactions ISO mocetinostat inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of CD69 protein] CTD PMID:24200994 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
JBrowse link
G Cdca8 cell division cycle associated 8 decreases expression ISO mocetinostat results in decreased expression of CDCA8 mRNA CTD PMID:26378038 NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO mocetinostat results in decreased expression of CDK1 mRNA CTD PMID:26378038 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 increases expression ISO mocetinostat results in increased expression of ERRFI1 mRNA CTD PMID:33770205 NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
JBrowse link
G Gpr183 G protein-coupled receptor 183 decreases expression ISO mocetinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
JBrowse link
G H3f4 H3.4 histone, cluster member increases acetylation ISO mocetinostat results in increased acetylation of H3-4 protein CTD PMID:19215824 NCBI chr10:43,740,702...43,741,262 JBrowse link
G Hdac1 histone deacetylase 1 decreases expression ISO mocetinostat results in decreased expression of HDAC1 protein CTD PMID:26378038 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hdac2 histone deacetylase 2 decreases expression ISO mocetinostat results in decreased expression of HDAC2 protein CTD PMID:26378038 NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
JBrowse link
G Hdac3 histone deacetylase 3 decreases expression ISO mocetinostat results in decreased expression of HDAC3 protein CTD PMID:26378038 NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
JBrowse link
G Ifng interferon gamma multiple interactions ISO mocetinostat inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IFNG protein] CTD PMID:24200994 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il2 interleukin 2 multiple interactions ISO mocetinostat inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL2 protein] CTD PMID:24200994 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 multiple interactions ISO mocetinostat inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL6 protein] CTD PMID:24200994 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [mocetinostat co-treated with (+)-JQ1 compound] results in decreased phosphorylation of MAPK1 protein CTD PMID:26378038 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [mocetinostat co-treated with (+)-JQ1 compound] results in decreased phosphorylation of MAPK3 protein CTD PMID:26378038 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Neu1 neuraminidase 1 decreases expression ISO mocetinostat results in decreased expression of NEU1 mRNA CTD PMID:33770205 NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745
JBrowse link
G Potem POTE ankyrin domain family member M increases expression ISO mocetinostat results in increased expression of POTEM mRNA CTD PMID:33770205 NCBI chr16:20,193,646...20,311,924
Ensembl chr16:19,949,230...19,976,541
JBrowse link
G Psd3 pleckstrin and Sec7 domain containing 3 increases expression ISO mocetinostat results in increased expression of PSD3 mRNA CTD PMID:33770205 NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
JBrowse link
G Ralgdsl1 ral guanine nucleotide dissociation stimulator like 1 increases expression ISO mocetinostat results in increased expression of RGL1 mRNA CTD PMID:33770205 NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases acetylation ISO mocetinostat results in increased acetylation of STAT3 protein CTD PMID:26775640 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Tmcc3 transmembrane and coiled-coil domain family 3 increases expression ISO mocetinostat results in increased expression of TMCC3 mRNA CTD PMID:33770205 NCBI chr 7:28,893,972...29,171,935
Ensembl chr 7:28,893,967...29,171,926
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO mocetinostat inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of TNF protein] CTD PMID:24200994 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tpcn1 two pore segment channel 1 increases expression ISO mocetinostat results in increased expression of TPCN1 mRNA CTD PMID:33770205 NCBI chr12:35,972,813...36,029,632
Ensembl chr12:35,972,846...36,029,626
JBrowse link
G Ugcg UDP-glucose ceramide glucosyltransferase increases expression ISO mocetinostat results in increased expression of UGCG mRNA CTD PMID:33770205 NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
JBrowse link
N(4)-hydroxycytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aars1 alanyl-tRNA synthetase 1 increases expression ISO N(4)-hydroxycytidine results in increased expression of AARS mRNA CTD PMID:37748715 NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
JBrowse link
G Abcf3 ATP binding cassette subfamily F member 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ABCF3 mRNA CTD PMID:37748715 NCBI chr11:80,340,476...80,352,211
Ensembl chr11:80,339,977...80,352,211
JBrowse link
G Ace angiotensin I converting enzyme decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ACE mRNA CTD PMID:37748715 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Adap2 ArfGAP with dual PH domains 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ADAP2 mRNA CTD PMID:37748715 NCBI chr10:65,138,006...65,166,147
Ensembl chr10:65,138,020...65,165,604
JBrowse link
G Adgra2 adhesion G protein-coupled receptor A2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ADGRA2 mRNA CTD PMID:37748715 NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483
JBrowse link
G Adgra3 adhesion G protein-coupled receptor A3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ADGRA3 mRNA CTD PMID:37748715 NCBI chr14:60,874,719...60,976,341
Ensembl chr14:60,874,715...60,976,332
JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ADGRG1 mRNA CTD PMID:37748715 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
JBrowse link
G Akirin1 akirin 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of AKIRIN1 mRNA CTD PMID:37748715 NCBI chr 5:135,989,378...136,004,782
Ensembl chr 5:135,989,465...136,004,762
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 increases expression ISO N(4)-hydroxycytidine results in increased expression of ALDH18A1 mRNA CTD PMID:37748715 NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
JBrowse link
G Alkbh5 alkB homolog 5, RNA demethylase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ALKBH5 mRNA CTD PMID:37748715 NCBI chr10:45,344,888...45,366,331
Ensembl chr10:45,343,395...45,366,331
JBrowse link
G Apbb1ip amyloid beta precursor protein binding family B member 1 interacting protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of APBB1IP mRNA CTD PMID:37748715 NCBI chr17:84,941,404...85,033,020
Ensembl chr17:84,982,243...85,033,010
JBrowse link
G Apela apelin receptor early endogenous ligand decreases expression ISO N(4)-hydroxycytidine results in decreased expression of APELA mRNA CTD PMID:37748715 NCBI chr16:24,694,356...24,703,466
Ensembl chr16:24,694,324...24,703,465
JBrowse link
G Arih2 ariadne RBR E3 ubiquitin protein ligase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ARIH2 mRNA CTD PMID:37748715 NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852
JBrowse link
G Arl14ep ADP-ribosylation factor like GTPase 14 effector protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ARL14EP mRNA CTD PMID:37748715 NCBI chr 3:93,441,952...93,454,282
Ensembl chr 3:93,443,183...93,454,155
JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ARNT mRNA CTD PMID:37748715 NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
JBrowse link
G Arrdc4 arrestin domain containing 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ARRDC4 mRNA CTD PMID:37748715 NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
JBrowse link
G Asb8 ankyrin repeat and SOCS box-containing 8 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ASB8 mRNA CTD PMID:37748715 NCBI chr 7:129,261,397...129,297,492
Ensembl chr 7:129,261,397...129,297,485
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions
ISO N(4)-hydroxycytidine results in increased expression of ASNS mRNA
4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of ASNS mRNA]
CTD PMID:37748715 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Ate1 arginyltransferase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ATE1 mRNA CTD PMID:37748715 NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908
JBrowse link
G Atf2 activating transcription factor 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ATF2 mRNA CTD PMID:37748715 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO N(4)-hydroxycytidine results in increased expression of ATF3 mRNA CTD PMID:37748715 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atf4 activating transcription factor 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ATF4 mRNA CTD PMID:37748715 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf5 activating transcription factor 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ATF5 mRNA CTD PMID:37748715 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
JBrowse link
G Atf6 activating transcription factor 6 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ATF6 mRNA CTD PMID:37748715 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Aup1 AUP1, lipid droplet regulating VLDL assembly factor decreases expression ISO N(4)-hydroxycytidine results in decreased expression of AUP1 mRNA CTD PMID:37748715 NCBI chr 4:115,560,274...115,563,346
Ensembl chr 4:115,560,261...115,563,346
JBrowse link
G Avil advillin decreases expression ISO N(4)-hydroxycytidine results in decreased expression of AVIL mRNA CTD PMID:37748715 NCBI chr 7:62,825,459...62,844,103
Ensembl chr 7:62,826,025...62,844,071
JBrowse link
G B3galnt1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) decreases expression ISO N(4)-hydroxycytidine results in decreased expression of B3GALNT1 mRNA CTD PMID:37748715 NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332
JBrowse link
G Bbx BBX high mobility group box domain containing decreases expression ISO N(4)-hydroxycytidine results in decreased expression of BBX mRNA CTD PMID:37748715 NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of BGLAP mRNA CTD PMID:37748715 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Brms1l BRMS1 like transcriptional repressor decreases expression ISO N(4)-hydroxycytidine results in decreased expression of BRMS1L mRNA CTD PMID:37748715 NCBI chr 6:73,266,673...73,300,630
Ensembl chr 6:73,266,691...73,300,631
JBrowse link
G Calml4 calmodulin-like 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CALML4 mRNA CTD PMID:37748715 NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:63,323,351...63,335,234
JBrowse link
G Carhsp1 calcium regulated heat stable protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CARHSP1 mRNA CTD PMID:37748715 NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019
JBrowse link
G Carmil1 capping protein regulator and myosin 1 linker 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of LRRC16A mRNA CTD PMID:37748715 NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326
JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 increases expression ISO N(4)-hydroxycytidine results in increased expression of CARS mRNA CTD PMID:37748715 NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
JBrowse link
G Cbx7 chromobox 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CBX7 mRNA CTD PMID:37748715 NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
JBrowse link
G Ccnb2 cyclin B2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CCNB2 mRNA CTD PMID:37748715 NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
JBrowse link
G Cd68 Cd68 molecule decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CD68 mRNA CTD PMID:37748715 NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
JBrowse link
G Cdca3 cell division cycle associated 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CDCA3 mRNA CTD PMID:37748715 NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
JBrowse link
G Cebpg CCAAT/enhancer binding protein gamma decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CEBPG mRNA CTD PMID:37748715 NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
JBrowse link
G Cep170 centrosomal protein 170 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CEP170 mRNA CTD PMID:37748715 NCBI chr13:88,669,672...88,754,011
Ensembl chr13:88,670,358...88,732,226
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of CHAC1 mRNA] CTD PMID:37748715 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Coa7 cytochrome c oxidase assembly factor 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of COA7 mRNA CTD PMID:37748715 NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
JBrowse link
G Commd5 COMM domain containing 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of COMMD5 mRNA CTD PMID:37748715 NCBI chr 7:108,621,766...108,623,616
Ensembl chr 7:108,598,673...108,624,764
JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of COX6A2 mRNA CTD PMID:37748715 NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CPT1A mRNA CTD PMID:37748715 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cryzl1 crystallin zeta like 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CRYZL1 mRNA CTD PMID:37748715 NCBI chr11:30,933,140...30,977,936
Ensembl chr11:30,933,144...30,977,867
JBrowse link
G Csf3r colony stimulating factor 3 receptor decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CSF3R mRNA CTD PMID:37748715 NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881
JBrowse link
G Ctps2 CTP synthase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of CTPS2 mRNA CTD PMID:37748715 NCBI chr  X:31,645,873...31,786,733
Ensembl chr  X:31,645,873...31,786,733
JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC1 protein] results in increased reduction of N(4)-hydroxycytidine; [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC2 protein] results in increased reduction of N(4)-hydroxycytidine CTD PMID:22924387 NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 multiple interactions ISO [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC1 protein] results in increased reduction of N(4)-hydroxycytidine; [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC2 protein] results in increased reduction of N(4)-hydroxycytidine CTD PMID:22924387 NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
JBrowse link
G Dcaf15 DDB1 and CUL4 associated factor 15 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DCAF15 mRNA CTD PMID:37748715 NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277
JBrowse link
G Ddhd2 DDHD domain containing 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DDHD2 mRNA CTD PMID:37748715 NCBI chr16:66,319,469...66,349,025
Ensembl chr16:66,319,466...66,349,023
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of DDIT3 mRNA] CTD PMID:37748715 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 increases expression ISO N(4)-hydroxycytidine results in increased expression of DDIT4 mRNA CTD PMID:37748715 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
JBrowse link
G Ddx19b DEAD-box helicase 19B decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DDX19B mRNA CTD PMID:37748715 NCBI chr19:38,968,215...38,998,907
Ensembl chr19:38,968,215...38,997,259
JBrowse link
G Ddx4 DEAD-box helicase 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DDX4 mRNA CTD PMID:37748715 NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723
JBrowse link
G Def8 differentially expressed in FDCP 8 homolog decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DEF8 mRNA CTD PMID:37748715 NCBI chr19:51,474,783...51,495,638
Ensembl chr19:51,474,878...51,495,638
JBrowse link
G Dnajc5g DnaJ heat shock protein family (Hsp40) member C5 gamma decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DNAJC5G mRNA CTD PMID:37748715 NCBI chr 6:25,260,087...25,264,251
Ensembl chr 6:25,260,088...25,264,152
JBrowse link
G Dnmt1 DNA methyltransferase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DNMT1 mRNA CTD PMID:37748715 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Dusp11 dual specificity phosphatase 11 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DUSP11 mRNA CTD PMID:37748715 NCBI chr 4:118,367,673...118,385,183
Ensembl chr 4:118,368,053...118,385,181
JBrowse link
G Dusp16 dual specificity phosphatase 16 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DUSP16 mRNA CTD PMID:37748715 NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980
JBrowse link
G Dusp19 dual specificity phosphatase 19 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DUSP19 mRNA CTD PMID:37748715 NCBI chr 3:65,538,424...65,554,465
Ensembl chr 3:65,538,420...65,553,534
JBrowse link
G Dynll1 dynein light chain LC8-type 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DYNLL1 mRNA CTD PMID:37748715 NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741
JBrowse link
G Dyrk4 dual specificity tyrosine phosphorylation regulated kinase 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of DYRK4 mRNA CTD PMID:37748715 NCBI chr 4:159,715,658...159,757,660
Ensembl chr 4:159,715,417...159,757,627
JBrowse link
G E2f8 E2F transcription factor 8 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of E2F8 mRNA CTD PMID:37748715 NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of EIF4EBP1 mRNA CTD PMID:37748715 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Elf1 E74 like ETS transcription factor 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ELF1 mRNA CTD PMID:37748715 NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
JBrowse link
G Emc9 ER membrane protein complex subunit 9 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of EMC9 mRNA CTD PMID:37748715 NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
JBrowse link
G Enpep glutamyl aminopeptidase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ENPEP mRNA CTD PMID:37748715 NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947
JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of EPB41L5 mRNA CTD PMID:37748715 NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360
JBrowse link
G Exosc6 exosome component 6 increases expression ISO N(4)-hydroxycytidine results in increased expression of EXOSC6 mRNA CTD PMID:37748715 NCBI chr19:39,022,171...39,023,585
Ensembl chr19:39,022,183...39,023,515
JBrowse link
G Fam98a family with sequence similarity 98, member A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FAM98A mRNA CTD PMID:37748715 NCBI chr 6:19,874,082...19,888,744
Ensembl chr 6:19,874,071...19,888,742
JBrowse link
G Fanca FA complementation group A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FANCA mRNA CTD PMID:37748715 NCBI chr19:51,304,126...51,362,586
Ensembl chr19:51,304,021...51,362,527
JBrowse link
G Fbxl12 F-box and leucine-rich repeat protein 12 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FBXL12 mRNA CTD PMID:37748715 NCBI chr 8:19,175,864...19,183,373
Ensembl chr 8:19,160,352...19,183,607
JBrowse link
G Fbxo5 F-box protein 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FBXO5 mRNA CTD PMID:37748715 NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
JBrowse link
G Fetub fetuin B decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FETUB mRNA CTD PMID:37748715 NCBI chr11:78,082,158...78,093,022
Ensembl chr11:78,082,156...78,095,135
JBrowse link
G Fhip2b FHF complex subunit HOOK interacting protein 2B decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FAM160B2 mRNA CTD PMID:37748715 NCBI chr15:45,656,641...45,674,603
Ensembl chr15:45,656,647...45,674,105
JBrowse link
G Foxk2 forkhead box K2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FOXK2 mRNA CTD PMID:37748715 NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563
JBrowse link
G Fzd4 frizzled class receptor 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of FZD4 mRNA CTD PMID:37748715 NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GADD45A mRNA CTD PMID:37748715 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gars1 glycyl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GARS mRNA CTD PMID:37748715 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
JBrowse link
G Gas2 growth arrest-specific 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GAS2 mRNA CTD PMID:37748715 NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:101,482,591...101,582,619
JBrowse link
G Gdf15 growth differentiation factor 15 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GDF15 mRNA CTD PMID:37748715 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
JBrowse link
G Gid4 GID complex subunit 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GID4 mRNA CTD PMID:37748715 NCBI chr10:45,221,556...45,247,627
Ensembl chr10:45,245,754...45,247,621
Ensembl chr10:45,245,754...45,247,621
JBrowse link
G Glb1 galactosidase, beta 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GLB1 mRNA CTD PMID:37748715 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Gpt2 glutamic--pyruvic transaminase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GPT2 mRNA CTD PMID:37748715 NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
JBrowse link
G Grb10 growth factor receptor bound protein 10 increases expression ISO N(4)-hydroxycytidine results in increased expression of GRB10 mRNA CTD PMID:37748715 NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
JBrowse link
G Grcc10 gene rich cluster, C10 gene decreases expression ISO N(4)-hydroxycytidine results in decreased expression of GRCC10 mRNA CTD PMID:37748715 NCBI chr 4:157,551,276...157,552,924 JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HADHA mRNA CTD PMID:37748715 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
JBrowse link
G Hadhb hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HADHB mRNA CTD PMID:37748715 NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
JBrowse link
G Hax1 HCLS1 associated protein X-1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HAX1 mRNA CTD PMID:37748715 NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
JBrowse link
G Helz helicase with zinc finger decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HELZ mRNA CTD PMID:37748715 NCBI chr10:92,479,403...92,645,234
Ensembl chr10:92,501,518...92,638,383
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression
multiple interactions
ISO N(4)-hydroxycytidine results in increased expression of HERPUD1 mRNA
4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of HERPUD1 mRNA]
CTD PMID:37748715 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
JBrowse link
G Herpud2 HERPUD family member 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HERPUD2 mRNA CTD PMID:37748715 NCBI chr 8:23,573,374...23,618,380
Ensembl chr 8:23,573,379...23,617,874
JBrowse link
G Hexa hexosaminidase subunit alpha decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HEXA mRNA CTD PMID:37748715 NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013
JBrowse link
G Hexim1 HEXIM P-TEFb complex subunit 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HEXIM1 mRNA CTD PMID:37748715 NCBI chr10:88,062,808...88,064,920
Ensembl chr10:88,062,803...88,066,189
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of HMOX1 mRNA CTD PMID:37748715 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Iars1 isoleucyl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of IARS mRNA CTD PMID:37748715 NCBI chr17:14,940,919...14,987,277
Ensembl chr17:14,940,924...14,987,237
JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ID2 mRNA CTD PMID:37748715 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
JBrowse link
G Inip INTS3 and NABP interacting protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of INIP mRNA CTD PMID:37748715 NCBI chr 5:74,648,392...74,662,628
Ensembl chr 5:74,648,392...74,662,628
JBrowse link
G Irak1bp1 interleukin-1 receptor-associated kinase 1 binding protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of IRAK1BP1 mRNA CTD PMID:37748715 NCBI chr 8:83,731,512...83,748,289
Ensembl chr 8:83,731,507...83,748,289
JBrowse link
G Irf2bp2 interferon regulatory factor 2 binding protein 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of IRF2BP2 mRNA CTD PMID:37748715 NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642
JBrowse link
G Jam3 junctional adhesion molecule 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of JAM3 mRNA CTD PMID:37748715 NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355
JBrowse link
G Jdp2 Jun dimerization protein 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of JDP2 mRNA CTD PMID:37748715 NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485
JBrowse link
G Lgals1 galectin 1 multiple interactions
decreases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in decreased expression of LGALS1 mRNA] CTD PMID:37748715 NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
JBrowse link
G Lig1 DNA ligase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of LIG1 mRNA CTD PMID:37748715 NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413
JBrowse link
G Lrfn1 leucine rich repeat and fibronectin type III domain containing 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of LRFN1 mRNA CTD PMID:37748715 NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449
JBrowse link
G Lyrm7 LYR motif containing 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of LYRM7 mRNA CTD PMID:37748715 NCBI chr10:38,964,299...38,983,628
Ensembl chr10:38,964,311...38,983,601
JBrowse link
G Map2k5 mitogen activated protein kinase kinase 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MAP2K5 mRNA CTD PMID:37748715 NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
JBrowse link
G Mapre3 microtubule-associated protein, RP/EB family, member 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MAPRE3 mRNA CTD PMID:37748715 NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881
JBrowse link
G Mcam melanoma cell adhesion molecule decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MCAM mRNA CTD PMID:37748715 NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
JBrowse link
G Mdh1 malate dehydrogenase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MDH1 mRNA CTD PMID:37748715 NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
JBrowse link
G Midn midnolin decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MIDN mRNA CTD PMID:37748715 NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MKNK1 mRNA CTD PMID:37748715 NCBI chr 5:129,318,128...129,357,641
Ensembl chr 5:129,318,170...129,357,639
JBrowse link
G Mob4 MOB family member 4, phocein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MOB4 mRNA CTD PMID:37748715 NCBI chr 9:56,617,374...56,641,336
Ensembl chr 9:56,617,368...56,641,329
JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MRPS12 mRNA CTD PMID:37748715 NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780
JBrowse link
G Mrps27 mitochondrial ribosomal protein S27 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MRPS27 mRNA CTD PMID:37748715 NCBI chr 2:30,740,007...30,808,577
Ensembl chr 2:30,740,033...30,808,577
JBrowse link
G Msmo1 methylsterol monooxygenase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MSMO1 mRNA CTD PMID:37748715 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
JBrowse link
G Mt2A metallothionein 2A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MT2 mRNA CTD PMID:37748715 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC1 protein] results in increased reduction of N(4)-hydroxycytidine CTD PMID:22924387 NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [CYB5B protein co-treated with CYB5R3 protein co-treated with MTARC2 protein] results in increased reduction of N(4)-hydroxycytidine CTD PMID:22924387 NCBI chr13:96,362,810...96,397,284 JBrowse link
G Mtbp MDM2 binding protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MTBP mRNA CTD PMID:37748715 NCBI chr 7:86,973,215...87,055,775
Ensembl chr 7:86,973,069...87,050,827
JBrowse link
G Mthfd1l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MTHFD1L mRNA CTD PMID:37748715 NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of MTHFD2 mRNA] CTD PMID:37748715 NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
JBrowse link
G Mtx1 Metaxin 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MTX1 mRNA CTD PMID:37748715 NCBI chr 2:174,615,460...174,621,383
Ensembl chr 2:174,615,461...174,620,982
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO N(4)-hydroxycytidine results in decreased expression of MYC mRNA CTD PMID:37748715 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nabp1 nucleic acid binding protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NABP1 mRNA CTD PMID:37748715 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107
JBrowse link
G Nars1 asparaginyl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NARS mRNA CTD PMID:37748715 NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622
JBrowse link
G Ncapd2 non-SMC condensin I complex, subunit D2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NCAPD2 mRNA CTD PMID:37748715 NCBI chr 4:157,968,814...157,992,314
Ensembl chr 4:157,968,815...157,992,020
JBrowse link
G Ncapg non-SMC condensin I complex, subunit G decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NCAPG mRNA CTD PMID:37748715 NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NCOR1 mRNA CTD PMID:37748715 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
JBrowse link
G Nectin1 nectin cell adhesion molecule 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PVRL1 mRNA CTD PMID:37748715 NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787
JBrowse link
G Nsf N-ethylmaleimide sensitive factor, vesicle fusing ATPase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NSF mRNA CTD PMID:37748715 NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
JBrowse link
G Nsun3 NOP2/Sun RNA methyltransferase 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NSUN3 mRNA CTD PMID:37748715 NCBI chr11:37,490,832...37,575,607
Ensembl chr11:37,490,838...37,568,543
JBrowse link
G Ntaq1 N-terminal glutamine amidase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of WDYHV1 mRNA CTD PMID:37748715 NCBI chr 7:89,684,318...89,704,484
Ensembl chr 7:89,684,323...89,704,474
JBrowse link
G Nup85 nucleoporin 85 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of NUP85 mRNA CTD PMID:37748715 NCBI chr10:100,806,482...100,825,029
Ensembl chr10:100,806,437...100,825,043
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of NUPR1 mRNA] CTD PMID:37748715 NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
JBrowse link
G Nxf7 nuclear RNA export factor 7 increases expression ISO N(4)-hydroxycytidine results in increased expression of NXF2 mRNA CTD PMID:37748715 NCBI chr  X:98,535,374...98,552,562
Ensembl chr  X:98,535,375...98,552,526
JBrowse link
G Ogdh oxoglutarate dehydrogenase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of OGDH mRNA CTD PMID:37748715 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Oip5 Opa interacting protein 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of OIP5 mRNA CTD PMID:37748715 NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250
JBrowse link
G Optn optineurin decreases expression ISO N(4)-hydroxycytidine results in decreased expression of OPTN mRNA CTD PMID:37748715 NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
JBrowse link
G Osgepl1 O-sialoglycoprotein endopeptidase-like 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of OSGEPL1 mRNA CTD PMID:37748715 NCBI chr 9:48,214,995...48,229,440
Ensembl chr 9:48,215,402...48,229,388
JBrowse link
G P2rx3 purinergic receptor P2X 3 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of P2RX3 mRNA CTD PMID:37748715 NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
JBrowse link
G P2rx7 purinergic receptor P2X 7 increases expression ISO N(4)-hydroxycytidine results in increased expression of P2RX7 mRNA CTD PMID:37748715 NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
JBrowse link
G P4ha2 prolyl 4-hydroxylase subunit alpha 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of P4HA2 mRNA CTD PMID:37748715 NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314
JBrowse link
G Pak2 p21 (RAC1) activated kinase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PAK2 mRNA CTD PMID:37748715 NCBI chr11:68,707,940...68,768,816
Ensembl chr11:68,707,969...68,768,816
JBrowse link
G Pde3a phosphodiesterase 3A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PDE3A mRNA CTD PMID:37748715 NCBI chr 4:174,172,804...174,443,944
Ensembl chr 4:174,172,868...174,438,274
JBrowse link
G Pde4dip phosphodiesterase 4D interacting protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PDE4DIP mRNA CTD PMID:37748715 NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
JBrowse link
G Pds5b PDS5 cohesin associated factor B decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PDS5B mRNA CTD PMID:37748715 NCBI chr12:202,481...345,596
Ensembl chr12:255,313...345,596
JBrowse link
G Pex1 peroxisomal biogenesis factor 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PEX1 mRNA CTD PMID:37748715 NCBI chr 4:30,519,950...30,558,953
Ensembl chr 4:30,519,955...30,558,921
JBrowse link
G Pgam2 phosphoglycerate mutase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PGAM2 mRNA CTD PMID:37748715 NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940
JBrowse link
G Pgp phosphoglycolate phosphatase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PGP mRNA CTD PMID:37748715 NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
JBrowse link
G Pmch pro-melanin-concentrating hormone decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PMCH mRNA CTD PMID:37748715 NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
JBrowse link
G Polr2a RNA polymerase II subunit A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of POLR2A mRNA CTD PMID:37748715 NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PPP1R15A mRNA CTD PMID:37748715 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PPP1R3C mRNA CTD PMID:37748715 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
JBrowse link
G Psat1 phosphoserine aminotransferase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PSAT1 mRNA CTD PMID:37748715 NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
JBrowse link
G Psph phosphoserine phosphatase increases expression ISO N(4)-hydroxycytidine results in increased expression of PSPH mRNA CTD PMID:37748715 NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074
JBrowse link
G Ptk2 protein tyrosine kinase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of PTK2 mRNA CTD PMID:37748715 NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
JBrowse link
G Rab21 RAB21, member RAS oncogene family decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RAB21 mRNA CTD PMID:37748715 NCBI chr 7:50,904,050...50,928,890
Ensembl chr 7:50,904,057...50,928,839
JBrowse link
G Rabggta Rab geranylgeranyltransferase subunit alpha decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RABGGTA mRNA CTD PMID:37748715 NCBI chr15:29,206,328...29,213,398
Ensembl chr15:29,206,157...29,213,348
JBrowse link
G Rad54l RAD54 like decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RAD54L mRNA CTD PMID:37748715 NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
JBrowse link
G Reep6 receptor accessory protein 6 increases expression ISO N(4)-hydroxycytidine results in increased expression of REEP6 mRNA CTD PMID:37748715 NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597
JBrowse link
G Rfc2 replication factor C subunit 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RFC2 mRNA CTD PMID:37748715 NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557
JBrowse link
G Rhbdd1 rhomboid domain containing 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RHBDD1 mRNA CTD PMID:37748715 NCBI chr 9:83,630,037...83,748,690
Ensembl chr 9:83,630,063...83,748,689
JBrowse link
G Rragc Ras-related GTP binding C decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RRAGC mRNA CTD PMID:37748715 NCBI chr 5:136,148,239...136,167,773
Ensembl chr 5:136,148,276...136,167,767
JBrowse link
G Rspry1 ring finger and SPRY domain containing 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of RSPRY1 mRNA CTD PMID:37748715 NCBI chr19:10,352,449...10,403,015
Ensembl chr19:10,353,821...10,401,102
JBrowse link
G Samm50 SAMM50 sorting and assembly machinery component decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SAMM50 mRNA CTD PMID:37748715 NCBI chr 7:115,317,472...115,341,682
Ensembl chr 7:115,317,404...115,341,682
JBrowse link
G Sars1 seryl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SARS mRNA CTD PMID:37748715 NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277
JBrowse link
G Sema6a semaphorin 6A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SEMA6A mRNA CTD PMID:37748715 NCBI chr18:40,050,623...40,171,954
Ensembl chr18:40,050,624...40,171,954
JBrowse link
G Sesn1 sestrin 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SESN1 mRNA CTD PMID:37748715 NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
JBrowse link
G Sesn2 sestrin 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SESN2 mRNA CTD PMID:37748715 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
JBrowse link
G Sh3tc1 SH3 domain and tetratricopeptide repeats 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SH3TC1 mRNA CTD PMID:37748715 NCBI chr14:75,005,691...75,050,001
Ensembl chr14:75,016,875...75,049,995
JBrowse link
G Shmt2 serine hydroxymethyltransferase 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SHMT2 mRNA CTD PMID:37748715 NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236
JBrowse link
G Ska2 spindle and kinetochore associated complex subunit 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SKA2 mRNA CTD PMID:37748715 NCBI chr10:71,921,474...71,939,461
Ensembl chr10:71,921,582...71,939,458
JBrowse link
G Slc1a4 solute carrier family 1 member 4 increases expression ISO N(4)-hydroxycytidine results in increased expression of SLC1A4 mRNA CTD PMID:37748715 NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418
JBrowse link
G Slc1a5 solute carrier family 1 member 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC1A5 mRNA CTD PMID:37748715 NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
JBrowse link
G Slc25a31 solute carrier family 25 member 31 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC25A31 mRNA CTD PMID:37748715 NCBI chr 2:123,695,387...123,711,275
Ensembl chr 2:123,695,408...123,710,795
JBrowse link
G Slc25a36 solute carrier family 25 member 36 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC25A36 mRNA CTD PMID:37748715 NCBI chr 8:97,659,848...97,693,735
Ensembl chr 8:97,662,127...97,693,703
JBrowse link
G Slc25a4 solute carrier family 25 member 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC25A4 mRNA CTD PMID:37748715 NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
JBrowse link
G Slc26a2 solute carrier family 26 member 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC26A2 mRNA CTD PMID:37748715 NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626
JBrowse link
G Slc2a1 solute carrier family 2 member 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC2A1 mRNA CTD PMID:37748715 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
JBrowse link
G Slc35a4 solute carrier family 35, member A4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC35A4 mRNA CTD PMID:37748715 NCBI chr18:28,280,483...28,284,610
Ensembl chr18:28,279,750...28,284,725
JBrowse link
G Slc38a1 solute carrier family 38, member 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC38A1 mRNA CTD PMID:37748715 NCBI chr 7:127,733,230...127,802,541
Ensembl chr 7:127,738,226...127,802,218
JBrowse link
G Slc38a2 solute carrier family 38, member 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC38A2 mRNA CTD PMID:37748715 NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
JBrowse link
G Slc38a7 solute carrier family 38, member 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC38A7 mRNA CTD PMID:37748715 NCBI chr19:9,209,203...9,225,472
Ensembl chr19:9,209,257...9,225,454
JBrowse link
G Slc39a4 solute carrier family 39 member 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC39A4 mRNA CTD PMID:37748715 NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:108,333,381...108,337,553
JBrowse link
G Slc3a2 solute carrier family 3 member 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC3A2 mRNA CTD PMID:37748715 NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
JBrowse link
G Slc44a4 solute carrier family 44, member 4 multiple interactions
decreases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in decreased expression of SLC44A4 mRNA] CTD PMID:37748715 NCBI chr20:3,903,099...3,919,215
Ensembl chr20:3,903,099...3,919,215
JBrowse link
G Slc6a9 solute carrier family 6 member 9 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC6A9 mRNA CTD PMID:37748715 NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
JBrowse link
G Slc7a1 solute carrier family 7 member 1 multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of SLC7A1 mRNA] CTD PMID:37748715 NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849
JBrowse link
G Slc7a3 solute carrier family 7 member 3 increases expression ISO N(4)-hydroxycytidine results in increased expression of SLC7A3 mRNA CTD PMID:37748715 NCBI chr  X:66,210,071...66,216,482
Ensembl chr  X:66,210,081...66,215,708
JBrowse link
G Slc7a5 solute carrier family 7 member 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC7A5 mRNA CTD PMID:37748715 NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
JBrowse link
G Slc7a7 solute carrier family 7 member 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SLC7A7 mRNA CTD PMID:37748715 NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648
JBrowse link
G Smcr8 SMCR8-C9orf72 complex subunit decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SMCR8 mRNA CTD PMID:37748715 NCBI chr10:45,457,962...45,465,101
Ensembl chr10:45,457,605...45,468,876
JBrowse link
G Smim22 small integral membrane protein 22 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SMIM22 mRNA CTD PMID:37748715 NCBI chr10:10,572,146...10,574,339 JBrowse link
G Snord1c small nucleolar RNA, C/D box 1C decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SNORD1C mRNA CTD PMID:37748715 NCBI chr10:101,905,797...101,905,872
Ensembl chr10:101,905,797...101,905,872
JBrowse link
G Snx4 sorting nexin 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SNX4 mRNA CTD PMID:37748715 NCBI chr11:67,460,872...67,518,143
Ensembl chr11:67,460,870...67,518,174
JBrowse link
G Spag7 sperm associated antigen 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SPAG7 mRNA CTD PMID:37748715 NCBI chr10:55,377,249...55,383,404
Ensembl chr10:55,377,249...55,383,404
JBrowse link
G Sqle squalene epoxidase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SQLE mRNA CTD PMID:37748715 NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
JBrowse link
G Srxn1 sulfiredoxin 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SRXN1 mRNA CTD PMID:37748715 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Stc2 stanniocalcin 2 multiple interactions
increases expression
ISO 4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of STC2 mRNA] CTD PMID:37748715 NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
JBrowse link
G Stil STIL, centriolar assembly protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of STIL mRNA CTD PMID:37748715 NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730
JBrowse link
G Stx7 syntaxin 7 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of STX7 mRNA CTD PMID:37748715 NCBI chr 1:21,197,075...21,237,320
Ensembl chr 1:21,197,075...21,237,279
JBrowse link
G Svil supervillin decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SVIL mRNA CTD PMID:37748715 NCBI chr17:52,648,502...52,844,114
Ensembl chr17:52,648,502...52,793,404
JBrowse link
G Sycp1 synaptonemal complex protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of SYCP1 mRNA CTD PMID:37748715 NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737
JBrowse link
G Tars1 threonyl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TARS mRNA CTD PMID:37748715 NCBI chr 2:60,368,893...60,387,715
Ensembl chr 2:60,367,796...60,387,717
JBrowse link
G Tas2r108 taste receptor, type 2, member 108 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TAS2R108 mRNA CTD PMID:37748715 NCBI chr 4:69,287,667...69,288,581
Ensembl chr 4:69,287,667...69,288,581
JBrowse link
G Tat tyrosine aminotransferase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TAT mRNA CTD PMID:37748715 NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
JBrowse link
G Tbcc tubulin folding cofactor C decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TBCC mRNA CTD PMID:37748715 NCBI chr 9:14,098,855...14,100,043
Ensembl chr 9:14,098,868...14,100,042
JBrowse link
G Tdg thymine-DNA glycosylase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TDG mRNA CTD PMID:37748715 NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567
JBrowse link
G Tec tec protein tyrosine kinase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TEC mRNA CTD PMID:37748715 NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557
JBrowse link
G Terf1 telomeric repeat binding factor 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TERF1 mRNA CTD PMID:37748715 NCBI chr 5:3,443,103...3,472,377
Ensembl chr 5:3,443,106...3,472,340
JBrowse link
G Thap4 THAP domain containing 4 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of THAP4 mRNA CTD PMID:37748715 NCBI chr 9:94,242,581...94,282,312
Ensembl chr 9:94,242,581...94,282,306
JBrowse link
G Tmppe transmembrane protein with metallophosphoesterase domain decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TMPPE mRNA CTD PMID:37748715 NCBI chr 8:114,085,497...114,093,388
Ensembl chr 8:114,084,831...114,094,286
JBrowse link
G Top2a DNA topoisomerase II alpha decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TOP2A mRNA CTD PMID:37748715 NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
JBrowse link
G Tor1aip1 torsin 1A interacting protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TOR1AIP1 mRNA CTD PMID:37748715 NCBI chr13:68,196,681...68,226,121
Ensembl chr13:68,196,681...68,225,862
JBrowse link
G Tp53inp1 tumor protein p53 inducible nuclear protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TRP53INP1 mRNA CTD PMID:37748715 NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
JBrowse link
G Tpcn2 two pore segment channel 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TPCN2 mRNA CTD PMID:37748715 NCBI chr 1:200,416,538...200,446,252
Ensembl chr 1:200,416,540...200,446,236
JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression
multiple interactions
ISO N(4)-hydroxycytidine results in increased expression of TRIB3 mRNA
4-nitrobenzylthioinosine inhibits the reaction [N(4)-hydroxycytidine results in increased expression of TRIB3 mRNA]
CTD PMID:37748715 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Trim32 tripartite motif-containing 32 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TRIM32 mRNA CTD PMID:37748715 NCBI chr 5:79,005,139...79,016,615
Ensembl chr 5:78,999,389...79,022,018
JBrowse link
G Trip12 thyroid hormone receptor interactor 12 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TRIP12 mRNA CTD PMID:37748715 NCBI chr 9:85,916,691...86,043,312
Ensembl chr 9:85,916,691...86,051,403
JBrowse link
G Trpm6 transient receptor potential cation channel, subfamily M, member 6 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TRPM6 mRNA CTD PMID:37748715 NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
JBrowse link
G Tubb5 tubulin, beta 5 class I decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TUBB5 mRNA CTD PMID:37748715 NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
JBrowse link
G Tug1 taurine up-regulated 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TUG1 mRNA CTD PMID:37748715 NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927
JBrowse link
G Txnip thioredoxin interacting protein decreases expression ISO N(4)-hydroxycytidine results in decreased expression of TXNIP mRNA CTD PMID:37748715 NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
JBrowse link
G Ugdh UDP-glucose 6-dehydrogenase decreases expression ISO N(4)-hydroxycytidine results in decreased expression of UGDH mRNA CTD PMID:37748715 NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
JBrowse link
G Vangl1 VANGL planar cell polarity protein 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of VANGL1 mRNA CTD PMID:37748715 NCBI chr 2:189,586,681...189,637,609
Ensembl chr 2:189,589,229...189,637,619
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO N(4)-hydroxycytidine results in decreased expression of VEGFA mRNA CTD PMID:37748715 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vtcn1 V-set domain containing T cell activation inhibitor 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of VTCN1 mRNA CTD PMID:37748715 NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658
JBrowse link
G Yars1 tyrosyl-tRNA synthetase 1 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of YARS mRNA CTD PMID:37748715 NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
JBrowse link
G Yipf2 Yip1 domain family, member 2 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of YIPF2 mRNA CTD PMID:37748715 NCBI chr 8:20,141,148...20,145,349
Ensembl chr 8:20,141,155...20,145,339
JBrowse link
G Ypel5 yippee-like 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of YPEL5 mRNA CTD PMID:37748715 NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691
JBrowse link
G Zfp516 zinc finger protein 516 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ZFP516 mRNA CTD PMID:37748715 NCBI chr18:76,286,453...76,386,526
Ensembl chr18:76,302,096...76,385,269
JBrowse link
G Zswim5 zinc finger, SWIM-type containing 5 decreases expression ISO N(4)-hydroxycytidine results in decreased expression of ZSWIM5 mRNA CTD PMID:37748715 NCBI chr 5:130,346,733...130,463,791
Ensembl chr 5:130,343,034...130,463,784
JBrowse link
nimustine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 increases expression
multiple interactions
ISO Nimustine results in increased expression of ABCC1 mRNA; Nimustine results in increased expression of ABCC1 protein
[Nimustine results in increased expression of ABCC1 protein] which results in increased transport of Leukotriene C4
CTD PMID:9393752 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
ISO BCL2L11 mutant form inhibits the reaction [Nimustine results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA]
Nimustine results in increased expression of BCL2L11 mRNA; Nimustine results in increased expression of BCL2L11 protein
CTD PMID:26418950 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Casp1 caspase 1 increases response to substance ISO CASP1 results in increased susceptibility to Nimustine CTD PMID:9491796 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Casp3 caspase 3 increases cleavage ISO Nimustine results in increased cleavage of CASP3 protein CTD PMID:26418950 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Nimustine results in increased cleavage of CASP8 protein CTD PMID:26418950 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
ISO BCL2L11 mutant form inhibits the reaction [Nimustine results in increased cleavage of CASP9 protein] CTD PMID:26418950 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions
increases phosphorylation
ISO FOSL1 protein affects the reaction [Nimustine results in increased phosphorylation of CHEK1 protein] CTD PMID:22609303 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
JBrowse link
G Ddb2 damage specific DNA binding protein 2 multiple interactions ISO TP53 affects the reaction [Nimustine results in increased expression of DDB2 mRNA] CTD PMID:18089819 NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit decreases response to substance ISO ERCC4 protein results in decreased susceptibility to Nimustine CTD PMID:26418950 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Faslg Fas ligand increases expression
multiple interactions
ISO Nimustine results in increased expression of FASLG mRNA
pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of FASLG mRNA]
CTD PMID:26418950 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases response to substance
ISO FOS mutant form inhibits the reaction [Nimustine results in increased expression of TREX1 mRNA]
FOS protein results in decreased susceptibility to Nimustine
CTD PMID:23578789 PMID:26418950 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions
increases expression
affects response to substance
ISO FOSL1 protein affects the reaction [Nimustine results in increased phosphorylation of CHEK1 protein]
Nimustine results in increased expression of FOSL1 mRNA; Nimustine results in increased expression of FOSL1 protein
FOSL1 protein affects the susceptibility to Nimustine
CTD PMID:22609303 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
JBrowse link
G Fxn frataxin increases expression ISO Nimustine results in increased expression of FXN protein CTD PMID:23418481 NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO Nimustine results in increased expression of GCLC mRNA CTD PMID:9393752 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G H2ax H2A.X variant histone increases phosphorylation ISO Nimustine results in increased phosphorylation of H2AX protein CTD PMID:26418950 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases phosphorylation
ISO JUN mutant form inhibits the reaction [Nimustine results in increased expression of TREX1 mRNA]; Nimustine promotes the reaction [JUN protein binds to TREX1 promoter]
Nimustine results in increased phosphorylation of JUN protein
CTD PMID:23578789 PMID:26418950 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO Nimustine results in increased phosphorylation of MAPK1 protein CTD PMID:26418950 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO Nimustine results in increased phosphorylation of MAPK3 protein CTD PMID:26418950 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase decreases response to substance
increases expression
multiple interactions
increases response to substance
ISO MGMT protein results in decreased susceptibility to Nimustine
Nimustine results in increased expression of MGMT mRNA
[Nimustine co-treated with Dexamethasone] results in increased expression of MGMT mRNA; [O(6)-benzylguanine results in decreased activity of MGMT protein] which results in increased susceptibility to Nimustine; [SP1 protein results in decreased susceptibility to Nimustine] which affects the expression of MGMT protein; Dexamethasone promotes the reaction [MGMT protein results in decreased susceptibility to Nimustine]
MGMT gene mutant form results in increased susceptibility to Nimustine
CTD PMID:11023546 PMID:12014639 PMID:15481722 PMID:15809756 PMID:29164620 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions
decreases response to substance
ISO [SP1 protein results in decreased susceptibility to Nimustine] which affects the expression of MGMT protein CTD PMID:29164620 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Tap1 transporter 1, ATP binding cassette subfamily B member affects response to substance ISO TAP1 protein affects the susceptibility to Nimustine CTD PMID:17523305 NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects response to substance
ISO TP53 affects the reaction [Nimustine results in increased expression of DDB2 mRNA]; TP53 affects the reaction [Nimustine results in increased expression of XPC mRNA]
TP53 protein affects the susceptibility to Nimustine
CTD PMID:15182437 PMID:18089819 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Trex1 three prime repair exonuclease 1 multiple interactions
affects response to substance
increases expression
ISO FOS mutant form inhibits the reaction [Nimustine results in increased expression of TREX1 mRNA]; JUN mutant form inhibits the reaction [Nimustine results in increased expression of TREX1 mRNA]; Nimustine promotes the reaction [JUN protein binds to TREX1 promoter]
TREX1 affects the susceptibility to Nimustine
Nimustine results in increased expression of TREX1 mRNA; Nimustine results in increased expression of TREX1 protein
CTD PMID:23578789 NCBI chr 8:109,706,613...109,707,913
Ensembl chr 8:109,706,613...109,708,796
JBrowse link
G Xpc XPC complex subunit, DNA damage recognition and repair factor increases expression
multiple interactions
ISO Nimustine results in increased expression of XPC mRNA
TP53 affects the reaction [Nimustine results in increased expression of XPC mRNA]
CTD PMID:18089819 NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
JBrowse link
NSC 23766 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO NSC 23766 inhibits the reaction [Particulate Matter results in increased phosphorylation of AKT1 protein] CTD PMID:31018152 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2L1 protein]] CTD PMID:28268219 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Casp3 caspase 3 multiple interactions ISO NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]] CTD PMID:28268219 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases secretion ISO NSC 23766 results in decreased secretion of CCL2 protein CTD PMID:36009428 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 decreases secretion ISO NSC 23766 results in decreased secretion of CCL3 protein CTD PMID:36009428 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 decreases secretion ISO NSC 23766 results in decreased secretion of CCL4 protein CTD PMID:36009428 NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA] CTD PMID:28710503 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Cd47 Cd47 molecule multiple interactions ISO NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2L1 protein]]; NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]]; NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:28268219 NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
JBrowse link
G Cdc42 cell division cycle 42 multiple interactions ISO NSC 23766 inhibits the reaction [Zinc Oxide results in increased activity of and results in increased phosphorylation of [RAC1 protein binds to CDC42 protein]] CTD PMID:22166487 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 affects expression ISO NSC 23766 affects the expression of DDIT3 protein CTD PMID:27351882 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 affects response to substance ISO FLT3 protein affects the susceptibility to NSC 23766 CTD PMID:36009428 NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA] CTD PMID:28710503 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form] CTD PMID:28710503 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hgf hepatocyte growth factor decreases secretion ISO NSC 23766 results in decreased secretion of HGF protein CTD PMID:36009428 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] CTD PMID:28710503 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO NSC 23766 inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of ICAM1 protein]; NSC 23766 inhibits the reaction [Zinc Oxide results in increased expression of ICAM1] CTD PMID:19632255 PMID:22166487 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; NSC 23766 inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; NSC 23766 inhibits the reaction [Particulate Matter results in increased secretion of IL1B protein] CTD PMID:21511011 PMID:31018152 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] CTD PMID:28710503 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO NSC 23766 inhibits the reaction [Zinc Oxide results in increased phosphorylation of and results in increased activity of JUN protein] CTD PMID:22166487 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Map3k11 mitogen-activated protein kinase kinase kinase 11 multiple interactions ISO NSC 23766 inhibits the reaction [Zinc Oxide results in increased expression of MAP3K11 protein] CTD PMID:22166487 NCBI chr 1:202,975,353...202,988,655
Ensembl chr 1:202,975,353...202,988,652
JBrowse link
G Mfn2 mitofusin 2 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA] CTD PMID:28710503 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions
decreases secretion
ISO NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]
NSC 23766 results in decreased secretion of MMP1 protein
CTD PMID:18625914 PMID:36009428 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA] CTD PMID:28710503 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] CTD PMID:21511011 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA] CTD PMID:28710503 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Npm1 nucleophosmin 1 affects response to substance ISO NPM1 protein affects the susceptibility to NSC 23766 CTD PMID:36009428 NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
JBrowse link
G Nppa natriuretic peptide A multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA] CTD PMID:28710503 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions ISO NSC 23766 inhibits the reaction [sodium arsenite results in increased expression of PECAM1 protein] CTD PMID:19033667 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA] CTD PMID:28710503 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions
decreases activity
ISO NSC 23766 inhibits the reaction [sodium arsenite results in increased activity of RAC1 protein]; NSC 23766 inhibits the reaction [Zinc Oxide results in increased activity of and results in increased phosphorylation of [RAC1 protein binds to CDC42 protein]]
NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; NSC 23766 inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of RAC1 protein]
NSC 23766 results in decreased activity of RAC1 protein
CTD PMID:19349368 PMID:21511011 PMID:22166487 PMID:28710503 PMID:31018152 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
JBrowse link
G Rac2 Rac family small GTPase 2 multiple interactions ISO NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased activity of RAC2 protein] CTD PMID:21511011 NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
JBrowse link
G Rhob ras homolog family member B multiple interactions ISO NSC 23766 inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB mRNA] CTD PMID:23732113 NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
JBrowse link
G Serpine1 serpin family E member 1 decreases secretion ISO NSC 23766 results in decreased secretion of SERPINE1 protein CTD PMID:36009428 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
JBrowse link
G Sirpa signal-regulatory protein alpha multiple interactions ISO NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2L1 protein]]; NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]]; NSC 23766 inhibits the reaction [[CD47 protein binds to SIRPA protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:28268219 NCBI chr 3:116,819,730...116,858,099
Ensembl chr 3:116,819,726...116,858,098
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases secretion
ISO NSC 23766 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
NSC 23766 results in decreased secretion of TNF protein
CTD PMID:21511011 PMID:36009428 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO NSC 23766 inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of VCAM1 protein] CTD PMID:19632255 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
osimertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein
osimertinib results in decreased phosphorylation of AKT1 protein
osimertinib decreases phosphorylation of AKT1 protein in lung
CTD
RGD
PMID:30145802 PMID:30623574 PMID:30993382 PMID:36807944 PMID:32276600 RGD:151357000 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO osimertinib results in decreased expression of BIRC5 protein CTD PMID:36807944 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
ISO [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form] CTD PMID:28237877 PMID:31916386 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions
decreases response to substance
ISO CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CAT protein results in decreased susceptibility to osimertinib
CTD PMID:28237877 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO osimertinib inhibits the reaction [Dronabinol results in decreased expression of and results in decreased activity of CFTR protein] CTD PMID:29928919 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Egf epidermal growth factor multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases phosphorylation
decreases activity
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein
osimertinib results in decreased phosphorylation of EGFR protein
osimertinib decreases phosphorylation of EGFR protein in lung
osimertinib results in decreased activity of EGFR protein
CTD
RGD
PMID:28237877 PMID:30145802 PMID:30623574 PMID:30993382 PMID:35970427 More... RGD:151357000 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO osimertinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Il6 interleukin 6 multiple interactions ISO osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein] CTD PMID:30623574 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein
osimertinib results in decreased phosphorylation of MAPK1 protein
CTD PMID:29928919 PMID:30623574 PMID:30993382 PMID:34861243 PMID:36807944 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein
osimertinib results in decreased phosphorylation of MAPK3 protein
CTD PMID:29928919 PMID:30623574 PMID:30993382 PMID:34861243 PMID:36807944 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO osimertinib decreases expression of MCL1 protein in lung RGD PMID:31301315 PMID:32276600 RGD:151356917, RGD:151357000 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO osimertinib results in decreased expression of and results in decreased phosphorylation of MET protein CTD PMID:34861243 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein CTD PMID:31916386 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression
increases cleavage
multiple interactions
ISO osimertinib results in increased expression of PARP1 protein modified form
osimertinib results in increased cleavage of PARP1 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CTD PMID:28237877 PMID:30171258 PMID:31916386 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sqstm1 sequestosome 1 decreases expression ISO osimertinib results in decreased expression of SQSTM1 protein CTD PMID:30145802 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases phosphorylation
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein]
osimertinib results in decreased phosphorylation of STAT3 protein
CTD PMID:30623574 PMID:35970427 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance
multiple interactions
affects response to substance
ISO TWIST1 protein results in decreased susceptibility to osimertinib
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]
TWIST1 protein affects the susceptibility to osimertinib
CTD PMID:30171258 PMID:30993382 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
decreases activity
ISO osimertinib inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]
osimertinib results in decreased activity of UGT1A1 protein
CTD PMID:34044055 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 decreases activity ISO osimertinib results in decreased activity of UGT1A3 protein CTD PMID:34044055 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 decreases activity ISO osimertinib results in decreased activity of UGT1A6 protein CTD PMID:34044055 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 decreases activity ISO osimertinib results in decreased activity of UGT2B7 protein CTD PMID:34044055 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
JBrowse link
pazopanib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO pazopanib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO pazopanib results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions ISO pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
JBrowse link
G Ar androgen receptor multiple interactions ISO pazopanib binds to and results in decreased activity of AR protein CTD PMID:25752796 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO pazopanib results in decreased activity of CYP1A1 protein CTD PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO pazopanib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO pazopanib results in increased expression of CYP2B6 mRNA CTD PMID:29356861 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases expression ISO pazopanib results in increased expression of CYP2C8 mRNA CTD PMID:29356861
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO pazopanib results in increased expression of CYP3A4 mRNA CTD PMID:29356861 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Il1b interleukin 1 beta increases secretion ISO pazopanib results in increased secretion of IL1B protein CTD PMID:33271325 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
ISO pazopanib results in decreased phosphorylation of MAPK1 protein
mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]
CTD PMID:27560553 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
ISO pazopanib results in decreased phosphorylation of MAPK3 protein
mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]
CTD PMID:27560553 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]] CTD PMID:29356861 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pazopanib inhibits the reaction [T0901317 results in increased activity of NR1I2 protein] CTD PMID:29356861 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Pgr progesterone receptor multiple interactions ISO pazopanib binds to and results in decreased activity of PGR protein CTD PMID:25752796 NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
JBrowse link
G Prtn3 proteinase 3 increases expression ISO pazopanib results in increased expression of PRTN3 protein CTD PMID:33271325 NCBI chr 7:9,822,123...9,831,300
Ensembl chr 7:9,822,122...9,831,944
JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO pazopanib binds to and results in decreased activity of THRA protein CTD PMID:25752796 NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
JBrowse link
G Thrb thyroid hormone receptor beta multiple interactions ISO pazopanib binds to and results in decreased activity of THRB protein CTD PMID:25752796 NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
JBrowse link
pirimicarb term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase decreases activity ISO pirimicarb results in decreased activity of ACHE protein CTD PMID:33037899 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases activity ISO pirimicarb results in increased activity of CYP19A1 protein CTD PMID:11884232 NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
JBrowse link
G Esr1 estrogen receptor 1 decreases expression ISO pirimicarb results in decreased expression of ESR1 mRNA CTD PMID:15261991 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A decreases expression ISO pirimicarb results in decreased expression of HSPA1A protein CTD PMID:16271832 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO pirimicarb results in increased expression of HSPA5 protein CTD PMID:16271832 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 decreases expression ISO pirimicarb results in decreased expression of HSPA8 protein CTD PMID:16271832 NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
JBrowse link
G Hspb2 heat shock protein family B (small) member 2 decreases expression ISO pirimicarb results in decreased expression of HSPB2 protein CTD PMID:16271832 NCBI chr 8:51,093,267...51,094,528
Ensembl chr 8:51,081,342...51,094,533
JBrowse link
G Lep leptin multiple interactions EXP [2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of LEP protein CTD PMID:29321614 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lepr leptin receptor multiple interactions EXP [2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of LEPR mRNA CTD PMID:29321614 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Nmb neuromedin B multiple interactions EXP [2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of NMB mRNA CTD PMID:29321614 NCBI chr 1:134,869,446...134,875,507
Ensembl chr 1:134,869,446...134,872,190
JBrowse link
G Nmbr neuromedin B receptor multiple interactions EXP [2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NMBR mRNA CTD PMID:29321614 NCBI chr 1:9,115,033...9,146,081
Ensembl chr 1:9,134,889...9,145,462
JBrowse link
G Npy1r neuropeptide Y receptor Y1 multiple interactions EXP [2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA CTD PMID:29321614 NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
JBrowse link
G Tp53 tumor protein p53 affects activity ISO pirimicarb metabolite affects the activity of TP53 protein CTD PMID:35435491 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
pirimiphos-methyl term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase decreases activity ISO pirimiphos methyl results in decreased activity of ACHE protein CTD PMID:8658539 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Anpep alanyl aminopeptidase, membrane decreases activity EXP pirimiphos methyl results in decreased activity of ANPEP protein CTD PMID:9204212 NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
JBrowse link
G Ar androgen receptor multiple interactions ISO pirimiphos methyl inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Ctsc cathepsin C decreases activity
increases activity
EXP pirimiphos methyl results in decreased activity of CTSC protein
pirimiphos methyl results in increased activity of CTSC protein
CTD PMID:9204212 NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
JBrowse link
G Ctsd cathepsin D decreases activity
increases activity
EXP pirimiphos methyl results in decreased activity of CTSD protein
pirimiphos methyl results in increased activity of CTSD protein
CTD PMID:9204212 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Ctsl cathepsin L increases activity EXP pirimiphos methyl results in increased activity of CTSL protein CTD PMID:9204212 NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
JBrowse link
G Dpp6 dipeptidyl peptidase like 6 decreases activity EXP pirimiphos methyl results in decreased activity of DPP6 protein CTD PMID:9204212 NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
JBrowse link
G Esr1 estrogen receptor 1 increases activity ISO pirimiphos methyl results in increased activity of ESR1 protein CTD PMID:15064155 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO pirimiphos methyl binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 increases activity ISO pirimiphos methyl results in increased activity of NR4A2 protein CTD PMID:20143881 NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
JBrowse link
G Park7 Parkinsonism associated deglycase decreases activity ISO pirimiphos methyl results in decreased activity of PARK7 protein CTD PMID:36842454 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
JBrowse link
G Prep prolyl endopeptidase decreases activity EXP pirimiphos methyl results in decreased activity of PREP protein CTD PMID:9204212 NCBI chr20:48,556,211...48,653,165
Ensembl chr20:48,556,280...48,654,466
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [pirimiphos methyl binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 CTD PMID:26359731 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rnpep arginyl aminopeptidase decreases activity EXP pirimiphos methyl results in decreased activity of RNPEP protein CTD PMID:9204212 NCBI chr13:46,699,458...46,717,829
Ensembl chr13:46,699,463...46,717,998
JBrowse link
G Tpp1 tripeptidyl peptidase 1 decreases activity EXP pirimiphos methyl results in decreased activity of TPP1 protein CTD PMID:9204212 NCBI chr 1:160,097,984...160,104,108
Ensembl chr 1:160,096,833...160,104,129
JBrowse link
poly(cytidylic acid) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions
increases expression
EXP Minocycline inhibits the reaction [Poly C results in increased expression of GRIA1 mRNA] CTD PMID:19660546 NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A increases expression
multiple interactions
EXP Poly C results in increased expression of GRIN2A mRNA
Minocycline inhibits the reaction [Poly C results in increased expression of GRIN2A mRNA]
CTD PMID:19660546 NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
JBrowse link
G Grin2c glutamate ionotropic receptor NMDA type subunit 2C multiple interactions
increases expression
EXP Minocycline inhibits the reaction [Poly C results in increased expression of GRIN2C mRNA] CTD PMID:19660546 NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
JBrowse link
G Il1b interleukin 1 beta increases expression EXP Poly C results in increased expression of IL1B protein CTD PMID:19660546 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
poly(I:C) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ABHD2 mRNA CTD PMID:26923065 NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
JBrowse link
G Ablim1 actin-binding LIM protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ABLIM1 mRNA CTD PMID:26923065 NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969
JBrowse link
G Acads acyl-CoA dehydrogenase short chain multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of ACADS mRNA CTD PMID:26923065 NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
JBrowse link
G Adam10 ADAM metallopeptidase domain 10 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ADAM10 mRNA CTD PMID:26923065 NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
JBrowse link
G Adar adenosine deaminase, RNA-specific affects localization ISO Poly I-C affects the localization of ADAR protein CTD PMID:22240577 NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282
JBrowse link
G Ahcyl1 adenosylhomocysteinase-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of AHCYL1 mRNA CTD PMID:26923065 NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
JBrowse link
G Ahr aryl hydrocarbon receptor increases expression ISO Poly I-C results in increased expression of AHR mRNA; Poly I-C results in increased expression of AHR protein CTD PMID:27783115 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Akap5 A-kinase anchoring protein 5 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of AKAP5 mRNA CTD PMID:26923065 NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
JBrowse link
G App amyloid beta precursor protein multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of APP mRNA CTD PMID:26923065 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 increases degradation
multiple interactions
ISO Poly I-C results in increased degradation of APPL1 protein
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]
CTD PMID:25780039 NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
JBrowse link
G Arc activity-regulated cytoskeleton-associated protein affects methylation EXP Poly I-C affects the methylation of ARC promoter CTD PMID:32843831 NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
JBrowse link
G Arfgef3 ARFGEF family member 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ARFGEF3 mRNA CTD PMID:26923065 NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084
JBrowse link
G Arg2 arginase 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of ARG2 mRNA CTD PMID:26923065 NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
JBrowse link
G Arhgap11a Rho GTPase activating protein 11A multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of ARHGAP11A mRNA CTD PMID:26923065 NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
JBrowse link
G Arhgap44 Rho GTPase activating protein 44 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ARHGAP44 mRNA CTD PMID:26923065 NCBI chr10:49,655,583...49,822,876
Ensembl chr10:49,655,584...49,824,297
JBrowse link
G Arhgap9 Rho GTPase activating protein 9 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of ARHGAP9 mRNA CTD PMID:26923065 NCBI chr 7:63,148,573...63,157,025
Ensembl chr 7:63,148,900...63,157,524
JBrowse link
G Arhgef12 Rho guanine nucleotide exchange factor 12 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF12 mRNA CTD PMID:26923065 NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
JBrowse link
G Arhgef7 Rho guanine nucleotide exchange factor 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF7 mRNA CTD PMID:26923065 NCBI chr16:77,671,021...77,782,593
Ensembl chr16:77,671,023...77,782,697
JBrowse link
G Arsb arylsulfatase B multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ARSB mRNA CTD PMID:26923065 NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
JBrowse link
G Art3 ADP-ribosyltransferase 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of ART3 mRNA CTD PMID:26923065 NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO Poly I-C results in increased expression of ATF3 mRNA CTD PMID:27783115 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atp2b2 ATPase plasma membrane Ca2+ transporting 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ATP2B2 mRNA CTD PMID:26923065 NCBI chr 4:146,894,602...147,208,060
Ensembl chr 4:146,896,332...147,140,665
JBrowse link
G Atxn3 ataxin 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ATXN3 mRNA CTD PMID:26923065 NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression ISO Poly I-C results in increased expression of BAX protein CTD PMID:21418039 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Poly I-C results in decreased expression of BCL2 protein CTD PMID:21418039 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of BCL2A1 mRNA CTD PMID:26923065 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
affects methylation
ISO
EXP
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of BDNF mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of BDNF mRNA]
Poly I-C affects the methylation of BDNF promoter
CTD PMID:24889602 PMID:32843831 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Bid BH3 interacting domain death agonist decreases expression ISO Poly I-C results in decreased expression of BID protein CTD PMID:21418039 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO Poly I-C promotes the reaction [arsenic trioxide results in decreased expression of BIRC5 protein] CTD PMID:21418039 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Birc6 baculoviral IAP repeat-containing 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of BIRC6 mRNA CTD PMID:26923065 NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434
JBrowse link
G Blmh bleomycin hydrolase multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of BLMH mRNA CTD PMID:26923065 NCBI chr10:61,772,112...61,815,212
Ensembl chr10:61,758,478...61,815,212
JBrowse link
G Bltp1 bridge-like lipid transfer protein family member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of BLTP1 mRNA CTD PMID:26923065 NCBI chr 2:119,708,114...119,924,697
Ensembl chr 2:119,708,209...119,924,695
JBrowse link
G Bola2-ps4 bolA family member 2, pseudogene 4 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of BOLA2-PS4 mRNA CTD PMID:26923065 NCBI chr 3:153,272,435...153,272,781 JBrowse link
G Brms1l BRMS1 like transcriptional repressor multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of BRMS1L mRNA CTD PMID:26923065 NCBI chr 6:73,266,673...73,300,630
Ensembl chr 6:73,266,691...73,300,631
JBrowse link
G Brox BRO1 domain and CAAX motif containing multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of BROX mRNA CTD PMID:26923065 NCBI chr13:94,920,107...94,940,189
Ensembl chr13:94,920,112...94,940,227
JBrowse link
G C10h16orf90 similar to human chromosome 16 open reading frame 90 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of C10H16ORF90 mRNA CTD PMID:26923065 NCBI chr10:11,618,867...11,632,151
Ensembl chr10:11,618,348...11,629,910
JBrowse link
G C1qtnf7 C1q and TNF related 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of C1QTNF7 mRNA CTD PMID:26923065 NCBI chr14:67,467,888...67,580,477
Ensembl chr14:67,468,014...67,580,410
JBrowse link
G Cage1 cancer antigen 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CAGE1 mRNA CTD PMID:26923065 NCBI chr17:26,789,975...26,828,210
Ensembl chr17:26,790,033...26,828,204
JBrowse link
G Car3 carbonic anhydrase 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CA3 mRNA CTD PMID:26923065 NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
ISO Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein] CTD PMID:21418039 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions
increases activity
ISO arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP8 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein] CTD PMID:21418039 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
ISO Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein] CTD PMID:21418039 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase decreases expression EXP Poly I-C results in decreased expression of CAT mRNA CTD PMID:23939143 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cav1 caveolin 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CAV1 mRNA CTD PMID:26923065 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
JBrowse link
G Cbx1 chromobox 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CBX1 mRNA CTD PMID:26923065 NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
JBrowse link
G Cbx6 chromobox 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CBX6 mRNA CTD PMID:26923065 NCBI chr 7:111,372,979...111,383,026
Ensembl chr 7:111,372,980...111,383,091
JBrowse link
G Ccdc113 coiled-coil domain containing 113 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CCDC113 mRNA CTD PMID:26923065 NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
JBrowse link
G Ccl1 C-C motif chemokine ligand 1 increases expression ISO Poly I-C results in increased expression of CCL1 mRNA CTD PMID:27783115 NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions
increases secretion
ISO methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL11 protein] CTD PMID:24056979 NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases secretion
increases expression
ISO
EXP
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL2 protein]
Poly I-C results in increased expression of CCL2 mRNA
CTD PMID:23939143 PMID:24056979 PMID:34740670 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions
increases expression
ISO Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL3 protein] CTD PMID:19500611 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 multiple interactions
increases expression
increases secretion
ISO Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL4 protein]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL4 protein]
6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]
CTD PMID:19500611 PMID:24056979 PMID:27783115 NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions
increases expression
increases secretion
ISO APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL5 protein]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]
Poly I-C results in increased expression of CCL5; Poly I-C results in increased expression of CCL5 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of CCL5]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of CCL5]
CTD PMID:23688403 PMID:24056979 PMID:24709138 PMID:25780039 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Cd40 CD40 molecule increases expression
multiple interactions
ISO Poly I-C results in increased expression of CD40 protein
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein
CTD PMID:15246609 PMID:16224278 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd80 Cd80 molecule increases expression ISO Poly I-C results in increased expression of CD80 protein CTD PMID:15246609 NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
JBrowse link
G Cd83 CD83 molecule increases expression
multiple interactions
ISO Poly I-C results in increased expression of CD83 protein
CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]
CTD PMID:17698565 NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
JBrowse link
G Cd86 CD86 molecule multiple interactions
increases expression
ISO [Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein] CTD PMID:15246609 PMID:16224278 PMID:16890772 PMID:17698565 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
JBrowse link
G Cdc42 cell division cycle 42 multiple interactions ISO [Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA CTD PMID:34696514 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
JBrowse link
G Cdx2 caudal type homeo box 2 multiple interactions ISO [Poly I-C co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of CDX2 mRNA; [Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDX2 mRNA CTD PMID:27783115 NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
JBrowse link
G Celf1 CUGBP, Elav-like family member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CELF1 mRNA CTD PMID:26923065 NCBI chr 3:76,924,591...76,999,429
Ensembl chr 3:76,924,613...76,999,426
JBrowse link
G Cfp complement factor properdin multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CFP mRNA CTD PMID:26923065 NCBI chr  X:1,162,014...1,167,576
Ensembl chr  X:1,161,979...1,167,573
JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CHSY1 mRNA CTD PMID:26923065 NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601
JBrowse link
G Cibar2 CBY1 interacting BAR domain containing 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CIBAR2 mRNA CTD PMID:26923065 NCBI chr19:48,217,617...48,229,418
Ensembl chr19:48,215,486...48,229,404
JBrowse link
G Clcc1 chloride channel CLIC-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CLCC1 mRNA CTD PMID:26923065 NCBI chr 2:196,296,350...196,326,914
Ensembl chr 2:196,296,393...196,326,913
JBrowse link
G Clec14a C-type lectin domain containing 14A multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CLEC14A mRNA CTD PMID:26923065 NCBI chr 6:75,881,470...75,884,612
Ensembl chr 6:75,881,473...75,884,612
JBrowse link
G Clip3 CAP-GLY domain containing linker protein 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CLIP3 mRNA CTD PMID:26923065 NCBI chr 1:85,547,170...85,563,187
Ensembl chr 1:85,547,206...85,563,184
JBrowse link
G Cnnm1 cyclin and CBS domain divalent metal cation transport mediator 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CNNM1 mRNA CTD PMID:26923065 NCBI chr 1:242,296,367...242,354,957
Ensembl chr 1:242,296,422...242,353,513
JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions EXP Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]]; Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein] CTD PMID:31202911 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cnr2 cannabinoid receptor 2 increases expression EXP Poly I-C results in increased expression of CNR2 mRNA CTD PMID:27317300 NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
JBrowse link
G Cntn1 contactin 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CNTN1 mRNA CTD PMID:26923065 NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CRABP1 mRNA CTD PMID:26923065 NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases secretion
increases expression
ISO Ethanol inhibits the reaction [Poly I-C results in increased expression of CSF2 protein]
Poly I-C results in increased secretion of CSF2 protein
Smoke inhibits the reaction [Poly I-C results in increased secretion of CSF2 protein]
CTD PMID:19500611 PMID:35817128 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Cttnbp2 cortactin binding protein 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CTTNBP2 mRNA CTD PMID:26923065 NCBI chr 4:46,800,975...46,964,681
Ensembl chr 4:46,800,981...46,964,631
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression EXP Poly I-C results in increased expression of CXCL1 mRNA CTD PMID:23939143 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
increases secretion
increases expression
ISO
EXP
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; chrysin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]
Poly I-C results in increased secretion of CXCL10 protein
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]
Poly I-C results in increased expression of CXCL10 mRNA; Poly I-C results in increased expression of CXCL10 protein
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; [Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; Phosphorothioate Oligonucleotides inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]
CTD PMID:19426678 PMID:25780039 PMID:26682054 PMID:28003376 PMID:28572013 More... NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression EXP Poly I-C results in increased expression of CXCL2 mRNA CTD PMID:23939143 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression
ISO Ethanol inhibits the reaction [Poly I-C results in increased expression of CXCL1 protein] CTD PMID:19500611 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions
increases secretion
increases expression
ISO Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CXCL9 protein] CTD PMID:19426678 PMID:24056979 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
JBrowse link
G Cyfip2 cytoplasmic FMR1 interacting protein 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CYFIP2 mRNA CTD PMID:26923065 NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO Poly I-C promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA] CTD PMID:27783115 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases expression EXP Poly I-C results in decreased expression of CYP2C11 mRNA CTD PMID:23939143 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases expression EXP Poly I-C results in decreased expression of CYP2C6V1 mRNA CTD PMID:23939143 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2c7 cytochrome P450, family 2, subfamily c, polypeptide 7 decreases expression EXP Poly I-C results in decreased expression of CYP2C7 mRNA CTD PMID:23939143 NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 decreases expression EXP Poly I-C results in decreased expression of CYP3A23-3A1 mRNA CTD PMID:23939143 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030
JBrowse link
G Cyria CYFIP related Rac1 interactor A multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of CYRIA mRNA CTD PMID:26923065 NCBI chr 6:35,045,208...35,150,669
Ensembl chr 6:35,045,208...35,150,668
JBrowse link
G Cysrt1 cysteine rich tail 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of CYSRT1 mRNA CTD PMID:26923065 NCBI chr 3:8,054,195...8,057,846
Ensembl chr 3:8,053,482...8,059,721
JBrowse link
G Dab1 DAB adaptor protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DAB1 mRNA CTD PMID:26923065 NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
JBrowse link
G Dck deoxycytidine kinase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DCK mRNA CTD PMID:26923065 NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
JBrowse link
G Dcun1d3 defective in cullin neddylation 1 domain containing 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D3 mRNA CTD PMID:26923065 NCBI chr 1:174,243,001...174,285,647
Ensembl chr 1:66,494,848...66,496,343
Ensembl chr 1:66,494,848...66,496,343
JBrowse link
G Dcun1d4 defective in cullin neddylation 1 domain containing 4 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D4 mRNA CTD PMID:26923065 NCBI chr14:34,652,723...34,733,122
Ensembl chr14:34,652,723...34,733,207
JBrowse link
G Ddx3x DEAD-box helicase 3, X-linked multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DDX3X mRNA CTD PMID:26923065 NCBI chr  X:9,479,532...9,493,169
Ensembl chr  X:9,479,532...9,493,168
JBrowse link
G Defb5 defensin beta 5 increases secretion ISO Poly I-C results in increased secretion of DEFB4 protein CTD PMID:17669408 NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of DLG1 mRNA CTD PMID:26923065 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dnm2 dynamin 2 multiple interactions ISO DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] CTD PMID:25780039 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT1 mRNA CTD PMID:34303791 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions ISO [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT3A mRNA CTD PMID:34303791 NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
JBrowse link
G Eea1 early endosome antigen 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of EEA1 mRNA CTD PMID:26923065 NCBI chr 7:30,554,686...30,722,186
Ensembl chr 7:30,554,552...30,718,487
JBrowse link
G Egr1 early growth response 1 multiple interactions
affects methylation
ISO
EXP
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of EGR1 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA]
Poly I-C affects the methylation of EGR1 promoter
CTD PMID:24889602 PMID:32843831 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 increases expression
increases phosphorylation
increases response to substance
ISO Poly I-C results in increased expression of EIF2AK2 mRNA
Poly I-C results in increased phosphorylation of EIF2AK2 protein
EIF2AK2 results in increased susceptibility to Poly I-C
CTD PMID:10944112 PMID:17669408 PMID:22240577 PMID:22558189 NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation ISO Poly I-C results in increased phosphorylation of EIF2S1 protein CTD PMID:22240577 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Epc2l1 enhancer of polycomb homolog 2 (Drosophila)-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of EPC2L1 mRNA CTD PMID:26923065 NCBI chr 1:81,931,963...81,934,681
Ensembl chr 1:81,932,016...81,934,442
JBrowse link
G F11r F11 receptor multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein] CTD PMID:20932985 NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
JBrowse link
G Fabp4 fatty acid binding protein 4 increases expression ISO Poly I-C results in increased expression of FABP4 mRNA CTD PMID:15705927 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fam107a family with sequence similarity 107, member A multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of FAM107A mRNA CTD PMID:26923065 NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396
JBrowse link
G Fmr1 fragile X messenger ribonucleoprotein 1 multiple interactions
decreases expression
ISO Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] CTD PMID:23516405 NCBI chr  X:147,240,239...147,278,057
Ensembl chr  X:147,240,301...147,278,050
JBrowse link
G Fxyd3 FXYD domain-containing ion transport regulator 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of FXYD3 mRNA CTD PMID:26923065 NCBI chr 1:86,305,531...86,312,455 JBrowse link
G Fyttd1 forty-two-three domain containing 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of FYTTD1 mRNA CTD PMID:26923065 NCBI chr11:67,877,967...67,907,500
Ensembl chr11:67,877,967...67,907,511
JBrowse link
G G3bp1 G3BP stress granule assembly factor 1 affects localization ISO Poly I-C affects the localization of G3BP1 protein CTD PMID:22240577 NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
JBrowse link
G G3bp2 G3BP stress granule assembly factor 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of G3BP2 mRNA CTD PMID:26923065 NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548
JBrowse link
G Gabra1 gamma-aminobutyric acid type A receptor subunit alpha 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GABRA1 mRNA CTD PMID:26923065 NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GABRB2 mRNA CTD PMID:26923065 NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
JBrowse link
G Gabrg2 gamma-aminobutyric acid type A receptor subunit gamma 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GABRG2 mRNA CTD PMID:26923065 NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
JBrowse link
G Gad1 glutamate decarboxylase 1 decreases expression
multiple interactions
EXP Poly I-C results in decreased expression of GAD1 protein
Cannabidiol inhibits the reaction [Poly I-C results in decreased expression of GAD1 protein]
CTD PMID:31202911 NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
JBrowse link
G Gdap1 ganglioside-induced differentiation-associated-protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GDAP1 mRNA CTD PMID:26923065 NCBI chr 5:1,932,613...1,951,691
Ensembl chr 5:1,932,613...2,030,061
JBrowse link
G Gdi1 GDP dissociation inhibitor 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GDI1 mRNA CTD PMID:26923065 NCBI chr  X:152,087,611...152,094,274
Ensembl chr  X:152,087,444...152,094,272
JBrowse link
G Get3 guided entry of tail-anchored proteins factor 3, ATPase multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of GET3 mRNA CTD PMID:26923065 NCBI chr19:23,130,109...23,138,196
Ensembl chr19:23,130,109...23,138,193
JBrowse link
G Gfap glial fibrillary acidic protein increases expression EXP Poly I-C results in increased expression of GFAP mRNA CTD PMID:27317300 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Gh1 growth hormone 1 decreases expression ISO Poly I-C results in decreased expression of GH protein CTD PMID:21195166 NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
JBrowse link
G Glce glucuronic acid epimerase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GLCE mRNA CTD PMID:26923065 NCBI chr 8:62,546,104...62,612,144
Ensembl chr 8:62,546,107...62,612,040
JBrowse link
G Glrb glycine receptor, beta multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GLRB mRNA CTD PMID:26923065 NCBI chr 2:166,134,616...166,207,498
Ensembl chr 2:166,134,626...166,207,489
JBrowse link
G Glyr1 glyoxylate reductase 1 homolog multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GLYR1 mRNA CTD PMID:26923065 NCBI chr10:10,532,036...10,567,639
Ensembl chr10:10,532,154...10,567,637
JBrowse link
G Gmfb glia maturation factor, beta multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GMFB mRNA CTD PMID:26923065 NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
JBrowse link
G Gmppb GDP-mannose pyrophosphorylase B multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of GMPPB mRNA CTD PMID:26923065 NCBI chr 8:108,737,429...108,740,437
Ensembl chr 8:108,693,060...108,767,286
JBrowse link
G Gpatch2l G patch domain containing 2-like multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GPATCH2L mRNA CTD PMID:26923065 NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888
JBrowse link
G Gpbp1 GC-rich promoter binding protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of GPBP1 mRNA CTD PMID:26923065 NCBI chr 2:43,023,504...43,091,146
Ensembl chr 2:43,023,504...43,090,907
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression EXP Poly I-C results in decreased expression of GSR mRNA CTD PMID:23939143 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gzmb granzyme B multiple interactions
increases expression
ISO Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB protein]
Poly I-C results in increased expression of GZMB mRNA; Poly I-C results in increased expression of GZMB protein
CTD PMID:23618096 NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of HEY2 mRNA CTD PMID:26923065 NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO Indoprofen inhibits the reaction [Poly I-C results in increased secretion of and affects the localization of HMGB1 protein]; Poly I-C results in increased secretion of and affects the localization of HMGB1 protein CTD PMID:34755645 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
EXP Diclofenac promotes the reaction [Poly I-C results in increased expression of HMOX1 mRNA] CTD PMID:23939143 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression EXP Poly I-C results in increased expression of HSP90AA1 mRNA CTD PMID:23939143 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A increases expression EXP Poly I-C results in increased expression of HSPA1A mRNA CTD PMID:23939143 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 increases expression EXP Poly I-C results in increased expression of HSPA8 mRNA CTD PMID:23939143 NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A increases expression ISO Poly I-C results in increased expression of HTR2A mRNA CTD PMID:24889602 NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
JBrowse link
G Ibtk inhibitor of Bruton tyrosine kinase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of IBTK mRNA CTD PMID:26923065 NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260
JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of IDO1 mRNA
poly(I:C) co-treated with tryptophan or alone increases activity and expression of IDO1 protein in Langerhans cell-like dendritic cells
CTD
RGD
PMID:27783115 PMID:26198597 RGD:11528429 NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
JBrowse link
G Ido2 indoleamine 2,3-dioxygenase 2 increases expression ISO Poly I-C results in increased expression of IDO2 mRNA CTD PMID:27783115 NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
JBrowse link
G Ifih1 interferon induced with helicase C domain 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of IFIH1 mRNA
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]
CTD PMID:30341573 PMID:31154625 NCBI chr 3:47,228,980...47,275,403
Ensembl chr 3:47,227,364...47,275,456
JBrowse link
G Ifit2 interferon-induced protein with tetratricopeptide repeats 2 multiple interactions
increases expression
ISO Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA] CTD PMID:34051100 NCBI chr 1:232,102,570...232,108,638
Ensembl chr 1:232,102,570...232,108,635
JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 increases expression ISO Poly I-C results in increased expression of IFITM1 mRNA CTD PMID:22240577 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
JBrowse link
G Ifna1 interferon, alpha 1 increases expression EXP Poly I-C results in increased expression of IFNA1 mRNA CTD PMID:28726298 NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
JBrowse link
G Ifnb1 interferon beta 1 increases expression
increases secretion
multiple interactions
ISO
EXP
Poly I-C results in increased expression of IFNB1 mRNA; Poly I-C results in increased expression of IFNB1 protein
Poly I-C results in increased secretion of IFNB1 protein
MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]
apilimod inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; BX795 inhibits the reaction [Poly I-C results in increased expression of IFNB1 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Resveratrol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Wortmannin inhibits the reaction [[Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA]
CTD PMID:16116226 PMID:16399790 PMID:17669408 PMID:18279804 PMID:18323514 More... NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
JBrowse link
G Ifng interferon gamma multiple interactions
increases secretion
increases expression
ISO
EXP
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNG mRNA]
Poly I-C results in increased secretion of IFNG protein
Ethanol inhibits the reaction [Poly I-C results in increased expression of IFNG protein]
Poly I-C results in increased expression of IFNG mRNA; Poly I-C results in increased expression of IFNG protein
CTD PMID:9328138 PMID:16224278 PMID:17321468 PMID:19500611 PMID:23618096 More... NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Ifnl1 interferon, lambda 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of IFNL1 mRNA
Smoke inhibits the reaction [Poly I-C results in increased expression of IFNL1 mRNA]
CTD PMID:35817128 NCBI chr 1:83,798,651...83,800,297
Ensembl chr 1:83,798,703...83,800,235
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions
decreases expression
ISO IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein]
Poly I-C results in decreased expression of IGF1 mRNA; Poly I-C results in decreased expression of IGF1 protein
CTD PMID:1705203 PMID:21195166 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions
decreases expression
ISO IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein] CTD PMID:21195166 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
JBrowse link
G Igsf6 immunoglobulin superfamily, member 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of IGSF6 mRNA CTD PMID:26923065 NCBI chr 1:175,610,167...175,620,662
Ensembl chr 1:175,610,167...175,620,722
JBrowse link
G Ikbke inhibitor of nuclear factor kappa B kinase subunit epsilon multiple interactions
increases phosphorylation
ISO APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein] CTD PMID:25780039 NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
JBrowse link
G Il10 interleukin 10 multiple interactions
increases expression
increases secretion
ISO
EXP
CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]
Poly I-C results in increased expression of IL10 mRNA
Poly I-C results in increased expression of IL10 mRNA; Poly I-C results in increased expression of IL10 protein
Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 protein]
CTD PMID:16224278 PMID:17698565 PMID:22771370 PMID:23618096 PMID:23939143 More... NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12a interleukin 12A multiple interactions
increases expression
ISO 6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; indole-3-carbinol inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA] CTD PMID:27783115 NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression
ISO [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein]
Poly I-C results in increased expression of IL12B mRNA; Poly I-C results in increased expression of IL12B protein
Ethanol inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA]
CTD PMID:16890772 PMID:19426678 PMID:19500611 PMID:23266719 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il17a interleukin 17A increases expression ISO Poly I-C results in increased expression of IL17A protein CTD PMID:30836164 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion
increases expression
ISO
EXP
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL1B mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]
Poly I-C results in increased secretion of IL1B protein
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Poly I-C results in increased expression of IL1B mRNA]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; Tetrachlorodibenzodioxin promotes the reaction [Poly I-C results in increased expression of IL1B mRNA]
Poly I-C results in increased expression of IL1B mRNA; Poly I-C results in increased expression of IL1B protein
CTD PMID:16687389 PMID:17321468 PMID:19500611 PMID:22771370 PMID:23618096 More... NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 increases expression
increases secretion
ISO Poly I-C results in increased expression of IL2 mRNA
Poly I-C results in increased secretion of IL2 protein
CTD PMID:9328138 PMID:23618096 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il27 interleukin 27 increases expression
multiple interactions
ISO Poly I-C results in increased expression of IL27 mRNA
Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA]
CTD PMID:19426678 NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
JBrowse link
G Il33 interleukin 33 increases expression
multiple interactions
ISO Poly I-C results in increased expression of IL33 protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Poly I-C results in increased expression of IL33 protein]
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL33 protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL33 protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL33 protein]
CTD PMID:25747661 PMID:30017638 NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
JBrowse link
G Il4 interleukin 4 multiple interactions
increases expression
increases secretion
increases response to substance
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; [Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Particulate Matter inhibits the reaction [Poly I-C results in increased secretion of IL4 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased secretion of IL4 protein]
IL4 protein results in increased susceptibility to Poly I-C
CTD PMID:23618096 PMID:23688403 PMID:30017638 PMID:30836164 PMID:34740670 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 multiple interactions
increases secretion
increases expression
ISO
EXP
[Vehicle Emissions analog co-treated with Poly I-C] results in increased secretion of IL6 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Particulate Matter promotes the reaction [Poly I-C results in increased expression of IL6]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]]; Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; Vehicle Emissions promotes the reaction [Poly I-C results in increased expression of IL6]
Poly I-C results in increased expression of IL6 mRNA; Poly I-C results in increased expression of IL6 protein
Ethanol inhibits the reaction [Poly I-C results in increased expression of IL6 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein]; IL6 protein affects the reaction [Poly I-C results in increased expression of PRL2B1 mRNA]; IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]
Poly I-C results in increased expression of IL6; Poly I-C results in increased expression of IL6 mRNA
CTD PMID:9328138 PMID:16399790 PMID:16687389 PMID:17698565 PMID:18323514 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Irf3 interferon regulatory factor 3 increases phosphorylation
affects localization
multiple interactions
ISO Poly I-C results in increased phosphorylation of IRF3 protein
Poly I-C affects the localization of IRF3 protein
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; BX795 inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; chrysin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Sodium Selenite inhibits the reaction [Poly I-C results in increased activity of IRF3 protein]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; [Vehicle Emissions analog co-treated with Poly I-C] affects the localization of IRF3 protein; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased localization of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]
CTD PMID:16399790 PMID:18279804 PMID:18779317 PMID:19426678 PMID:25780039 More... NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
JBrowse link
G Irf7 interferon regulatory factor 7 multiple interactions
increases expression
ISO
EXP
IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]
CTD PMID:22240577 PMID:28726298 PMID:31154625 NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
JBrowse link
G Irf9 interferon regulatory factor 9 multiple interactions
increases expression
ISO IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA] CTD PMID:22240577 PMID:31154625 NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
JBrowse link
G Isg15 ISG15 ubiquitin-like modifier increases expression
multiple interactions
ISO Poly I-C results in increased expression of ISG15 mRNA
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]
CTD PMID:31154625 PMID:36958387 NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
JBrowse link
G Itgam integrin subunit alpha M increases expression EXP Poly I-C results in increased expression of ITGAM mRNA; Poly I-C results in increased expression of ITGAM protein CTD PMID:27317300 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
JBrowse link
G Jcad junctional cadherin 5 associated multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of JCAD mRNA CTD PMID:26923065 NCBI chr17:53,089,382...53,130,996
Ensembl chr17:53,089,382...53,130,967
JBrowse link
G Kcna2 potassium voltage-gated channel subfamily A member 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KCNA2 mRNA CTD PMID:26923065 NCBI chr 2:194,704,555...194,718,387
Ensembl chr 2:194,704,639...194,718,400
JBrowse link
G Kcnip4 potassium voltage-gated channel interacting protein 4 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KCNIP4 mRNA CTD PMID:26923065 NCBI chr14:61,380,699...62,531,399
Ensembl chr14:61,381,076...62,530,144
JBrowse link
G Kcnq5 potassium voltage-gated channel subfamily Q member 5 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KCNQ5 mRNA CTD PMID:26923065 NCBI chr 9:23,830,185...24,395,984
Ensembl chr 9:23,833,087...24,394,704
JBrowse link
G Kif5b kinesin family member 5B multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KIF5B mRNA CTD PMID:26923065 NCBI chr17:51,489,904...51,527,508
Ensembl chr17:51,489,944...51,527,508
JBrowse link
G Kif5c kinesin family member 5C multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KIF5C mRNA CTD PMID:26923065 NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
JBrowse link
G Klf4 KLF transcription factor 4 increases expression
multiple interactions
ISO Poly I-C results in increased expression of KLF4 protein
Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein]
CTD PMID:29486283 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Klrk1 killer cell lectin like receptor K1 increases expression ISO Poly I-C results in increased expression of KLRK1 mRNA; Poly I-C results in increased expression of KLRK1 protein CTD PMID:16472598 NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459
JBrowse link
G Kpna3 karyopherin subunit alpha 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of KPNA3 mRNA CTD PMID:26923065 NCBI chr15:35,536,310...35,610,066
Ensembl chr15:35,536,316...35,610,419
JBrowse link
G Kpna7 karyopherin subunit alpha 7 multiple interactions
increases expression
ISO Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] CTD PMID:34696514 NCBI chr12:9,576,378...9,635,247
Ensembl chr12:9,576,378...9,612,833
JBrowse link
G Lsm14b LSM family member 14B multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of LSM14B mRNA CTD PMID:26923065 NCBI chr 3:167,125,633...167,136,417
Ensembl chr 3:167,125,628...167,136,432
JBrowse link
G Mal2 mal, T-cell differentiation protein 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MAL2 mRNA CTD PMID:26923065 NCBI chr 7:85,900,453...85,933,433
Ensembl chr 7:85,900,453...85,933,429
JBrowse link
G Map3k11 mitogen-activated protein kinase kinase kinase 11 increases phosphorylation ISO Poly I-C results in increased phosphorylation of MAP3K11 protein CTD PMID:17698565 NCBI chr 1:202,975,353...202,988,655
Ensembl chr 1:202,975,353...202,988,652
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
increases phosphorylation
multiple interactions
ISO Poly I-C results in decreased phosphorylation of MAPK1 protein
Poly I-C results in increased phosphorylation of MAPK1 protein
Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]
CTD PMID:23516405 PMID:25780039 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
increases phosphorylation
multiple interactions
ISO Poly I-C results in decreased phosphorylation of MAPK3 protein
Poly I-C results in increased phosphorylation of MAPK3 protein
Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]
CTD PMID:23516405 PMID:25780039 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk4 mitogen-activated protein kinase 4 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MAPK4 mRNA CTD PMID:26923065 NCBI chr18:67,512,805...67,661,271
Ensembl chr18:67,512,807...67,661,842
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MAPK9 mRNA CTD PMID:26923065 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mapre1 microtubule-associated protein, RP/EB family, member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MAPRE1 mRNA CTD PMID:26923065 NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983
JBrowse link
G Marchf7 membrane associated ring-CH-type finger 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MARCHF7 mRNA CTD PMID:26923065 NCBI chr 3:44,680,229...44,720,172
Ensembl chr 3:44,681,632...44,720,168
JBrowse link
G Mblac2 metallo-beta-lactamase domain containing 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MBLAC2 mRNA CTD PMID:26923065 NCBI chr 2:11,986,075...12,028,882
Ensembl chr 2:11,986,027...12,030,950
JBrowse link
G Mbp myelin basic protein multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MBP mRNA CTD PMID:26923065 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
JBrowse link
G Mef2c myocyte enhancer factor 2C multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MEF2C mRNA CTD PMID:26923065 NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
JBrowse link
G Micos13 mitochondrial contact site and cristae organizing system subunit 13 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of MICOS13 mRNA CTD PMID:26923065 NCBI chr 9:1,439,841...1,441,782
Ensembl chr 9:1,439,058...1,442,076
JBrowse link
G Micu3 mitochondrial calcium uptake family, member 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MICU3 mRNA CTD PMID:26923065 NCBI chr16:51,919,859...52,010,705
Ensembl chr16:51,925,225...52,010,613
JBrowse link
G Mir148b microRNA 148b multiple interactions ISO [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR148B mRNA CTD PMID:34303791 NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494
JBrowse link
G Mir152 microRNA 152 multiple interactions ISO [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR152 mRNA CTD PMID:34303791 NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020
JBrowse link
G Mir155 microRNA 155 multiple interactions
increases expression
ISO MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]]; Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA] CTD PMID:22546503 NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
JBrowse link
G Mir26a microRNA 26a multiple interactions EXP MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] CTD PMID:24423102 NCBI chr 8:118,755,289...118,755,378
Ensembl chr 8:118,755,289...118,755,378
JBrowse link
G Mrps15 mitochondrial ribosomal protein S15 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of MRPS15 mRNA CTD PMID:26923065 NCBI chr 5:138,321,610...138,332,205
Ensembl chr 5:138,321,593...138,332,205
JBrowse link
G Msi1 musashi RNA-binding protein 1 multiple interactions ISO Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein] CTD PMID:29486283 NCBI chr12:41,158,301...41,251,134
Ensembl chr12:41,158,599...41,191,076
JBrowse link
G Mtpn myotrophin multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MTPN mRNA CTD PMID:26923065 NCBI chr 4:64,159,273...64,186,686
Ensembl chr 4:64,157,641...64,186,724
JBrowse link
G Mtrex Mtr4 exosome RNA helicase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of MTREX mRNA CTD PMID:26923065 NCBI chr 2:44,500,326...44,560,624
Ensembl chr 2:44,461,444...44,560,627
JBrowse link
G Mx1 MX dynamin like GTPase 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of MX1 mRNA
Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]
CTD PMID:17669408 PMID:22558189 PMID:34051100 NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression
ISO Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein]
Poly I-C results in increased expression of MYC protein
CTD PMID:29486283 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor increases expression
multiple interactions
ISO Poly I-C results in increased expression of MYD88 mRNA
cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of MYD88 mRNA]
CTD PMID:18306459 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
JBrowse link
G Naa60 N(alpha)-acetyltransferase 60, NatF catalytic subunit multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NAA60 mRNA CTD PMID:26923065 NCBI chr10:11,622,554...11,653,078
Ensembl chr10:11,587,916...11,642,755
JBrowse link
G Napb NSF attachment protein beta multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NAPB mRNA CTD PMID:26923065 NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345
JBrowse link
G Napepld N-acyl phosphatidylethanolamine phospholipase D multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NAPEPLD mRNA CTD PMID:26923065 NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748
JBrowse link
G Nbea neurobeachin multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NBEA mRNA CTD PMID:26923065 NCBI chr 2:139,780,021...140,338,639
Ensembl chr 2:139,780,021...140,340,584
JBrowse link
G Ndst3 N-deacetylase and N-sulfotransferase 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NDST3 mRNA CTD PMID:26923065 NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584
JBrowse link
G Necab1 N-terminal EF-hand calcium binding protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NECAB1 mRNA CTD PMID:26923065 NCBI chr 5:28,357,859...28,578,642
Ensembl chr 5:28,357,859...28,578,642
Ensembl chr 5:28,357,859...28,578,642
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of NFKB1 mRNA
[Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]
CTD PMID:34696514 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation
multiple interactions
ISO Poly I-C results in increased phosphorylation of NFKBIA protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]
CTD PMID:18779317 PMID:20932985 PMID:23688403 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nlgn3 neuroligin 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NLGN3 mRNA CTD PMID:26923065 NCBI chr  X:66,427,926...66,457,378
Ensembl chr  X:66,429,458...66,451,876
JBrowse link
G Nmu neuromedin U multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of NMU mRNA CTD PMID:26923065 NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
ISO
EXP
pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein]
Diclofenac promotes the reaction [Poly I-C results in increased expression of NOS2 mRNA]
Poly I-C results in increased expression of NOS2 mRNA; Poly I-C results in increased expression of NOS2 protein
CTD PMID:17321468 PMID:18279804 PMID:18323514 PMID:21195166 PMID:23939143 More... NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nrsn1 neurensin 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of NRSN1 mRNA CTD PMID:26923065 NCBI chr17:39,806,238...39,824,550
Ensembl chr17:39,806,238...39,823,813
JBrowse link
G Nuf2 NUF2 component of NDC80 kinetochore complex multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of NUF2 mRNA CTD PMID:26923065 NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A increases expression
multiple interactions
ISO Poly I-C results in increased expression of OAS1 mRNA
[[Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein] which results in increased abundance of 2',5'-oligoadenylate; [Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]
CTD PMID:17669408 PMID:22240577 PMID:26055709 PMID:31154625 NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517
JBrowse link
G Oas2 2'-5' oligoadenylate synthetase 2 increases expression ISO Poly I-C results in increased expression of OAS2 mRNA CTD PMID:22240577 PMID:22558189 NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
JBrowse link
G Or4e1 olfactory receptor family 4 subfamily E member 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of OR4E1 mRNA CTD PMID:26923065 NCBI chr15:25,201,369...25,211,302
Ensembl chr15:25,196,602...25,211,463
JBrowse link
G P2rx7 purinergic receptor P2X 7 decreases expression
multiple interactions
ISO Poly I-C results in decreased expression of P2RX7 protein
Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein]
CTD PMID:23516405 NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
JBrowse link
G P2ry2 purinergic receptor P2Y2 decreases expression
multiple interactions
ISO Poly I-C results in decreased expression of P2RY2 protein
Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein]
CTD PMID:23516405 NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
JBrowse link
G Pak2 p21 (RAC1) activated kinase 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PAK2 mRNA CTD PMID:26923065 NCBI chr11:68,707,940...68,768,816
Ensembl chr11:68,707,969...68,768,816
JBrowse link
G Pard6g par-6 family cell polarity regulator gamma multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PARD6G mRNA CTD PMID:26923065 NCBI chr18:73,497,992...73,565,048
Ensembl chr18:73,498,021...73,565,029
JBrowse link
G Pcmtd1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PCMTD1 mRNA CTD PMID:26923065 NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899
JBrowse link
G Pdap1 PDGFA associated protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of PDAP1 mRNA CTD PMID:26923065 NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374
JBrowse link
G Pdcd6ip programmed cell death 6 interacting protein multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PDCD6IP mRNA CTD PMID:26923065 NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773
JBrowse link
G Pdha1l1 pyruvate dehydrogenase (lipoamide) alpha 1-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PDHA1L1 mRNA CTD PMID:26923065 NCBI chr16:82,511,483...82,514,378
Ensembl chr16:82,511,511...82,514,372
JBrowse link
G Pgam1-ps11 phosphoglycerate mutase 1, pseudogene 11 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PGAM1-PS11 mRNA CTD PMID:26923065 NCBI chr10:51,449,141...51,480,570 JBrowse link
G Phactr1 phosphatase and actin regulator 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PHACTR1 mRNA CTD PMID:26923065 NCBI chr17:21,560,364...22,040,166
Ensembl chr17:21,562,721...22,039,831
JBrowse link
G Phf7 PHD finger protein 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of PHF7 mRNA CTD PMID:26923065 NCBI chr16:6,433,535...6,446,314
Ensembl chr16:6,433,537...6,446,911
JBrowse link
G Pkib cAMP-dependent protein kinase inhibitor beta multiple interactions
decreases expression
EXP [Poly I-C co-treated with HU 211] results in decreased expression of PKIB mRNA
Poly I-C results in decreased expression of PKIB mRNA
CTD PMID:26923065 NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187
JBrowse link
G Plcb1 phospholipase C beta 1 increases expression ISO Poly I-C results in increased expression of PLCB1 mRNA CTD PMID:24889602 NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
JBrowse link
G Plcxd2 phosphatidylinositol-specific phospholipase C, X domain containing 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PLCXD2 mRNA CTD PMID:26923065 NCBI chr11:54,800,977...54,853,348
Ensembl chr11:54,789,477...54,853,344
JBrowse link
G Plekha8 pleckstrin homology domain containing A8 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of PLEKHA8 mRNA CTD PMID:26923065 NCBI chr 4:83,723,470...83,774,081
Ensembl chr 4:83,723,561...83,774,081
JBrowse link
G Plppr4 phospholipid phosphatase related 4 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PLPPR4 mRNA CTD PMID:26923065 NCBI chr 2:205,371,317...205,412,302
Ensembl chr 2:205,371,322...205,412,302
JBrowse link
G Pmvk phosphomevalonate kinase multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of PMVK mRNA CTD PMID:26923065 NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions
increases expression
ISO Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein]
Poly I-C results in increased expression of POU5F1 protein
CTD PMID:29486283 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Prf1 perforin 1 multiple interactions
increases expression
ISO Particulate Matter inhibits the reaction [Poly I-C results in increased expression of PRF1 protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of PRF1 protein]
Poly I-C results in increased expression of PRF1 mRNA; Poly I-C results in increased expression of PRF1 protein
CTD PMID:23618096 NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
JBrowse link
G Prkci protein kinase C, iota multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of PRKCI mRNA CTD PMID:26923065 NCBI chr 2:112,321,919...112,382,305
Ensembl chr 2:112,321,929...112,382,352
JBrowse link
G Prodh2 proline dehydrogenase 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of PRODH2 mRNA CTD PMID:26923065 NCBI chr 1:85,753,558...85,767,165
Ensembl chr 1:85,753,644...85,767,162
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Poly I-C results in increased expression of PTGS2 protein
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of PTGS2 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]
CTD PMID:16116226 PMID:18279804 PMID:24889602 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pvalb parvalbumin multiple interactions EXP [Poly I-C co-treated with Cannabidiol] results in increased expression of PVALB protein CTD PMID:31326506 NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions EXP
ISO
[Poly I-C co-treated with HU 211] results in decreased expression of RAC1 mRNA
[Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; [Poly I-C co-treated with Ivermectin] results in decreased expression of RAC1 mRNA
CTD PMID:26923065 PMID:34696514 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
JBrowse link
G Rarb retinoic acid receptor, beta multiple interactions ISO [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB protein; [Arsenicals co-treated with Poly I-C] affects the expression of RARB mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of RARB protein CTD PMID:34303791 NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
JBrowse link
G Rdm1 RAD52 motif containing 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of RDM1 mRNA CTD PMID:26923065 NCBI chr10:86,562,871...86,573,034
Ensembl chr10:86,539,553...86,573,034
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects localization
increases phosphorylation
multiple interactions
ISO Poly I-C affects the localization of RELA protein
Poly I-C results in increased phosphorylation of RELA protein
TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]
CTD PMID:18779317 PMID:24709138 PMID:27836898 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rgs4 regulator of G-protein signaling 4 increases expression ISO Poly I-C results in increased expression of RGS4 mRNA CTD PMID:24889602 NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
JBrowse link
G Rhoa ras homolog family member A multiple interactions ISO [Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA CTD PMID:34696514 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
JBrowse link
G Rig1 RNA sensor RIG-1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of RIGI mRNA
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]
CTD PMID:27183587 PMID:30341573 PMID:31154625 NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819
JBrowse link
G Rimbp2 RIMS binding protein 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of RIMBP2 mRNA CTD PMID:26923065 NCBI chr12:27,747,615...27,946,256
Ensembl chr12:27,747,980...27,956,763
JBrowse link
G Rimoc1 RAB7A interacting MON1-CCZ1 complex subunit 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of RIMOC1 mRNA CTD PMID:26923065 NCBI chr 2:53,189,787...53,203,981
Ensembl chr 2:53,189,790...53,203,821
JBrowse link
G rnf141 ring finger protein 141 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of RNF141 mRNA CTD PMID:26923065 NCBI chr 1:164,933,972...164,957,081
Ensembl chr 1:164,931,077...164,957,118
JBrowse link
G Rpl31 ribosomal protein L31 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of RPL31 mRNA CTD PMID:26923065 NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129
JBrowse link
G Rps6kb2 ribosomal protein S6 kinase B2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of RPS6KB2 mRNA CTD PMID:26923065 NCBI chr 1:201,451,265...201,458,096
Ensembl chr 1:201,451,265...201,458,078
JBrowse link
G Rtn4rl1 reticulon 4 receptor-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of RTN4RL1 mRNA CTD PMID:26923065 NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978
JBrowse link
G S100a3 S100 calcium binding protein A3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of S100A3 mRNA CTD PMID:26923065 NCBI chr 2:176,034,283...176,089,702
Ensembl chr 2:176,049,520...176,089,702
JBrowse link
G Sema6d semaphorin 6D multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SEMA6D mRNA CTD PMID:26923065 NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094
JBrowse link
G Septin6 septin 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SEPTIN6 mRNA CTD PMID:26923065 NCBI chr  X:116,153,255...116,230,334
Ensembl chr  X:116,153,255...116,230,115
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions
increases expression
ISO Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]
Poly I-C results in increased expression of SERPINE1 mRNA; Poly I-C results in increased expression of SERPINE1 protein
CTD PMID:30341573 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
JBrowse link
G Sesn2 sestrin 2 increases expression ISO Poly I-C results in increased expression of SESN2 mRNA CTD PMID:25637945 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
JBrowse link
G Sgtb small glutamine rich tetratricopeptide repeat co-chaperone beta multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SGTB mRNA CTD PMID:26923065 NCBI chr 2:35,233,045...35,269,527
Ensembl chr 2:35,233,042...35,269,518
JBrowse link
G Sh3rf1 SH3 domain containing ring finger 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SH3RF1 mRNA CTD PMID:26923065 NCBI chr16:28,735,522...28,901,261
Ensembl chr16:28,735,440...28,901,644
JBrowse link
G Shroom2 shroom family member 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SHROOM2 mRNA CTD PMID:26923065 NCBI chr  X:21,812,469...21,983,724
Ensembl chr  X:21,812,469...21,984,153
JBrowse link
G Sidt1 SID1 transmembrane family, member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SIDT1 mRNA CTD PMID:26923065 NCBI chr11:56,362,788...56,459,939
Ensembl chr11:56,363,512...56,459,050
JBrowse link
G Slc14a1 solute carrier family 14 member 1 (Kidd blood group) multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC14A1 mRNA CTD PMID:26923065 NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC17A7 mRNA CTD PMID:26923065 NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
JBrowse link
G Slc25a12 solute carrier family 25 member 12 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC25A12 mRNA CTD PMID:26923065 NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100
JBrowse link
G Slc25a14 solute carrier family 25 member 14 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC25A14 mRNA CTD PMID:26923065 NCBI chr  X:127,807,630...127,845,823
Ensembl chr  X:127,807,449...127,845,823
JBrowse link
G Slc2a13 solute carrier family 2 member 13 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC2A13 mRNA CTD PMID:26923065 NCBI chr 7:122,399,329...122,726,605
Ensembl chr 7:122,399,330...122,726,605
JBrowse link
G Slc3a1 solute carrier family 3 member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC3A1 mRNA CTD PMID:26923065 NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
JBrowse link
G Slc4a10 solute carrier family 4 member 10 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SLC4A10 mRNA CTD PMID:26923065 NCBI chr 3:46,665,076...46,959,088
Ensembl chr 3:46,665,265...46,957,268
JBrowse link
G Smarcd1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SMARCD1 mRNA CTD PMID:26923065 NCBI chr 7:130,829,783...130,840,323
Ensembl chr 7:130,829,768...130,840,323
JBrowse link
G Snd1 staphylococcal nuclease and tudor domain containing 1 affects localization ISO Poly I-C affects the localization of SND1 protein CTD PMID:22240577 NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
JBrowse link
G Snrk SNF related kinase multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SNRK mRNA CTD PMID:26923065 NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323
JBrowse link
G Socs1 suppressor of cytokine signaling 1 increases expression
multiple interactions
ISO Poly I-C results in increased expression of SOCS1 mRNA
Progesterone promotes the reaction [Poly I-C results in increased expression of SOCS1 mRNA]
CTD PMID:22546503 NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression ISO Poly I-C results in increased expression of SOCS3 mRNA CTD PMID:21195166 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Poly I-C results in increased expression of SOD2 mRNA CTD PMID:23939143 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression
multiple interactions
ISO Poly I-C results in increased expression of SOX2 protein
Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein]
CTD PMID:29486283 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
JBrowse link
G Spag6 sperm associated antigen 6 decreases expression EXP Poly I-C results in decreased expression of SPAG6 mRNA CTD PMID:26923065 NCBI chr17:81,352,372...81,401,504
Ensembl chr17:81,349,084...81,401,501
JBrowse link
G Srsf12 serine and arginine rich splicing factor 12 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SRSF12 mRNA CTD PMID:26923065 NCBI chr 5:47,606,526...47,631,509
Ensembl chr 5:47,606,285...47,629,778
JBrowse link
G Srsf7 serine and arginine rich splicing factor 7 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SRSF7 mRNA CTD PMID:26923065 NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions
increases expression
increases phosphorylation
ISO sodium arsenite inhibits the reaction [Poly I-C results in increased phosphorylation of STAT1 protein]
Poly I-C results in increased expression of STAT1 mRNA
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]
CTD PMID:30726814 PMID:31154625 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
JBrowse link
G Stat2 signal transducer and activator of transcription 2 multiple interactions
increases expression
ISO IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA] CTD PMID:31154625 NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein CTD PMID:21195166 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Stxbp6 syntaxin binding protein 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of STXBP6 mRNA CTD PMID:26923065 NCBI chr 6:61,920,756...62,157,405
Ensembl chr 6:61,920,756...62,158,024
JBrowse link
G Svip small VCP interacting protein multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SVIP mRNA CTD PMID:26923065 NCBI chr 1:101,587,128...101,592,818
Ensembl chr 1:101,587,128...101,593,116
JBrowse link
G Syt11 synaptotagmin 11 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of SYT11 mRNA CTD PMID:26923065 NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
JBrowse link
G Tbc1d9 TBC1 domain family member 9 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TBC1D9 mRNA CTD PMID:26923065 NCBI chr19:24,842,166...24,951,383
Ensembl chr19:24,842,205...24,943,129
JBrowse link
G Tbk1 TANK-binding kinase 1 multiple interactions
increases phosphorylation
ISO APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] CTD PMID:25780039 NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
JBrowse link
G Tecrl2 trans-2,3-enoyl-CoA reductase like 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TECRL2 mRNA CTD PMID:26923065 NCBI chr 1:47,263,647...47,264,682 JBrowse link
G Terf2ip TERF2 interacting protein multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TERF2IP mRNA CTD PMID:26923065 NCBI chr19:39,976,965...39,984,055
Ensembl chr19:39,976,906...39,984,064
JBrowse link
G Tfb1m transcription factor B1, mitochondrial multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of TFB1M mRNA CTD PMID:26923065 NCBI chr 1:44,115,240...44,161,737
Ensembl chr 1:44,119,166...44,161,709
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases secretion ISO Poly I-C results in increased secretion of TGFB1 protein CTD PMID:34740670 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Thy1 Thy-1 cell surface antigen multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of THY1 mRNA CTD PMID:26923065 NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
JBrowse link
G Tial1 Tia1 cytotoxic granule-associated RNA binding protein-like 1 affects localization ISO Poly I-C affects the localization of TIAL1 protein CTD PMID:22240577 NCBI chr 1:183,008,358...183,045,092
Ensembl chr 1:183,009,253...183,031,637
JBrowse link
G Ticam1 TIR domain containing adaptor molecule 1 increases expression ISO Poly I-C results in increased expression of TICAM1 mRNA CTD PMID:21418039 NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression ISO Poly I-C results in increased expression of TIMP1 mRNA CTD PMID:21195166 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Tlr2 toll-like receptor 2 increases expression ISO Poly I-C results in increased expression of TLR2 mRNA CTD PMID:17669408 NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions
increases activity
increases expression
ISO
EXP
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-aminopyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-nitropyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to pyrene; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 mRNA; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 protein; Chloroquine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; Poly I-C binds to and results in increased activity of TLR3 protein; Quinacrine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]
MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]
Poly I-C results in increased expression of TLR3 mRNA
cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of TLR3 mRNA]
CTD PMID:16399790 PMID:17669408 PMID:18306459 PMID:18779317 PMID:21398612 More... NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
JBrowse link
G Tlr7 toll-like receptor 7 increases expression ISO Poly I-C results in increased expression of TLR7 mRNA CTD PMID:17669408 NCBI chr  X:27,027,380...27,054,309
Ensembl chr  X:27,027,425...27,054,754
JBrowse link
G Tmem266 transmembrane protein 266 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of TMEM266 mRNA CTD PMID:26923065 NCBI chr 8:55,707,122...55,820,692
Ensembl chr 8:55,707,122...55,820,692
JBrowse link
G Tmem273 transmembrane protein 273 multiple interactions EXP [Poly I-C co-treated with HU 211] results in increased expression of TMEM273 mRNA CTD PMID:26923065 NCBI chr16:8,049,565...8,081,981
Ensembl chr16:8,049,669...8,081,981
JBrowse link
G Tmx1 thioredoxin-related transmembrane protein 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TMX1 mRNA CTD PMID:26923065 NCBI chr 6:88,960,691...88,971,744
Ensembl chr 6:88,960,695...88,971,301
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases secretion
ISO
EXP
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of TNF protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TNF protein]; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TNF protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]
Poly I-C results in increased expression of TNF mRNA; Poly I-C results in increased expression of TNF protein
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein]
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol promotes the reaction [Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]]; Hydroxamic Acids analog inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]
CTD PMID:16687389 PMID:17238832 PMID:17321468 PMID:17669408 PMID:17698565 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf10 TNF superfamily member 10 increases expression ISO Poly I-C results in increased expression of TNFSF10 mRNA; Poly I-C results in increased expression of TNFSF10 protein CTD PMID:16472598 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tnks2 tankyrase 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TNKS2 mRNA CTD PMID:26923065 NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]; TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil] CTD PMID:18779317 PMID:20367642 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tpd52 tumor protein D52 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TPD52 mRNA CTD PMID:26923065 NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]] CTD PMID:16399790 NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
JBrowse link
G Trim2 tripartite motif-containing 2 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TRIM2 mRNA CTD PMID:26923065 NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927
JBrowse link
G Tslp thymic stromal lymphopoietin multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]
Poly I-C results in increased expression of TSLP mRNA; Poly I-C results in increased expression of TSLP protein
CTD PMID:23688403 PMID:30017638 NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
JBrowse link
G Tspyl5 TSPY-like 5 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TSPYL5 mRNA CTD PMID:26923065 NCBI chr 7:64,881,504...64,885,512
Ensembl chr 7:64,884,225...64,885,457
JBrowse link
G Ttc3 tetratricopeptide repeat domain 3 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TTC3 mRNA CTD PMID:26923065 NCBI chr11:33,689,119...33,788,976
Ensembl chr11:33,688,952...33,788,975
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases expression EXP Poly I-C results in decreased expression of TWIST1 mRNA CTD PMID:26923065 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
JBrowse link
G Twsg1 twisted gastrulation BMP signaling modulator 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of TWSG1 mRNA CTD PMID:26923065 NCBI chr 9:105,533,116...105,567,460
Ensembl chr 9:105,533,136...105,567,479
JBrowse link
G Txn1 thioredoxin 1 multiple interactions
increases expression
EXP Diclofenac inhibits the reaction [Poly I-C results in increased expression of TXN1 mRNA] CTD PMID:23939143 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
JBrowse link
G Ubl4a ubiquitin-like 4A multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of UBL4A mRNA CTD PMID:26923065 NCBI chr  X:152,151,242...152,154,094
Ensembl chr  X:152,151,460...152,154,069
JBrowse link
G Ubr1 ubiquitin protein ligase E3 component n-recognin 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of UBR1 mRNA CTD PMID:26923065 NCBI chr 3:107,813,721...107,921,701
Ensembl chr 3:107,811,392...107,922,204
JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 decreases expression EXP Poly I-C results in decreased expression of UGT2B1 mRNA CTD PMID:23939143 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
JBrowse link
G Usp32 ubiquitin specific peptidase 32 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of USP32 mRNA CTD PMID:26923065 NCBI chr10:69,855,895...70,029,075
Ensembl chr10:69,855,885...70,029,137
JBrowse link
G Vsnl1 visinin-like 1 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of VSNL1 mRNA CTD PMID:26923065 NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479
JBrowse link
G Wac WW domain containing adaptor with coiled-coil multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of WAC mRNA CTD PMID:26923065 NCBI chr17:55,922,686...55,984,286
Ensembl chr17:55,923,123...55,982,301
JBrowse link
G Wdr47 WD repeat domain 47 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of WDR47 mRNA CTD PMID:26923065 NCBI chr 2:196,226,757...196,287,739
Ensembl chr 2:196,205,238...196,287,739
JBrowse link
G Zbtb6 zinc finger and BTB domain containing 6 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ZBTB6 mRNA CTD PMID:26923065 NCBI chr 3:21,189,160...21,207,561
Ensembl chr 3:21,187,483...21,207,849
JBrowse link
G Zdhhc21 zinc finger DHHC-type palmitoyltransferase 21 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ZDHHC21 mRNA CTD PMID:26923065 NCBI chr 5:97,227,621...97,286,866
Ensembl chr 5:97,229,345...97,286,537
JBrowse link
G Zfp354c zinc finger protein 354C multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ZFP354C mRNA CTD PMID:26923065 NCBI chr10:35,129,720...35,145,717
Ensembl chr10:35,132,959...35,145,661
JBrowse link
G Zfp663 zinc finger protein 663 multiple interactions EXP [Poly I-C co-treated with HU 211] results in decreased expression of ZFP763 mRNA CTD PMID:26923065 NCBI chr 3:154,084,553...154,102,521
Ensembl chr 3:154,085,957...154,093,160
JBrowse link
pyrimethamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl6 BCL6, transcription repressor multiple interactions ISO Leucovorin inhibits the reaction [Pyrimethamine inhibits the reaction [Oncostatin M results in increased expression of BCL6 mRNA]]; Pyrimethamine inhibits the reaction [Oncostatin M results in increased expression of BCL6 mRNA] CTD PMID:34953855 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
ISO [Pyrimethamine co-treated with temozolomide] results in increased cleavage of CASP3 protein; Palmitic Acid promotes the reaction [Pyrimethamine results in increased activity of CASP3 protein] CTD PMID:19435820 PMID:22700542 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 multiple interactions
increases activity
ISO Palmitic Acid promotes the reaction [Pyrimethamine results in increased activity of CASP7 protein] CTD PMID:22700542 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 increases activity ISO Pyrimethamine results in increased activity of CASP8 protein CTD PMID:18593930 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Cat catalase increases expression ISO Pyrimethamine results in increased expression of CAT mRNA; Pyrimethamine results in increased expression of CAT protein CTD PMID:20193682 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ctsb cathepsin B increases activity ISO Pyrimethamine results in increased activity of CTSB protein CTD PMID:18593930 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Dhfr dihydrofolate reductase multiple interactions ISO Pyrimethamine binds to and results in increased stability of DHFR protein; Pyrimethamine results in increased expression of and affects the activity of DHFR protein CTD PMID:34953855 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression ISO Pyrimethamine results in increased expression of FOS mRNA CTD PMID:12730611 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gpx4 glutathione peroxidase 4 increases expression ISO Pyrimethamine results in increased expression of GPX4 mRNA CTD PMID:20193682 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases activity
multiple interactions
ISO Pyrimethamine results in decreased activity of GSTP1 protein
Pyrimethamine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]
CTD PMID:11807801 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G H2ax H2A.X variant histone increases phosphorylation ISO Pyrimethamine results in increased phosphorylation of H2AX protein CTD PMID:19435820 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hexb hexosaminidase subunit beta affects binding ISO Pyrimethamine binds to HEXB protein CTD PMID:21265544 NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Pyrimethamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Sulfadiazine co-treated with Pyrimethamine] results in decreased expression of IL6 protein CTD PMID:37722575 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression ISO Pyrimethamine results in increased expression of NOS2 mRNA CTD PMID:20193682 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G RT1-M3-1 RT1 class Ib, locus M3, gene 1 affects expression ISO Pyrimethamine affects the expression of HLA-G mRNA CTD PMID:25811541 NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO Pyrimethamine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:27504015 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Pyrimethamine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:27504015 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc46a1 solute carrier family 46 member 1 decreases activity ISO Pyrimethamine results in decreased activity of SLC46A1 protein CTD PMID:19762432 NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions
decreases activity
ISO Pyrimethamine analog inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Pyrimethamine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Pyrimethamine inhibits the reaction [SLC47A1 protein results in increased uptake of Metformin]; Pyrimethamine inhibits the reaction [SLC47A1 protein results in increased uptake of Tetraethylammonium]
Pyrimethamine results in decreased activity of SLC47A1 protein
CTD PMID:22419765 PMID:32305507 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions
decreases activity
ISO Pyrimethamine analog inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Pyrimethamine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Pyrimethamine inhibits the reaction [SLC47A2 protein results in increased uptake of Tetraethylammonium]
Pyrimethamine results in decreased activity of SLC47A2 protein
CTD PMID:22419765 PMID:32305507 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 multiple interactions ISO Pyrimethamine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate] CTD PMID:27504015 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions
decreases expression
ISO Leucovorin inhibits the reaction [Pyrimethamine results in decreased expression of SOCS3 mRNA] CTD PMID:34953855 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
JBrowse link
G Sod1 superoxide dismutase 1 increases expression ISO Pyrimethamine results in increased expression of SOD1 mRNA CTD PMID:20193682 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
pyrimethanil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO pyrimethanil binds to and results in increased activity of AHR protein CTD PMID:23436777 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of AIF1 protein
CTD PMID:31939705 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions
ISO pyrimethanil binds to APP protein modified form
[APP gene mutant form results in increased expression of APP protein modified form] which results in increased susceptibility to pyrimethanil; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of AIF1 protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein]; [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein]; APP protein modified form results in increased susceptibility to [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil]
CTD PMID:31939705 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Ar androgen receptor increases expression
multiple interactions
ISO pyrimethanil results in increased expression of AR mRNA
pyrimethanil inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]
CTD PMID:21310686 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of BACE1 protein CTD PMID:31939705 NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
JBrowse link
G Casp3 caspase 3 multiple interactions
affects expression
ISO [pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of CASP3 mRNA
pyrimethanil affects the expression of CASP3 mRNA
CTD PMID:22880100 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased expression of CYP3A4 mRNA CTD PMID:25028461 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Esr1 estrogen receptor 1 increases activity EXP pyrimethanil results in increased activity of ESR1 protein CTD PMID:33352482 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of GFAP protein]
[cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] results in increased expression of GFAP protein
CTD PMID:31939705 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Gpx1 glutathione peroxidase 1 affects expression
multiple interactions
ISO pyrimethanil affects the expression of GPX1 mRNA
[pyrimethanil co-treated with cyprodinil co-treated with fludioxonil] results in increased expression of GPX1 mRNA
CTD PMID:22880100 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL1B protein] CTD PMID:31939705 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [cyprodinil co-treated with mepanipyrim co-treated with pyrimethanil] promotes the reaction [[APP gene mutant form results in increased expression of APP protein modified form] which results in increased expression of IL6 protein] CTD PMID:31939705 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased activity of NR1I2 protein CTD PMID:25028461 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nrf1 nuclear respiratory factor 1 increases expression ISO pyrimethanil results in increased expression of NRF1 mRNA CTD PMID:33352482 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [pyrimethanil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 CTD PMID:26359731 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Tff1 trefoil factor 1 increases expression ISO pyrimethanil results in increased expression of TFF1 mRNA CTD PMID:33352482 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
pyrimidifen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadvl acyl-CoA dehydrogenase, very long chain decreases expression ISO pyrimidifen results in decreased expression of ACADVL mRNA CTD PMID:33512557 NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
JBrowse link
G Adi1 acireductone dioxygenase 1 increases expression ISO pyrimidifen results in increased expression of ADI1 mRNA CTD PMID:33512557 NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
JBrowse link
G Ahcy adenosylhomocysteinase increases expression ISO pyrimidifen results in increased expression of AHCY mRNA CTD PMID:33512557 NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 decreases expression ISO pyrimidifen results in decreased expression of AKR1B1 mRNA CTD PMID:33512557 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 decreases expression ISO pyrimidifen results in decreased expression of AKR7A2 mRNA CTD PMID:33512557 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member decreases expression ISO pyrimidifen results in decreased expression of ALDH2 mRNA CTD PMID:33512557 NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
JBrowse link
G Alg8 ALG8, alpha-1,3-glucosyltransferase increases expression ISO pyrimidifen results in increased expression of ALG8 mRNA CTD PMID:33512557 NCBI chr 1:151,684,344...151,704,310
Ensembl chr 1:151,684,396...151,704,302
JBrowse link
G Amdhd2 amidohydrolase domain containing 2 decreases expression ISO pyrimidifen results in decreased expression of AMDHD2 mRNA CTD PMID:33512557 NCBI chr10:13,187,579...13,196,148
Ensembl chr10:13,187,578...13,196,095
JBrowse link
G Amer1 APC membrane recruitment protein 1 decreases expression ISO pyrimidifen results in decreased expression of AMER1 mRNA CTD PMID:33512557 NCBI chr  X:60,300,595...60,316,480
Ensembl chr  X:60,295,751...60,316,440
JBrowse link
G Amh anti-Mullerian hormone increases expression ISO pyrimidifen results in increased expression of AMH mRNA CTD PMID:33512557 NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
JBrowse link
G Anln anillin, actin binding protein increases expression ISO pyrimidifen results in increased expression of ANLN mRNA CTD PMID:33512557 NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
JBrowse link
G Aplp1 amyloid beta precursor like protein 1 decreases expression ISO pyrimidifen results in decreased expression of APLP1 mRNA CTD PMID:33512557 NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155
JBrowse link
G Arhgap8 Rho GTPase activating protein 8 increases expression ISO pyrimidifen results in increased expression of ARHGAP8 mRNA CTD PMID:33512557 NCBI chr 7:115,842,223...115,902,094
Ensembl chr 7:115,850,654...115,902,093
JBrowse link
G Arrdc4 arrestin domain containing 4 decreases expression ISO pyrimidifen results in decreased expression of ARRDC4 mRNA CTD PMID:33512557 NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression ISO pyrimidifen results in increased expression of ASNS mRNA CTD PMID:33512557 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression ISO pyrimidifen results in increased expression of ASS1 mRNA CTD PMID:33512557 NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO pyrimidifen results in increased expression of ATF4 mRNA CTD PMID:33512557 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atmin ATM interactor decreases expression ISO pyrimidifen results in decreased expression of ATMIN mRNA CTD PMID:33512557 NCBI chr19:44,996,506...45,013,606
Ensembl chr19:44,996,356...45,013,605
JBrowse link
G Atp5mk ATP synthase membrane subunit K increases expression ISO pyrimidifen results in increased expression of ATP5MK mRNA CTD PMID:33512557 NCBI chr 1:245,973,910...245,980,702
Ensembl chr 1:245,973,914...245,980,761
Ensembl chr10:245,973,914...245,980,761
JBrowse link
G Atraid all-trans retinoic acid-induced differentiation factor increases expression ISO pyrimidifen results in increased expression of ATRAID mRNA CTD PMID:33512557 NCBI chr 6:25,315,236...25,319,821 JBrowse link
G Aurkb aurora kinase B increases expression ISO pyrimidifen results in increased expression of AURKB mRNA CTD PMID:33512557 NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
JBrowse link
G B2m beta-2 microglobulin increases expression ISO pyrimidifen results in increased expression of B2M mRNA CTD PMID:33512557 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
JBrowse link
G B3galt6 Beta-1,3-galactosyltransferase 6 decreases expression ISO pyrimidifen results in decreased expression of B3GALT6 mRNA CTD PMID:33512557 NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338
JBrowse link
G Banf1 BAF nuclear assembly factor 1 increases expression ISO pyrimidifen results in increased expression of BANF1 mRNA CTD PMID:33512557 NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
JBrowse link
G Bcl2l13 Bcl2-like 13 decreases expression ISO pyrimidifen results in decreased expression of BCL2L13 mRNA CTD PMID:33512557 NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression ISO pyrimidifen results in increased expression of BIRC5 mRNA CTD PMID:33512557 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Brd3 bromodomain containing 3 decreases expression ISO pyrimidifen results in decreased expression of BRD3 mRNA CTD PMID:33512557 NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577
JBrowse link
G C2cd5 C2 calcium-dependent domain containing 5 decreases expression ISO pyrimidifen results in decreased expression of C2CD5 mRNA CTD PMID:33512557 NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558
JBrowse link
G Calcoco1 calcium binding and coiled coil domain 1 decreases expression ISO pyrimidifen results in decreased expression of CALCOCO1 mRNA CTD PMID:33512557 NCBI chr 7:133,834,705...133,849,515
Ensembl chr 7:133,834,707...133,849,422
JBrowse link
G Calm1 calmodulin 1 decreases expression ISO pyrimidifen results in decreased expression of CALM1 mRNA CTD PMID:33512557 NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta decreases expression ISO pyrimidifen results in decreased expression of CAMK2B mRNA CTD PMID:33512557 NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
JBrowse link
G Caps calcyphosine decreases expression ISO pyrimidifen results in decreased expression of CAPS mRNA CTD PMID:33512557 NCBI chr 9:1,544,597...1,545,631
Ensembl chr 9:1,544,719...1,545,647
JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 increases expression ISO pyrimidifen results in increased expression of CARS1 mRNA CTD PMID:33512557 NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
JBrowse link
G Cblb Cbl proto-oncogene B decreases expression ISO pyrimidifen results in decreased expression of CBLB mRNA CTD PMID:33512557 NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839
JBrowse link
G Ccna2 cyclin A2 increases expression ISO pyrimidifen results in increased expression of CCNA2 mRNA CTD PMID:33512557 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb1 cyclin B1 increases expression ISO pyrimidifen results in increased expression of CCNB1 mRNA CTD PMID:33512557 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnb2 cyclin B2 increases expression ISO pyrimidifen results in increased expression of CCNB2 mRNA CTD PMID:33512557 NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
JBrowse link
G Ccng1 cyclin G1 increases expression ISO pyrimidifen results in increased expression of CCNG1 mRNA CTD PMID:33512557 NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
JBrowse link
G Ccnh cyclin H increases expression ISO pyrimidifen results in increased expression of CCNH mRNA CTD PMID:33512557 NCBI chr 2:15,835,064...15,855,648
Ensembl chr 2:15,834,833...15,855,819
JBrowse link
G Cd24 CD24 molecule decreases expression ISO pyrimidifen results in decreased expression of CD24 mRNA CTD PMID:33512557 NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
JBrowse link
G Cdh10 cadherin 10 decreases expression ISO pyrimidifen results in decreased expression of CDH10 mRNA CTD PMID:33512557 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
JBrowse link
G Cdh2 cadherin 2 decreases expression ISO pyrimidifen results in decreased expression of CDH2 mRNA CTD PMID:33512557 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases expression ISO pyrimidifen results in increased expression of CDK1 mRNA CTD PMID:33512557 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 decreases expression ISO pyrimidifen results in decreased expression of CDK5R1 mRNA CTD PMID:33512557 NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
JBrowse link
G Cdkn3 cyclin-dependent kinase inhibitor 3 increases expression ISO pyrimidifen results in increased expression of CDKN3 mRNA CTD PMID:33512557 NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression ISO pyrimidifen results in increased expression of CEBPB mRNA CTD PMID:33512557 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cel carboxyl ester lipase decreases expression ISO pyrimidifen results in decreased expression of CEL mRNA CTD PMID:33512557 NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO pyrimidifen results in increased expression of CHAC1 mRNA CTD PMID:33512557 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Chac2 ChaC glutathione specific gamma-glutamylcyclotransferase 2 increases expression ISO pyrimidifen results in increased expression of CHAC2 mRNA CTD PMID:33512557 NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO pyrimidifen results in increased expression of CHEK1 mRNA CTD PMID:33512557 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
JBrowse link
G Chmp6 charged multivesicular body protein 6 decreases expression ISO pyrimidifen results in decreased expression of CHMP6 mRNA CTD PMID:33512557 NCBI chr10:105,191,972...105,197,642
Ensembl chr10:105,191,950...105,197,640
JBrowse link
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit decreases expression ISO pyrimidifen results in decreased expression of CHRNA4 mRNA CTD PMID:33512557 NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
JBrowse link
G Ciao2b cytosolic iron-sulfur assembly component 2B increases expression ISO pyrimidifen results in increased expression of CIAO2B mRNA CTD PMID:33512557 NCBI chr19:344,194...346,068
Ensembl chr19:344,203...346,068
JBrowse link
G Ciao3 cytosolic iron-sulfur assembly component 3 decreases expression ISO pyrimidifen results in decreased expression of CIAO3 mRNA CTD PMID:33512557 NCBI chr10:14,795,888...14,804,953
Ensembl chr10:14,795,961...14,804,950
JBrowse link
G Cks1b CDC28 protein kinase regulatory subunit 1B increases expression ISO pyrimidifen results in increased expression of CKS1B mRNA CTD PMID:33512557 NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 increases expression ISO pyrimidifen results in increased expression of CKS2 mRNA CTD PMID:33512557 NCBI chr17:13,570,611...13,575,770 JBrowse link
G Clic4 chloride intracellular channel 4 increases expression ISO pyrimidifen results in increased expression of CLIC4 mRNA CTD PMID:33512557 NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
JBrowse link
G Clstn1 calsyntenin 1 decreases expression ISO pyrimidifen results in decreased expression of CLSTN1 mRNA CTD PMID:33512557 NCBI chr 5:160,031,235...160,094,585
Ensembl chr 5:160,031,308...160,094,583
JBrowse link
G Coasy Coenzyme A synthase increases expression ISO pyrimidifen results in increased expression of COASY mRNA CTD PMID:33512557 NCBI chr10:86,014,566...86,018,849
Ensembl chr10:86,014,597...86,018,841
JBrowse link
G Cox6b1 cytochrome c oxidase subunit 6B1 increases expression ISO pyrimidifen results in increased expression of COX6B1 mRNA CTD PMID:33512557 NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A increases expression ISO pyrimidifen results in increased expression of COX8A mRNA CTD PMID:33512557 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cpsf4 cleavage and polyadenylation specific factor 4 decreases expression ISO pyrimidifen results in decreased expression of CPSF4 mRNA CTD PMID:33512557 NCBI chr12:9,429,765...9,445,586
Ensembl chr12:9,429,523...9,445,586
JBrowse link
G Crk CRK proto-oncogene, adaptor protein decreases expression ISO pyrimidifen results in decreased expression of CRK mRNA CTD PMID:33512557 NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
JBrowse link
G Ctnnd1 catenin delta 1 decreases expression ISO pyrimidifen results in decreased expression of CTNND1 mRNA CTD PMID:33512557 NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
JBrowse link
G Cttn cortactin decreases expression ISO pyrimidifen results in decreased expression of CTTN mRNA CTD PMID:33512557 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
JBrowse link
G Daam1 dishevelled associated activator of morphogenesis 1 decreases expression ISO pyrimidifen results in decreased expression of DAAM1 mRNA CTD PMID:33512557 NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114
JBrowse link
G Dad1 defender against cell death 1 increases expression ISO pyrimidifen results in increased expression of DAD1 mRNA CTD PMID:33512557 NCBI chr15:27,677,286...27,697,120
Ensembl chr15:27,677,268...27,697,347
JBrowse link
G Dbf4 DBF4-CDC7 kinase regulatory subunit increases expression ISO pyrimidifen results in increased expression of DBF4 mRNA CTD PMID:33512557 NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
JBrowse link
G Ddc dopa decarboxylase decreases expression ISO pyrimidifen results in decreased expression of DDC mRNA CTD PMID:34642769 NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO pyrimidifen results in increased expression of DDIT3 mRNA CTD PMID:33512557 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddr1 discoidin domain receptor tyrosine kinase 1 decreases expression ISO pyrimidifen results in decreased expression of DDR1 mRNA CTD PMID:33512557 NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
JBrowse link
G Ddx10 DEAD-box helicase 10 decreases expression ISO pyrimidifen results in decreased expression of DDX10 mRNA CTD PMID:33512557 NCBI chr 8:53,488,656...53,643,373
Ensembl chr 8:53,488,656...53,643,373
JBrowse link
G Ddx42 DEAD-box helicase 42 decreases expression ISO pyrimidifen results in decreased expression of DDX42 mRNA CTD PMID:33512557 NCBI chr10:91,148,926...91,180,940
Ensembl chr10:91,148,254...91,180,939
JBrowse link
G Dek DEK proto-oncogene increases expression ISO pyrimidifen results in increased expression of DEK mRNA CTD PMID:33512557 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
JBrowse link
G Dennd3 DENN domain containing 3 decreases expression ISO pyrimidifen results in decreased expression of DENND3 mRNA CTD PMID:33512557 NCBI chr 7:105,415,870...105,473,583
Ensembl chr 7:105,415,677...105,473,592
JBrowse link
G Depdc1b DEP domain containing 1B increases expression ISO pyrimidifen results in increased expression of DEPDC1B mRNA CTD PMID:33512557 NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
JBrowse link
G Dll4 delta like canonical Notch ligand 4 decreases expression ISO pyrimidifen results in decreased expression of DLL4 mRNA CTD PMID:33512557 NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931
JBrowse link
G Drd2 dopamine receptor D2 decreases expression ISO pyrimidifen results in decreased expression of DRD2 mRNA CTD PMID:33512557 NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Eef1b2 eukaryotic translation elongation factor 1 beta 2 increases expression ISO pyrimidifen results in increased expression of EEF1B2 mRNA CTD PMID:33512557 NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737
JBrowse link
G Eif3k eukaryotic translation initiation factor 3, subunit K increases expression ISO pyrimidifen results in increased expression of EIF3K mRNA CTD PMID:33512557 NCBI chr 1:84,260,127...84,270,051
Ensembl chr 1:84,259,673...84,270,302
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases expression ISO pyrimidifen results in increased expression of EIF4EBP1 mRNA CTD PMID:33512557 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Elmod1 ELMO domain containing 1 decreases expression ISO pyrimidifen results in decreased expression of ELMOD1 mRNA CTD PMID:33512557 NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
JBrowse link
G Etv1 ETS variant transcription factor 1 decreases expression ISO pyrimidifen results in decreased expression of ETV1 mRNA CTD PMID:33512557 NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
JBrowse link
G Exosc8 exosome component 8 increases expression ISO pyrimidifen results in increased expression of EXOSC8 mRNA CTD PMID:33512557 NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
JBrowse link
G Fam13a family with sequence similarity 13, member A decreases expression ISO pyrimidifen results in decreased expression of FAM13A mRNA CTD PMID:33512557 NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
JBrowse link
G Fam72a family with sequence similarity 72, member A increases expression ISO pyrimidifen results in increased expression of FAM72A mRNA CTD PMID:33512557 NCBI chr13:42,967,701...42,979,083
Ensembl chr13:42,967,578...42,984,208
JBrowse link
G Fbl fibrillarin increases expression ISO pyrimidifen results in increased expression of FBL mRNA CTD PMID:33512557 NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
JBrowse link
G Fzd1 frizzled class receptor 1 decreases expression ISO pyrimidifen results in decreased expression of FZD1 mRNA CTD PMID:33512557 NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643
Ensembl chr 4:29,310,091...29,312,643
JBrowse link
G Gaa alpha glucosidase decreases expression ISO pyrimidifen results in decreased expression of GAA mRNA CTD PMID:33512557 NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 decreases expression ISO pyrimidifen results in decreased expression of GALNT3 mRNA CTD PMID:33512557 NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
JBrowse link
G Gap43 growth associated protein 43 decreases expression ISO pyrimidifen results in decreased expression of GAP43 mRNA CTD PMID:33512557 NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
JBrowse link
G Gata2 GATA binding protein 2 increases expression ISO pyrimidifen results in increased expression of GATA2 mRNA CTD PMID:33512557 NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression ISO pyrimidifen results in increased expression of GCLM mRNA CTD PMID:33512557 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression ISO pyrimidifen results in increased expression of GDF15 mRNA CTD PMID:33512557 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
JBrowse link
G Gfus GDP-L-fucose synthase increases expression ISO pyrimidifen results in increased expression of GFUS mRNA CTD PMID:33512557 NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948
JBrowse link
G Glb1 galactosidase, beta 1 increases expression ISO pyrimidifen results in increased expression of GLB1 mRNA CTD PMID:33512557 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Gldc glycine decarboxylase decreases expression ISO pyrimidifen results in decreased expression of GLDC mRNA CTD PMID:33512557 NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097
JBrowse link
G Gli3 GLI family zinc finger 3 decreases expression ISO pyrimidifen results in decreased expression of GLI3 mRNA CTD PMID:33512557 NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
JBrowse link
G Gmnn geminin, DNA replication inhibitor increases expression ISO pyrimidifen results in increased expression of GMNN mRNA CTD PMID:33512557 NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression ISO pyrimidifen results in decreased expression of GNAI2 mRNA CTD PMID:33512557 NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
JBrowse link
G Gpc1 glypican 1 decreases expression ISO pyrimidifen results in decreased expression of GPC1 mRNA CTD PMID:33512557 NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
JBrowse link
G Gpx4 glutathione peroxidase 4 increases expression ISO pyrimidifen results in increased expression of GPX4 mRNA CTD PMID:33512557 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
JBrowse link
G Grb10 growth factor receptor bound protein 10 increases expression ISO pyrimidifen results in increased expression of GRB10 mRNA CTD PMID:33512557 NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 decreases expression ISO pyrimidifen results in decreased expression of GRIA2 mRNA CTD PMID:33512557 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Grik5 glutamate ionotropic receptor kainate type subunit 5 decreases expression ISO pyrimidifen results in decreased expression of GRIK5 mRNA CTD PMID:33512557 NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
JBrowse link
G Grm4 glutamate metabotropic receptor 4 decreases expression ISO pyrimidifen results in decreased expression of GRM4 mRNA CTD PMID:33512557 NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
JBrowse link
G Gstm2 glutathione S-transferase mu 2 decreases expression ISO pyrimidifen results in decreased expression of GSTM2 mRNA CTD PMID:33512557 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression ISO pyrimidifen results in increased expression of GSTP1 mRNA CTD PMID:33512557 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gucy2c guanylate cyclase 2C decreases expression ISO pyrimidifen results in decreased expression of GUCY2C mRNA CTD PMID:33512557 NCBI chr 4:169,568,505...169,649,092
Ensembl chr 4:169,568,529...169,649,092
JBrowse link
G H1f2 H1.2 linker histone, cluster member increases expression ISO pyrimidifen results in increased expression of H1-2 mRNA CTD PMID:33512557 NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
JBrowse link
G H2az1 H2A.Z variant histone 1 increases expression ISO pyrimidifen results in increased expression of H2AZ1 mRNA CTD PMID:33512557 NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485
JBrowse link
G H2bc12 H2B clustered histone 12 increases expression ISO pyrimidifen results in increased expression of H2BC12 mRNA CTD PMID:33512557 NCBI chr17:42,485,699...42,486,162 JBrowse link
G H2bc9 H2B clustered histone 9 increases expression ISO pyrimidifen results in increased expression of H2BC9 mRNA CTD PMID:33512557 NCBI chr17:42,470,593...42,478,590 JBrowse link
G Hba-a3 hemoglobin alpha, adult chain 3 increases expression ISO pyrimidifen results in increased expression of HBA2 mRNA CTD PMID:33512557 NCBI chr10:15,311,637...15,312,481
Ensembl chr10:15,311,634...15,312,481
JBrowse link
G Hcst hematopoietic cell signal transducer increases expression ISO pyrimidifen results in increased expression of HCST mRNA CTD PMID:33512557 NCBI chr 1:85,676,976...85,679,083
Ensembl chr 1:85,676,979...85,679,012
JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO pyrimidifen results in increased expression of HECTD2 mRNA CTD PMID:33512557 NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression ISO pyrimidifen results in increased expression of HERPUD1 mRNA CTD PMID:33512557 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
JBrowse link
G Hes1 hes family bHLH transcription factor 1 increases expression ISO pyrimidifen results in increased expression of HES1 mRNA CTD PMID:33512557 NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
JBrowse link
G Hexa hexosaminidase subunit alpha decreases expression ISO pyrimidifen results in decreased expression of HEXA mRNA CTD PMID:33512557 NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013
JBrowse link
G Hexb hexosaminidase subunit beta increases expression ISO pyrimidifen results in increased expression of HEXB mRNA CTD PMID:33512557 NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
JBrowse link
G Hikeshi heat shock protein nuclear import factor hikeshi increases expression ISO pyrimidifen results in increased expression of HIKESHI mRNA CTD PMID:33512557 NCBI chr 1:143,825,399...143,849,361
Ensembl chr 1:143,825,923...143,849,363
JBrowse link
G Hist1h2af histone cluster 1 H2A family member F increases expression ISO pyrimidifen results in increased expression of H2AC8 mRNA CTD PMID:33512557 NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
JBrowse link
G Hist1h2ah histone cluster 1 H2A family member H increases expression ISO pyrimidifen results in increased expression of H2AC11 mRNA CTD PMID:33512557 NCBI chr17:41,384,521...41,385,018 JBrowse link
G Hist1h2al1 histone cluster 1 H2A family like 1 increases expression ISO pyrimidifen results in increased expression of H2AC6 mRNA CTD PMID:33512557 NCBI chr17:42,707,954...42,708,420 JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D increases expression ISO pyrimidifen results in increased expression of H2BC5 mRNA CTD PMID:33512557 NCBI chr17:42,792,887...42,793,268 JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO pyrimidifen results in increased expression of HMOX1 mRNA CTD PMID:33512557 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hnrnpm heterogeneous nuclear ribonucleoprotein M decreases expression ISO pyrimidifen results in decreased expression of HNRNPM mRNA CTD PMID:33512557 NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression ISO pyrimidifen results in increased expression of HSPA1B mRNA CTD PMID:33512557 NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240
JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO pyrimidifen results in increased expression of HSPA6 mRNA CTD PMID:33512557 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 increases expression ISO pyrimidifen results in increased expression of HSPA8 mRNA CTD PMID:33512557 NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression ISO pyrimidifen results in increased expression of HSPB1 mRNA CTD PMID:33512557 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
JBrowse link
G Hspe1 heat shock protein family E (Hsp10) member 1 increases expression ISO pyrimidifen results in increased expression of HSPE1 mRNA CTD PMID:33512557 NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
JBrowse link
G Ifi44l interferon-induced protein 44-like increases expression ISO pyrimidifen results in increased expression of IFI44L mRNA CTD PMID:33512557 NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359
JBrowse link
G Ifrd1 interferon-related developmental regulator 1 increases expression ISO pyrimidifen results in increased expression of IFRD1 mRNA CTD PMID:33512557 NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
JBrowse link
G Ifrd2 interferon-related developmental regulator 2 increases expression ISO pyrimidifen results in increased expression of IFRD2 mRNA CTD PMID:33512557 NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194
JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO pyrimidifen results in decreased expression of IGF1R mRNA CTD PMID:33512557 NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Igfbp2 insulin-like growth factor binding protein 2 decreases expression ISO pyrimidifen results in decreased expression of IGFBP2 mRNA CTD PMID:33512557 NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 increases expression ISO pyrimidifen results in increased expression of IGFBP4 mRNA CTD PMID:33512557 NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
JBrowse link
G Ikbip IKBKB interacting protein increases expression ISO pyrimidifen results in increased expression of IKBIP mRNA CTD PMID:33512557 NCBI chr 7:25,579,865...25,598,548
Ensembl chr 7:25,579,832...25,605,162
JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO pyrimidifen results in decreased expression of IKZF1 mRNA CTD PMID:33512557 NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
JBrowse link
G Ilk integrin-linked kinase decreases expression ISO pyrimidifen results in decreased expression of ILK mRNA CTD PMID:33512557 NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
JBrowse link
G Ina internexin neuronal intermediate filament protein, alpha decreases expression ISO pyrimidifen results in decreased expression of INA mRNA CTD PMID:33512557 NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
JBrowse link
G Insm1 INSM transcriptional repressor 1 decreases expression ISO pyrimidifen results in decreased expression of INSM1 mRNA CTD PMID:33512557 NCBI chr 3:133,640,030...133,642,963
Ensembl chr 3:133,639,580...133,643,003
JBrowse link
G Itgae integrin subunit alpha E increases expression ISO pyrimidifen results in increased expression of ITGAE mRNA CTD PMID:33512557 NCBI chr10:57,704,813...57,764,093
Ensembl chr10:57,591,753...57,764,093
Ensembl chr10:57,591,753...57,764,093
JBrowse link
G Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase increases expression ISO pyrimidifen results in increased expression of JMJD6 mRNA CTD PMID:33512557 NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO pyrimidifen results in decreased expression of KAT6B mRNA CTD PMID:33512557 NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
JBrowse link
G Kdelr2 KDEL endoplasmic reticulum protein retention receptor 2 increases expression ISO pyrimidifen results in increased expression of KDELR2 mRNA CTD PMID:33512557 NCBI chr12:11,138,820...11,157,117
Ensembl chr12:11,138,820...11,157,153
JBrowse link
G Kdm3a lysine demethylase 3A decreases expression ISO pyrimidifen results in decreased expression of KDM3A mRNA CTD PMID:33512557 NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
JBrowse link
G Kdm5b lysine demethylase 5B decreases expression ISO pyrimidifen results in decreased expression of KDM5B mRNA CTD PMID:33512557 NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
JBrowse link
G Kif15 kinesin family member 15 increases expression ISO pyrimidifen results in increased expression of KIF15 mRNA CTD PMID:33512557 NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
JBrowse link
G Kif20a kinesin family member 20A increases expression ISO pyrimidifen results in increased expression of KIF20A mRNA CTD PMID:33512557 NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
JBrowse link
G Kif5c kinesin family member 5C decreases expression ISO pyrimidifen results in decreased expression of KIF5C mRNA CTD PMID:33512557 NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
JBrowse link
G Klhl24 kelch-like family member 24 increases expression ISO pyrimidifen results in increased expression of KLHL24 mRNA CTD PMID:34642769 NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636
JBrowse link
G Krt18 keratin 18 decreases expression ISO pyrimidifen results in decreased expression of KRT18 mRNA CTD PMID:33512557 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
JBrowse link
G L1cam L1 cell adhesion molecule decreases expression ISO pyrimidifen results in decreased expression of L1CAM mRNA CTD PMID:33512557 NCBI chr  X:151,597,270...151,623,776
Ensembl chr  X:151,597,277...151,623,857
JBrowse link
G Ldha lactate dehydrogenase A increases expression ISO pyrimidifen results in increased expression of LDHA mRNA CTD PMID:33512557 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
JBrowse link
G Lmna lamin A/C decreases expression ISO pyrimidifen results in decreased expression of LMNA mRNA CTD PMID:33512557 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
JBrowse link
G Lmod1 leiomodin 1 decreases expression ISO pyrimidifen results in decreased expression of LMOD1 mRNA CTD PMID:33512557 NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
JBrowse link
G LOC102549061 histone H2B type 1-N-like increases expression ISO pyrimidifen results in increased expression of H2BC3 mRNA CTD PMID:33512557 NCBI chr17:41,380,056...41,380,686 JBrowse link
G Loxl1 lysyl oxidase-like 1 decreases expression ISO pyrimidifen results in decreased expression of LOXL1 mRNA CTD PMID:33512557 NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
JBrowse link
G Lsm2 LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated increases expression ISO pyrimidifen results in increased expression of LSM2 mRNA CTD PMID:33512557 NCBI chr20:3,843,467...3,847,217
Ensembl chr20:3,843,466...3,847,266
JBrowse link
G Lsm5 LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated increases expression ISO pyrimidifen results in increased expression of LSM5 mRNA CTD PMID:33512557 NCBI chr 4:85,951,073...85,954,289
Ensembl chr 6:104,652,477...104,654,165
Ensembl chr 4:104,652,477...104,654,165
JBrowse link
G Lsm6 LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated increases expression ISO pyrimidifen results in increased expression of LSM6 mRNA CTD PMID:33512557 NCBI chr19:29,098,254...29,112,858
Ensembl chr13:42,114,032...42,116,484
Ensembl chr19:42,114,032...42,116,484
JBrowse link
G Mad2l1 mitotic arrest deficient 2 like 1 increases expression ISO pyrimidifen results in increased expression of MAD2L1 mRNA CTD PMID:33512557 NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
JBrowse link
G Map1b microtubule-associated protein 1B decreases expression ISO pyrimidifen results in decreased expression of MAP1B mRNA CTD PMID:33512557 NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
JBrowse link
G Map2 microtubule-associated protein 2 decreases expression ISO pyrimidifen results in decreased expression of MAP2 mRNA CTD PMID:33512557 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Map6 microtubule-associated protein 6 decreases expression ISO pyrimidifen results in decreased expression of MAP6 mRNA CTD PMID:33512557 NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414
JBrowse link
G Mapre3 microtubule-associated protein, RP/EB family, member 3 decreases expression ISO pyrimidifen results in decreased expression of MAPRE3 mRNA CTD PMID:33512557 NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 increases expression ISO pyrimidifen results in increased expression of MCM7 mRNA CTD PMID:33512557 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
JBrowse link
G Mdk midkine increases expression ISO pyrimidifen results in increased expression of MDK mRNA CTD PMID:33512557 NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
JBrowse link
G Me1 malic enzyme 1 increases expression ISO pyrimidifen results in increased expression of ME1 mRNA CTD PMID:33512557 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
JBrowse link
G Med22 mediator complex subunit 22 decreases expression ISO pyrimidifen results in decreased expression of MED22 mRNA CTD PMID:33512557 NCBI chr 3:10,233,754...10,238,836
Ensembl chr 3:10,233,754...10,238,836
JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor decreases expression ISO pyrimidifen results in decreased expression of MLLT11 mRNA CTD PMID:33512557 NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
JBrowse link
G Morn2 MORN repeat containing 2 decreases expression ISO pyrimidifen results in decreased expression of MORN2 mRNA CTD PMID:33512557 NCBI chr 6:14,718,799...14,725,281 JBrowse link
G Mrpl12 mitochondrial ribosomal protein L12 increases expression ISO pyrimidifen results in increased expression of MRPL12 mRNA CTD PMID:33512557 NCBI chr10:105,758,410...105,762,913
Ensembl chr10:105,758,410...105,762,913
JBrowse link
G Mrpl14 mitochondrial ribosomal protein L14 increases expression ISO pyrimidifen results in increased expression of MRPL14 mRNA CTD PMID:33512557 NCBI chr 9:15,302,840...15,315,195
Ensembl chr 9:15,302,427...15,315,267
JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO pyrimidifen results in increased expression of MRPL19 mRNA CTD PMID:33512557 NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053
JBrowse link
G Mrps17 mitochondrial ribosomal protein S17 increases expression ISO pyrimidifen results in increased expression of MRPS17 mRNA CTD PMID:33512557 NCBI chr12:26,948,535...26,951,828
Ensembl chr12:26,948,730...26,951,737
Ensembl chr12:26,948,730...26,951,737
JBrowse link
G Msi2 musashi RNA-binding protein 2 decreases expression ISO pyrimidifen results in decreased expression of MSI2 mRNA CTD PMID:33512557 NCBI chr10:73,143,760...73,510,566
Ensembl chr10:73,147,380...73,510,157
JBrowse link
G Mt-nd6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 decreases expression ISO pyrimidifen results in decreased expression of ND6 mRNA CTD PMID:33512557 NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase increases expression ISO pyrimidifen results in increased expression of MTHFD2 mRNA CTD PMID:33512557 NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO pyrimidifen results in decreased expression of MUC1 mRNA CTD PMID:33512557 NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Nav1 neuron navigator 1 decreases expression ISO pyrimidifen results in decreased expression of NAV1 mRNA CTD PMID:33512557 NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449
JBrowse link
G Ncam1 neural cell adhesion molecule 1 decreases expression ISO pyrimidifen results in decreased expression of NCAM1 mRNA CTD PMID:33512557 NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
JBrowse link
G Ncan neurocan decreases expression ISO pyrimidifen results in decreased expression of NCAN mRNA CTD PMID:33512557 NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
JBrowse link
G Ncaph non-SMC condensin I complex, subunit H increases expression ISO pyrimidifen results in increased expression of NCAPH mRNA CTD PMID:33512557 NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 increases expression ISO pyrimidifen results in increased expression of NDUFA1 mRNA CTD PMID:33512557 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 increases expression ISO pyrimidifen results in increased expression of NDUFA13 mRNA CTD PMID:33512557 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufv3 NADH:ubiquinone oxidoreductase subunit V3 increases expression ISO pyrimidifen results in increased expression of NDUFV3 mRNA CTD PMID:33512557 NCBI chr20:9,612,462...9,621,622
Ensembl chr20:9,612,431...9,623,074
Ensembl chr13:9,612,431...9,623,074
JBrowse link
G Nek2 NIMA-related kinase 2 increases expression ISO pyrimidifen results in increased expression of NEK2 mRNA CTD PMID:33512557 NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
JBrowse link
G Nhlh1 nescient helix loop helix 1 decreases expression ISO pyrimidifen results in decreased expression of NHLH1 mRNA CTD PMID:33512557 NCBI chr13:84,517,347...84,522,548
Ensembl chr13:84,517,289...84,525,094
JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 increases expression ISO pyrimidifen results in increased expression of NME1 mRNA CTD PMID:33512557 NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
JBrowse link
G Nme2 NME/NM23 nucleoside diphosphate kinase 2 increases expression ISO pyrimidifen results in increased expression of NME2 mRNA CTD PMID:33512557 NCBI chr10:78,898,097...78,903,514
Ensembl chr10:78,897,770...78,903,538
JBrowse link
G Nop58 NOP58 ribonucleoprotein increases expression ISO pyrimidifen results in increased expression of NOP58 mRNA CTD PMID:33512557 NCBI chr 9:61,120,939...61,144,810
Ensembl chr 9:61,120,929...61,144,810
JBrowse link
G Notch3 notch receptor 3 decreases expression ISO pyrimidifen results in decreased expression of NOTCH3 mRNA CTD PMID:33512557 NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO pyrimidifen results in increased expression of NQO1 mRNA CTD PMID:33512557 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases expression ISO pyrimidifen results in increased expression of NR3C1 mRNA CTD PMID:33512557 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression ISO pyrimidifen results in decreased expression of NRCAM mRNA CTD PMID:33512557 NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
JBrowse link
G Nrg1 neuregulin 1 decreases expression ISO pyrimidifen results in decreased expression of NRG1 mRNA CTD PMID:33512557 NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
JBrowse link
G Nrxn1 neurexin 1 decreases expression ISO pyrimidifen results in decreased expression of NRXN1 mRNA CTD PMID:33512557 NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
JBrowse link
G Ntrk1 neurotrophic receptor tyrosine kinase 1 decreases expression ISO pyrimidifen results in decreased expression of NTRK1 mRNA CTD PMID:33512557 NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
JBrowse link
G Nup88 nucleoporin 88 decreases expression ISO pyrimidifen results in decreased expression of NUP88 mRNA CTD PMID:33512557 NCBI chr10:55,667,903...55,692,249
Ensembl chr10:55,667,906...55,692,257
JBrowse link
G Oaz1 ornithine decarboxylase antizyme 1 increases expression ISO pyrimidifen results in increased expression of OAZ1 mRNA CTD PMID:33512557 NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
JBrowse link
G Oip5 Opa interacting protein 5 increases expression ISO pyrimidifen results in increased expression of OIP5 mRNA CTD PMID:33512557 NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250
JBrowse link
G Olfml2b olfactomedin-like 2B decreases expression ISO pyrimidifen results in decreased expression of OLFML2B mRNA CTD PMID:33512557 NCBI chr13:82,869,414...82,906,607
Ensembl chr13:82,869,433...82,906,607
JBrowse link
G Onecut1 one cut homeobox 1 decreases expression ISO pyrimidifen results in decreased expression of ONECUT1 mRNA CTD PMID:33512557 NCBI chr 8:75,599,432...75,633,598
Ensembl chr 8:75,599,740...75,627,277
JBrowse link
G Ost4 oligosaccharyltransferase complex subunit 4, non-catalytic increases expression ISO pyrimidifen results in increased expression of OST4 mRNA CTD PMID:33512557 NCBI chr 6:25,471,254...25,472,478 JBrowse link
G Ostc oligosaccharyltransferase complex non-catalytic subunit increases expression ISO pyrimidifen results in increased expression of OSTC mRNA CTD PMID:33512557 NCBI chr 2:219,250,549...219,266,076
Ensembl chr 2:219,236,952...219,266,107
JBrowse link
G Otud7b OTU deubiquitinase 7B decreases expression ISO pyrimidifen results in decreased expression of OTUD7B mRNA CTD PMID:33512557 NCBI chr 2:183,661,955...183,722,584
Ensembl chr 2:183,662,163...183,718,674
JBrowse link
G P2rx3 purinergic receptor P2X 3 decreases expression ISO pyrimidifen results in decreased expression of P2RX3 mRNA CTD PMID:33512557 NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
JBrowse link
G Park7 Parkinsonism associated deglycase increases expression ISO pyrimidifen results in increased expression of PARK7 mRNA CTD PMID:33512557 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression ISO pyrimidifen results in increased expression of PARP1 mRNA CTD PMID:33512557 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pcdha9 protocadherin alpha 9 decreases expression ISO pyrimidifen results in decreased expression of PCDHA9 mRNA CTD PMID:33512557 Ensembl chr18:28,581,225...28,846,211 JBrowse link
G Pde4c phosphodiesterase 4C decreases expression ISO pyrimidifen results in decreased expression of PDE4C mRNA CTD PMID:33512557 NCBI chr16:18,690,727...18,711,555
Ensembl chr16:18,691,700...18,710,640
JBrowse link
G Pdgfb platelet derived growth factor subunit B decreases expression ISO pyrimidifen results in decreased expression of PDGFB mRNA CTD PMID:33512557 NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 increases expression ISO pyrimidifen results in increased expression of PDIA6 mRNA CTD PMID:33512557 NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
JBrowse link
G Pebp1 phosphatidylethanolamine binding protein 1 decreases expression ISO pyrimidifen results in decreased expression of PEBP1 mRNA CTD PMID:33512557 NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
JBrowse link
G Peg10 paternally expressed 10 decreases expression ISO pyrimidifen results in decreased expression of PEG10 mRNA CTD PMID:33512557 NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
JBrowse link
G Pfkp phosphofructokinase, platelet increases expression ISO pyrimidifen results in increased expression of PFKP mRNA CTD PMID:34642769 NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
JBrowse link
G Pga5 pepsinogen A5 increases expression ISO pyrimidifen results in increased expression of PGA5 mRNA CTD PMID:33512557 NCBI chr 1:207,317,021...207,327,156
Ensembl chr 1:207,317,021...207,327,156
JBrowse link
G Phgdh phosphoglycerate dehydrogenase increases expression ISO pyrimidifen results in increased expression of PHGDH mRNA CTD PMID:33512557 NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta decreases expression ISO pyrimidifen results in decreased expression of PIK3C2B mRNA CTD PMID:33512557 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612
JBrowse link
G Pink1 PTEN induced kinase 1 decreases expression ISO pyrimidifen results in decreased expression of PINK1 mRNA CTD PMID:33512557 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
JBrowse link
G Pirb paired Ig-like receptor B decreases expression ISO pyrimidifen results in decreased expression of LILRB3 mRNA CTD PMID:33512557 NCBI chr 1:65,499,195...65,506,666
Ensembl chr 1:65,499,195...65,506,666
JBrowse link
G Pitpna phosphatidylinositol transfer protein, alpha decreases expression ISO pyrimidifen results in decreased expression of PITPNA mRNA CTD PMID:33512557 NCBI chr10:60,430,712...60,473,564
Ensembl chr10:60,430,748...60,471,342
JBrowse link
G Plscr3 phospholipid scramblase 3 decreases expression ISO pyrimidifen results in decreased expression of PLSCR3 mRNA CTD PMID:33512557 NCBI chr10:54,566,556...54,573,240
Ensembl chr10:54,566,873...54,578,709
JBrowse link
G Pole3 DNA polymerase epsilon 3, accessory subunit increases expression ISO pyrimidifen results in increased expression of POLE3 mRNA CTD PMID:33512557 NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231
Ensembl chr 7:75,974,717...75,977,231
JBrowse link
G Polr2h RNA polymerase II, I and III subunit H increases expression ISO pyrimidifen results in increased expression of POLR2H mRNA CTD PMID:33512557 NCBI chr11:80,192,017...80,197,468
Ensembl chr11:80,192,032...80,197,515
Ensembl chr10:80,192,032...80,197,515
JBrowse link
G Polr2i RNA polymerase II subunit I increases expression ISO pyrimidifen results in increased expression of POLR2I mRNA CTD PMID:33512557 NCBI chr 1:85,483,515...85,484,952
Ensembl chr 1:85,483,515...85,484,952
JBrowse link
G Pou4f2 POU class 4 homeobox 2 decreases expression ISO pyrimidifen results in decreased expression of POU4F2 mRNA CTD PMID:33512557 NCBI chr19:29,486,686...29,490,327
Ensembl chr19:29,486,686...29,490,327
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases expression ISO pyrimidifen results in decreased expression of PPARA mRNA CTD PMID:33512557 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Ppp1cb protein phosphatase 1 catalytic subunit beta increases expression ISO pyrimidifen results in increased expression of PPP1CB mRNA CTD PMID:33512557 NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
JBrowse link
G Ppp1cc protein phosphatase 1 catalytic subunit gamma increases expression ISO pyrimidifen results in increased expression of PPP1CC mRNA CTD PMID:33512557 NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
JBrowse link
G Ppp1r17 protein phosphatase 1, regulatory subunit 17 decreases expression ISO pyrimidifen results in decreased expression of PPP1R17 mRNA CTD PMID:33512557 NCBI chr 4:85,213,595...85,230,607
Ensembl chr 4:85,213,887...85,230,603
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha decreases expression ISO pyrimidifen results in decreased expression of PRKACA mRNA CTD PMID:33512557 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases expression ISO pyrimidifen results in decreased expression of PRKN mRNA CTD PMID:33512557 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
JBrowse link
G Prr11 proline rich 11 increases expression ISO pyrimidifen results in increased expression of PRR11 mRNA CTD PMID:33512557 NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
JBrowse link
G Psat1 phosphoserine aminotransferase 1 increases expression ISO pyrimidifen results in increased expression of PSAT1 mRNA CTD PMID:33512557 NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
JBrowse link
G Psenen presenilin enhancer gamma secretase subunit increases expression ISO pyrimidifen results in increased expression of PSENEN mRNA CTD PMID:33512557 NCBI chr 1:85,814,905...85,816,654
Ensembl chr 1:85,814,905...85,816,192
JBrowse link
G Psmb3 proteasome 20S subunit beta 3 increases expression ISO pyrimidifen results in increased expression of PSMB3 mRNA CTD PMID:33512557 NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin increases expression ISO pyrimidifen results in increased expression of PTTG1 mRNA CTD PMID:33512557 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
JBrowse link
G Rab31 RAB31, member RAS oncogene family decreases expression ISO pyrimidifen results in decreased expression of RAB31 mRNA CTD PMID:33512557 NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253
JBrowse link
G Rabggtb Rab geranylgeranyltransferase subunit beta increases expression ISO pyrimidifen results in increased expression of RABGGTB mRNA CTD PMID:33512557 NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050
JBrowse link
G Rala RAS like proto-oncogene A increases expression ISO pyrimidifen results in increased expression of RALA mRNA CTD PMID:33512557 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063
JBrowse link
G Rbx1 ring-box 1 decreases expression ISO pyrimidifen results in decreased expression of RBX1 mRNA CTD PMID:33512557 NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
JBrowse link
G Reln reelin decreases expression ISO pyrimidifen results in decreased expression of RELN mRNA CTD PMID:33512557 NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 decreases expression ISO pyrimidifen results in decreased expression of ROCK1 mRNA CTD PMID:33512557 NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
JBrowse link
G Rpl11 ribosomal protein L11 increases expression ISO pyrimidifen results in increased expression of RPL11 mRNA CTD PMID:33512557 NCBI chr 5:148,274,060...148,277,708
Ensembl chr 5:148,274,069...148,277,599
JBrowse link
G Rpl17 ribosomal protein L17 increases expression ISO pyrimidifen results in increased expression of RPL17 mRNA CTD PMID:33512557 NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253
JBrowse link
G Rpl19 ribosomal protein L19 increases expression ISO pyrimidifen results in increased expression of RPL19 mRNA CTD PMID:33512557 NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
JBrowse link
G Rpl22 ribosomal protein L22 increases expression ISO pyrimidifen results in increased expression of RPL22 mRNA CTD PMID:33512557 NCBI chr 5:162,835,241...162,843,394
Ensembl chr 5:162,833,740...162,843,368
Ensembl chr 7:162,833,740...162,843,368
Ensembl chr 4:162,833,740...162,843,368
JBrowse link
G Rpl26 ribosomal protein L26 increases expression ISO pyrimidifen results in increased expression of RPL26 mRNA CTD PMID:33512557 NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966
JBrowse link
G Rpl27 ribosomal protein L27 increases expression ISO pyrimidifen results in increased expression of RPL27 mRNA CTD PMID:33512557 NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
JBrowse link
G Rpl28 ribosomal protein L28 increases expression ISO pyrimidifen results in increased expression of RPL28 mRNA CTD PMID:33512557 NCBI chr 1:69,052,148...69,054,735
Ensembl chr 1:69,053,203...69,055,032
JBrowse link
G Rpl3 ribosomal protein L3 increases expression ISO pyrimidifen results in increased expression of RPL3 mRNA CTD PMID:33512557 NCBI chr 7:111,622,255...111,627,640
Ensembl chr 7:111,621,610...111,636,468
JBrowse link
G Rpl32 ribosomal protein L32 increases expression ISO pyrimidifen results in increased expression of RPL32 mRNA CTD PMID:33512557 NCBI chr 4:148,864,048...148,867,612
Ensembl chr 4:148,864,044...148,867,612
JBrowse link
G Rpl35 ribosomal protein L35 increases expression ISO pyrimidifen results in increased expression of RPL35 mRNA CTD PMID:33512557 NCBI chr 3:22,753,255...22,756,217
Ensembl chr 3:22,753,253...22,756,243
JBrowse link
G Rpl36 ribosomal protein L36 increases expression ISO pyrimidifen results in increased expression of RPL36 mRNA CTD PMID:33512557 NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897
JBrowse link
G Rpl8 ribosomal protein L8 increases expression ISO pyrimidifen results in increased expression of RPL8 mRNA CTD PMID:33512557 NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482
Ensembl chr 3:108,622,324...108,628,482
JBrowse link
G Rpl9 ribosomal protein L9 increases expression ISO pyrimidifen results in increased expression of RPL9 mRNA CTD PMID:33512557 NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136
Ensembl chr 3:42,893,942...42,897,136
JBrowse link
G Rps13 ribosomal protein S13 increases expression ISO pyrimidifen results in increased expression of RPS13 mRNA CTD PMID:33512557 NCBI chr 1:170,572,925...170,575,355
Ensembl chr 1:170,572,921...170,575,355
Ensembl chr 3:170,572,921...170,575,355
JBrowse link
G Rps18 ribosomal protein S18 increases expression ISO pyrimidifen results in increased expression of RPS18 mRNA CTD PMID:33512557 NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146
Ensembl chr20:101,204,500...101,205,146
JBrowse link
G Rps2 ribosomal protein S2 increases expression ISO pyrimidifen results in increased expression of RPS2 mRNA CTD PMID:33512557 NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
JBrowse link
G Rps20 ribosomal protein S20 increases expression ISO pyrimidifen results in increased expression of RPS20 mRNA CTD PMID:33512557 NCBI chr 5:16,819,095...16,820,476
Ensembl chr 5:16,819,304...16,820,475
Ensembl chr 9:16,819,304...16,820,475
Ensembl chr 3:16,819,304...16,820,475
JBrowse link
G Rps25 ribosomal protein s25 increases expression ISO pyrimidifen results in increased expression of RPS25 mRNA CTD PMID:33512557 NCBI chr 8:44,733,623...44,735,999
Ensembl chr 8:44,733,029...44,737,271
JBrowse link
G Rps27a ribosomal protein S27a increases expression ISO pyrimidifen results in increased expression of RPS27A mRNA CTD PMID:33512557 NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011
JBrowse link
G Rps27l ribosomal protein S27-like increases expression ISO pyrimidifen results in increased expression of RPS27L mRNA CTD PMID:33512557 NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418
JBrowse link
G Rps3 ribosomal protein S3 increases expression ISO pyrimidifen results in increased expression of RPS3 mRNA CTD PMID:33512557 NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
JBrowse link
G Rps5 ribosomal protein S5 increases expression ISO pyrimidifen results in increased expression of RPS5 mRNA CTD PMID:33512557 NCBI chr 1:73,538,776...73,543,073
Ensembl chr 1:73,538,776...73,543,073
JBrowse link
G Rps7 ribosomal protein S7 increases expression ISO pyrimidifen results in increased expression of RPS7 mRNA CTD PMID:33512557 NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145
JBrowse link
G Rsl24d1 ribosomal L24 domain containing 1 increases expression ISO pyrimidifen results in increased expression of RSL24D1 mRNA CTD PMID:33512557 NCBI chr 8:73,852,991...73,861,996
Ensembl chr 8:73,852,996...73,862,001
JBrowse link
G Rwdd4 RWD domain containing 4 increases expression ISO pyrimidifen results in increased expression of RWDD4 mRNA CTD PMID:33512557 NCBI chr16:44,714,698...44,733,090
Ensembl chr16:44,714,699...44,733,098
JBrowse link
G Rxylt1 ribitol xylosyltransferase 1 increases expression ISO pyrimidifen results in increased expression of RXYLT1 mRNA CTD PMID:33512557 NCBI chr 7:57,770,841...57,782,695
Ensembl chr 7:57,770,842...57,782,657
JBrowse link
G S100a13 S100 calcium binding protein A13 increases expression ISO pyrimidifen results in increased expression of S100A13 mRNA CTD PMID:33512557 NCBI chr 2:175,999,439...176,005,933 JBrowse link
G S100a4 S100 calcium-binding protein A4 increases expression ISO pyrimidifen results in increased expression of S100A4 mRNA CTD PMID:33512557 NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
JBrowse link
G Satb1 SATB homeobox 1 decreases expression ISO pyrimidifen results in decreased expression of SATB1 mRNA CTD PMID:33512557 NCBI chr 9:4,677,817...4,773,061
Ensembl chr 9:4,680,920...4,753,251
JBrowse link
G Scrn1 secernin 1 decreases expression ISO pyrimidifen results in decreased expression of SCRN1 mRNA CTD PMID:33512557 NCBI chr 4:83,632,125...83,694,225
Ensembl chr 4:83,632,131...83,693,852
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B increases expression ISO pyrimidifen results in increased expression of SDHB mRNA CTD PMID:33512557 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Sec11a SEC11 homolog A, signal peptidase complex subunit increases expression ISO pyrimidifen results in increased expression of SEC11A mRNA CTD PMID:33512557 NCBI chr 1:134,881,448...134,909,427
Ensembl chr 1:134,875,265...134,915,069
JBrowse link
G Sema4b semaphorin 4B decreases expression ISO pyrimidifen results in decreased expression of SEMA4B mRNA CTD PMID:33512557 NCBI chr 1:134,136,646...134,177,777
Ensembl chr 1:134,149,536...134,177,775
JBrowse link
G Sema6d semaphorin 6D decreases expression ISO pyrimidifen results in decreased expression of SEMA6D mRNA CTD PMID:33512557 NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094
JBrowse link
G Septin10 septin 10 increases expression ISO pyrimidifen results in increased expression of SEPTIN10 mRNA CTD PMID:33512557 NCBI chr20:27,101,764...27,194,997
Ensembl chr20:27,101,752...27,194,780
JBrowse link
G Sertad1 SERTA domain containing 1 increases expression ISO pyrimidifen results in increased expression of SERTAD1 mRNA CTD PMID:33512557 NCBI chr 1:82,775,692...82,778,961
Ensembl chr 1:82,775,252...82,779,091
JBrowse link
G Sesn2 sestrin 2 increases expression ISO pyrimidifen results in increased expression of SESN2 mRNA CTD PMID:33512557 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
JBrowse link
G Slc17a6 solute carrier family 17 member 6 decreases expression ISO pyrimidifen results in decreased expression of SLC17A6 mRNA CTD PMID:33512557 NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
JBrowse link
G Slc1a2 solute carrier family 1 member 2 decreases expression ISO pyrimidifen results in decreased expression of SLC1A2 mRNA CTD PMID:33512557 NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
JBrowse link
G Slc25a5 solute carrier family 25 member 5 increases expression ISO pyrimidifen results in increased expression of SLC25A5 mRNA CTD PMID:33512557 NCBI chr  X:116,031,896...116,034,963
Ensembl chr  X:116,031,803...116,034,967
JBrowse link
G Slc2a6 solute carrier family 2 member 6 decreases expression ISO pyrimidifen results in decreased expression of SLC2A6 mRNA CTD PMID:33512557 NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
JBrowse link
G Slc35f2 solute carrier family 35, member F2 increases expression ISO pyrimidifen results in increased expression of SLC35F2 mRNA CTD PMID:33512557 NCBI chr 8:54,159,970...54,203,614
Ensembl chr 8:54,159,970...54,203,612
JBrowse link
G Slc7a5 solute carrier family 7 member 5 increases expression ISO pyrimidifen results in increased expression of SLC7A5 mRNA CTD PMID:33512557 NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
JBrowse link
G Slit2 slit guidance ligand 2 decreases expression ISO pyrimidifen results in decreased expression of SLIT2 mRNA CTD PMID:33512557 NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
JBrowse link
G Slitrk1 SLIT and NTRK-like family, member 1 decreases expression ISO pyrimidifen results in decreased expression of SLITRK1 mRNA CTD PMID:33512557 NCBI chr15:85,723,252...85,727,290
Ensembl chr15:85,724,475...85,727,509
JBrowse link
G Smc1a structural maintenance of chromosomes 1A decreases expression ISO pyrimidifen results in decreased expression of SMC1A mRNA CTD PMID:33512557 NCBI chr  X:21,103,323...21,148,053
Ensembl chr  X:21,103,282...21,148,056
JBrowse link
G Snai2 snail family transcriptional repressor 2 increases expression ISO pyrimidifen results in increased expression of SNAI2 mRNA CTD PMID:33512557 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
JBrowse link
G Snrpd3 small nuclear ribonucleoprotein D3 polypeptide increases expression ISO pyrimidifen results in increased expression of SNRPD3 mRNA CTD PMID:33512557 NCBI chr20:13,130,112...13,145,947
Ensembl chr20:13,130,119...13,145,978
JBrowse link
G Snrpg small nuclear ribonucleoprotein polypeptide G increases expression ISO pyrimidifen results in increased expression of SNRPG mRNA CTD PMID:33512557 NCBI chr 4:118,812,278...118,819,827
Ensembl chr 4:118,812,252...118,819,826
JBrowse link
G Sox4 SRY-box transcription factor 4 decreases expression ISO pyrimidifen results in decreased expression of SOX4 mRNA CTD PMID:33512557 NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
JBrowse link
G Spag5 sperm associated antigen 5 increases expression ISO pyrimidifen results in increased expression of SPAG5 mRNA CTD PMID:33512557 NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
JBrowse link
G Spc25 SPC25 component of NDC80 kinetochore complex increases expression ISO pyrimidifen results in increased expression of SPC25 mRNA CTD PMID:33512557 NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
JBrowse link
G Spdef SAM pointed domain containing ets transcription factor decreases expression ISO pyrimidifen results in decreased expression of SPDEF mRNA CTD PMID:33512557 NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893
JBrowse link
G Syp synaptophysin decreases expression ISO pyrimidifen results in decreased expression of SYP mRNA CTD PMID:33512557 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745
JBrowse link
G Tacc3 transforming, acidic coiled-coil containing protein 3 increases expression ISO pyrimidifen results in increased expression of TACC3 mRNA CTD PMID:33512557 NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
JBrowse link
G Tagln transgelin increases expression ISO pyrimidifen results in increased expression of TAGLN mRNA CTD PMID:33512557 NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
JBrowse link
G Tcf4 transcription factor 4 decreases expression ISO pyrimidifen results in decreased expression of TCF4 mRNA CTD PMID:33512557 NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
JBrowse link
G Tcta T-cell leukemia translocation altered decreases expression ISO pyrimidifen results in decreased expression of TCTA mRNA CTD PMID:33512557 NCBI chr 8:108,988,588...108,992,324
Ensembl chr 8:108,988,590...108,991,564
JBrowse link
G Tgfb3 transforming growth factor, beta 3 decreases expression ISO pyrimidifen results in decreased expression of TGFB3 mRNA CTD PMID:33512557 NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
JBrowse link
G Tlk2 tousled-like kinase 2 decreases expression ISO pyrimidifen results in decreased expression of TLK2 mRNA CTD PMID:33512557 NCBI chr10:90,154,449...90,248,562
Ensembl chr10:90,156,813...90,248,561
JBrowse link
G Tm9sf3 transmembrane 9 superfamily member 3 decreases expression ISO pyrimidifen results in decreased expression of TM9SF3 mRNA CTD PMID:33512557 NCBI chr 1:240,032,060...240,085,125
Ensembl chr 1:240,035,003...240,084,776
JBrowse link
G Tmbim6 transmembrane BAX inhibitor motif containing 6 increases expression ISO pyrimidifen results in increased expression of TMBIM6 mRNA CTD PMID:33512557 NCBI chr 7:130,527,313...130,542,567
Ensembl chr 7:130,527,316...130,543,633
JBrowse link
G Tmed2 transmembrane p24 trafficking protein 2 increases expression ISO pyrimidifen results in increased expression of TMED2 mRNA CTD PMID:33512557 NCBI chr12:32,052,542...32,061,628
Ensembl chr12:32,052,543...32,071,903
JBrowse link
G Tmem185a transmembrane protein 185A decreases expression ISO pyrimidifen results in decreased expression of TMEM185A mRNA CTD PMID:33512557 NCBI chr  X:149,143,026...149,167,757
Ensembl chr  X:149,143,031...149,167,757
JBrowse link
G Tmem65 transmembrane protein 65 decreases expression ISO pyrimidifen results in decreased expression of TMEM65 mRNA CTD PMID:33512557 NCBI chr 7:90,336,997...90,378,930
Ensembl chr 7:90,274,142...90,379,474
JBrowse link
G Tmem97 transmembrane protein 97 increases expression ISO pyrimidifen results in increased expression of TMEM97 mRNA CTD PMID:33512557 NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730
JBrowse link
G Tnc tenascin C decreases expression ISO pyrimidifen results in decreased expression of TNC mRNA CTD PMID:33512557 NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
JBrowse link
G Tomm34 translocase of outer mitochondrial membrane 34 decreases expression ISO pyrimidifen results in decreased expression of TOMM34 mRNA CTD PMID:33512557 NCBI chr 3:152,729,345...152,746,295
Ensembl chr 3:152,729,349...152,746,373
JBrowse link
G Tpd52l2 TPD52 like 2 decreases expression ISO pyrimidifen results in decreased expression of TPD52L2 mRNA CTD PMID:33512557 NCBI chr 3:168,598,449...168,618,201
Ensembl chr 3:168,594,609...168,619,762
JBrowse link
G Tpr translocated promoter region, nuclear basket protein decreases expression ISO pyrimidifen results in decreased expression of TPR mRNA CTD PMID:33512557 NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496
JBrowse link
G Tpx2 TPX2, microtubule nucleation factor increases expression ISO pyrimidifen results in increased expression of TPX2 mRNA CTD PMID:33512557 NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression ISO pyrimidifen results in increased expression of TRIB3 mRNA CTD PMID:33512557 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Trim13 tripartite motif-containing 13 decreases expression ISO pyrimidifen results in decreased expression of TRIM13 mRNA CTD PMID:33512557 NCBI chr15:35,733,548...35,772,676
Ensembl chr15:35,734,107...35,772,677
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 decreases expression ISO pyrimidifen results in decreased expression of TRPV1 mRNA CTD PMID:33512557 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
JBrowse link
G Tst thiosulfate sulfurtransferase decreases expression ISO pyrimidifen results in decreased expression of TST mRNA CTD PMID:33512557 NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
JBrowse link
G Ttk Ttk protein kinase increases expression ISO pyrimidifen results in increased expression of TTK mRNA CTD PMID:33512557 NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
JBrowse link
G Tubb2b tubulin, beta 2B class IIb decreases expression ISO pyrimidifen results in decreased expression of TUBB2B mRNA CTD PMID:33512557 NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
JBrowse link
G Txndc5 thioredoxin domain containing 5 increases expression ISO pyrimidifen results in increased expression of TXNDC5 mRNA CTD PMID:33512557 NCBI chr17:26,289,880...26,318,025
Ensembl chr17:26,289,880...26,318,025
JBrowse link
G Txnip thioredoxin interacting protein decreases expression ISO pyrimidifen results in decreased expression of TXNIP mRNA CTD PMID:33512557 NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO pyrimidifen results in increased expression of TXNRD1 mRNA CTD PMID:33512557 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 increases expression ISO pyrimidifen results in increased expression of UBA52 mRNA CTD PMID:33512557 NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807
JBrowse link
G Ubb ubiquitin B increases expression ISO pyrimidifen results in increased expression of UBB mRNA CTD PMID:33512557 NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
JBrowse link
G Ube2c ubiquitin-conjugating enzyme E2C increases expression ISO pyrimidifen results in increased expression of UBE2C mRNA CTD PMID:33512557 NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
JBrowse link
G Uevld UEV and lactate/malate dehyrogenase domains decreases expression ISO pyrimidifen results in decreased expression of UEVLD mRNA CTD PMID:33512557 NCBI chr 1:97,454,188...97,486,004
Ensembl chr 1:97,453,946...97,486,000
JBrowse link
G Uqcrq ubiquinol-cytochrome c reductase, complex III subunit VII increases expression ISO pyrimidifen results in increased expression of UQCRQ mRNA CTD PMID:33512557 NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
JBrowse link
G Usp7 ubiquitin specific peptidase 7 decreases expression ISO pyrimidifen results in decreased expression of USP7 mRNA CTD PMID:33512557 NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355
JBrowse link
G Vapb VAMP associated protein B and C decreases expression ISO pyrimidifen results in decreased expression of VAPB mRNA CTD PMID:34642769 NCBI chr 3:162,535,974...162,578,747
Ensembl chr 3:162,535,905...162,573,763
JBrowse link
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 increases expression ISO pyrimidifen results in increased expression of VKORC1 mRNA CTD PMID:33512557 NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
JBrowse link
G Wars1 tryptophanyl-tRNA synthetase 1 increases expression ISO pyrimidifen results in increased expression of WARS1 mRNA CTD PMID:33512557 NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
JBrowse link
G Wdtc1 WD and tetratricopeptide repeats 1 decreases expression ISO pyrimidifen results in decreased expression of WDTC1 mRNA CTD PMID:33512557 NCBI chr 5:145,491,460...145,559,631
Ensembl chr 5:145,491,466...145,540,408
JBrowse link
G Ywhab tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta decreases expression ISO pyrimidifen results in decreased expression of YWHAB mRNA CTD PMID:33512557 NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105
JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 decreases expression ISO pyrimidifen results in decreased expression of ZEB2 mRNA CTD PMID:33512557 NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157
JBrowse link
G Zfand2a zinc finger AN1-type containing 2A increases expression ISO pyrimidifen results in increased expression of ZFAND2A mRNA CTD PMID:33512557 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
JBrowse link
G Zmiz1 zinc finger, MIZ-type containing 1 decreases expression ISO pyrimidifen results in decreased expression of ZMIZ1 mRNA CTD PMID:33512557 NCBI chr16:1,027,083...1,232,616
Ensembl chr16:1,027,325...1,232,597
JBrowse link
G Zranb2 zinc finger RANBP2-type containing 2 increases expression ISO pyrimidifen results in increased expression of ZRANB2 mRNA CTD PMID:33512557 NCBI chr 2:246,573,110...246,586,942
Ensembl chr 2:246,573,166...246,586,942
JBrowse link
pyrimidin-2-amine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 affects binding EXP 2-aminopyrimidine analog binds to CYP2C11 protein CTD PMID:19317514 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity ISO 2-aminopyrimidine analog results in decreased activity of CYP3A4 protein CTD PMID:19317514 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 affects binding EXP 2-aminopyrimidine analog binds to FMO1 protein CTD PMID:19317514 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 affects binding EXP 2-aminopyrimidine analog binds to MGST1 protein CTD PMID:19317514 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
JBrowse link
pyrimidine-2,4-diamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alk ALK receptor tyrosine kinase decreases phosphorylation
multiple interactions
decreases response to substance
ISO 2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form
ALK gene SNP inhibits the reaction [2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form]
ALK gene SNP results in decreased susceptibility to 2,4-diaminopyrimidine analog
CTD PMID:20979473 NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
JBrowse link
riociguat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases metabolic processing ISO CYP1A1 protein results in increased metabolism of riociguat CTD PMID:30950278 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Kcnk3 potassium two pore domain channel subfamily K member 3 decreases response to substance
increases activity
ISO KCNK3 protein mutant form results in decreased susceptibility to riociguat
riociguat results in increased activity of KCNK3 protein
CTD PMID:30365877 NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153
JBrowse link
thiamine(1+) chloride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in decreased phosphorylation of AKT1 protein] CTD PMID:31419397 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aqp7 aquaporin 7 increases expression
multiple interactions
EXP
ISO
Thiamine results in increased expression of AQP7 mRNA
Thiamine inhibits the reaction [citreoviridin results in decreased expression of AQP7 mRNA]
CTD PMID:31419397 NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in increased expression of BAX protein] CTD PMID:31419397 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO
EXP
Thiamine inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein] CTD PMID:31419397 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Casp1 caspase 1 multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased cleavage of CASP1 protein] CTD PMID:36690085 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Thiamine inhibits the reaction [Pentylenetetrazole results in increased expression of CASP3 protein] CTD PMID:33771525 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ckb creatine kinase B multiple interactions ISO
EXP
Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]] CTD PMID:31419397 NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
JBrowse link
G Ckm creatine kinase, M-type multiple interactions EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [Glycerol results in increased secretion of CKM protein] CTD PMID:31419397 PMID:36690085 NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions
increases expression
EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in decreased expression of FABP4 mRNA]
Thiamine results in increased expression of FABP4 mRNA
CTD PMID:31419397 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Gsdmd gasdermin D multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased cleavage of GSDMD protein] CTD PMID:36690085 NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased cleavage of IL1B protein] CTD PMID:36690085 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO
EXP
Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form] CTD PMID:31419397 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased expression of MYC protein] CTD PMID:36690085 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO NFE2L2 protein affects the reaction [Thiamine results in increased expression of NQO1 mRNA] CTD PMID:29860433 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased expression of NLRP3 protein] CTD PMID:36690085 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [Thiamine results in increased expression of NQO1 mRNA] CTD PMID:29860433 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases activity
multiple interactions
EXP Thiamine results in increased activity of PPARG protein
Thiamine inhibits the reaction [citreoviridin results in decreased activity of PPARG protein]
CTD PMID:31419397 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP [Thiamine deficiency results in increased expression of PTGS2 mRNA] which results in increased expression of Dinoprostone; Thiamine deficiency results in increased expression of PTGS2 mRNA CTD PMID:18481165 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Slc19a2 solute carrier family 19 member 2 increases uptake
multiple interactions
increases expression
ISO SLC19A2 protein results in increased uptake of Thiamine
[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A2 protein] which results in decreased uptake of Thiamine
Thiamine deficiency results in increased expression of SLC19A2 mRNA; Thiamine deficiency results in increased expression of SLC19A2 protein
CTD PMID:16705148 PMID:24244374 NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172
JBrowse link
G Slc19a3 solute carrier family 19 member 3 increases expression
multiple interactions
increases uptake
ISO Thiamine deficiency results in increased expression of SLC19A3 mRNA; Thiamine deficiency results in increased expression of SLC19A3 protein
Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Chloroquine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Metformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Phenformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Verapamil inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]
[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A3 protein] which results in decreased uptake of Thiamine
CTD PMID:16705148 PMID:24244374 PMID:26528626 NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein] CTD PMID:31419397 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased expression of TLR4 protein] CTD PMID:36690085 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Thiamine inhibits the reaction [Glycerol results in increased expression of TNF protein] CTD PMID:36690085 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnnt2 troponin T2, cardiac type multiple interactions EXP
ISO
Thiamine inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein] CTD PMID:31419397 NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
JBrowse link
trimethoprim term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd74 CD74 molecule affects expression ISO Trimethoprim affects the expression of CD74 mRNA CTD PMID:25811541 NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions
decreases activity
ISO [Trimethoprim results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Amodiaquine CTD PMID:26599973 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing
decreases activity
ISO CYP2C8 protein results in increased metabolism of Trimethoprim
Trimethoprim results in decreased activity of CYP2C8 protein
CTD PMID:12464242 PMID:15570183
G Dhfr dihydrofolate reductase multiple interactions ISO [Trimethoprim results in decreased activity of DHFR protein] which results in increased susceptibility to Valproic Acid CTD PMID:8318756 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Trimethoprim co-treated with Sulfadiazine] results in increased expression of IL6 protein CTD PMID:10888991 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G RT1-DOb RT1 class II, locus DOb affects expression ISO Trimethoprim affects the expression of HLA-DOB mRNA CTD PMID:25811541 NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667
JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO Trimethoprim inhibits the reaction [SLC22A1 protein results in increased uptake of Quercetin] CTD PMID:24947867 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a3 solute carrier family 22 member 3 increases transport ISO SLC22A3 protein results in increased transport of Trimethoprim CTD PMID:18253050 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO Trimethoprim inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO Trimethoprim inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19831
    role 19807
      application 19650
        NMR chemical shift reference compound 17958
          ammonia 17818
            organic amino compound 17818
              aromatic amine 15425
                aminopyrimidine 1928
                  ((2-bromo-4-methylphenyl)\{6-[(4-\{[3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino)acetonitrile + 0
                  (2R)-1-(dimethylamino)-3-\{4-[(6-\{[2-fluoro-5-(trifluoromethyl)phenyl]amino\}pyrimidin-4-yl)amino]phenoxy\}propan-2-ol 0
                  (2R)-1-[4-(\{4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                  (2R)-1-[4-(\{6-[(2,6-difluorophenyl)amino]pyrimidin-4-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                  (2R)-1-\{4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy\}-3-(dimethylamino)propan-2-ol 0
                  (2R,3Z)-4-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}-2-hydroxy-3-sulfanylpent-3-en-1-yl trihydrogen diphosphate 0
                  (2S)-1-(dimethylamino)-3-(4-\{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino\}phenoxy)propan-2-ol 0
                  (2S)-1-(dimethylamino)-3-\{4-[(6-\{[2-fluoro-5-(trifluoromethyl)phenyl]amino\}pyrimidin-4-yl)amino]phenoxy\}propan-2-ol 0
                  (2S)-1-[4-(\{4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                  (2S)-1-[4-(\{6-[(2,6-difluorophenyl)amino]pyrimidin-4-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                  (2S)-1-\{4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy\}-3-(dimethylamino)propan-2-ol 0
                  (2S)-2-(3-\{2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy\}propyl)pentanedioate 0
                  (2S)-2-[(2R,4S,5S)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-\{[(R)-hydroxy(phosphonooxy)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazolidin-2-yl]-2-hydroxypropanoic acid 0
                  (2S)-2-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}propane-1-thiol 0
                  (2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one 0
                  (2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2H-1,4-benzoxazin-3(4H)-one 0
                  (3E)-4-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}pent-3-en-1-yl trihydrogen diphosphate 0
                  (3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine 0
                  (4-amino-2-\{[1-(methylsulfonyl)piperidin-4-yl]amino\}pyrimidin-5-yl)(2,3-difluoro-6-methoxyphenyl)methanone 0
                  (4-amino-2-methylpyrimidin-5-yl)methyl dihydrogen phosphate 0
                  (4S)-4-\{[(5-amino-6-oxo-2-thiophen-2-ylpyrimidin-1(6H)-yl)acetyl]amino\}-2,2-difluoro-5-methyl-N-(2-morpholin-4-ylethyl)-3-oxohexanamide 0
                  1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                  1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                  1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                  1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                  1-[(2,4-diamino-6-methylpyrimidin-5-yl)methyl]-1,2-dicarba-closo-dodecaborane(12) 0
                  1-[(4-amino-2-methylpyrimidin-5-yl)methyl]pyridinium 0
                  1-methylcytosine 0
                  2,4,6-triaminopyrimidine 0
                  2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidin-1-ium 0
                  2,5,6-triamino-4-hydroxypyrimidine 0
                  2,5-diamino-4-hydroxy-6-(5-phosphoribosylamino)pyrimidine 0
                  2,5-diamino-6-(1-D-ribitylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                  2,5-diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate 0
                  2,5-diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                  2,5-diamino-6-(5-phosphono)ribitylamino-4(3H)-pyrimidinone 0
                  2,5-diamino-6-(5-triphosphoryl-3,4-trihydroxy-2-oxopentyl)amino-4-oxopyrimidine 0
                  2,5-diamino-6-ribosylamino-4(3H)pyrimidinone 5'-triphosphate 0
                  2,5-diaminopyrimidine-4,6-diol 0
                  2,5-dimethylpyrimidin-4-amine 0
                  2,6-diamino-4-hydroxy-5-(N-methylformamido)pyrimidine 0
                  2,6-diamino-5-formamido-4-hydroxypyrimidine 2
                  2,6-dimethylphenyl 2-\{3,5-dimethoxy-4-[3-(4-methylpiperazin-1-yl)propoxy]phenylamino\}pyrimidin-4-yl-(2,4-dimethoxyphenyl)carbamate 0
                  2-(3,5-dimethyl-1-pyrazolyl)-N,6-dimethyl-4-pyrimidinamine 0
                  2-(3-\{[4-(hydroxyamino)-2-methylpyrimidin-5-yl]methyl\}-4-methyl-2,3-dihydro-1,3-thiazol-5-yl)ethyl trihydrogen diphosphate 0
                  2-(3-\{[4-amino-2-(trifluoromethyl)pyrimidin-5-yl]methyl\}-4-methyl-1,3-thiazol-3-ium-5-yl)ethyl phosphate 0
                  2-(\{2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl\}amino)benzamide 0
                  2-(dimethylamino)-5,6-dimethylpyrimidin-4-ol 0
                  2-Amino-4,6-dimethylpyrimidine 0
                  2-Amino-4-methylpyrimidine 0
                  2-O-methylcytosine 0
                  2-[(2E)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-(1,2-dihydroxyethylidene)-4-methyl-2,3-dihydro-1,3-thiazol-5-yl]ethyl trihydrogen diphosphate 0
                  2-[(2E)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-(1-hydroxyethylidene)-4-methyl-2,3-dihydro-1,3-thiazol-5-yl]ethyl trihydrogen diphosphate 0
                  2-[3-[(6-amino-2-methyl-4-pyrimidinyl)methyl]-4-methyl-5-thiazol-3-iumyl]ethanol 0
                  2-[5-(benzylamino)-2-(methylsulfanyl)-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]acetamide 0
                  2-[5-amino-2-(3-methylphenyl)-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]acetamide 0
                  2-[5-amino-6-oxo-2-phenylpyrimidin-1(6H)-yl]-N-\{(1S)-1-[(S)-(5-tert-butyl-1,3,4-oxadiazol-2-yl)(hydroxy)methyl]-2-methylpropyl\}acetamide 0
                  2-[[2-(3,5-dimethyl-1-pyrazolyl)-6-methyl-4-pyrimidinyl]amino]ethanol 0
                  2-\{(2E)-1-benzyl-3-[2-chloro-5-(2,4-diamino-6-ethylpyrimidin-5-yl)phenyl]triaz-2-en-1-yl\}ethyl acetate 0
                  2-\{(2R)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-isobutyrylpiperazin-2-yl\}-N-[2-(4-methoxyphenyl)ethyl]acetamide 0
                  2-\{3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yl\}ethyl trihydrogen diphosphate 0
                  2-\{4-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-methylthiophen-2-yl\}ethyl trihydrogen diphosphate 0
                  2-amino-4-\{[(3-carbamoyl-1,2,4-oxadiazol-5-yl)methyl]amino\}-6-isopropylpyrimidin-1-ium 0
                  2-amino-4-chloro-6-methylpyrimidine 0
                  2-amino-4-hydroxy-6-methylpyrimidine 0
                  2-amino-4-hydroxypyrimidine + 0
                  2-amino-5-bromo-6-phenylpyrimidin-4-ol 0
                  2-amino-5-formylamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate 0
                  2-amino-5-formylamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                  2-diethylamino-6-methylpyrimidin-4(1H)-one + 15
                  2-dimethylamino-5,6-dimethylpyrimidin-4-ol 0
                  2-methyl-1-hydroxypropylthiamine diphosphate 0
                  2-methyl-5-[(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]-4-pyrimidinamine 0
                  3-(2-chlorobenzyl)-1-(2-\{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino\}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea 0
                  3-(2-chlorophenyl)-1-(2-\{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino\}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea 0
                  3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-\{(1S)-1-hydroxy-1-[(R)-hydroxy(methoxy)phosphoryl]ethyl\}-5-(2-\{[(R)-hydroxy(phosphonooxy)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazol-3-ium 0
                  3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-\{[(S)-hydroxy(phosphonoamino)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazol-3-ium 0
                  3-\{[2-(1H-benzimidazol-1-yl)-6-\{[2-(diethylamino)ethyl]amino\}pyrimidin-4-yl]amino\}-4-methylphenol 0
                  3-\{[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino\}phenol 0
                  3-ethylcytosine 0
                  3-methylcytosine 0
                  4,6-diamino-5-formamidopyrimidine 1
                  4-(2,4-dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine 0
                  4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine 0
                  4-(2,5-dichlorothiophen-3-yl)pyrimidin-2-amine 0
                  4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-(3-nitrophenyl)pyrimidin-2-amine 0
                  4-(2-furanyl)-N-(3-pyridinylmethyl)-6-(trifluoromethyl)-2-pyrimidinamine 0
                  4-(4-fluorophenyl)-1-methyl-5-(2-\{[(1S)-1-phenylethyl]amino\}pyrimidin-4-yl)-2-piperidin-4-yl-1,2-dihydro-3H-pyrazol-3-one 0
                  4-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,2-dihydropyrimidin-2-one 0
                  4-(5-methyl-3-phenylisoxazol-4-yl)pyrimidin-2-amine 0
                  4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(morpholin-4-yl)phenyl]pyrimidin-2-amine 0
                  4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-phenylpyrimidin-2-amine 0
                  4-(\{4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl\}amino)benzonitrile 0
                  4-(\{4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl\}amino)phenol 0
                  4-(\{5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)pyrimidin-4-yl\}oxy)-3,5-dimethylbenzonitrile 0
                  4-(\{6-amino-5-bromo-2-[(4-cyanophenyl)amino]pyrimidin-4-yl\}oxy)-3,5-dimethylbenzonitrile 0
                  4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide 0
                  4-[(6-aminopyrimidin-4-yl)amino]benzenesulfonamide 0
                  4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine 0
                  4-[2-(hydroxymethyl)pyrimidin-4-yl]-N,N-dimethylpiperazine-1-sulfonamide 0
                  4-[4-(1-amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine 0
                  4-[4-(4-fluorophenyl)-1-piperidin-4-yl-1H-imidazol-5-yl]pyrimidin-2-amine 0
                  4-\{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl\}-N-[(1S)-1-phenylethyl]pyrimidin-2-amine 0
                  4-\{2-[4-(2-aminoethyl)piperazin-1-yl]pyridin-4-yl\}-N-(3-chloro-4-methylphenyl)pyrimidin-2-amine 0
                  4-\{[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino\}benzamide 0
                  4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                  4-amino-1,2-dihydropyrimidine 0
                  4-amino-2-methyl-5-diphosphooxymethylpyrimidine 0
                  4-amino-2-methyl-5-phosphooxymethylpyrimidine 0
                  4-amino-5-aminomethyl-2-methylpyrimidine 0
                  4-amino-5-formamidomethyl-2-methylpyrimidine 0
                  4-amino-5-hydroxy-6-(5-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2,5-dihydropyrimidin-2-one 0
                  4-amino-5-hydroxymethyl-2-methylpyrimidine 0
                  4-methyl-6-(2,2,3,3,4,4,5,5-octafluoropentoxy)-2-pyrimidinamine 0
                  5',6'-diamino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-4',5'-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                  5',6'-diamino-1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-4',5'-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                  5,6-dimethylpyrimidine-2,4-diamine 0
                  5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine 0
                  5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine 0
                  5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine 0
                  5-(beta-D-glucosylmethyl)cytosine 0
                  5-(hydroxymethyl)cytosine + 20
                  5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine + 0
                  5-[4-(dimethylamino)phenyl]-6-[(6-morpholin-4-ylpyridin-3-yl)ethynyl]pyrimidin-4-amine 0
                  5-\{3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy\}pentanoic acid 0
                  5-\{4-[(3,5-difluorobenzyl)amino]phenyl\}-6-ethylpyrimidine-2,4-diamine 0
                  5-\{[ethyl(methyl)amino]methyl\}-2-methylpyrimidin-4-amine 0
                  5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                  5-carboxycytosine 0
                  5-chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine 0
                  5-chloro-N-\{1-[4-(difluoromethoxy)phenyl]propyl\}-6-methylpyrimidin-4-amine + 0
                  5-formylcytosine 0
                  6'-amino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                  6'-amino-1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                  6-(2,4-diamino-6-ethylpyrimidin-5-yl)-4-(3-methoxypropyl)-2,2-dimethyl-2H-1,4-benzoxazin-3(4H)-one 0
                  6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                  6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine 8
                  6-[4-amino-4-hydroxy-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]-3-[3-amino-5-(N-methylguanidino)pentanoylamino]-3,6-dihydro-2H-pyran-2-carboxylic acid 0
                  6-\{5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl\}hex-5-ynoic acid 0
                  6-chloro-2-\{[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]sulfanyl\}pyrimidin-4-amine 0
                  6-chlorotrimethoprim 0
                  6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine 0
                  6-ethyl-5-[1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]-N(4)-(2-phenylethyl)pyrimidine-2,4-diamine 0
                  6-ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine 0
                  6-ethyl-5-phenylpyrimidine-2,4-diamine 0
                  6-hydroxytrimethoprim 0
                  7-(2,4-diamino-6-ethylpyrimidin-5-yl)-1-(3-methoxypropyl)quinolinium 0
                  7-[(2,4-diamino-6-methylpyrimidin-5-yl)methyl]-7,8-dicarba-nido-undecaborane(11) + 0
                  7-methylpyrimido[4,5-d]pyrimidin-4-amine 0
                  8-(pyrimidin-2-ylamino)naphthalene-2-carboximidamide 0
                  AMMP 0
                  AZD3463 0
                  Allithiamine 0
                  BAY 41-2272 0
                  BGJ-398 0
                  BKM120 2
                  Bisibuthiamine 5
                  CD532 0
                  CHIR 99021 212
                  CHIR-98014 3
                  CZC-25146 0
                  CZC8004 0
                  Cycotiamine hydrochloride 0
                  HG-10-102-01 0
                  HG-9-91-01 0
                  N'-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-N,N-dimethylbenzene-1,4-diamine 0
                  N(2)-[3-methoxy-4-(morpholin-4-yl)phenyl]-N(4)-(quinolin-3-yl)pyrimidine-2,4-diamine 0
                  N(4)-methylcytosine 0
                  N-(3-\{[5-bromo-2-(\{3-[(pyrrolidin-1-ylcarbonyl)amino]phenyl\}amino)pyrimidin-4-yl]amino\}propyl)-2,2-dimethylmalonamide 0
                  N-(\{4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-glutamic acid 0
                  N-(\{4-[(1S)-4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid 0
                  N-(\{4-[(1S)-4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-gamma-glutamyl-gamma-glutamylglutamic acid 0
                  N-[(1S)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide 0
                  N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[2-(3,4-dichlorophenyl)-5-[(1-methylethyl)amino]-6-oxopyrimidin-1(6H)-yl]acetamide 0
                  N-[(2S)-2-[(4S)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-2-(\{[(1S)-1-carboxy-2-phenylethyl]carbamoyl\}amino)acetyl]-L-leucyl-L-phenylalanine 0
                  N-[(4-\{[(2,5-diamino-6-hydroxypyrimidin-4-yl)carbamoyl]amino\}phenyl)carbonyl]-L-glutamic acid 0
                  N-[(4-\{[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl](2-[(4-phosphonooxybutyl)carbamoylmethylsulfanyl]acetyl)amino\}phenyl)carbonyl]-L-glutamic acid 0
                  N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[5-hydroxy-3-(2-oxolanylmethyldisulfanyl)pent-2-en-2-yl]formamide 0
                  N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-D-prolinamide 0
                  N-[2-(\{2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl\}amino)ethyl]naphthalene-2-sulfonamide 0
                  N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-\{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl\}-3-(trifluoromethyl)benzamide 0
                  N-\{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzothiazin-4-yl]ethyl\}acetamide 0
                  N-\{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]ethyl\}acetamide 0
                  N-\{3-[(4-\{[3-(trifluoromethyl)phenyl]amino\}pyrimidin-2-yl)amino]phenyl\}cyclopropanecarboxamide 0
                  N-\{3-[(5-cyclopropyl-2-\{[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]amino\}pyrimidin-4-yl)amino]propyl\}cyclobutanecarboxamide 0
                  N-\{4-[4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl]phenyl\}cyclopropanecarboxamide 0
                  N-\{5-[(7-\{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy\}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl\}benzamide 0
                  N-cyclohexyl-4-(imidazo[1,2-a]pyridin-3-yl)-N-methylpyrimidin-2-amine 0
                  N-cyclohexyl-4-[4-(3,4-dichlorophenyl)-2-piperidin-4-yl-1-propyl-1H-imidazol-5-yl]pyrimidin-2-amine 0
                  N-cyclopropyl-4-[4-(3,4-dichlorophenyl)-2-(1-methylpiperidin-4-yl)-1-propylimidazol-5-yl]pyrimidin-2-amine 0
                  N-isopropyl-4-(trifluoromethyl)pyrimidin-2-amine 0
                  NSC 23766 + 36
                  PF-670462 free base 0
                  SB220025 0
                  TAK-580 0
                  THZ531 0
                  Thiamine disulfide 0
                  [(1R,2S,4R)-4-\{[2-amino-5-(formylamino)-6-oxo-3,6-dihydropyrimidin-4-yl]amino\}-2-hydroxycyclopentyl]methyl dihydrogen phosphate 0
                  [(2-chloro-5-methylphenyl)\{6-[(4-\{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino]acetonitrile 0
                  [4-amino-2-(trifluoromethyl)pyrimidin-5-yl]methyl trihydrogen diphosphate 0
                  aminouracil + 0
                  annomontine 3
                  benfotiamine 15
                  brodimoprim 0
                  bupirimate 2
                  ceritinib 17
                  cetotiamine 0
                  copanlisib + 3
                  cyprodinil 32
                  cytosine + 1372
                  dabrafenib + 24
                  dasatinib (anhydrous) + 0
                  diaveridine 0
                  dimethirimol 0
                  ethirimol 1
                  ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate 0
                  etravirine 0
                  flucytosine 3
                  flufenerim 0
                  isaxonine 0
                  mepanipyrim 9
                  methyl 3-\{2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl\}-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrazine-1(4H)-carboxylate 0
                  methylcytosine + 5
                  minoxidil 6
                  mocetinostat 24
                  momelotinib 0
                  nelociguat 0
                  nimustine 24
                  osimertinib 22
                  pazopanib 18
                  pirimicarb 13
                  pirimiphos-methyl 15
                  praliciguat 0
                  pyrimethamine 25
                  pyrimethanil 16
                  pyrimidifen 342
                  pyrimidin-2-amine + 7
                  pyrimidin-4-amine 0
                  pyrimidin-5-amine 0
                  pyrimidinamine pesticide + 342
                  pyrimidine-2,4-diamine + 1
                  rilpivirine 0
                  riociguat 2
                  thiamine phosphate + 0
                  trimethoprim + 11
                  vericiguat 0
                  vitamin B1 + 36
Path 2
Term Annotations click to browse term
  CHEBI ontology 19831
    subatomic particle 19829
      composite particle 19829
        hadron 19829
          baryon 19829
            nucleon 19829
              atomic nucleus 19829
                atom 19829
                  main group element atom 19779
                    main group molecular entity 19779
                      s-block molecular entity 19617
                        hydrogen molecular entity 19604
                          hydrides 19102
                            inorganic hydride 18114
                              pnictogen hydride 18103
                                nitrogen hydride 18010
                                  azane 17819
                                    ammonia 17818
                                      organic amino compound 17818
                                        aromatic amine 15425
                                          aminopyrimidine 1928
                                            ((2-bromo-4-methylphenyl)\{6-[(4-\{[3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino)acetonitrile + 0
                                            (2R)-1-(dimethylamino)-3-\{4-[(6-\{[2-fluoro-5-(trifluoromethyl)phenyl]amino\}pyrimidin-4-yl)amino]phenoxy\}propan-2-ol 0
                                            (2R)-1-[4-(\{4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                                            (2R)-1-[4-(\{6-[(2,6-difluorophenyl)amino]pyrimidin-4-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                                            (2R)-1-\{4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy\}-3-(dimethylamino)propan-2-ol 0
                                            (2R,3Z)-4-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}-2-hydroxy-3-sulfanylpent-3-en-1-yl trihydrogen diphosphate 0
                                            (2S)-1-(dimethylamino)-3-(4-\{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino\}phenoxy)propan-2-ol 0
                                            (2S)-1-(dimethylamino)-3-\{4-[(6-\{[2-fluoro-5-(trifluoromethyl)phenyl]amino\}pyrimidin-4-yl)amino]phenoxy\}propan-2-ol 0
                                            (2S)-1-[4-(\{4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                                            (2S)-1-[4-(\{6-[(2,6-difluorophenyl)amino]pyrimidin-4-yl\}amino)phenoxy]-3-(dimethylamino)propan-2-ol 0
                                            (2S)-1-\{4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy\}-3-(dimethylamino)propan-2-ol 0
                                            (2S)-2-(3-\{2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy\}propyl)pentanedioate 0
                                            (2S)-2-[(2R,4S,5S)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-\{[(R)-hydroxy(phosphonooxy)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazolidin-2-yl]-2-hydroxypropanoic acid 0
                                            (2S)-2-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}propane-1-thiol 0
                                            (2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one 0
                                            (2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2H-1,4-benzoxazin-3(4H)-one 0
                                            (3E)-4-\{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino\}pent-3-en-1-yl trihydrogen diphosphate 0
                                            (3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine 0
                                            (4-amino-2-\{[1-(methylsulfonyl)piperidin-4-yl]amino\}pyrimidin-5-yl)(2,3-difluoro-6-methoxyphenyl)methanone 0
                                            (4-amino-2-methylpyrimidin-5-yl)methyl dihydrogen phosphate 0
                                            (4S)-4-\{[(5-amino-6-oxo-2-thiophen-2-ylpyrimidin-1(6H)-yl)acetyl]amino\}-2,2-difluoro-5-methyl-N-(2-morpholin-4-ylethyl)-3-oxohexanamide 0
                                            1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                                            1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                                            1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                                            1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                                            1-[(2,4-diamino-6-methylpyrimidin-5-yl)methyl]-1,2-dicarba-closo-dodecaborane(12) 0
                                            1-[(4-amino-2-methylpyrimidin-5-yl)methyl]pyridinium 0
                                            1-methylcytosine 0
                                            2,4,6-triaminopyrimidine 0
                                            2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidin-1-ium 0
                                            2,5,6-triamino-4-hydroxypyrimidine 0
                                            2,5-diamino-4-hydroxy-6-(5-phosphoribosylamino)pyrimidine 0
                                            2,5-diamino-6-(1-D-ribitylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                                            2,5-diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate 0
                                            2,5-diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                                            2,5-diamino-6-(5-phosphono)ribitylamino-4(3H)-pyrimidinone 0
                                            2,5-diamino-6-(5-triphosphoryl-3,4-trihydroxy-2-oxopentyl)amino-4-oxopyrimidine 0
                                            2,5-diamino-6-ribosylamino-4(3H)pyrimidinone 5'-triphosphate 0
                                            2,5-diaminopyrimidine-4,6-diol 0
                                            2,5-dimethylpyrimidin-4-amine 0
                                            2,6-diamino-4-hydroxy-5-(N-methylformamido)pyrimidine 0
                                            2,6-diamino-5-formamido-4-hydroxypyrimidine 2
                                            2,6-dimethylphenyl 2-\{3,5-dimethoxy-4-[3-(4-methylpiperazin-1-yl)propoxy]phenylamino\}pyrimidin-4-yl-(2,4-dimethoxyphenyl)carbamate 0
                                            2-(3,5-dimethyl-1-pyrazolyl)-N,6-dimethyl-4-pyrimidinamine 0
                                            2-(3-\{[4-(hydroxyamino)-2-methylpyrimidin-5-yl]methyl\}-4-methyl-2,3-dihydro-1,3-thiazol-5-yl)ethyl trihydrogen diphosphate 0
                                            2-(3-\{[4-amino-2-(trifluoromethyl)pyrimidin-5-yl]methyl\}-4-methyl-1,3-thiazol-3-ium-5-yl)ethyl phosphate 0
                                            2-(\{2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl\}amino)benzamide 0
                                            2-(dimethylamino)-5,6-dimethylpyrimidin-4-ol 0
                                            2-Amino-4,6-dimethylpyrimidine 0
                                            2-Amino-4-methylpyrimidine 0
                                            2-O-methylcytosine 0
                                            2-[(2E)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-(1,2-dihydroxyethylidene)-4-methyl-2,3-dihydro-1,3-thiazol-5-yl]ethyl trihydrogen diphosphate 0
                                            2-[(2E)-3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-(1-hydroxyethylidene)-4-methyl-2,3-dihydro-1,3-thiazol-5-yl]ethyl trihydrogen diphosphate 0
                                            2-[3-[(6-amino-2-methyl-4-pyrimidinyl)methyl]-4-methyl-5-thiazol-3-iumyl]ethanol 0
                                            2-[5-(benzylamino)-2-(methylsulfanyl)-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]acetamide 0
                                            2-[5-amino-2-(3-methylphenyl)-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]acetamide 0
                                            2-[5-amino-6-oxo-2-phenylpyrimidin-1(6H)-yl]-N-\{(1S)-1-[(S)-(5-tert-butyl-1,3,4-oxadiazol-2-yl)(hydroxy)methyl]-2-methylpropyl\}acetamide 0
                                            2-[[2-(3,5-dimethyl-1-pyrazolyl)-6-methyl-4-pyrimidinyl]amino]ethanol 0
                                            2-\{(2E)-1-benzyl-3-[2-chloro-5-(2,4-diamino-6-ethylpyrimidin-5-yl)phenyl]triaz-2-en-1-yl\}ethyl acetate 0
                                            2-\{(2R)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-isobutyrylpiperazin-2-yl\}-N-[2-(4-methoxyphenyl)ethyl]acetamide 0
                                            2-\{3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yl\}ethyl trihydrogen diphosphate 0
                                            2-\{4-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-methylthiophen-2-yl\}ethyl trihydrogen diphosphate 0
                                            2-amino-4-\{[(3-carbamoyl-1,2,4-oxadiazol-5-yl)methyl]amino\}-6-isopropylpyrimidin-1-ium 0
                                            2-amino-4-chloro-6-methylpyrimidine 0
                                            2-amino-4-hydroxy-6-methylpyrimidine 0
                                            2-amino-4-hydroxypyrimidine + 0
                                            2-amino-5-bromo-6-phenylpyrimidin-4-ol 0
                                            2-amino-5-formylamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate 0
                                            2-amino-5-formylamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate(2-) 0
                                            2-diethylamino-6-methylpyrimidin-4(1H)-one + 15
                                            2-dimethylamino-5,6-dimethylpyrimidin-4-ol 0
                                            2-methyl-1-hydroxypropylthiamine diphosphate 0
                                            2-methyl-5-[(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]-4-pyrimidinamine 0
                                            3-(2-chlorobenzyl)-1-(2-\{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino\}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea 0
                                            3-(2-chlorophenyl)-1-(2-\{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino\}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea 0
                                            3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-\{(1S)-1-hydroxy-1-[(R)-hydroxy(methoxy)phosphoryl]ethyl\}-5-(2-\{[(R)-hydroxy(phosphonooxy)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazol-3-ium 0
                                            3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-\{[(S)-hydroxy(phosphonoamino)phosphoryl]oxy\}ethyl)-4-methyl-1,3-thiazol-3-ium 0
                                            3-\{[2-(1H-benzimidazol-1-yl)-6-\{[2-(diethylamino)ethyl]amino\}pyrimidin-4-yl]amino\}-4-methylphenol 0
                                            3-\{[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino\}phenol 0
                                            3-ethylcytosine 0
                                            3-methylcytosine 0
                                            4,6-diamino-5-formamidopyrimidine 1
                                            4-(2,4-dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine 0
                                            4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine 0
                                            4-(2,5-dichlorothiophen-3-yl)pyrimidin-2-amine 0
                                            4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-(3-nitrophenyl)pyrimidin-2-amine 0
                                            4-(2-furanyl)-N-(3-pyridinylmethyl)-6-(trifluoromethyl)-2-pyrimidinamine 0
                                            4-(4-fluorophenyl)-1-methyl-5-(2-\{[(1S)-1-phenylethyl]amino\}pyrimidin-4-yl)-2-piperidin-4-yl-1,2-dihydro-3H-pyrazol-3-one 0
                                            4-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,2-dihydropyrimidin-2-one 0
                                            4-(5-methyl-3-phenylisoxazol-4-yl)pyrimidin-2-amine 0
                                            4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(morpholin-4-yl)phenyl]pyrimidin-2-amine 0
                                            4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-phenylpyrimidin-2-amine 0
                                            4-(\{4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl\}amino)benzonitrile 0
                                            4-(\{4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl\}amino)phenol 0
                                            4-(\{5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)pyrimidin-4-yl\}oxy)-3,5-dimethylbenzonitrile 0
                                            4-(\{6-amino-5-bromo-2-[(4-cyanophenyl)amino]pyrimidin-4-yl\}oxy)-3,5-dimethylbenzonitrile 0
                                            4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide 0
                                            4-[(6-aminopyrimidin-4-yl)amino]benzenesulfonamide 0
                                            4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine 0
                                            4-[2-(hydroxymethyl)pyrimidin-4-yl]-N,N-dimethylpiperazine-1-sulfonamide 0
                                            4-[4-(1-amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine 0
                                            4-[4-(4-fluorophenyl)-1-piperidin-4-yl-1H-imidazol-5-yl]pyrimidin-2-amine 0
                                            4-\{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl\}-N-[(1S)-1-phenylethyl]pyrimidin-2-amine 0
                                            4-\{2-[4-(2-aminoethyl)piperazin-1-yl]pyridin-4-yl\}-N-(3-chloro-4-methylphenyl)pyrimidin-2-amine 0
                                            4-\{[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino\}benzamide 0
                                            4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                                            4-amino-1,2-dihydropyrimidine 0
                                            4-amino-2-methyl-5-diphosphooxymethylpyrimidine 0
                                            4-amino-2-methyl-5-phosphooxymethylpyrimidine 0
                                            4-amino-5-aminomethyl-2-methylpyrimidine 0
                                            4-amino-5-formamidomethyl-2-methylpyrimidine 0
                                            4-amino-5-hydroxy-6-(5-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2,5-dihydropyrimidin-2-one 0
                                            4-amino-5-hydroxymethyl-2-methylpyrimidine 0
                                            4-methyl-6-(2,2,3,3,4,4,5,5-octafluoropentoxy)-2-pyrimidinamine 0
                                            5',6'-diamino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-4',5'-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                                            5',6'-diamino-1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-4',5'-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                                            5,6-dimethylpyrimidine-2,4-diamine 0
                                            5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine 0
                                            5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine 0
                                            5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine 0
                                            5-(beta-D-glucosylmethyl)cytosine 0
                                            5-(hydroxymethyl)cytosine + 20
                                            5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine + 0
                                            5-[4-(dimethylamino)phenyl]-6-[(6-morpholin-4-ylpyridin-3-yl)ethynyl]pyrimidin-4-amine 0
                                            5-\{3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy\}pentanoic acid 0
                                            5-\{4-[(3,5-difluorobenzyl)amino]phenyl\}-6-ethylpyrimidine-2,4-diamine 0
                                            5-\{[ethyl(methyl)amino]methyl\}-2-methylpyrimidin-4-amine 0
                                            5-amino-5-methyl-6-\{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl\}-1,3-diazinane-2,4-dione 0
                                            5-carboxycytosine 0
                                            5-chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine 0
                                            5-chloro-N-\{1-[4-(difluoromethoxy)phenyl]propyl\}-6-methylpyrimidin-4-amine + 0
                                            5-formylcytosine 0
                                            6'-amino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                                            6'-amino-1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione 0
                                            6-(2,4-diamino-6-ethylpyrimidin-5-yl)-4-(3-methoxypropyl)-2,2-dimethyl-2H-1,4-benzoxazin-3(4H)-one 0
                                            6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one 0
                                            6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine 8
                                            6-[4-amino-4-hydroxy-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]-3-[3-amino-5-(N-methylguanidino)pentanoylamino]-3,6-dihydro-2H-pyran-2-carboxylic acid 0
                                            6-\{5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl\}hex-5-ynoic acid 0
                                            6-chloro-2-\{[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]sulfanyl\}pyrimidin-4-amine 0
                                            6-chlorotrimethoprim 0
                                            6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine 0
                                            6-ethyl-5-[1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]-N(4)-(2-phenylethyl)pyrimidine-2,4-diamine 0
                                            6-ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine 0
                                            6-ethyl-5-phenylpyrimidine-2,4-diamine 0
                                            6-hydroxytrimethoprim 0
                                            7-(2,4-diamino-6-ethylpyrimidin-5-yl)-1-(3-methoxypropyl)quinolinium 0
                                            7-[(2,4-diamino-6-methylpyrimidin-5-yl)methyl]-7,8-dicarba-nido-undecaborane(11) + 0
                                            7-methylpyrimido[4,5-d]pyrimidin-4-amine 0
                                            8-(pyrimidin-2-ylamino)naphthalene-2-carboximidamide 0
                                            AMMP 0
                                            AZD3463 0
                                            Allithiamine 0
                                            BAY 41-2272 0
                                            BGJ-398 0
                                            BKM120 2
                                            Bisibuthiamine 5
                                            CD532 0
                                            CHIR 99021 212
                                            CHIR-98014 3
                                            CZC-25146 0
                                            CZC8004 0
                                            Cycotiamine hydrochloride 0
                                            HG-10-102-01 0
                                            HG-9-91-01 0
                                            N'-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-N,N-dimethylbenzene-1,4-diamine 0
                                            N(2)-[3-methoxy-4-(morpholin-4-yl)phenyl]-N(4)-(quinolin-3-yl)pyrimidine-2,4-diamine 0
                                            N(4)-methylcytosine 0
                                            N-(3-\{[5-bromo-2-(\{3-[(pyrrolidin-1-ylcarbonyl)amino]phenyl\}amino)pyrimidin-4-yl]amino\}propyl)-2,2-dimethylmalonamide 0
                                            N-(\{4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-glutamic acid 0
                                            N-(\{4-[(1S)-4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid 0
                                            N-(\{4-[(1S)-4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl\}carbonyl)-L-gamma-glutamyl-gamma-glutamylglutamic acid 0
                                            N-[(1S)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide 0
                                            N-[(1S)-4-carbamimidamido-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[2-(3,4-dichlorophenyl)-5-[(1-methylethyl)amino]-6-oxopyrimidin-1(6H)-yl]acetamide 0
                                            N-[(2S)-2-[(4S)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-2-(\{[(1S)-1-carboxy-2-phenylethyl]carbamoyl\}amino)acetyl]-L-leucyl-L-phenylalanine 0
                                            N-[(4-\{[(2,5-diamino-6-hydroxypyrimidin-4-yl)carbamoyl]amino\}phenyl)carbonyl]-L-glutamic acid 0
                                            N-[(4-\{[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl](2-[(4-phosphonooxybutyl)carbamoylmethylsulfanyl]acetyl)amino\}phenyl)carbonyl]-L-glutamic acid 0
                                            N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[5-hydroxy-3-(2-oxolanylmethyldisulfanyl)pent-2-en-2-yl]formamide 0
                                            N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-D-prolinamide 0
                                            N-[2-(\{2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl\}amino)ethyl]naphthalene-2-sulfonamide 0
                                            N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-\{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl\}-3-(trifluoromethyl)benzamide 0
                                            N-\{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzothiazin-4-yl]ethyl\}acetamide 0
                                            N-\{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]ethyl\}acetamide 0
                                            N-\{3-[(4-\{[3-(trifluoromethyl)phenyl]amino\}pyrimidin-2-yl)amino]phenyl\}cyclopropanecarboxamide 0
                                            N-\{3-[(5-cyclopropyl-2-\{[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]amino\}pyrimidin-4-yl)amino]propyl\}cyclobutanecarboxamide 0
                                            N-\{4-[4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl]phenyl\}cyclopropanecarboxamide 0
                                            N-\{5-[(7-\{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy\}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl\}benzamide 0
                                            N-cyclohexyl-4-(imidazo[1,2-a]pyridin-3-yl)-N-methylpyrimidin-2-amine 0
                                            N-cyclohexyl-4-[4-(3,4-dichlorophenyl)-2-piperidin-4-yl-1-propyl-1H-imidazol-5-yl]pyrimidin-2-amine 0
                                            N-cyclopropyl-4-[4-(3,4-dichlorophenyl)-2-(1-methylpiperidin-4-yl)-1-propylimidazol-5-yl]pyrimidin-2-amine 0
                                            N-isopropyl-4-(trifluoromethyl)pyrimidin-2-amine 0
                                            NSC 23766 + 36
                                            PF-670462 free base 0
                                            SB220025 0
                                            TAK-580 0
                                            THZ531 0
                                            Thiamine disulfide 0
                                            [(1R,2S,4R)-4-\{[2-amino-5-(formylamino)-6-oxo-3,6-dihydropyrimidin-4-yl]amino\}-2-hydroxycyclopentyl]methyl dihydrogen phosphate 0
                                            [(2-chloro-5-methylphenyl)\{6-[(4-\{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino]acetonitrile 0
                                            [4-amino-2-(trifluoromethyl)pyrimidin-5-yl]methyl trihydrogen diphosphate 0
                                            aminouracil + 0
                                            annomontine 3
                                            benfotiamine 15
                                            brodimoprim 0
                                            bupirimate 2
                                            ceritinib 17
                                            cetotiamine 0
                                            copanlisib + 3
                                            cyprodinil 32
                                            cytosine + 1372
                                            dabrafenib + 24
                                            dasatinib (anhydrous) + 0
                                            diaveridine 0
                                            dimethirimol 0
                                            ethirimol 1
                                            ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate 0
                                            etravirine 0
                                            flucytosine 3
                                            flufenerim 0
                                            isaxonine 0
                                            mepanipyrim 9
                                            methyl 3-\{2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl\}-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrazine-1(4H)-carboxylate 0
                                            methylcytosine + 5
                                            minoxidil 6
                                            mocetinostat 24
                                            momelotinib 0
                                            nelociguat 0
                                            nimustine 24
                                            osimertinib 22
                                            pazopanib 18
                                            pirimicarb 13
                                            pirimiphos-methyl 15
                                            praliciguat 0
                                            pyrimethamine 25
                                            pyrimethanil 16
                                            pyrimidifen 342
                                            pyrimidin-2-amine + 7
                                            pyrimidin-4-amine 0
                                            pyrimidin-5-amine 0
                                            pyrimidinamine pesticide + 342
                                            pyrimidine-2,4-diamine + 1
                                            rilpivirine 0
                                            riociguat 2
                                            thiamine phosphate + 0
                                            trimethoprim + 11
                                            vericiguat 0
                                            vitamin B1 + 36
paths to the root